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Colorectal cancer (CRC) represents a major public health problem worldwide. 
Fortunately most CRCs originate from a precursor lesion, the adenoma, which is 
accessible and removable. This is the rationale for CRC screening programs, which 
are aimed to diagnose CRC at an early stage or even better to detect and resect the 
advanced adenoma before CRC has developed. In this background colonoscopy 
emerges as the main tool to achieve these goals with recent evidence supporting its role 
in CRC prevention. This book deals with several topics to be faced when implementing 
a CRC screening program. The interested reader will learn about the rationale and 
challenges of implementing such a program, the management of the detected lesions, 
the prevention of complications of colonoscopy, and finally the use of other screening 
modalities that are emerging as valuable alternatives. The relevance of the topics 
covered in it and the updated evidence included by the authors turn this book into a 
very useful tool to introduce the reader in this amazing and evolving field.
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Preface
Colorectal cancer (CRC) is the third more commonly diagnosed cancer in both sexes and it is also
the third leading cause of cancer-related death among men and women in the United States.It
represents a global public health problem and a heavy burdenfor any healthcare system. Fortu‐
nately, most CRCs originate from an adenoma, a precursor lesion that is easily accessible and re‐
movable. This is the rationale for CRC screening programs, which are aimed to diagnose CRC at
an early stage or even better, to detect and resect the advanced adenoma before CRC has devel‐
oped. Recent evidence suggests that colonoscopy with polypectomy is efficient in reducing the in‐
cidence of and mortality from CRC. Moreover, the CRC resection rates have recently been shown
to be reduced after the implementation of colonoscopy-based screening programs. As a conse‐
quence, CRC screening programs, either directly with colonoscopy or based on fecal occult blood
test, are being implemented in most countries. The physicians who are devoted to endoscopy or
who are involved in CRC screening programs face several challenges. They are requested to par‐
ticipate in the organization of population-based CRC screening programs; screening colonoscop‐
ies have to be performed accomplishing quality standards; difficult endoscopic resections are
expected because performing colonoscopy in asymptomatic individuals makes possible an early
diagnosis of advanced adenomas; and finally clinical decisions have to be made based on the in‐
formation provided by the number and histology of the detected adenomas.
In this background, this book providesaccurate and updated information on several topics to be
faced when implementing a CRC screening program.It is divided in four sections, the first one
dealing with the epidemiology of CRC and the rationale and challenges of implementing such a
program both from a European and American point of view. The second section tackles the issue
of managing the findings of a screening colonoscopy, commenting on the use of endoscopic sub‐
mucosal dissection to resect difficult polyps, the significance and management of the malignant
polyp and the possibility of using image enhancing technologies to make a presumptive histologi‐
cal diagnosis of diminutive polyps reducing costs without losing efficacy. The third section sum‐
marizes the main risks of diagnostic and therapeutic colonoscopy and how to manage them. And
finally the last section comments on virtual colonoscopy and colon capsule endoscopy, technolo‐
gies that are being developed and soon will become part of our screening armamentarium.
The relevance of the topics covered in it and the updated evidence included by the authors turns
this book into a very useful tool to introduce the reader in the amazing and evolving field of
colonoscopy and CRC screening.
Marco Bustamante, MD, PhD
University Hospital La Fe
Valencia, Spain
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1. Introduction
1.1. Epidemiology – Clinical presentation-screening
Colorectal cancer (CRC) is a common and lethal disease. The risk of developing CRC is
influenced by both environmental and genetic factors. Colorectal cancer is the third most
common cancer worldwide. Clinical symptoms develop late in the course of the disease, and
precursor lesions (adenomas) can be easily detected and removed. The disease is a candidate
for early detection and prevention by screening. The epidemiology of CRC and risk factors for
its development will be discussed here.
Epidemiology — CRC incidence and mortality rates vary markedly around the world [1].
Globally, CRC is the third most commonly diagnosed cancer in males and the second in
females, with over 1.2 million new cases and 608,700 deaths estimated to have occurred in
2008.Incidence and mortality rates are substantially higher in males than in females [2]. It is
the fourth most common cause of cancer death after lung, stomach, and liver cancer. It is more
common in developed than developing countries.
In the United States, both the incidence and mortality have been slowly but steadily decreasing.
Annually approximately 143,460 new cases of large bowel cancer are diagnosed, of which
103,170 are colon and the remainder rectal cancers. Annually, approximately 51,690 Americans
die of CRC, accounting for approximately 9 percent of all cancer deaths [6].
Incidence — There is significant geographical variation in age-standardized and cumulative,
0-74 year incidence and mortality rates. Globally, the incidence of CRC varies over 10-fold.
The highest incidence rates are in Australia and New Zealand, Europe and North America,
and the lowest rates are found in Africa and South-Central Asia [5]. The highest incidence rate
of CRC is estimated in the Czech Republic [39-42]. These geographic differences appear to be
© 2013 Georgios and Bampali; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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attributable to differences in dietary and environmental exposures that are imposed upon a
background of genetically determined susceptibility.
In Europe, the incidence of colorectal cancer is increasing, particularly in Southern and Eastern
Europe, where rates were originally lower than in Western Europe [7]. In the USA, incidence
rose until the mid-1980s but in the last two decades the rates have fallen for both men and
women. Countries that have had a rapid ‘westernization’ of diet, such as Japan, have seen a
rapid increase in incidence of colorectal cancer. Consumption of meat and dairy products in
Japan increased tenfold between the 1950s and 1990s.
Figure 1. Age-adjusted colorectal cancer incidence and death rates in the United States 1975–2006.
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Colorectal cancer (CRC) is a disease with a major worldwide burden. The worldwide inci‐
dence of CRC is increasing. In 1975, the worldwide incidence of CRC was only 500,000.In
western countries, some of the increase is due to the aging of the population. However, in
countries with a low baseline rate of CRC, the incidence is increasing even after age-adjust‐
ment. Prior to 1985, the age-adjusted incidence of CRC in the USA also increased (figure 1).
However, since this time the rates have declined an average of −1.6% per year. In the time
period 1998–2005, the rate of decline accelerated; −2.8% per year in men and −2.3% per year
in women. This reduction has been mainly confined to those of white race and is largely lim‐
ited to a decrease in the incidence of distal cancers. Although the cause of the decrease in
incidence is unknown, and may have been influenced by many factors, it is likely that much
may be attributable to screening by sigmoidoscopy and colonoscopy. In contrast, the inci‐
dence of proximal cancers has remained relatively stable over the same time period. Cur‐
rently, the overall probability of an individual developing CRC in the USA over a lifetime is
5.5% in men and 5.1% in women.
From a population perspective, age is the most important risk factor for CRC. CRC is pre‐
dominantly a disease of older individuals. 90% of cases are diagnosed over the age of 50. The
risk of CRC continues to increase with age (Figure 2). The incidence per 100,000 people age
80–84 is over seven times the incidence in people age 50–54. However, CRC can occur at any
age and the incidence of CRC occurring before age 40 may be increasing.
In the USA, the risk of CRC differs by sex. The age-adjusted incidence of CRC is over 40%
higher in men than women [8]. Overall, the incidence of CRC in men is 61 per 100,000 males
as compared to 45 per 100,000 females. In addition, the ratio of colon to rectal cancer differs
by sex; the ratio of colon to rectal cases for women is 3:1 as compared to 2:1 for males.
Race and ethnicity influence CRC risk [20]. Ashkenazi Jewish individuals appear to be at a
slightly increased risk of CRC. At least part of this increased incidence may be due to a higher
prevalence of the I1307K mutation of the adenomatous polyposis gene (APC), a mutation that
confers an increased risk of CRC development (18–30% lifetime risk). The I1307K mutation is
found in 6.1% of unselected Ashkenazi Jewish individuals and 28% of Jewish individuals with
CRC, while the mutation is rare in other populations. In the USA, the incidence of CRC is
higher in African Americans of either sex as compared to white Americans. Asian American/
Pacific Islanders, Native Americans, and Hispanic Americans experience a lower incidence of
CRC than Caucasians (Table 1).African Americans have not experienced the substantial
reduction in incidence of CRC found to have occurred in whites; prior to 1980 incidence in
African Americans was actually lower than in white Americans. In African Americans, the
increased rate of cancer is predominantly due to a higher rate of proximal cancers.
There is substantial geographic variation in the incidence of CRC, with relatively high rates in
North America, Western Europe, and Australia and relatively low rates in Africa and Asia
(Figure 3) Such observations led to Burkitt’s hypothesis; that dietary differences, specifically
fiber and fat intake, between populations were responsible for the marked variation in rates
of CRC found around the world. Burkitt observed that populations in low-risk areas of the
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Incidence Male 58.9 71.2 48.0 46.0 47.3
Female 43.2 54.5 35.4 41.2 32.8
Mortality Male 22.1 31.8 14.4 20.5 16.5
Female 15.3 22.4 10.2 14.2 10.8
*per 100,000 age-adjusted to the 2000 US standard population
Table 1. Incidence and mortality rates* for CRC by site, race and ethnicity, US 2001–2005
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than populations in high-risk, westernized regions. Although such ecological studies are
confounded by numerous factors (for example, variations in average life expectancy, cancer
detection methods, etc.), environmental factors (most prominently dietary factors) are still
considered to have a major role in this disease. This is supported by studies of migrants from
low prevalence areas to high prevalence areas. Such studies generally demonstrate that the
incidence of CRC in the migrants increases rapidly to become similar and in some cases to
exceed the incidence of the high-risk area. Interestingly, there is less variation in the incidence
of rectal cancer between countries as compared to the incidence of colon cancer.
Figure 3. A Age-Standardized (to the world population) incidence rates of cancer of the large bowel among females,
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The lifetime incidence of CRC in patients at average risk is about 5 percent, with 90 percent
of cases occurring after age 50. In the US, CRC incidence is about 25 percent higher in men
than in women and is about 20 percent higher in African Americans than in whites. The inci‐
dence is higher in patients with specific inherited conditions that predispose them to the de‐
velopment of CRC.
Mortality — Death rates from CRC have declined progressively since the mid-1980s in the
United States and in many other western countries. This improvement in outcome can be
attributed, at least in part, to detection and removal of colonic polyps, detection of CRCs at
an earlier stage, and more effective treatments, particularly adjuvant therapy. Globally, the
United States has one of the highest survival rates from CRC. However, mortality rates con‐
tinue to increase in many countries with more limited resources and health infrastructure,
particularly in Central and South America and Eastern Europe [43-44]. African Americans
suffer the highest mortality rate from CRC in the USA (Table 1).The reasons for the higher
mortality rate are likely multifactorial, including the higher incidence of CRC, and the dif‐
ferences in stage distribution. Differences in incidence, stage distribution and survival of
CRC between white and African Americans are in part due to differences in socioeconomic
status, screening rates and treatment. However, the differences may also be due to genetic
and environmental factors that have yet to be elucidated. The highest mortality rates in both
sexes are estimated in Central Europe (20.3/100000 for male patients, 12.1/100000 for female
patients), and the lowest in the Middle Africa (3.5 and 2.7 respectively). The majority of
deaths of CRC occur in older people, around 80% in people aged 65 and above and almost
two-fifths of deaths appear in the group with age over 80.
Because CRC is a survivable cancer, with a 5-year survival rates adjusted for life expectan‐
cy of 64% the prevalence of people living with a diagnosis of CRC in the population is
substantial.
Factors that may have contributed to the worldwide variation in colorectal cancer incidence
patterns include differences in the prevalence of risk factors and screening practices. Estab‐
lished and suspected modifiable risk factors for colorectal cancer, including obesity, physical
inactivity, smoking, heavy alcohol consumption, a diet high in red or processed meats, and
inadequate consumption of fruits and vegetables, are also factors associated with economic
development or westernization [35].This partially explains the historically high albeit decreas‐
ing colorectal cancer incidence rates observed in long-standing developed countries such as
the United States, Canada, and New Zealand over the past several years [36]. Colorectal cancer
screening can also influence colorectal cancer incidence rates. All screening tests including
stool blood tests (e.g. fecal occult blood test) and structural screening tests (e.g. sigmoidoscopy
and colonoscopy) may increase colorectal cancer incidence rates initially as they detect
previously undiagnosed cases.
Riskfactors-Although the exact cause for the development of colorectal cancer is not known,
there are factors that increase risk for developing adenomas, polyps and cancer. These include
numerous suspect factors.
Environmental and genetic factors can increase the likelihood of developing CRC. Although
inherited susceptibility results in the most striking increases in risk, the majority of CRCs are
sporadic rather than familial. These include:
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1. HereditaryCRCsyndromes such as: Familial adenomatous polyposis (FAP) and Lynch
Syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)) which are the most
common of the familial colon cancer syndromes, but together these two conditions
account for only about 5 percent of CRC cases.
a. Familialadenomatouspolyposis(FAP) and its variants (Gardner's syndrome, Turcot's
syndrome, and attenuated adenomatous polyposis coli) account for less than 1 percent of
colorectal cancers. In typical FAP, numerous colonic adenomas appear during childhood.
Symptoms appear at an average age of approximately 16 years and colonic cancer occurs
in 90 percent of untreated individuals by age 45. An attenuated form of APC (AAPC)
carries a similarly high risk of colon cancer but is characterized by fewer adenomas and
an older average age of cancer diagnosis of 54 years.
FAP is caused by germline mutations in the adenomatous polyposis coli (APC) gene which is
located on chromosome 5. The same gene is involved in the attenuated form of FAP, but the
sites of the APC gene mutations are different.
b. Lynchsyndrome — Lynch syndrome is an autosomal dominant syndrome, which is more
common than FAP, and accounts for approximately 3 to 5 percent of all colonic adeno‐
carcinomas. The name Lynch syndrome honors the pioneering work of Dr. Henry Lynch
in drawing attention to the syndrome. The term Lynch syndrome is now commonly used
for families who have been genetically determined to have a disease-causing defect in one
of the mismatch repair genes, most commonly hMLH1, hMSH2, hMSH6, or PMS2. As a
general rule, patients with Lynch syndrome have a germline mutation in one allele of a
MMR gene and the second allele is inactivated in the colorectal cancers by somatic
mutation, loss of heterozygosity, or epigenetic silencing by promoter hypermethylation.
The colorectal tumors that develop in patients with Lynch syndrome are characterized by early
age of onset and predominance of right-sided lesions [21]. The mean age at initial cancer
diagnosis is 48 years, with some patients presenting in their 20s. Nearly 70 percent of first
lesions arise proximal to the splenic flexure, and approximately 10 percent will have synchro‐
nous (simultaneous onset of two or more distinct tumors separated by normal bowel) or
metachronous cancers (non-anastomotic new tumors developing at least six months after the
initial diagnosis).
Extracolonic cancers are very common in Lynch syndrome, particularly endometrial carcino‐
ma, which may occur in up to 60 percent of female mutation carriers in some families. Other
sites at increased risk of neoplasm formation include the ovary, stomach, small bowel,
hepatobiliary system, brain and renal pelvis or ureter.
2. Personal or family history of sporadic CRCs or adenomatous polyps
Patients with a personal history of CRC or adenomatous polyps of the colon are at risk for the
future development of colon cancer. The clustering of risk in families may be attributed to an
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influence of a more distant family history of CRC on individual risk has not been determined
with certainty. Some of the increased risk attributed to family history is due to inheritance of
known susceptibility genes, such as mutations in the APC gene, p53 gene, or in MMR genes,
particularly MSH2, MLH1, and MSH6.
Importantly, the majority of cases of CRC cannot be attributed to known genetic defects even
when associated with a family history of CRC as recognized genetic syndromes account for
only a small proportion of all cases of CRC. Additional autosomal dominant genetic defects
conferring a high risk of CRC almost certainly is found. However, at least some of the increased
risk of CRC associated with a family history is likely attributable to other genetic factors, such
as recessive susceptibility genes, autosomal dominant genes with low penetrance, or complex
interactions between an individual’s genetic makeup and environmental factors.
Despite the importance of family history on the risk of CRC, up to 25% of individuals with a
first-degree relative with confirmed CRC do not report having such a family history and even
those that do report a history may not be aware of the increased risk associated with this. This
has important implications for the assessment of family history as well as patient and family
counseling.
3. Inflammatory bowel disease
Patients with long-standing inflammatory bowel disease (IBD) are known to be at an elevated
risk of CRC, although it is difficult to precisely estimate the risk. The magnitude of the risk has
been studied extensively in ulcerative colitis (UC).
Ulcerativecolitis— There is a well documented association between chronic ulcerative colitis
and colonic neoplasia, with the extent, duration, and activity of disease being the primary
determinants while for Crohn’s disease there are less data. However, there is an association
between pancolitis due to Crohn’s disease and the risk of colon malignancy. The extent of
disease does appear to have a significant influence on CRC risk in UC [38]. Other factors that
may modify the risk of CRC in patients with UC include the coexistence of primary sclerosing
colangitis (PSC), presence of inflammatory pseudopolyps, and severity of inflammation. For
patients with long-standing, extensive UC, colectomy is an effective strategy for the prevention
of CRC. Other strategies include endoscopic surveillance for dysplasia and/or the use of
chemopreventive agents.
The relationship between Crohn’s disease and the development of CRC has been less consis‐
tently demonstrated. In studies using data from referral-based practices, the risk of develop‐
ment of CRC appears to be significantly increased in patients with extensive Crohn’s colitis.
Finally, the risk of CRC in patients with Crohn’s disease is elevated, but the exact magnitude
of increased risk remains unclear and requires further investigation.
Several additional risk factors have been identified mostly in observational studies. These may
include: race/ethnicity and gender, acromegaly, renal transplantation, diabetes mellitus and
insulin resistance, use of androgen deprivation therapy, cholecystectomy, alcohol, obesity.
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Protectivefactors — A large number of factors have been reported by at least some studies to
be associated with a decreased risk of CRC. These include regular physical activity, a variety
of dietary factors, the regular use of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs),
and hormone replacement therapy in postmenopausal women. None of these factors are
currently used to stratify CRC screening recommendations.
1. Physical Activity
Over 50 studies have been conducted to evaluate the influence of physical activity on CRC
risk. Overall, the literature is relatively consistent with respect to the effect: Greater physical
activity (occupational, recreational, or total activity) is associated with a reduced risk of CRC.
The effect is relatively small; the estimated increased risk of colon cancer in the sedentary
ranges from 1.6 to 2.0. The biological mechanisms that explain the relationship between
physical activity and CRC risk are unclear. Increased physical activity leads to changes in
insulin sensitivity and IGF levels, and both insulin and IGF are potentially involved with
colorectal carcinogenesis. Additional proposed mechanisms include effects of physical activity
on prostaglandin synthesis, effects on antitumor immune defenses, and the reduction in
percent body fat associated with exercise. The mechanism is almost certainly multifactorial.
Nonetheless, for a host of health-related reasons, frequent moderate to vigorous physical
activity can be recommended to most patients without hesitation.
2. Fruit and Vegetable Intake
The effect of dietary intake of fruit and vegetables on CRC risk has been evaluated extensively
[22]. Fruits and vegetables are a source of antioxidants, including carotenoids and ascorbate.
Other bioactive constituents in fruits and vegetables that may protect against carcinogenesis
include the indoles and isothiocyanates. The evidence for an association between fruit and
vegetable intake and the risk of CRC is inconsistent [23]. Given this, it is unlikely that a large
number of cases of CRC can be attributed directly to a lack of intake of fruits or vegetables, or
that major additional interventions to increase consumption would lead to a substantial
reduction in the incidence of CRC.
3. Aspirin and Nonsteroidal Anti-inflammatory Drugs
There is considerable observational evidence that the use of aspirin or other nonsteroidal anti-
inflammatory drugs (NSAIDs) has protective effects at all stages of colorectal carcinogenesis
(aberrant crypt foci, adenoma, carcinoma, and death from CRC [14]. The mechanism of
antineoplastic action of NSAIDs is incompletely understood, but it is believed that both
cyclooxygenase (COX)-dependent and COX-independent pathways may be involved.
NSAIDs and aspirin may play an important role in secondary chemoprevention of colorectal
adenomas and cancer. Because chemopreventive agents must be used in the general popula‐
tion to substantially reduce the burden of disease, the risks of chemoprophylaxis with aspirin
or NSAIDs may outweigh the benefits. Serious GI complications occur in regular users of
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4. Hormone Replacement Therapy
Observational studies have demonstrated an association between hormone replacement
therapy (HRT) in women and a reduction in both incidence and mortality from CRC. Possible
mechanisms for the effect of HRT include a reduction in bile acid secretion (a potential
promoter or initiator of CRC), as well as estrogen effects on colonic epithelium, both directly
and through alterations in insulin-like growth factor with the use of estrogens. Overall, there
appears to be a consistent reduction in the risk of CRC with the use of HRT. However, given




Symptoms are common and prominent late in colon cancer when the prognosis is poor but are
less common and less obvious early in the disease. Common symptoms include abdominal
pain, rectal bleeding, altered bowel habits, and involuntary weight loss [58]. Although colon
cancer can present with either diarrhea or constipation, a recent change in bowel habits is much
more likely to be from colon cancer than chronically abnormal bowel habits. Less common
symptoms include nausea and vomiting, malaise, anorexia, and abdominal distention.
Symptoms depend on cancer location, cancer size, and presence of metastases. Left colonic
cancers are more likely than right colon cancers to cause partial or complete intestinal ob‐
struction because the left colonic lumen is narrower and the stool in the left colon tends to be
better formed because of reabsorption of water in the proximal colon [59]. Large exophytic
cancers are also more likely to obstruct the colonic lumen. Partial obstruction produces
constipation, nausea, abdominal distention, and abdominal pain. Partial obstruction occa‐
sionally paradoxically produces intermittent diarrhea as stool moves beyond the obstruction.
Distal cancers sometimes cause gross rectal bleeding, but proximal cancers rarely produce this
symptom because the blood becomes mixed with stool and chemically degraded during
colonic transit. Bleeding from proximal cancers tends to be occult, and the patient may present
with iron deficiency anemia without gross rectal bleeding. The anemia may produce weakness,
fatigue, dyspnea, or palpitations. Advanced cancer, particularly with metastasis, can cause
cancer cachexia, characterized by a symptomatic tetrad of involuntary weight loss, anorexia,
muscle weakness, and a feeling of poor health.
4.2. Signs
Just as with symptoms, colon cancer tends not to produce signs until advanced. Anemia from
gastrointestinal bleeding may produce pallor. Iron deficiency anemia can cause koilonychia
manifested by brittle, longitudinally furrowed, and spooned nails; glossitis manifested by
lingual erythema and papillae loss; and cheilitis manifested by scaling or fissuring of the lips.
Hypoalbuminemia may clinically manifest as peripheral edema, ascites, or anasarca. Hypo‐
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active or high-pitched bowel sounds suggest gastrointestinal obstruction. A palpable abdomi‐
nal mass is a rare finding that suggests advanced disease. Rectal examination, including fecal
occult blood testing (FOBT), is important in the evaluation of possible colon cancer. Rectal
cancer may be palpable by digital rectal examination. Other physical findings, although rare,
should be systematically searched for, including peripheral lymphadenopathy, especially a
Virchow’s node in the left supraclavicular space; hepatomegaly from hepatic metastases; and
temporal or intercostal muscle wasting from cancer cachexia. Very rare findings with colon
cancer include a Sister Mary Joseph node caused by metastases to a periumbilical node, and a
Blumer’s shelf caused by perirectal extension of the primary tumor.
4.3. Laboratory abnormalities
Patients with suspected colon cancer should have routine blood tests including a hemogram
with platelet count determination, serum electrolytes and glucose determination, evaluation
of routine serum biochemical parameters of liver function, and a routine coagulation profile.
About half of patients with colon cancer are anemic. Anemia, however, is very common, so
that only a small minority of patients with anemia have colon cancer. Iron deficiency anemia
of undetermined etiology, however, warrants evaluation for colon cancer, particularly in the
elderly [60]. Hypoalbuminemia is uncommon, but not rare, in colon cancer. It usually indicates
poor nutritional status from advanced cancer. Routine serum biochemical parameters of liver
function are usually within normal limits in patients with colon cancer. Abnormalities,
particularly elevation of the alkaline phosphatase level, often indicate hepatic metastases. The
serum lactate dehydrogenase level may increase with colon cancer. Diarrhea associated with
colon cancer can rarely produce electrolyte derangements or dehydration. Nausea and
vomiting from colon cancer can rarely produce metabolic derangements of hypovolemia,
hypokalemia, or alkalosis.
The serum carcinoembryonic antigen level is not useful to screen for colon cancer. It is only
moderately sensitive. Although patients with very advanced cancer tend to have highly
elevated levels, patients with early and highly curable colon cancer tend to have only mini‐
mally elevated levels, with considerable overlap with the levels of patients without colon
cancer. It is poorly specific. Other colonic diseases or systemic disorders can cause a carci‐
noembryonic antigen elevation. Preoperative testing is, however, useful to determine cancer
prognosis and to provide a baseline for comparison with postoperative levels. An elevated
serum level preoperatively is a poor prognostic indicator: the higher the serum level the more
likely the cancer is extensive and will recur postoperatively. After apparently complete colon
cancer resection the serum level almost always normalizes; failure to normalize postopera‐
tively suggests incomplete resection. A sustained and progressive rise after postoperative
normalization strongly suggests cancer recurrence. Patients with this finding require prompt
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4.4. Unusual clinical syndromes caused by colon cancer
Colon cancer can cause acute colonic obstruction, most commonly from exophytic intralu‐
minal  growth,  and  most  uncommonly  from  intussusception  or  volvulus.  Obstruction
typically occurs in the sigmoid colon because of the narrow lumen and hard stool in this
region. Patients present with abdominal pain, nausea and vomiting, obstipation, abdomi‐
nal tenderness, abdominal distention, and hypoactive bowel sounds. Colon cancer can rarely
perforate acutely through the colonic wall and cause acute generalized peritonitis, and can
rarely perforate slowly to form a walled-off inflammatory mass or abscess with localized
peritoneal signs [61]. Factors promoting colonic perforation include disruption of mucosal
integrity  because  of  transmural  malignant  extension  or  colonic  ischemia,  and  increased
intraluminal  pressure  because  of  colonic  obstruction.  Presentation  with  colonic  obstruc‐
tion or perforation indicates a poor prognosis. Colon cancer rarely causes ischemic colitis
because of colonic dilatation proximal to malignant obstruction or malignant infiltration of
blood vessels.  Colon cancer  occasionally  causes  gross  rectal  bleeding because of  cancer‐
ous mucosal ulceration.
5. Colorectal cancer (crc) – screening
Colorectal cancer is theoretically a preventable disease and is ideally suited to a population
screening programme, as there is a long premalignant phase, during which there is ample
opportunity to intervene with a variety of different screening modalities.
Most CRCs are thought to arise from benign adenomatous polyps, a process that takes
approximately five to ten years. This long premalignant phase makes the disease ideally suited
to a population screening programme.
Early detection and removal of precancerous colon polyps and CRC may reduce both incidence
and death rates related of CRC. It is recommended to begin screening at age 50 for asympto‐
matic persons who are at average risk. High-risk patients should have regular colorectal
surveillance [45]. Several screening methods are used to detect CRC lesions. Colonoscopy is
the best method and final assessment step for detection of CRC.
The ultimate aim of a screening programme for CRC is to reduce mortality from the disease,
which may be achieved in two ways. As five-year survival is closely related to the stage at
which the cancer is detected (patients with Dukes’ stage A cancer have a greater than 90 per
cent five-year survival rate, while those with Dukes’ stage D disease have a 7 per cent five-
year survival rate), any screening modality that results in early detection of the disease will
have a beneficial effect on survival through more effective treatment (figure 5). Additionally,
if benign adenomatous polyps are removed, cancer development is prevented, resulting in
decreased mortality.
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6. Who is at risk of developing colorectal cancer
There is strong tendency that countries with an obviously rising CRC incidence are more
“Westernized” in lifestyle, especially in dietary habits, with increased consumption of high fat
and protein but less fiber in diet. The change is more evident in urban areas than rural areas of
the same country. Most of CRC is sporadic, i.e., caused by the interaction of genetic and
environmental factors via the adenomacarcinoma sequence, and cancer may take up to ten years
to develop in this way. Adenomas are more common with age, and one in four of the popula‐
tion aged over 50 will develop one or more polyps, with 10% of these polyps progressing to
cancer over time.The most common indicator of high risk is a first-degree relative with CRC.
7. Tests for colorectal cancer screening
Tests for CRC include: colonoscopy, flexible sigmoidoscopy (FS), virtual colonoscopy and
faecal occult blood testing (FOBt).
7.1. Faecal Occult Blood testing (FOBt)
FOBt has been used widely in CRC screening for several decades. Screening at age 50 for
asymptomatic persons who are at average risk with annual and biennial FOBt has been shown
in multiple randomized trails to reduce CRC incidence and mortality rates [49].
FOBt can detect occult blood in a small amount of stool sample. It is cheap, non-invasive and
easily performed at home. FOBt is based on the propensity of CRC and adenomas to bleed
microscopically.
There are two different types of FOBT, guaiac FOBT (gFOBT) and immunochemical FOBT
(iFOBT). The gFOBT uses a guaiac-impregnated card to detect heme. The basis of the test
involves the detection of the peroxidase activity of heme when a hydrogen peroxide developer
is added. Therefore, the presence of any other peroxidases, e.g. from fruit/ vegetables, can
result in a false positive test, as can the presence of heme in red meat. There can also be bleeding
within the intestine for other reasons, again resulting in false positive results. False negative
results can occur due to the irregular nature of the bleeding from the tumor; several samples
are usually requested to attempt to overcome this problem [50]. The sensitivity of gFOBT is
about only 50% of cancers will be picked up in population screening (figure 6).
iFOBT test have been developed which specifically detect the hemoglobin in human feces by
antibodies and is widely available now [51]. It is more sensitive and specific for human
hemoglobin than gFOBT and thus does not require dietary or drug restriction. However,
iFOBT is more expensive than gFOBT and the high analytical sensitivity of most of the
commercially available tests results in a greater number of participants requiring colonoscopy
and a greater false positive rate [54]. However, recent developments in quantitative iFOBT
may overcome this problem, asthe trigger for investigation can be set at any concentration of
fecal hemoglobin. Clinical trials have shown that persons with positive occult-blood tests have
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a risk of cancer that is three to four times as high as that among persons with negative tests,
and that colonoscopy should be recommended for persons with these positive tests. In a recent
study (Quintero et al) it has been shown that both iFOBT and colonoscopy are effective for
detecting colorectal cancer but iFOBT is less effective for early detection of premalignant
lesions (adenomas) than colonoscopy or sigmoidoscopy [57]. However, comparative studies
have shown that iFOBT is more accurate than the gFOBT for the detection of colorectal cancer
and advanced adenomas and this new test is now recommended as the first-choice fecal occult
blood test in colorectal-cancer screening.
Figure 6. Dukes’ stage of colorectal cancers detected by faecal occult blood test screening compared to those diag‐
nosed in patients presenting with symptoms
7.2. Flexible sigmoidoscopy
Flexible sigmoidoscopy has also been used as a screening tool for CRC detection, as half of all
cancers are seen in the rectum or sigmoid colon. There have been several studies suggesting
benefit from flexible sigmoidoscopy, and their data suggest that flexible sigmoidoscopy would
be an effective screening tool. Flexible sigmoidoscopy as an alternative to colonoscopy has the
advantage that no oral bowel preparation is required, as the subject uses an enema that can be
taken at home.The procedure is quick, requires no sedation and examines the left colon, which
is the site of 75 per cent of all colorectal neoplasia. If CO2 insufflation is used, adenomas can
be resected at the initial screening examination. This procedure does not, however, examine
the right colon. For many clinicians and patients, colonoscopy is more appealing than flexible
sigmoidoscopy because patients can be sedated and undergo a complete colon examination
with polypectomy.
7.3. Virtual colonoscopy
Virtual colonoscopy, or computed tomography colonography (CTC), is another modality used
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increased patient satisfaction when compared to colonoscopy, but with similar sensitivity and
specificity for the detection of pathology. There is no requirement for sedation and it has the
advantage of detecting extracolonic pathology. It does, however, still require bowel prepara‐
tion and colonic insufflation with CO2, the latter still causing discomfort. Furthermore, it is not
therapeutic and the lesions detected require endoscopic evaluation and resection.
7.4. Colonoscopy
Colonoscopy is the gold standard investigation for the diagnosis of CRC. It is highly sensitive
and specific for detecting both cancers and adenomas of at least 1 cm in diameter and has the
added benefit not only of providing tissue for diagnostic purposes, but also affords the
opportunity of removing adenomas by polypectomy and hence preventing colorectal cancer
(CRC). Several large cohort studies show that among patients at average risk who undergo
screening colonoscopy, 0.5 to 1.0% have colon cancer and 5 to 10% have advanced neoplasia
that can be removed. Several studies have shown that among patients with an adenoma that
is detected and removed at screening colonoscopy, colorectal cancer may develop in 0.3 to
0.9% within 3 to 5 years after screening. In a recent study (Zauber et al) it has been evaluated
the long -term effect of colonoscopic polypectomy on mortality from colorectal cancer.
According to the results of this study, the endoscopic removal of adenomas ends in reduced
mortality from colorectal cancer [56]. To sum up, this procedure is considered the most accurate
test for early detection and prevention of colorectal cancer as it markedly reduces the risk of
CRC and death. Unfortunately, there are limitations to its use as a screening modality on a
population level, although it may be the ideal choice of examination for an individual.
Colonoscopy is invasive and time consuming,and requires full bowel preparation; the
complication rate, although low, may still be unacceptable within a screening population.
Figure 7. British Society of Gastroenterology guidelines for follow-up of adenoma removal.
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8. Conclusions and recommendations
Although there are several methods available for CRC screening, none is optimal. Patients at
average risk for CRC should begin screening at age 50 with either annual FOBT, flexible
sigmoidoscopy every 5 years or colonoscopy every 10 years. Evidence does not show any
strategy as optimal, so clinicians should discuss the advantages and disadvantages of the
various screening techniques with patients. Patients with a family history of CRC or adenomas
or a personal history of high-risk polyps or inflammatory bowel disease should begin screening
earlier (figure 7). Routine screening in persons older than 75 years of age is not recommended.
Life expectancy, rather than age alone, should guide decisions about when to stop CRC
screening.
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1. Introduction
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world.
However timely screening and treatment can dramatically impact outcomes. The association
with well-defined precancerous lesions and long asymptomatic period provides the oppor‐
tunity for effective screening and early treatment of CRC. The current options for CRC
screening are strongly anchored in evidence demonstrating utility in reducing morbidity
and mortality. This chapter will review the epidemiology of CRC, risk stratification, strat‐
egies for screening, as well as factors that threaten achieving health equity through appro‐
priate screening programs.
2. Epidemiologic trends in colorectal cancer
Worldwide CRC is the third most common cancer and fourth most common cause of death.
Interestingly this disease affects men and women almost equally (Haggar and Boushey,
2009). In the United States CRC is the third most commonly diagnosed cancer and consti‐
tutes 10% of new cancers in men and women (Society, 2011). In 2011, there were approxi‐
mately 141,120 new cases and it is estimated that 143,460 Americans will be diagnosed with
colorectal cancer in 2012 (NIH, 2009). Furthermore it is estimated up to 30% of new cases are
found in the general population without known risk factors for this disease (Imperiale et al.,
2000). Although there are still approximately one million new cases of CRC diagnosed each
year, incidence has been steadily declining over the past 15 years (Bresalier, 2009; Ferlay et
al., 2010; Kohler et al., 2011). In the United States mortality from CRC has also declined with
a 7% decrease in men and 12% decrease in women between 1980 and 1990 (Jemal et al.,
2008). Since 1990 decreases in CRC incidence and mortality have been even more substan‐
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tial, and is largely attributable to improvements in screening rates (Lieberman, 2010), espe‐
cially the growing use of colonoscopy procedures (Edwards et al., 2010). Nevertheless,
important trends remain in the worldwide epidemiology of CRC.
2.1. Geographic variations in CRC epidemiology
There is significant diversity in colorectal cancer incidence worldwide. Surprisingly indus‐
trialized nations have a remarkably greater occurrence of CRC accounting for 63% of all cas‐
es. In fact CRC incidence rates range from more than 40 per 100,000 people in the United
States, Australia, New Zealand, and Western Europe to less than 5 per 100,000 in Africa and
parts of Asia. It is notable that the US is the only country with significantly declining CRC
incidence rates for both genders, and this is most likely a reflection of better screening prac‐
tices and early prevention (Jemal et al., 2011).
While there is substantial disparity in CRC occurrence globally, CRC incidence has been in‐
creasing in places previously reporting low rates. For example the number of new CRC di‐
agnoses has been rising in a number of Asian countries that recently transitioned from low-
income to high-income economies. Individuals residing in China, Japan, India, Singapore,
and Eastern European countries were previously reported to have the lowest rates of CRC.
Countries with the highest incidence rates include Australia, New Zealand, Canada, the
United States, and parts of Europe, however incidence has started stabilizing and even de‐
clining in these regions (Haggar and Boushey, 2009; Jemal et al., 2010).
Interestingly CRC incidence seems to have a close association with location. In fact studies
show that migrants rapidly acquire the risk patterns for CRC associated with their new sur‐
roundings. For example the incidence rates in Japanese immigrants have been found to sig‐
nificantly increase after moving to the United States. Geographic influence is also evident in
a study done in Israel where male Jews of Western descent were found to have a higher like‐
lihood of developing CRC than those born in Africa or Asia. Furthermore environment may
be responsible for variations within ethnic groups. This is demonstrated by higher rates of
CRC among American Indians living in Alaska than those residing in the Southwest. Inci‐
dence rates among black males were found to range from 46.4 cases per 100,000 individuals
in Arizona to 82.4 per 100,000 in Kentucky. In white men rates range from 44.4 per 100,000
in Utah to 68.7 per 100,000 in North Dakota (The Centers for Disease Control and Prevention
[CDC], 2011).
The importance of location can also be seen by differences in CRC incidence within specific
genders. CRC mortality rates for men are lower in Western states excluding Nevada, and
higher in Southern and Midwestern states. These differences in CRC rates may be attributa‐
ble to regional variations in risk factors including diet and lifestyle as well as access to
screening and treatment. In fact one study found that up to 43% of colorectal cancers are
preventable through diet and lifestyle modifications (Perera P.S., 2012).
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2.2. Racial and ethnic variations
There is substantial evidence demonstrating racial disparities in CRC risk particularly for
black men. In the USA this group has been found to have 20% higher incidence rate and 45%
higher mortality rate from colorectal cancer compared to whites (Jemal et al., 2008; Wallace and
Suzuki, 2012). There are also significant differences in life expectancy among blacks compared
to whites. While there was a 39% reduction in mortality rate for white men between 1960-2005,
during the same period there was a dramatic 28% increase in mortality for black men (Soneji et
al., 2010). Of note incidence rates among other racial groups including Hispanics, Asian Amer‐
icans, and American Indians are lower than those among whites. The factors that underlie
these differences have not been fully elucidated but most likely encompass both modifiable
factors (e.g. smoking, socioeconomic status, body mass index, and cultural beliefs) as well as
non-modifiable factors (e.g. race/ethnicity, gender, and genetic predisposition). These findings
do suggest there is a need for appropriate risk stratification for CRC and for more aggressive
screening in high-risk populations, particularly among blacks in the United States. Such an ap‐
proach has been recommended by both the American College of Gastroenterology as well as
the American Society for Gastrointestinal Endoscopy with the suggestion to start screening
blacks at the age of 45 (Cash et al., 2010; Rex et al., 2009).
2.3. The gender gap
According to SEER 2012 statistics, the overall prevalence of colorectal cancer does not vary
substantially between the genders. The lifetime risk of being diagnosed with CRC is similar
for men 5.7% and women 5.2%. The lifetime risk of dying from CRC is also similar; 2.3% and
2.1% for men and women respectively (NIH, 2009). Even though annually the new diagno‐
ses of CRC have roughly been equal in men (187,973) and women (185,983), men have high‐
er age-adjusted CRC incidence rates (Abotchie et al., 2012). Women seem have a delay of
approximately 7-8 years in the development of advanced polyps (Jaroslaw Regula, 2012; Lie‐
berman et al., 2005). Additionally age adjusted mortality rates can be up to 35-40% higher in
men compared to women (CDC, 2011). Gender related disparities are not completely under‐
stood but may be attributable to variations in hormonal exposure (Chlebowski et al., 2004).
These biological differences related to sex raise the issue of whether men and women should
be screened differently for CRC. However current screening guidelines have not been modi‐
fied based on gender (Levin et al., 2008).
2.4. Modifiers of the epidemiologic trends
Despite some overall gains, several factors remain that impact the epidemiology of CRC.
Advancements in elucidating CRC pathogenesis allow for explanations of the above epide‐
miologic trends and have the potential for more efficient screening and treatment. It is esti‐
mated that up to 70% of CRC cases occur sporadically in individuals with no identifiable
risks (Hardy et al., 2000). Factors that predispose individuals to a higher risk for developing
CRC include any personal or family history of CRC or adenomatous polyps, inflammatory
bowel disease (IBD), and inherited genetic syndromes such as familial adenomatous polypo‐
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black men. In the USA this group has been found to have 20% higher incidence rate and 45%
higher mortality rate from colorectal cancer compared to whites (Jemal et al., 2008; Wallace and
Suzuki, 2012). There are also significant differences in life expectancy among blacks compared
to whites. While there was a 39% reduction in mortality rate for white men between 1960-2005,
during the same period there was a dramatic 28% increase in mortality for black men (Soneji et
al., 2010). Of note incidence rates among other racial groups including Hispanics, Asian Amer‐
icans, and American Indians are lower than those among whites. The factors that underlie
these differences have not been fully elucidated but most likely encompass both modifiable
factors (e.g. smoking, socioeconomic status, body mass index, and cultural beliefs) as well as
non-modifiable factors (e.g. race/ethnicity, gender, and genetic predisposition). These findings
do suggest there is a need for appropriate risk stratification for CRC and for more aggressive
screening in high-risk populations, particularly among blacks in the United States. Such an ap‐
proach has been recommended by both the American College of Gastroenterology as well as
the American Society for Gastrointestinal Endoscopy with the suggestion to start screening
blacks at the age of 45 (Cash et al., 2010; Rex et al., 2009).
2.3. The gender gap
According to SEER 2012 statistics, the overall prevalence of colorectal cancer does not vary
substantially between the genders. The lifetime risk of being diagnosed with CRC is similar
for men 5.7% and women 5.2%. The lifetime risk of dying from CRC is also similar; 2.3% and
2.1% for men and women respectively (NIH, 2009). Even though annually the new diagno‐
ses of CRC have roughly been equal in men (187,973) and women (185,983), men have high‐
er age-adjusted CRC incidence rates (Abotchie et al., 2012). Women seem have a delay of
approximately 7-8 years in the development of advanced polyps (Jaroslaw Regula, 2012; Lie‐
berman et al., 2005). Additionally age adjusted mortality rates can be up to 35-40% higher in
men compared to women (CDC, 2011). Gender related disparities are not completely under‐
stood but may be attributable to variations in hormonal exposure (Chlebowski et al., 2004).
These biological differences related to sex raise the issue of whether men and women should
be screened differently for CRC. However current screening guidelines have not been modi‐
fied based on gender (Levin et al., 2008).
2.4. Modifiers of the epidemiologic trends
Despite some overall gains, several factors remain that impact the epidemiology of CRC.
Advancements in elucidating CRC pathogenesis allow for explanations of the above epide‐
miologic trends and have the potential for more efficient screening and treatment. It is esti‐
mated that up to 70% of CRC cases occur sporadically in individuals with no identifiable
risks (Hardy et al., 2000). Factors that predispose individuals to a higher risk for developing
CRC include any personal or family history of CRC or adenomatous polyps, inflammatory
bowel disease (IBD), and inherited genetic syndromes such as familial adenomatous polypo‐
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sis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC). Guidelines recommend ear‐
lier and more aggressive screening for this high-risk population.
As evidenced by the presence of both modifiable and non-modifiable risk factors, the patho‐
genesis of CRC seems to be influenced by a combination of genetics and the environment. In‐
deed  the  disease  results  from  the  progressive  accumulation  of  both  genetic  as  well  as
epigenetic changes in the colonic epithelium. Currently genetic tests are available that identify
patients with inherited mutations associated with FAP and HNPCC. While this technology is
promising, only 2-6% of CRC cases are attributable to common inherited mutations, suggest‐
ing other variables are playing a role in the development of this disease (Winawer et al., 2003).
Some of the environmental influences that have been investigated include the role of Strepto‐
coccus Bovis. Although infections are recognized as a major preventable cause in cancer, an in‐
fectious etiology has not been identified in cases of sporadic CRC, strongly suggesting that
more factors are involved in the development of this disease (Boleij and Tjalsma, 2012). Similar
to many other cancers, an important common thread in the pathogenesis of CRC is the pres‐
ence of chronic inflammation that is thought to increase the probability of mutagenic events
that lead to the production of oxidative species and damage DNA causing genomic instability
(Zauber et al., 2008). This is demonstrated by patients with inherited genetic mutations who
are found on colonoscopic examination to have chronic inflammatory changes that precede tu‐
mor development (Terzic et al., 2010). This can also be seen in patients colonized with S. Bovis
who are found to have inflammatory changes in the bowel wall (Terzic et al., 2010). Further
support for an inflammatory basis is found in recent studies showing aspirin and non-steroi‐
dal, anti-inflammatory drugs greatly reduce the risk of CRC (Rothwell et al., 2012).
2.5. Impact of screening on the epidemiology of CRC
Numerous studies show favorable CRC outcomes if the cancer is identified and treated at an
early stage. In fact the 5-year survival rate is greater than 90% if CRC is identified at an early
stage. However if the cancer extends beyond the colon, 5-year survival is less than 10% (Col‐
lett et al., 1999). Continuing advances in CRC therapies hold the promise of adequate treat‐
ment for advanced stages of the disease. A recent study in Nature suggests the possibility of
helping patients with advanced stage CRC with targeted drugs. This study suggests that
there are a finite number of genetic pathways in CRC that can be therapeutically targeted.
Although these findings are promising much work is still needed before there will be a cure
for CRC (Muzny et al., 2012).
Given the limited effective treatment for advanced CRC, prevention through early detection
is paramount. CRC is a model disease for routine population screening since it is prevalent,
has a long asymptomatic period, and precancerous lesions can be identified and treated
(Pezzoli et al., 2007). Compared to other cancers where the primary goal is early detection of
neoplasia, CRC can actually be prevented with detection and removal of cancer precursor
lesions (Inadomi et al., 2012). It is estimated that 30% of people over the age of 50 with no
history of CRC risk factors harbor adenomatous polyps (Alberti et al., 2012; Pezzoli et al.,
2007), and the incidence of these polyps increases with age. Early adenoma resection is asso‐
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ciated with considerable reductions in CRC (Rex et al., 2009; Winawer et al., 1993b), and has
now been demonstrated to have mortality benefit (Zauber et al., 2012).
Although it is difficult to identify precisely which adenomas will undergo neoplastic trans‐
formation, there are certain pathologic features that can help predict their level of risk: in‐
creased size ≥10 mm, increased number of 3 or more adenomas, villous histology, and high-
grade dysplasia (Alberti et al., 2012; Lieberman et al., 2012). Most adenomas undergo a
similar progression to invasive cancer termed the adenoma-carcinoma sequence (Levin et
al., 2008; Sano et al., 2009). Given that these cancer precursors are often asymptomatic, there
is compelling evidence to support early screening for healthy individuals. In fact the aver‐
age-risk individuals compose 70-75% of the CRC population (Lieberman, 2010). In response
to mounting evidence suggesting that screening of average-risk individuals allows for early
cancer detection and prevention, CRC guidelines from several organizations were updated
in 2008 (USPSTF, 2008).
2.6. CRC prevention tests
Colonoscopy allows for the direct visualization of the entire colon and for the potential to
remove lesions that are identified. Results from the National Polyp Study confirm that colo‐
noscopy and adenoma removal is associated with decreased rates of developing colon can‐
cer in the future (Winawer S.J., 2006) and reduces mortality (Zauber et al., 2012). The finding
that mortality is reduced by polypectomy is of major significance because it suggests that
colonoscopy can identify a subset of adenomas which can potentially become aggressive
cancers and provides further evidence that colonoscopy is in fact the best screening option
because of its added benefit of decreased mortality, particularly in individuals at increased
risk. In patients with no lesions detected during a screening colonoscopic examination, the
interval for follow-up surveillance can be extended to 10 years compared to 5 years for sig‐
moidoscopy (which visualizes only the left side of the colon) along with FOBT every 3 years.
The known draw backs to colonoscopy include the need for bowel prep, sedation that may
be associated with cardiopulmonary risks, higher cost compared to other methods, associa‐
tion with greater risk of bleeding and perforation, and a miss rate of up to 5% for malignant
colon lesions.
While colonoscopy remains the gold standard for CRC prevention, economic constraints
and patient attitudes may prevent screening with this technique. In an effort to improve
participation alternative tests have been endorsed. There are a range of screening meth‐
ods that are categorized into two major groups, prevention and detection. Prevention tests
detect cancer as well as pre-cancerous polyps, and are generally structural exams such as
the  colonoscopy,  flexible  sigmoidoscopy,  CT  colonography,  and  double-contrast  barium
enema. Detection tests are only able to identify CRC lesions and consist of fecal tests in‐
cluding the fecal immunochemical test (FIT), fecal occult blood testing (FOBT), and Fecal
DNA testing (Rex et al., 2009).
Flexible Sigmoidoscopy remains an acceptable alternative to colonoscopy for colorectal can‐
cer screening (Levin et al., 2008; USPSTF, 2008; Winawer et al., 2003; Winawer et al., 1997).
Although both screening techniques are similar, sigmoidoscopy requires more frequent
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sis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC). Guidelines recommend ear‐
lier and more aggressive screening for this high-risk population.
As evidenced by the presence of both modifiable and non-modifiable risk factors, the patho‐
genesis of CRC seems to be influenced by a combination of genetics and the environment. In‐
deed  the  disease  results  from  the  progressive  accumulation  of  both  genetic  as  well  as
epigenetic changes in the colonic epithelium. Currently genetic tests are available that identify
patients with inherited mutations associated with FAP and HNPCC. While this technology is
promising, only 2-6% of CRC cases are attributable to common inherited mutations, suggest‐
ing other variables are playing a role in the development of this disease (Winawer et al., 2003).
Some of the environmental influences that have been investigated include the role of Strepto‐
coccus Bovis. Although infections are recognized as a major preventable cause in cancer, an in‐
fectious etiology has not been identified in cases of sporadic CRC, strongly suggesting that
more factors are involved in the development of this disease (Boleij and Tjalsma, 2012). Similar
to many other cancers, an important common thread in the pathogenesis of CRC is the pres‐
ence of chronic inflammation that is thought to increase the probability of mutagenic events
that lead to the production of oxidative species and damage DNA causing genomic instability
(Zauber et al., 2008). This is demonstrated by patients with inherited genetic mutations who
are found on colonoscopic examination to have chronic inflammatory changes that precede tu‐
mor development (Terzic et al., 2010). This can also be seen in patients colonized with S. Bovis
who are found to have inflammatory changes in the bowel wall (Terzic et al., 2010). Further
support for an inflammatory basis is found in recent studies showing aspirin and non-steroi‐
dal, anti-inflammatory drugs greatly reduce the risk of CRC (Rothwell et al., 2012).
2.5. Impact of screening on the epidemiology of CRC
Numerous studies show favorable CRC outcomes if the cancer is identified and treated at an
early stage. In fact the 5-year survival rate is greater than 90% if CRC is identified at an early
stage. However if the cancer extends beyond the colon, 5-year survival is less than 10% (Col‐
lett et al., 1999). Continuing advances in CRC therapies hold the promise of adequate treat‐
ment for advanced stages of the disease. A recent study in Nature suggests the possibility of
helping patients with advanced stage CRC with targeted drugs. This study suggests that
there are a finite number of genetic pathways in CRC that can be therapeutically targeted.
Although these findings are promising much work is still needed before there will be a cure
for CRC (Muzny et al., 2012).
Given the limited effective treatment for advanced CRC, prevention through early detection
is paramount. CRC is a model disease for routine population screening since it is prevalent,
has a long asymptomatic period, and precancerous lesions can be identified and treated
(Pezzoli et al., 2007). Compared to other cancers where the primary goal is early detection of
neoplasia, CRC can actually be prevented with detection and removal of cancer precursor
lesions (Inadomi et al., 2012). It is estimated that 30% of people over the age of 50 with no
history of CRC risk factors harbor adenomatous polyps (Alberti et al., 2012; Pezzoli et al.,
2007), and the incidence of these polyps increases with age. Early adenoma resection is asso‐
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ciated with considerable reductions in CRC (Rex et al., 2009; Winawer et al., 1993b), and has
now been demonstrated to have mortality benefit (Zauber et al., 2012).
Although it is difficult to identify precisely which adenomas will undergo neoplastic trans‐
formation, there are certain pathologic features that can help predict their level of risk: in‐
creased size ≥10 mm, increased number of 3 or more adenomas, villous histology, and high-
grade dysplasia (Alberti et al., 2012; Lieberman et al., 2012). Most adenomas undergo a
similar progression to invasive cancer termed the adenoma-carcinoma sequence (Levin et
al., 2008; Sano et al., 2009). Given that these cancer precursors are often asymptomatic, there
is compelling evidence to support early screening for healthy individuals. In fact the aver‐
age-risk individuals compose 70-75% of the CRC population (Lieberman, 2010). In response
to mounting evidence suggesting that screening of average-risk individuals allows for early
cancer detection and prevention, CRC guidelines from several organizations were updated
in 2008 (USPSTF, 2008).
2.6. CRC prevention tests
Colonoscopy allows for the direct visualization of the entire colon and for the potential to
remove lesions that are identified. Results from the National Polyp Study confirm that colo‐
noscopy and adenoma removal is associated with decreased rates of developing colon can‐
cer in the future (Winawer S.J., 2006) and reduces mortality (Zauber et al., 2012). The finding
that mortality is reduced by polypectomy is of major significance because it suggests that
colonoscopy can identify a subset of adenomas which can potentially become aggressive
cancers and provides further evidence that colonoscopy is in fact the best screening option
because of its added benefit of decreased mortality, particularly in individuals at increased
risk. In patients with no lesions detected during a screening colonoscopic examination, the
interval for follow-up surveillance can be extended to 10 years compared to 5 years for sig‐
moidoscopy (which visualizes only the left side of the colon) along with FOBT every 3 years.
The known draw backs to colonoscopy include the need for bowel prep, sedation that may
be associated with cardiopulmonary risks, higher cost compared to other methods, associa‐
tion with greater risk of bleeding and perforation, and a miss rate of up to 5% for malignant
colon lesions.
While colonoscopy remains the gold standard for CRC prevention, economic constraints
and patient attitudes may prevent screening with this technique. In an effort to improve
participation alternative tests have been endorsed. There are a range of screening meth‐
ods that are categorized into two major groups, prevention and detection. Prevention tests
detect cancer as well as pre-cancerous polyps, and are generally structural exams such as
the  colonoscopy,  flexible  sigmoidoscopy,  CT  colonography,  and  double-contrast  barium
enema. Detection tests are only able to identify CRC lesions and consist of fecal tests in‐
cluding the fecal immunochemical test (FIT), fecal occult blood testing (FOBT), and Fecal
DNA testing (Rex et al., 2009).
Flexible Sigmoidoscopy remains an acceptable alternative to colonoscopy for colorectal can‐
cer screening (Levin et al., 2008; USPSTF, 2008; Winawer et al., 2003; Winawer et al., 1997).
Although both screening techniques are similar, sigmoidoscopy requires more frequent
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screenings at 5–year intervals and the benefits are confined to the distal colon only. In addi‐
tion the USPSTF recommends screening with FOBT every 3 years (USPSTF, 2008). Prior
studies have demonstrated a significant mortality benefit for the section of the colon exam‐
ined (Wilkins and Reynolds, 2008). A recent study in the NEJM confirmed this data showing
that flexible sigmoidoscopy decreases CRC incidence and mortality (Schoen et al., 2012). The
advantages of sigmoidoscopy include lower cost, lower risk profile, and need for less bowel
preparation compared to colonoscopy. However a major setback for this alternative is that
polyp visualization is limited to the distal colon. Studies have shown that up to 30% of pa‐
tients with distal colon cancer also have synchronous proximal lesions that will be missed
by sigmoidoscopy (Francois et al., 2006; Imperiale et al., 2000; Lieberman et al., 2000). As
such individuals with polyps in the distal colon should undergo follow up with colonosco‐
py given the increased prevalence of synchronous right-sided lesions. Screening only 50% of
colon will preclude detection of the lesions in the portion of the colon not within reach of the
sigmoidoscope. This test would also not be an appropriate screening tool for women, pa‐
tients over the age of 60, patients with HIV, and African Americans who have a higher like‐
lihood of harboring proximal polyps (Bini et al., 2006; Lieberman et al., 2000; Lieberman et
al., 2005; Schoenfeld et al., 2005).
Double contrast Barium enema allows for visualization of the entire colon and must be com‐
pleted every 5 years. Its high polyp miss rate (as high as 23%), lack of therapeutic interven‐
tion (another procedure is needed to remove detected polyps), and concerns regarding
radiation exposure, have limited its use (Toma et al., 2008; Wilkins and Reynolds, 2008).
CT colonography is able to provide information about the entire colon and has been pro‐
posed as a possible screening option for patients who decline conventional colonoscopy.
This test is less invasive compared to conventional colonoscopy, is associated with de‐
creased risk of perforation and does not require sedation (Lieberman, 2010). Not only are de‐
tection rates far superior to the barium enema, but CT colonography (CTC) has comparable
sensitivity to colonoscopy for polyps 10mm or greater in size (Johnson et al., 2008). However
relative to other options, this modality is costly, and has poor sensitivity for polyps less than
7mm (Lieberman, 2010). Due to insufficient evidence for performance metrics this test is cur‐
rently not supported by established guidelines. The United States Preventive Services Task
Force expresses additional concern about the impact and extra costs related to following-up
extra-colonic findings (USPSTF, 2008). In fact an estimated 27% to 69% of tests performed
uncover abnormal extra-colonic findings (Lieberman, 2010). More studies are needed to as‐
sess this procedure’s benefits and risks, particularly to determine whether this method may
be missing significant lesions.
Capsule Endoscopy provides direct visualization of the colonic mucosa via an ingestible
capsule with video cameras at both ends that wireless transmits images to a receiver. Given
that bowel motility significantly affects results, this test is not performed regularly and is not
supported by current guidelines.
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2.7. CRC detection tests
Fecal occult blood testing (FOBT) is an annual stool test that detects cancer at an early stage.
The USPSTF now specifically recommends the high-sensitivity guaiac-based testing (He‐
moccult Sensa) over the standard guaiac-based testing (Hemoccult II) (USPSTF, 2008). Based
on the premise that colon cancer intermittently bleeds, the FOBT tests for blood by detecting
the peroxidase activity of heme (Lieberman, 2010). Not only is the test economical and con‐
venient, patients with a positive test result have an almost 4 fold increased likelihood having
cancer (Winawer et al., 2003). In fact studies have found FOBT reduces mortality by approxi‐
mately 33% over a 10-year period (Lieberman, 2010). Another study reported approximately
20% reduction in mortality when FOBT was compared to controls over an 18-year period
(Lieberman, 2010). Supporters of the FOBT question whether invasive measures such as the
colonoscopy are harmful given that computer simulated modeling shows similar life-years
gained in both tests (Zauber et al., 2008). Furthermore advocates assert that FOBT has the
greatest potential for impact at the population level because it is directed at healthy people
(Harvard Medical School, 2012). Additionally asymptomatic people may be more willing to
participate in a less invasive and generally less inconvenient test.
While a case can be made that FOBT has some quantifiable mortality benefits, evidence sug‐
gests that colonoscopy is still the superior screening option. FOBT has many disadvantages.
One major drawback of this modality is the high false positive rate because the test is not
specific for human blood. In fact the test will not be accurate if patients consume red meat or
any other peroxidase containing substances. Additionally three-stool sample are required on
separate days (Lieberman, 2010). Single sample FOBT is estimated to miss 95% of CRC (Wil‐
kins and Reynolds, 2008). Furthermore the test must be repeated annually to be effective. In
addition to these drawbacks, this test only detects potentially high-risk individuals which
means that abnormal test results require subsequent follow up with colonoscopy. Compli‐
ance with all of the aforementioned recommendations is unknown making the effectiveness
of the test uncertain. In fact one survey found that up to 30% of doctors recommended inap‐
propriate forms of follow up rendering the FOBT not useful (Nadel et al., 2005). Despite
these drawbacks the FOBT sampling test is still preferable to the no screening option.
Fecal immunochemical testing (FIT) is a newer test that is easier to use and specific for hu‐
mans. This means that the FIT is less susceptible to interference by diet or drugs. This mo‐
dality uses antibodies to detect human blood components such as hemoglobin and albumin
in stool samples (School, 2012). This alternative is appealing because it is less invasive than
colonoscopy but potentially more accurate than the FOBT. Studies show over 50% sensitivi‐
ty for cancer after using as small an amount as one stool sample (Lieberman, 2010). FIT may
be superior to the FOBT given that one study showed higher participation in the FIT group.
Participation is key for fecal tests making the previously mentioned study clinically rele‐
vant. However no randomized trials have shown that FIT decreases mortality (Wilkins and
Reynolds, 2008).
Given that participation may be negatively impacted by hesitation to undergo colonoscopy
screening, a recent study investigated whether FIT can serve as a valid screening alternative
and no significant differences were found between FIT and colonoscopy in terms of partici‐
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screenings at 5–year intervals and the benefits are confined to the distal colon only. In addi‐
tion the USPSTF recommends screening with FOBT every 3 years (USPSTF, 2008). Prior
studies have demonstrated a significant mortality benefit for the section of the colon exam‐
ined (Wilkins and Reynolds, 2008). A recent study in the NEJM confirmed this data showing
that flexible sigmoidoscopy decreases CRC incidence and mortality (Schoen et al., 2012). The
advantages of sigmoidoscopy include lower cost, lower risk profile, and need for less bowel
preparation compared to colonoscopy. However a major setback for this alternative is that
polyp visualization is limited to the distal colon. Studies have shown that up to 30% of pa‐
tients with distal colon cancer also have synchronous proximal lesions that will be missed
by sigmoidoscopy (Francois et al., 2006; Imperiale et al., 2000; Lieberman et al., 2000). As
such individuals with polyps in the distal colon should undergo follow up with colonosco‐
py given the increased prevalence of synchronous right-sided lesions. Screening only 50% of
colon will preclude detection of the lesions in the portion of the colon not within reach of the
sigmoidoscope. This test would also not be an appropriate screening tool for women, pa‐
tients over the age of 60, patients with HIV, and African Americans who have a higher like‐
lihood of harboring proximal polyps (Bini et al., 2006; Lieberman et al., 2000; Lieberman et
al., 2005; Schoenfeld et al., 2005).
Double contrast Barium enema allows for visualization of the entire colon and must be com‐
pleted every 5 years. Its high polyp miss rate (as high as 23%), lack of therapeutic interven‐
tion (another procedure is needed to remove detected polyps), and concerns regarding
radiation exposure, have limited its use (Toma et al., 2008; Wilkins and Reynolds, 2008).
CT colonography is able to provide information about the entire colon and has been pro‐
posed as a possible screening option for patients who decline conventional colonoscopy.
This test is less invasive compared to conventional colonoscopy, is associated with de‐
creased risk of perforation and does not require sedation (Lieberman, 2010). Not only are de‐
tection rates far superior to the barium enema, but CT colonography (CTC) has comparable
sensitivity to colonoscopy for polyps 10mm or greater in size (Johnson et al., 2008). However
relative to other options, this modality is costly, and has poor sensitivity for polyps less than
7mm (Lieberman, 2010). Due to insufficient evidence for performance metrics this test is cur‐
rently not supported by established guidelines. The United States Preventive Services Task
Force expresses additional concern about the impact and extra costs related to following-up
extra-colonic findings (USPSTF, 2008). In fact an estimated 27% to 69% of tests performed
uncover abnormal extra-colonic findings (Lieberman, 2010). More studies are needed to as‐
sess this procedure’s benefits and risks, particularly to determine whether this method may
be missing significant lesions.
Capsule Endoscopy provides direct visualization of the colonic mucosa via an ingestible
capsule with video cameras at both ends that wireless transmits images to a receiver. Given
that bowel motility significantly affects results, this test is not performed regularly and is not
supported by current guidelines.
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2.7. CRC detection tests
Fecal occult blood testing (FOBT) is an annual stool test that detects cancer at an early stage.
The USPSTF now specifically recommends the high-sensitivity guaiac-based testing (He‐
moccult Sensa) over the standard guaiac-based testing (Hemoccult II) (USPSTF, 2008). Based
on the premise that colon cancer intermittently bleeds, the FOBT tests for blood by detecting
the peroxidase activity of heme (Lieberman, 2010). Not only is the test economical and con‐
venient, patients with a positive test result have an almost 4 fold increased likelihood having
cancer (Winawer et al., 2003). In fact studies have found FOBT reduces mortality by approxi‐
mately 33% over a 10-year period (Lieberman, 2010). Another study reported approximately
20% reduction in mortality when FOBT was compared to controls over an 18-year period
(Lieberman, 2010). Supporters of the FOBT question whether invasive measures such as the
colonoscopy are harmful given that computer simulated modeling shows similar life-years
gained in both tests (Zauber et al., 2008). Furthermore advocates assert that FOBT has the
greatest potential for impact at the population level because it is directed at healthy people
(Harvard Medical School, 2012). Additionally asymptomatic people may be more willing to
participate in a less invasive and generally less inconvenient test.
While a case can be made that FOBT has some quantifiable mortality benefits, evidence sug‐
gests that colonoscopy is still the superior screening option. FOBT has many disadvantages.
One major drawback of this modality is the high false positive rate because the test is not
specific for human blood. In fact the test will not be accurate if patients consume red meat or
any other peroxidase containing substances. Additionally three-stool sample are required on
separate days (Lieberman, 2010). Single sample FOBT is estimated to miss 95% of CRC (Wil‐
kins and Reynolds, 2008). Furthermore the test must be repeated annually to be effective. In
addition to these drawbacks, this test only detects potentially high-risk individuals which
means that abnormal test results require subsequent follow up with colonoscopy. Compli‐
ance with all of the aforementioned recommendations is unknown making the effectiveness
of the test uncertain. In fact one survey found that up to 30% of doctors recommended inap‐
propriate forms of follow up rendering the FOBT not useful (Nadel et al., 2005). Despite
these drawbacks the FOBT sampling test is still preferable to the no screening option.
Fecal immunochemical testing (FIT) is a newer test that is easier to use and specific for hu‐
mans. This means that the FIT is less susceptible to interference by diet or drugs. This mo‐
dality uses antibodies to detect human blood components such as hemoglobin and albumin
in stool samples (School, 2012). This alternative is appealing because it is less invasive than
colonoscopy but potentially more accurate than the FOBT. Studies show over 50% sensitivi‐
ty for cancer after using as small an amount as one stool sample (Lieberman, 2010). FIT may
be superior to the FOBT given that one study showed higher participation in the FIT group.
Participation is key for fecal tests making the previously mentioned study clinically rele‐
vant. However no randomized trials have shown that FIT decreases mortality (Wilkins and
Reynolds, 2008).
Given that participation may be negatively impacted by hesitation to undergo colonoscopy
screening, a recent study investigated whether FIT can serve as a valid screening alternative
and no significant differences were found between FIT and colonoscopy in terms of partici‐
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pation (Quintero et al., 2012). Furthermore colonoscopy still detected substantially higher
numbers of cancerous polyps. It is difficult from this study to declare that FIT testing is non-
inferior because of colonoscopy’s mortality benefit.
Fecal DNA testing detects a finite number of gene mutations in stool samples associated
with colon neoplasia (Alberti et al., 2012). One large prospective trial found stool DNA test‐
ing to have greater sensitivity for cancer than standard FOBT (Imperiale et al., 2004). Fur‐
thermore patients were found to prefer fecal DNA testing to both FOBT and colonoscopy
(Wilkins and Reynolds, 2008). However this option is not recommended by current guide‐
lines because of insufficient evidence. Also there have been other studies comparing stool
DNA testing to FOBT that suggest this fecal DNA testing does not measure up in terms of
cost or efficacy (Lansdorp-Vogelaar et al., 2010).
2.8. Which screening test should be done?
Each of the aforementioned screening options has strengths and setbacks, however patient
adherence to CRC screening remains more critical than the specific method chosen (Vijan et
al., 2001). Simply put, the best test is the one that the patient accepts and complies with. De‐
spite mounting evidence that screening is life saving, screening rates remain surprisingly
low for this preventable cancer. In fact awareness of the importance of CRC screening has
only recently started to approach that of other cancers. Statistics indicate only 24% of Ameri‐
cans have completed the FOBT within the past few years and only 57.1% have ever had a
sigmoidoscopy or colonoscopy (Wilkins and Reynolds, 2008). Data from the NHIS, a nation‐
al survey of the general population, shows that only 58.3% of the US population met recom‐
mendations for CRC screening in 2010 (Shapiro et al., 2012). This is increased from 54.5% in
2008. Although there has been progress in the use of CRC testing, 40-50% of individuals
over the age of 50 still are not receiving routine screening for colorectal cancer.
It is apparent from these suboptimal screening rates that there is a demand for novel screen‐
ing strategies that are not only effective but also economical and non-invasive. Continued
research in this field is ongoing and in a fascinating study published in Gut, Citarda et al
(Citarda et al., 2001) took steps towards attempting to find this desired formula. Their study
is evidence of the increasing knowledge about the molecular properties of cancer. Based on
the theory that a specific cancer smell exists, they found that a trained labrador retriever
could detect the presence of colorectal cancer with 91% sensitivity and 99% specificity in
breath samples and 97% sensitivity and 99% specificity in watery stool samples. Surprising‐
ly the study dog’s ability to detect cancer was not confounded by benign colorectal disease,
inflammatory bowel disease, or smoking. Even though the routine use of canines for cancer
screening is not practical, this study suggests there is potential for future screening tests
based on cancer-specific chemical compounds.
2.9. Cost effectiveness of CRC screening
CRC screening has been found to reduce mortality and to be cost-effective. The challenge
remains to make screening affordable and available to individuals who will experience the
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greatest benefit. Several models have been proposed to estimate the costs of various screen‐
ing programs. The 2005 Institute of Medicine comprehensive summary of CRC screening ef‐
fectiveness concluded that all of the screening options are relatively comparable in terms of
life-years gained as well as cost when compared with a no-screening option. FOBT was the
least costly option, however most modalities are estimated to cost <$40,000 per life-year
saved (Lieberman, 2010; Pignone et al., 2002). However it is difficult to rely on these models
alone as they may not be entirely accurate and are not able to account for other factors such
as patient compliance. In general cost benefit analysis studies suggest that CRC screening is
overall a cost-effective measure and it is estimated that routine screening can save more
than 18,800 lives per year (Maciosek et al., 2006; Wilkins and Reynolds, 2008).
2.10. Surveillance guidelines
Currently the United States Multi-Society Task Force (MSTF) on CRC supports a 10-year inter‐
val between subsequent screening colonoscopies for average risk patients. Case-control and
observational studies indicate that the mortality benefit from colonoscopy lasts at least 10
years. However patients who are found to have adenomas on baseline colonoscopy are at in‐
creased risk of developing future adenomas and cancerous lesions (Martinez et al., 2009). Cer‐
tain higher-risk patients can develop cancer as soon as 3-5 years after a colonoscopy. These are
termed interval cancers. These patients require a shorter interval between subsequent follow
up because this has been shown to reduce colorectal cancer incidence by as much as 66% (Cit‐
arda et al., 2001; Winawer et al., 1993a). Guidelines from the GI consortium panel advocate re‐
peat colonoscopy 5 years after removal of a low-risk polyp and after 3 years if the polyp has
higher risk features. The selection of a 3-year screening interval for subsequent follow-up is
based on evidence that shows detection of advanced lesions is not improved at 1 year versus 3
years (Winawer et al., 1993b). Further research is still needed to determine whether a single
negative follow up colonoscopy is sufficient (Lieberman et al., 2012).
The use of risk stratification to determine the optimal screening interval is important be‐
cause physicians that refer patients for surveillance at intervals shorter than recommended
may be exposing patients to unnecessary risks and costs (Lieberman, 2010). In fact a recent
study revealed underuse of colonoscopies in high-risk patients and overuse in low risk pa‐
tients. By ineffective allocation of resources high-risk patients are placed at increased risk for
developing cancer. Furthermore optimization of screening is important in light of low
screening rates for a preventable cancer. Customized screening recommendations based on
risk allows for more streamlined and effective screening leaving resources that can be devot‐
ed to colon cancer education targeting the challenging subset of the population at high risk
with poor adherence. Ultimately screening program success depends not only on quality
but patient participation (Lieberman et al., 2012). In addition to risk stratification, the MSTF
on CRC believes that high-quality baseline examination is key for effective surveillance. In‐
terval cancers have been found to occur more frequently in patients with negative baseline
exams. There is evidence to suggest that important lesions are often missed at baseline colo‐
noscopy and it is estimated that up to 17% of 10 mm lesions are missed. This variability in
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pation (Quintero et al., 2012). Furthermore colonoscopy still detected substantially higher
numbers of cancerous polyps. It is difficult from this study to declare that FIT testing is non-
inferior because of colonoscopy’s mortality benefit.
Fecal DNA testing detects a finite number of gene mutations in stool samples associated
with colon neoplasia (Alberti et al., 2012). One large prospective trial found stool DNA test‐
ing to have greater sensitivity for cancer than standard FOBT (Imperiale et al., 2004). Fur‐
thermore patients were found to prefer fecal DNA testing to both FOBT and colonoscopy
(Wilkins and Reynolds, 2008). However this option is not recommended by current guide‐
lines because of insufficient evidence. Also there have been other studies comparing stool
DNA testing to FOBT that suggest this fecal DNA testing does not measure up in terms of
cost or efficacy (Lansdorp-Vogelaar et al., 2010).
2.8. Which screening test should be done?
Each of the aforementioned screening options has strengths and setbacks, however patient
adherence to CRC screening remains more critical than the specific method chosen (Vijan et
al., 2001). Simply put, the best test is the one that the patient accepts and complies with. De‐
spite mounting evidence that screening is life saving, screening rates remain surprisingly
low for this preventable cancer. In fact awareness of the importance of CRC screening has
only recently started to approach that of other cancers. Statistics indicate only 24% of Ameri‐
cans have completed the FOBT within the past few years and only 57.1% have ever had a
sigmoidoscopy or colonoscopy (Wilkins and Reynolds, 2008). Data from the NHIS, a nation‐
al survey of the general population, shows that only 58.3% of the US population met recom‐
mendations for CRC screening in 2010 (Shapiro et al., 2012). This is increased from 54.5% in
2008. Although there has been progress in the use of CRC testing, 40-50% of individuals
over the age of 50 still are not receiving routine screening for colorectal cancer.
It is apparent from these suboptimal screening rates that there is a demand for novel screen‐
ing strategies that are not only effective but also economical and non-invasive. Continued
research in this field is ongoing and in a fascinating study published in Gut, Citarda et al
(Citarda et al., 2001) took steps towards attempting to find this desired formula. Their study
is evidence of the increasing knowledge about the molecular properties of cancer. Based on
the theory that a specific cancer smell exists, they found that a trained labrador retriever
could detect the presence of colorectal cancer with 91% sensitivity and 99% specificity in
breath samples and 97% sensitivity and 99% specificity in watery stool samples. Surprising‐
ly the study dog’s ability to detect cancer was not confounded by benign colorectal disease,
inflammatory bowel disease, or smoking. Even though the routine use of canines for cancer
screening is not practical, this study suggests there is potential for future screening tests
based on cancer-specific chemical compounds.
2.9. Cost effectiveness of CRC screening
CRC screening has been found to reduce mortality and to be cost-effective. The challenge
remains to make screening affordable and available to individuals who will experience the
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greatest benefit. Several models have been proposed to estimate the costs of various screen‐
ing programs. The 2005 Institute of Medicine comprehensive summary of CRC screening ef‐
fectiveness concluded that all of the screening options are relatively comparable in terms of
life-years gained as well as cost when compared with a no-screening option. FOBT was the
least costly option, however most modalities are estimated to cost <$40,000 per life-year
saved (Lieberman, 2010; Pignone et al., 2002). However it is difficult to rely on these models
alone as they may not be entirely accurate and are not able to account for other factors such
as patient compliance. In general cost benefit analysis studies suggest that CRC screening is
overall a cost-effective measure and it is estimated that routine screening can save more
than 18,800 lives per year (Maciosek et al., 2006; Wilkins and Reynolds, 2008).
2.10. Surveillance guidelines
Currently the United States Multi-Society Task Force (MSTF) on CRC supports a 10-year inter‐
val between subsequent screening colonoscopies for average risk patients. Case-control and
observational studies indicate that the mortality benefit from colonoscopy lasts at least 10
years. However patients who are found to have adenomas on baseline colonoscopy are at in‐
creased risk of developing future adenomas and cancerous lesions (Martinez et al., 2009). Cer‐
tain higher-risk patients can develop cancer as soon as 3-5 years after a colonoscopy. These are
termed interval cancers. These patients require a shorter interval between subsequent follow
up because this has been shown to reduce colorectal cancer incidence by as much as 66% (Cit‐
arda et al., 2001; Winawer et al., 1993a). Guidelines from the GI consortium panel advocate re‐
peat colonoscopy 5 years after removal of a low-risk polyp and after 3 years if the polyp has
higher risk features. The selection of a 3-year screening interval for subsequent follow-up is
based on evidence that shows detection of advanced lesions is not improved at 1 year versus 3
years (Winawer et al., 1993b). Further research is still needed to determine whether a single
negative follow up colonoscopy is sufficient (Lieberman et al., 2012).
The use of risk stratification to determine the optimal screening interval is important be‐
cause physicians that refer patients for surveillance at intervals shorter than recommended
may be exposing patients to unnecessary risks and costs (Lieberman, 2010). In fact a recent
study revealed underuse of colonoscopies in high-risk patients and overuse in low risk pa‐
tients. By ineffective allocation of resources high-risk patients are placed at increased risk for
developing cancer. Furthermore optimization of screening is important in light of low
screening rates for a preventable cancer. Customized screening recommendations based on
risk allows for more streamlined and effective screening leaving resources that can be devot‐
ed to colon cancer education targeting the challenging subset of the population at high risk
with poor adherence. Ultimately screening program success depends not only on quality
but patient participation (Lieberman et al., 2012). In addition to risk stratification, the MSTF
on CRC believes that high-quality baseline examination is key for effective surveillance. In‐
terval cancers have been found to occur more frequently in patients with negative baseline
exams. There is evidence to suggest that important lesions are often missed at baseline colo‐
noscopy and it is estimated that up to 17% of 10 mm lesions are missed. This variability in
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adenoma detection rates may be attributable to biologic differences in missed adenomas or
disparities in endoscopist proficiency.
3. When to start screening?
As with any effective screening technique, the most important issue is always when to start
offering the test. Although the lifetime risk of CRC is estimated to be 6%, we now under‐
stand that the chance of developing the disease increases with age. In the United States the
annual incidence of CRC in people of ages 50 to 54 was found to be approximately double
that found in individuals ages 45 to 49 (Imperiale et al., 2000). A successful screening test, if
used on 100% of the population has the potential to save many more lives than if the test is
used on only a portion of the population. However given limited medical resources, strate‐
gic optimization is necessary for maximum impact. Current recommendations support ini‐
tiation of screening at age 50 for average risk men and women with earlier screening
recommended for high-risk populations (Levin et al., 2008; Rex et al., 2009; USPSTF, 2008;
Winawer et al., 2003). In addition to identifying optimal timing for initiation, the goals of
screening have shifted to focus on cancer prevention rather than simply cancer detection
(Winawer et al., 2003). As a result recent guidelines from the American College of Gastroen‐
terology (ACG) and USPSTF now endorse colonoscopy as the preferred modality for screen‐
ing (Rex et al., 2009; USPSTF, 2008).
Screening guidelines must be tailored to maximize benefit while minimizing cost to both the
individual and society as a whole (Rembold, 1998). The term “number needed to screen” is
defined as the amount of people needed to be screened over a timed duration to prevent one
death or adverse event. Many studies have looked at the cost-effectiveness of colon cancer
screening with the three most common methods (i.e. fecal occult blood annually, sigmoido‐
scopy every 5 years, colonoscopy every 10 years - all beginning at age 50 and stopping at
age 85). Current estimates range from $6,000 – $11,900 spent for every year of life gained
(Maciosek et al., 2006; Telford et al., 2010). In contrast, studies on the cost effectiveness of
screening mammography estimate roughly $58,000 spent for every one year of life gained
(Stout et al.). Many experts suggest that a screening policy should result in expenditure of
$50,000 or less per year of life gained. Thus, it is clear that colon cancer screening makes
sense medically and financially. The question of when colon cancer screening should begin
and end remains, and is a complex one. While colon cancer is typically a disease of the mid‐
dle age to elderly, there are many groups of high-risk patients that need screening much ear‐
lier than current guidelines. The remainder of this section will attempt to elucidate screening
strategies in low-risk, average-risk, and high-risk groups.
It is important to emphasize that colon cancer is a diverse entity with many paths leading to
a common endpoint, carcinoma. The adenoma-carcinoma sequence can encompass a multi‐
tude of genetic mutations that lead to the eventual progression to cancer (i.e. mismatch re‐
pair genes, tumor suppressor genes, base excision repair genes, micro-satellite genes). No
single mutation results in adenocarcinoma, but as mutations compile, a carcinoma eventual‐
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ly develops. For the majority of colon cancers, there is a significant amount of time between
development of an adenoma and its progression to a malignant lesion. The time interval for
progression is often determined by type of adenoma found. Current studies estimate that
the dwelling time for a tubular adenoma is roughly 26 years, 9 years for tubulovillous ade‐
noma, and 4 years for a villous adenoma (with an overall annual transition rate of 2.2%)
(Chen et al.). It is this significant window period of detection time that allows screening for
colon cancer to be so incredibly effective, and thus important to optimize timing and fre‐
quency of screening. While these concepts hold true for the majority of colon cancers, not all
cancers are created equal. Certain high-risk groups progress to cancer much more rapidly
than the above data suggests, and these groups will be detailed ahead.
3.1. Distribution of colorectal cancer types
The vast majority (70-75%) of colorectal cancers develop in sporadic (nonhereditary) fashion
and no risk factors are identified in the individuals. The next most common form (15-20%)
occurs in those with a family history of colon cancer (excluding known cancer syndromes).
Hereditary Non-polyposis colorectal cancer (i.e. Lynch Syndrome) makes up roughly 3-8%.
Familial Adenomatous Polyposis 1%, and Colitis Associated Cancer (i.e. Inflammatory Bow‐
el Disease) also 1% (Winawer et al.). Keeping these figures in mind, colon cancer screening
has the largest absolute impact on average-risk individuals. As such, the next section will
focus on screening recommendations for the average-risk group.
3.2. Approach to average-risk individuals
As mentioned before, colon cancer is a disease of the middle age to elderly. According to a
review by the National Cancer Institute conducted from 2005-2009, the median age at time
of diagnosis of a colorectal cancer is 69. Thus, if we extrapolate from the data provided pre‐
viously (~2% annual transformation from adenoma to carcinoma), we can see that it makes
sense to exclude the younger population from screening tests. In fact, the most recent
USPSTF recommendations support the initiation of colon cancer screening in average-risk
individuals at age 50 (Grade A Recommendation) (USPSTF). These recommendations were
made based in part on the results of two microsimulation models (MISCAN and SimCRC
models) that incorporated current data on colon cancer incidence and adenoma progression,
and simulated the natural history of colon cancer in a large population. The models then es‐
timated the life-years gained if screening colonoscopy was performed vs. no screening at all.
Further data analysis detailed age to begin screening, age to stop screening, and time inter‐
vals between screening. The models concluded that the optimal age to initiate screening is
50 (when compared to ages 40 and 60). Of note, one simulation showed better outcomes
when screening was initiated at age 40, however the alternate simulation did not corrobo‐
rate the data. The Task Force concluded, “Because the evidence for both adenoma preva‐
lence at age 40 and the duration of the adenoma-carcinoma sequence is weak, we restricted
further analysis to start ages of 50 and 60.” This led to the recommendation of initiating
screening at age 50. Regarding interval time period between colonoscopy, the authors re‐
viewed data on 5-year, 10-year, and 20-year intervals. They concluded, as could be expected,
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adenoma detection rates may be attributable to biologic differences in missed adenomas or
disparities in endoscopist proficiency.
3. When to start screening?
As with any effective screening technique, the most important issue is always when to start
offering the test. Although the lifetime risk of CRC is estimated to be 6%, we now under‐
stand that the chance of developing the disease increases with age. In the United States the
annual incidence of CRC in people of ages 50 to 54 was found to be approximately double
that found in individuals ages 45 to 49 (Imperiale et al., 2000). A successful screening test, if
used on 100% of the population has the potential to save many more lives than if the test is
used on only a portion of the population. However given limited medical resources, strate‐
gic optimization is necessary for maximum impact. Current recommendations support ini‐
tiation of screening at age 50 for average risk men and women with earlier screening
recommended for high-risk populations (Levin et al., 2008; Rex et al., 2009; USPSTF, 2008;
Winawer et al., 2003). In addition to identifying optimal timing for initiation, the goals of
screening have shifted to focus on cancer prevention rather than simply cancer detection
(Winawer et al., 2003). As a result recent guidelines from the American College of Gastroen‐
terology (ACG) and USPSTF now endorse colonoscopy as the preferred modality for screen‐
ing (Rex et al., 2009; USPSTF, 2008).
Screening guidelines must be tailored to maximize benefit while minimizing cost to both the
individual and society as a whole (Rembold, 1998). The term “number needed to screen” is
defined as the amount of people needed to be screened over a timed duration to prevent one
death or adverse event. Many studies have looked at the cost-effectiveness of colon cancer
screening with the three most common methods (i.e. fecal occult blood annually, sigmoido‐
scopy every 5 years, colonoscopy every 10 years - all beginning at age 50 and stopping at
age 85). Current estimates range from $6,000 – $11,900 spent for every year of life gained
(Maciosek et al., 2006; Telford et al., 2010). In contrast, studies on the cost effectiveness of
screening mammography estimate roughly $58,000 spent for every one year of life gained
(Stout et al.). Many experts suggest that a screening policy should result in expenditure of
$50,000 or less per year of life gained. Thus, it is clear that colon cancer screening makes
sense medically and financially. The question of when colon cancer screening should begin
and end remains, and is a complex one. While colon cancer is typically a disease of the mid‐
dle age to elderly, there are many groups of high-risk patients that need screening much ear‐
lier than current guidelines. The remainder of this section will attempt to elucidate screening
strategies in low-risk, average-risk, and high-risk groups.
It is important to emphasize that colon cancer is a diverse entity with many paths leading to
a common endpoint, carcinoma. The adenoma-carcinoma sequence can encompass a multi‐
tude of genetic mutations that lead to the eventual progression to cancer (i.e. mismatch re‐
pair genes, tumor suppressor genes, base excision repair genes, micro-satellite genes). No
single mutation results in adenocarcinoma, but as mutations compile, a carcinoma eventual‐
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ly develops. For the majority of colon cancers, there is a significant amount of time between
development of an adenoma and its progression to a malignant lesion. The time interval for
progression is often determined by type of adenoma found. Current studies estimate that
the dwelling time for a tubular adenoma is roughly 26 years, 9 years for tubulovillous ade‐
noma, and 4 years for a villous adenoma (with an overall annual transition rate of 2.2%)
(Chen et al.). It is this significant window period of detection time that allows screening for
colon cancer to be so incredibly effective, and thus important to optimize timing and fre‐
quency of screening. While these concepts hold true for the majority of colon cancers, not all
cancers are created equal. Certain high-risk groups progress to cancer much more rapidly
than the above data suggests, and these groups will be detailed ahead.
3.1. Distribution of colorectal cancer types
The vast majority (70-75%) of colorectal cancers develop in sporadic (nonhereditary) fashion
and no risk factors are identified in the individuals. The next most common form (15-20%)
occurs in those with a family history of colon cancer (excluding known cancer syndromes).
Hereditary Non-polyposis colorectal cancer (i.e. Lynch Syndrome) makes up roughly 3-8%.
Familial Adenomatous Polyposis 1%, and Colitis Associated Cancer (i.e. Inflammatory Bow‐
el Disease) also 1% (Winawer et al.). Keeping these figures in mind, colon cancer screening
has the largest absolute impact on average-risk individuals. As such, the next section will
focus on screening recommendations for the average-risk group.
3.2. Approach to average-risk individuals
As mentioned before, colon cancer is a disease of the middle age to elderly. According to a
review by the National Cancer Institute conducted from 2005-2009, the median age at time
of diagnosis of a colorectal cancer is 69. Thus, if we extrapolate from the data provided pre‐
viously (~2% annual transformation from adenoma to carcinoma), we can see that it makes
sense to exclude the younger population from screening tests. In fact, the most recent
USPSTF recommendations support the initiation of colon cancer screening in average-risk
individuals at age 50 (Grade A Recommendation) (USPSTF). These recommendations were
made based in part on the results of two microsimulation models (MISCAN and SimCRC
models) that incorporated current data on colon cancer incidence and adenoma progression,
and simulated the natural history of colon cancer in a large population. The models then es‐
timated the life-years gained if screening colonoscopy was performed vs. no screening at all.
Further data analysis detailed age to begin screening, age to stop screening, and time inter‐
vals between screening. The models concluded that the optimal age to initiate screening is
50 (when compared to ages 40 and 60). Of note, one simulation showed better outcomes
when screening was initiated at age 40, however the alternate simulation did not corrobo‐
rate the data. The Task Force concluded, “Because the evidence for both adenoma preva‐
lence at age 40 and the duration of the adenoma-carcinoma sequence is weak, we restricted
further analysis to start ages of 50 and 60.” This led to the recommendation of initiating
screening at age 50. Regarding interval time period between colonoscopy, the authors re‐
viewed data on 5-year, 10-year, and 20-year intervals. They concluded, as could be expected,
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shorter intervals resulted in more life-years gained (their primary endpoint). However,
when comparing 5-year to 10-year, there was only a modest increase in life years gained
when compared to the corresponding increase in colonoscopies performed. 20-year intervals
resulted in significantly less life-years gained, so was not considered optimal. While these
authors agree with the recommendations by the USPSTF for average-risk individuals, it is
important that practitioners further tailor their screening strategies based on several addi‐
tional factors. As mentioned, 75% of colon cancers occur in average-risk individuals, thus
representing a large absolute number of persons. As such, there is much variability and as‐
sociated risks among the average-risk population.
Factors that increase the risk for colorectal cancer or are protective have been identified.
While these factors have not been incorporated into the USPSTF Guidelines, knowledge
about their existence and influence on overall risk may be helpful in directing clinicians to‐
ward screening colonoscopy practices. Additionally, and some may argue more important‐
ly, clinicians must take into account a patient's expected adherence to their colonoscopy
recommendations. Will the patient have regular and predictable access to a skilled gastroen‐
terologist? Will they be willing to comply with frequent colonoscopy should their risk fac‐
tors or findings require it? A new concept known as once in a lifetime screening with
colonoscopy is being proposed as an effective technique in some groups. Knowledge of risk
factors can be especially helpful in these cases, in which a clinician can strongly encourage
adherence to recommendations based on each individual's risk factors. Additionally, it is
important to note that the following discussion applies only to individuals classified as aver‐
age-risk, and excludes those with a family history, diagnosed genetic condition, and Inflam‐
matory Bowel Disease. These groups will be discussed separately.
3.3. Modifiable CRC risk factors
To date, several modifiable risk factors have been clearly linked with the development of
colorectal carcinoma. Starting from the 10,000-foot view, many of the risk factors can be col‐
lectively grouped under the heading of total energy balance (i.e. caloric intake vs. caloric ex‐
penditure). Numerous studies have shown a clear link between Body Mass Index and
resultant risk of colon cancer. For example, investigators looked at the lifetime incidence of
colon cancer among the Framingham Cohort in Massachusetts, and divided the group by
age group to a 30-54 year old group and a 55-79 year old group. They then looked at the
overall incidence of colon cancer among the groups, and related the information to average
Body Mass Index. In the 55-79 year old group, they separated the cohort into BMI >30 and
BMI <30 groups. They noticed a significant 2.4 fold increased risk for the development of co‐
lon cancer for those with a BMI >30 (95% CI: 1.5-3.9) (Moore et al., 2004). Interestingly, the
same study also analyzed the results with relation to waist size measurement. As BMI can
be notoriously misleading, especially among males, the authors pursued this alternate meas‐
ure for further support. They concluded that central adiposity (defined as a waist size >39
inches), was associated with a two-fold increase in risk for colon cancer. They further noted
that the risk increased linearly with increases in waist size. This data has been replicated
among many other studies, in both men and women. A large study by the Nurses' Health
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Study Research Group concluded similarly that increasing BMI is associated with increased
risk of colon cancer, and particularly noted a higher risk among women with an increased
waist-to-hip ratio (Martinez et al., 1997). It is now widely accepted that obesity, and particu‐
larly central obesity, is an independent risk factor for the development of colon cancer. Sev‐
eral theories have been proposed as to why exactly this clear association exists. For now, the
most supported theory proposes that insulin resistance (along with hyperinsulinemia and
increased Insulin-like Growth Factor-1) plays a large role in this relationship. In fact, a re‐
cent meta-analysis has concluded that Diabetes Mellitus is itself an independent risk factor
for colon cancer. Even after controlling for physical activity, smoking, and obesity, the au‐
thors found an increase in relative risk among those with Diabetes Mellitus of 1.43 and 1.35
in men and women, respectively (both statistically significant) (Yuhara et al., 2011). Patho‐
physiologically, both insulin and IGF-1 are involved in cell proliferation and regulation of
apoptosis and it is enough to recognize that states with elevated levels of both hormones
have been clearly linked to increased risk for colon cancer. Additionally, multiple studies
have looked at the effect of physical activity and its influence on colon cancer. These studies
and their respective meta-analyses have shown clearly an inverse relationship between
physical activity and colon cancer. Among data taken from the group exhibiting the highest
level of exercise, one study showed a 50% reduction in lifetime colon cancer risk (Colditz et
al., 1997). Thus, an important conclusion can be reached based on the data reviewed as well
as others: obese, sedentary individuals are at higher risk for colon cancer. While the USPSTF
guidelines do not currently reflect this information for screening recommendations, clini‐
cians most certainly can make use of it to provide patient-centered care. Patients should be
counseled regarding overall health and the potential for primary prevention of colon cancer
via improved dieting and exercise habits.
The next most common modifiable risk factors a clinician is likely to encounter is tobacco
and/or alcohol use, both clearly linked with colon cancer. Multitudes of studies have been
undertaken in the last two decades examining the potential link between cigarette smoking
and colorectal cancer. A meta-analysis from 2009 conducted by Liang et al examined 36 such
studies (Liang et al., 2009). The results of the analysis showed a clear association between
age of initiation of tobacco use, amount smoked per day, and total duration of tobacco use.
Data showed a relative-risk of 1.38 for an increase in 40-cigarretes per day, 1.20 for an in‐
crease of 40 years total duration, and 1.51 for an increase of 60-pack years. Interestingly, they
also noted a predilection for rectal cancer over colon cancer when analyzing incidence of
site-specific carcinoma. Next, studies emerging over the last decade have begun to note in‐
creases in risk for colorectal cancer even in light to moderate alcohol use. A pooled analysis
of 8 cohort studies involving nearly 490,000 men and women was published in the Annals of
Internal Medicine in 2004. Data showed, when compared with non-drinkers, a relative-risk
of 1.41 (CI 1.16-1.72) in individuals who consumed 45g of daily alcohol (roughly three
drinks) (Cho et al., 2004). There was no statistically significant correlation among daily con‐
sumption of 30-44g/daily. More recently, a meta-analysis from 2011 from the Annals of On‐
cology examined 27 cohort studies and 34 case-control studies (Fedirko et al., 2011). They
also concluded a strong association between alcohol consumption and colorectal cancer risk.
The association was strongest among heavy drinkers, relative-risk 1.82 if >100g/day. Surpris‐
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shorter intervals resulted in more life-years gained (their primary endpoint). However,
when comparing 5-year to 10-year, there was only a modest increase in life years gained
when compared to the corresponding increase in colonoscopies performed. 20-year intervals
resulted in significantly less life-years gained, so was not considered optimal. While these
authors agree with the recommendations by the USPSTF for average-risk individuals, it is
important that practitioners further tailor their screening strategies based on several addi‐
tional factors. As mentioned, 75% of colon cancers occur in average-risk individuals, thus
representing a large absolute number of persons. As such, there is much variability and as‐
sociated risks among the average-risk population.
Factors that increase the risk for colorectal cancer or are protective have been identified.
While these factors have not been incorporated into the USPSTF Guidelines, knowledge
about their existence and influence on overall risk may be helpful in directing clinicians to‐
ward screening colonoscopy practices. Additionally, and some may argue more important‐
ly, clinicians must take into account a patient's expected adherence to their colonoscopy
recommendations. Will the patient have regular and predictable access to a skilled gastroen‐
terologist? Will they be willing to comply with frequent colonoscopy should their risk fac‐
tors or findings require it? A new concept known as once in a lifetime screening with
colonoscopy is being proposed as an effective technique in some groups. Knowledge of risk
factors can be especially helpful in these cases, in which a clinician can strongly encourage
adherence to recommendations based on each individual's risk factors. Additionally, it is
important to note that the following discussion applies only to individuals classified as aver‐
age-risk, and excludes those with a family history, diagnosed genetic condition, and Inflam‐
matory Bowel Disease. These groups will be discussed separately.
3.3. Modifiable CRC risk factors
To date, several modifiable risk factors have been clearly linked with the development of
colorectal carcinoma. Starting from the 10,000-foot view, many of the risk factors can be col‐
lectively grouped under the heading of total energy balance (i.e. caloric intake vs. caloric ex‐
penditure). Numerous studies have shown a clear link between Body Mass Index and
resultant risk of colon cancer. For example, investigators looked at the lifetime incidence of
colon cancer among the Framingham Cohort in Massachusetts, and divided the group by
age group to a 30-54 year old group and a 55-79 year old group. They then looked at the
overall incidence of colon cancer among the groups, and related the information to average
Body Mass Index. In the 55-79 year old group, they separated the cohort into BMI >30 and
BMI <30 groups. They noticed a significant 2.4 fold increased risk for the development of co‐
lon cancer for those with a BMI >30 (95% CI: 1.5-3.9) (Moore et al., 2004). Interestingly, the
same study also analyzed the results with relation to waist size measurement. As BMI can
be notoriously misleading, especially among males, the authors pursued this alternate meas‐
ure for further support. They concluded that central adiposity (defined as a waist size >39
inches), was associated with a two-fold increase in risk for colon cancer. They further noted
that the risk increased linearly with increases in waist size. This data has been replicated
among many other studies, in both men and women. A large study by the Nurses' Health
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Study Research Group concluded similarly that increasing BMI is associated with increased
risk of colon cancer, and particularly noted a higher risk among women with an increased
waist-to-hip ratio (Martinez et al., 1997). It is now widely accepted that obesity, and particu‐
larly central obesity, is an independent risk factor for the development of colon cancer. Sev‐
eral theories have been proposed as to why exactly this clear association exists. For now, the
most supported theory proposes that insulin resistance (along with hyperinsulinemia and
increased Insulin-like Growth Factor-1) plays a large role in this relationship. In fact, a re‐
cent meta-analysis has concluded that Diabetes Mellitus is itself an independent risk factor
for colon cancer. Even after controlling for physical activity, smoking, and obesity, the au‐
thors found an increase in relative risk among those with Diabetes Mellitus of 1.43 and 1.35
in men and women, respectively (both statistically significant) (Yuhara et al., 2011). Patho‐
physiologically, both insulin and IGF-1 are involved in cell proliferation and regulation of
apoptosis and it is enough to recognize that states with elevated levels of both hormones
have been clearly linked to increased risk for colon cancer. Additionally, multiple studies
have looked at the effect of physical activity and its influence on colon cancer. These studies
and their respective meta-analyses have shown clearly an inverse relationship between
physical activity and colon cancer. Among data taken from the group exhibiting the highest
level of exercise, one study showed a 50% reduction in lifetime colon cancer risk (Colditz et
al., 1997). Thus, an important conclusion can be reached based on the data reviewed as well
as others: obese, sedentary individuals are at higher risk for colon cancer. While the USPSTF
guidelines do not currently reflect this information for screening recommendations, clini‐
cians most certainly can make use of it to provide patient-centered care. Patients should be
counseled regarding overall health and the potential for primary prevention of colon cancer
via improved dieting and exercise habits.
The next most common modifiable risk factors a clinician is likely to encounter is tobacco
and/or alcohol use, both clearly linked with colon cancer. Multitudes of studies have been
undertaken in the last two decades examining the potential link between cigarette smoking
and colorectal cancer. A meta-analysis from 2009 conducted by Liang et al examined 36 such
studies (Liang et al., 2009). The results of the analysis showed a clear association between
age of initiation of tobacco use, amount smoked per day, and total duration of tobacco use.
Data showed a relative-risk of 1.38 for an increase in 40-cigarretes per day, 1.20 for an in‐
crease of 40 years total duration, and 1.51 for an increase of 60-pack years. Interestingly, they
also noted a predilection for rectal cancer over colon cancer when analyzing incidence of
site-specific carcinoma. Next, studies emerging over the last decade have begun to note in‐
creases in risk for colorectal cancer even in light to moderate alcohol use. A pooled analysis
of 8 cohort studies involving nearly 490,000 men and women was published in the Annals of
Internal Medicine in 2004. Data showed, when compared with non-drinkers, a relative-risk
of 1.41 (CI 1.16-1.72) in individuals who consumed 45g of daily alcohol (roughly three
drinks) (Cho et al., 2004). There was no statistically significant correlation among daily con‐
sumption of 30-44g/daily. More recently, a meta-analysis from 2011 from the Annals of On‐
cology examined 27 cohort studies and 34 case-control studies (Fedirko et al., 2011). They
also concluded a strong association between alcohol consumption and colorectal cancer risk.
The association was strongest among heavy drinkers, relative-risk 1.82 if >100g/day. Surpris‐
Issues in Screening and Surveillance Colonoscopy
http://dx.doi.org/10.5772/53111
37
ingly, they even found a statistically significant increase in relative-risk to 1.07 for individu‐
als drinking one alcoholic beverage per day (10g/day), which throws into question the
current recommendations of the USDA (two drinks or less daily for men, one drink or less
daily for women). Interestingly, even stronger associations were noted in studies examined
the Asian population (specifically Japanese men). Clearly, there is a link between both tobac‐
co and alcohol use and risk of colorectal cancer. Over the next few years, additional studies
and meta-analyses will likely emerge further elucidating just which populations are at risk
and what usage levels are most harmful. For now, clinicians should clearly state that tobacco
use and even light daily alcohol ingestion increases their likelihood of developing colorectal
cancer. As the current data suggests only a modest increase in relative-risk, this information
may be more pertinent among individuals with additional risk factors. Clinicians should
certainly take a patient's tobacco and alcohol use into account when determining how fre‐
quent they will advise screening colonoscopies.
3.4. Protective measures against CRC
Just as risk factors have been identified, there are also several clear factors that are protective
against colon cancer. Physical activity was discussed earlier, thus will not be repeated here,
but suffice it to mention again that it is highly protective against colon cancer. Moreover, the
medical community already advocates daily exercise for a multitude of other health bene‐
fits, and the fact that it also protects against colon cancer would not alter a clinician's man‐
agement of colonoscopy screening. However, several studies have clearly shown a
protective relationship between common pharmaceuticals and colon cancer. Both Aspirin
and Non-steroidal anti-inflammatory drugs have been shown to decrease the incidence of
colon cancer. Studies from as early as the 1980s began to show a relationship between anti-
inflammatory medications and colon cancer. Initial studies performed on patients with
Rheumatoid Arthritis, as they were often on chronic NSAID therapy, were the first to show
this relationship in the 1980s. Further studies conducted in patients on long-term aspirin
therapy showed similar results. The exact mechanism by which anti-inflammatory medica‐
tions provide this protective benefit currently remains unknown. Several hypotheses exist
which primarily center on COX-1 and COX-2 inhibition, as they are known to promote in‐
flammation, tumorigenesis, and angiogenesis. In a study published in the Lancet in 2007 by
Flossman et al, British researchers pooled data from two large Aspirin trials in the UK (Brit‐
ish Doctors Aspirin Trial, UK-TIA Aspirin Trial) (Flossmann and Rothwell, 2007). Among
patients with complete compliance for 5 years or more of aspirin therapy, they found a stat‐
istically significant relative-risk of 0.26 (CI 0.12-0.56). The effect was less substantial among
non-compliant patients, but nevertheless protective (RR 0.37). It is important to note in this
study, as in many other studies, the protective benefit was most clearly seen after a latency
period of at least 10 years. Moreover, study data pooled from trials related to cardiovascular
protection often have used differing doses of aspirin (or NSAIDs). At this time, no clear
dose, duration of therapy or type of NSAID has shown to be of greatest benefit in primary
colorectal cancer chemoprevention. As such, the USPSTF has not recommended NSAIDS as
a primary preventive measure for colorectal cancer. As more and more studies specifically
geared and powered toward colorectal carcinoma prevention (as opposed to data analysis of
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trials geared toward cardiovascular effects), it can likely be expected that clearer relation‐
ships between NSAID type, dosing, and duration will be elucidated. As it is not officially
recommended by the USPSTF, clinicians are not currently advocating for NSAID use as pri‐
mary prevention. However, a large portion of those at greatest risk for developing colorectal
cancer (i.e. middle-age to elderly) are already on Aspirin for its cardiovascular benefits.
Thus, clinicians can take this fact into account when assessing an individual's colorectal can‐
cer risk. Again, there is no current recommendation to decrease screening intervals in pa‐
tients on Aspirin therapy, however, when taken collectively with other risk factors,
clinicians may further tailor how aggressive they wish to be with screening.
Another common protective measure a clinician may encounter regards the use of post-
menopausal hormonal therapy. Again, as early as the 1980s, studies emerged showing an
unexpected link between hormonal therapy and colorectal cancers. As in many other associ‐
ations, the exact mechanism by which estrogen/progestin can inhibit cancer development is
unknown. However, speculations on its pathophysiology are under active investigation. Re‐
searchers hypothesize that hormonal therapy can alter levels of bile acids, Insulin-Like
Growth Factor-1, and IGF Binding Protein-3. Moreover, estrogen receptors have been found
on colonic epithelial cells, and it is unclear if this may also provide a route of protection.
Nevertheless, numerous studies (one of which will be described below) have shown the in‐
verse relationship between hormonal therapy and colon cancer risk. In a prospective study
of nearly 57,000 women (taken from the Breast Cancer Detection Demonstration Project)
published in 2009, Johnson et al looked at hormonal therapy (including estrogen alone, com‐
bination with progestin, and duration of therapy) and its relation to colon cancer incidence
(Johnson et al., 2009). Results are astoundingly clear that hormonal therapy is protective
against colon cancer. The results were as follows: ever users of unopposed estrogen RR 0.83
(95% CI, 0.70-0.99), current users unopposed estrogen >10 years RR 0.74 (95% CI, 0.56-0.96).
The results among estrogen + progestin users showed an even stronger relationship: estro‐
gen + progestin RR 0.78 (95% CI, 0.6-1.02), estrogen + sequential progestin RR 0.64 (95% CI,
0.43-0.95), and strongest effect with 2-5yr use of estrogen + sequential progestin RR 0.52
(95% CI, 0.32-0.87). Similar studies conducted by the WHI (Women's Health Initiative) have
shown similar results for estrogen + progestin therapy, but not estrogen therapy alone. Inter‐
estingly, they also noted that although the frequency of cancer was less in the hormonal
group, the cancers were detected at later stages (increased lymph node involvement and
metastatic disease) (Chlebowski et al., 2004). So, as before, we have clear evidence of a pro‐
tective measure against colon cancer. Unfortunately, the same WHI trial showed an increase
in myocardial infarction, stroke, dementia, pulmonary emboli, and breast cancer among hor‐
monal therapy users. As such, there have been no widespread recommendations for pri‐
mary prevention of colorectal cancer by means of hormonal therapy. However, clinicians
may encounter women who are on hormonal therapy. While estrogen therapy alone may
not have clear benefits, estrogen + progestin therapy has repeatedly shown to be of benefit
in prevention of colorectal cancer. In fact, based on the results of the first-mentioned study,
risk was decreased by a staggering 25-46%. Taking this information into account, assuming
no additional risk factors exist, and clinician may be able to tailor their screening colonosco‐
py frequency toward a less aggressive and frequent approach.
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ingly, they even found a statistically significant increase in relative-risk to 1.07 for individu‐
als drinking one alcoholic beverage per day (10g/day), which throws into question the
current recommendations of the USDA (two drinks or less daily for men, one drink or less
daily for women). Interestingly, even stronger associations were noted in studies examined
the Asian population (specifically Japanese men). Clearly, there is a link between both tobac‐
co and alcohol use and risk of colorectal cancer. Over the next few years, additional studies
and meta-analyses will likely emerge further elucidating just which populations are at risk
and what usage levels are most harmful. For now, clinicians should clearly state that tobacco
use and even light daily alcohol ingestion increases their likelihood of developing colorectal
cancer. As the current data suggests only a modest increase in relative-risk, this information
may be more pertinent among individuals with additional risk factors. Clinicians should
certainly take a patient's tobacco and alcohol use into account when determining how fre‐
quent they will advise screening colonoscopies.
3.4. Protective measures against CRC
Just as risk factors have been identified, there are also several clear factors that are protective
against colon cancer. Physical activity was discussed earlier, thus will not be repeated here,
but suffice it to mention again that it is highly protective against colon cancer. Moreover, the
medical community already advocates daily exercise for a multitude of other health bene‐
fits, and the fact that it also protects against colon cancer would not alter a clinician's man‐
agement of colonoscopy screening. However, several studies have clearly shown a
protective relationship between common pharmaceuticals and colon cancer. Both Aspirin
and Non-steroidal anti-inflammatory drugs have been shown to decrease the incidence of
colon cancer. Studies from as early as the 1980s began to show a relationship between anti-
inflammatory medications and colon cancer. Initial studies performed on patients with
Rheumatoid Arthritis, as they were often on chronic NSAID therapy, were the first to show
this relationship in the 1980s. Further studies conducted in patients on long-term aspirin
therapy showed similar results. The exact mechanism by which anti-inflammatory medica‐
tions provide this protective benefit currently remains unknown. Several hypotheses exist
which primarily center on COX-1 and COX-2 inhibition, as they are known to promote in‐
flammation, tumorigenesis, and angiogenesis. In a study published in the Lancet in 2007 by
Flossman et al, British researchers pooled data from two large Aspirin trials in the UK (Brit‐
ish Doctors Aspirin Trial, UK-TIA Aspirin Trial) (Flossmann and Rothwell, 2007). Among
patients with complete compliance for 5 years or more of aspirin therapy, they found a stat‐
istically significant relative-risk of 0.26 (CI 0.12-0.56). The effect was less substantial among
non-compliant patients, but nevertheless protective (RR 0.37). It is important to note in this
study, as in many other studies, the protective benefit was most clearly seen after a latency
period of at least 10 years. Moreover, study data pooled from trials related to cardiovascular
protection often have used differing doses of aspirin (or NSAIDs). At this time, no clear
dose, duration of therapy or type of NSAID has shown to be of greatest benefit in primary
colorectal cancer chemoprevention. As such, the USPSTF has not recommended NSAIDS as
a primary preventive measure for colorectal cancer. As more and more studies specifically
geared and powered toward colorectal carcinoma prevention (as opposed to data analysis of
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trials geared toward cardiovascular effects), it can likely be expected that clearer relation‐
ships between NSAID type, dosing, and duration will be elucidated. As it is not officially
recommended by the USPSTF, clinicians are not currently advocating for NSAID use as pri‐
mary prevention. However, a large portion of those at greatest risk for developing colorectal
cancer (i.e. middle-age to elderly) are already on Aspirin for its cardiovascular benefits.
Thus, clinicians can take this fact into account when assessing an individual's colorectal can‐
cer risk. Again, there is no current recommendation to decrease screening intervals in pa‐
tients on Aspirin therapy, however, when taken collectively with other risk factors,
clinicians may further tailor how aggressive they wish to be with screening.
Another common protective measure a clinician may encounter regards the use of post-
menopausal hormonal therapy. Again, as early as the 1980s, studies emerged showing an
unexpected link between hormonal therapy and colorectal cancers. As in many other associ‐
ations, the exact mechanism by which estrogen/progestin can inhibit cancer development is
unknown. However, speculations on its pathophysiology are under active investigation. Re‐
searchers hypothesize that hormonal therapy can alter levels of bile acids, Insulin-Like
Growth Factor-1, and IGF Binding Protein-3. Moreover, estrogen receptors have been found
on colonic epithelial cells, and it is unclear if this may also provide a route of protection.
Nevertheless, numerous studies (one of which will be described below) have shown the in‐
verse relationship between hormonal therapy and colon cancer risk. In a prospective study
of nearly 57,000 women (taken from the Breast Cancer Detection Demonstration Project)
published in 2009, Johnson et al looked at hormonal therapy (including estrogen alone, com‐
bination with progestin, and duration of therapy) and its relation to colon cancer incidence
(Johnson et al., 2009). Results are astoundingly clear that hormonal therapy is protective
against colon cancer. The results were as follows: ever users of unopposed estrogen RR 0.83
(95% CI, 0.70-0.99), current users unopposed estrogen >10 years RR 0.74 (95% CI, 0.56-0.96).
The results among estrogen + progestin users showed an even stronger relationship: estro‐
gen + progestin RR 0.78 (95% CI, 0.6-1.02), estrogen + sequential progestin RR 0.64 (95% CI,
0.43-0.95), and strongest effect with 2-5yr use of estrogen + sequential progestin RR 0.52
(95% CI, 0.32-0.87). Similar studies conducted by the WHI (Women's Health Initiative) have
shown similar results for estrogen + progestin therapy, but not estrogen therapy alone. Inter‐
estingly, they also noted that although the frequency of cancer was less in the hormonal
group, the cancers were detected at later stages (increased lymph node involvement and
metastatic disease) (Chlebowski et al., 2004). So, as before, we have clear evidence of a pro‐
tective measure against colon cancer. Unfortunately, the same WHI trial showed an increase
in myocardial infarction, stroke, dementia, pulmonary emboli, and breast cancer among hor‐
monal therapy users. As such, there have been no widespread recommendations for pri‐
mary prevention of colorectal cancer by means of hormonal therapy. However, clinicians
may encounter women who are on hormonal therapy. While estrogen therapy alone may
not have clear benefits, estrogen + progestin therapy has repeatedly shown to be of benefit
in prevention of colorectal cancer. In fact, based on the results of the first-mentioned study,
risk was decreased by a staggering 25-46%. Taking this information into account, assuming
no additional risk factors exist, and clinician may be able to tailor their screening colonosco‐
py frequency toward a less aggressive and frequent approach.
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A clinician may also encounter questions from a patient regarding diet recommendations.
While a healthy, balanced diet high in non-processed, low animal fat calories is always recom‐
mended, there has been non conclusive data regarding diet and its relation to colorectal cancer.
As such, the decision on when to initiate and how often to perform screening colonoscopies
should not be influenced by a patient's diet. It is possible that more clear relationships will be
clarified in the future, but for now, data displaying strong associations does not exist.
The next question that must be answered is what role should gender and race/ethnicity of a
patient play in a clinician's screening colonoscopy recommendations? According to the most
recent data from the Center for Disease Control (CDC) males have a higher incidence of col‐
orectal cancer vs females (52.7 vs. 39.7/100,000) (Prevention). The highest incidence is found
in African American males (62/100,000), followed by Caucasian males (51.5/100,000). His‐
panics, Asians, and Native American/Alaskan Native groups all had a lower incidence than
the comparative African-American and Caucasian groups in both the male and female cate‐
gories. When comparing death rates from colorectal cancer by race, again males have an
overall higher rate vs. females (20.2 vs 14.1/100,000).(NIH, 2009) African-American males
displayed the highest rate at 29.8/100,000, and African-American Females the next highest
rate at 19.8/100,000. The remainder of the groups showed death rates below the average of
respective male and female groups analyzed. Compiling the above data, it is evident that
African-Americans are most affected by colorectal cancer in comparison to other race/ethnic‐
ities. In fact, a study examining 5-year survival rates among Caucasians vs. African-Ameri‐
cans (among all stages of colorectal cancer) revealed a staggering difference of 64% vs. 52%
(Ries). Initially, arguments were made postulating that perhaps the African-American com‐
munity rate of screening colonoscopy was much lower, thus accounting for the higher inci‐
dence and mortality rate. According to the CDC data on screening rates, Caucasians are
most screened at 66.2% and African-Americans are next most screened at 62.9% (Rim S.H.,
2011). The lowest screening rate is found in the Hispanic population at 51.2%. While Afri‐
can-Americans have a higher mortality rate from colorectal cancer, it is clear that it is not
solely due to inadequate screening, as African-Americans have much higher screening rates
than Hispanics, yet also a much higher mortality rate. A study examining this finding con‐
cluded that African-Americans are more likely to be diagnosed at an earlier age and present
at later stages of disease, as compared to Caucasians, however this data has not been consis‐
tently replicated (Chien et al., 2005). Another study postulated that socioeconomic status
and access to medical care may be partially involved in this mortality discrepancy (Wudel et
al., 2002). This study found that African-Americans are more likely to be treated at city hos‐
pital vs university hospitals (which are associated with better outcomes). However, when
comparing survival data even among Caucasians and African-Americans at each type of
hospital, African-Americans fared worse. Another study has pointed to type of care offered
(i.e. adjuvant chemotherapy and radiation) as a potential factor (Govindarajan et al., 2003).
This study found that African-Americans are treated less with both chemotherapy and radi‐
ation therapy vs. Caucasian patients. It is still unclear why exactly African-Americans are
more often diagnosed and more often killed by colorectal cancer. Regardless of the reason, it
is clear that there is a difference that needs to be addressed. It seems that while the reasons
are being elucidated, more aggressive screening among African-Americans needs to be es‐
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tablished. Data may eventually and conclusively show that colorectal cancer appears earlier
and is more aggressive in African-Americans. In the meantime, these authors would argue
for earlier age at initiation of screening and more frequent screening intervals.
Finally, in the average-risk population, the issue of access to colonoscopy need always re‐
main in the back of a clinician's mind. Many patients may not have access due to socioeco‐
nomic or geographic barriers, or simply they may choose not to undergo screening based on
underlying psychological barriers or misconceptions regarding colon cancer and/or colono‐
scopy. As mentioned previously, many organizations are working toward colon cancer and
screening awareness, however clinicians must keep public unawareness as part of their
screening practice. If a patient presents at age 45 and there is concern for eventual adherence
to the screening guidelines at age 50, he/she should be screened at age 45.
3.5. Risk associated with family history of CRC
As mentioned previously, the next largest group of the population diagnosed with colon
cancer involves those with a family history (excluding individuals with a known colorectal
cancer syndrome). This group makes up ~15-20% of all diagnoses. Currently, there are mul‐
tiple efforts and studies looking into what exactly confers this higher risk among individuals
with a positive family history of colon cancer. At this time, it remains unclear what genetic
and/or environmental factors are involved in the pathogenesis, however, it is abundantly
clear that patients with 1st degree relatives diagnosed with colon cancer, are at a significantly
higher risk of developing colon cancer themselves. In fact, in one of the seminal studies pub‐
lished on the topic from the New England Journal Of Medicine, individuals with one 1st-de‐
gree relative with colon cancer were found to have a 1.7 fold increase in their own risk for
colon cancer (Rex et al., 2009). This risk increased further as the number of diseased 1st-de‐
gree relatives increased as well. Further, they found that the increased risk was irrespective
of location of diagnosed tumor in the relative (i.e. proximal vs. distal site of malignancy). As
such, the American College of Gastroenterology revised its guidelines regarding individuals
with a positive family history. If an individual has a 1st degree relative that was diagnosed
with colon cancer before the age of 60 (or 2 or more relatives with colon cancer or advanced
adenomas irrespective of age at diagnosis), they are considered to have a positive family his‐
tory. If a patient is identified as having a positive family history, they should then begin co‐
lonoscopy screening at age 40 (or 10 years before the youngest age of diagnosis), and they
should have an interval follow-up colonoscopy every 5 years. According to these recom‐
mendations, 2nd-degree relatives or relatives diagnosed >60 years of age are not considered
as a conferring a positive family history.
3.6. Polyposis syndromes
While the exact genetic predisposition for the majority of colon cancer remains unknown,
there are several well-known (and identifiable) cancer syndromes that a clinician must take
into account when making colon cancer screening advice. The most common of these is
Familial Adenomatous Polyposis. It affects roughly 1 in 5,000-7,000 individuals and confers
a 100% risk of eventual colorectal cancer, with the average age at diagnosis 40 (Bussey et al.,
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A clinician may also encounter questions from a patient regarding diet recommendations.
While a healthy, balanced diet high in non-processed, low animal fat calories is always recom‐
mended, there has been non conclusive data regarding diet and its relation to colorectal cancer.
As such, the decision on when to initiate and how often to perform screening colonoscopies
should not be influenced by a patient's diet. It is possible that more clear relationships will be
clarified in the future, but for now, data displaying strong associations does not exist.
The next question that must be answered is what role should gender and race/ethnicity of a
patient play in a clinician's screening colonoscopy recommendations? According to the most
recent data from the Center for Disease Control (CDC) males have a higher incidence of col‐
orectal cancer vs females (52.7 vs. 39.7/100,000) (Prevention). The highest incidence is found
in African American males (62/100,000), followed by Caucasian males (51.5/100,000). His‐
panics, Asians, and Native American/Alaskan Native groups all had a lower incidence than
the comparative African-American and Caucasian groups in both the male and female cate‐
gories. When comparing death rates from colorectal cancer by race, again males have an
overall higher rate vs. females (20.2 vs 14.1/100,000).(NIH, 2009) African-American males
displayed the highest rate at 29.8/100,000, and African-American Females the next highest
rate at 19.8/100,000. The remainder of the groups showed death rates below the average of
respective male and female groups analyzed. Compiling the above data, it is evident that
African-Americans are most affected by colorectal cancer in comparison to other race/ethnic‐
ities. In fact, a study examining 5-year survival rates among Caucasians vs. African-Ameri‐
cans (among all stages of colorectal cancer) revealed a staggering difference of 64% vs. 52%
(Ries). Initially, arguments were made postulating that perhaps the African-American com‐
munity rate of screening colonoscopy was much lower, thus accounting for the higher inci‐
dence and mortality rate. According to the CDC data on screening rates, Caucasians are
most screened at 66.2% and African-Americans are next most screened at 62.9% (Rim S.H.,
2011). The lowest screening rate is found in the Hispanic population at 51.2%. While Afri‐
can-Americans have a higher mortality rate from colorectal cancer, it is clear that it is not
solely due to inadequate screening, as African-Americans have much higher screening rates
than Hispanics, yet also a much higher mortality rate. A study examining this finding con‐
cluded that African-Americans are more likely to be diagnosed at an earlier age and present
at later stages of disease, as compared to Caucasians, however this data has not been consis‐
tently replicated (Chien et al., 2005). Another study postulated that socioeconomic status
and access to medical care may be partially involved in this mortality discrepancy (Wudel et
al., 2002). This study found that African-Americans are more likely to be treated at city hos‐
pital vs university hospitals (which are associated with better outcomes). However, when
comparing survival data even among Caucasians and African-Americans at each type of
hospital, African-Americans fared worse. Another study has pointed to type of care offered
(i.e. adjuvant chemotherapy and radiation) as a potential factor (Govindarajan et al., 2003).
This study found that African-Americans are treated less with both chemotherapy and radi‐
ation therapy vs. Caucasian patients. It is still unclear why exactly African-Americans are
more often diagnosed and more often killed by colorectal cancer. Regardless of the reason, it
is clear that there is a difference that needs to be addressed. It seems that while the reasons
are being elucidated, more aggressive screening among African-Americans needs to be es‐
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tablished. Data may eventually and conclusively show that colorectal cancer appears earlier
and is more aggressive in African-Americans. In the meantime, these authors would argue
for earlier age at initiation of screening and more frequent screening intervals.
Finally, in the average-risk population, the issue of access to colonoscopy need always re‐
main in the back of a clinician's mind. Many patients may not have access due to socioeco‐
nomic or geographic barriers, or simply they may choose not to undergo screening based on
underlying psychological barriers or misconceptions regarding colon cancer and/or colono‐
scopy. As mentioned previously, many organizations are working toward colon cancer and
screening awareness, however clinicians must keep public unawareness as part of their
screening practice. If a patient presents at age 45 and there is concern for eventual adherence
to the screening guidelines at age 50, he/she should be screened at age 45.
3.5. Risk associated with family history of CRC
As mentioned previously, the next largest group of the population diagnosed with colon
cancer involves those with a family history (excluding individuals with a known colorectal
cancer syndrome). This group makes up ~15-20% of all diagnoses. Currently, there are mul‐
tiple efforts and studies looking into what exactly confers this higher risk among individuals
with a positive family history of colon cancer. At this time, it remains unclear what genetic
and/or environmental factors are involved in the pathogenesis, however, it is abundantly
clear that patients with 1st degree relatives diagnosed with colon cancer, are at a significantly
higher risk of developing colon cancer themselves. In fact, in one of the seminal studies pub‐
lished on the topic from the New England Journal Of Medicine, individuals with one 1st-de‐
gree relative with colon cancer were found to have a 1.7 fold increase in their own risk for
colon cancer (Rex et al., 2009). This risk increased further as the number of diseased 1st-de‐
gree relatives increased as well. Further, they found that the increased risk was irrespective
of location of diagnosed tumor in the relative (i.e. proximal vs. distal site of malignancy). As
such, the American College of Gastroenterology revised its guidelines regarding individuals
with a positive family history. If an individual has a 1st degree relative that was diagnosed
with colon cancer before the age of 60 (or 2 or more relatives with colon cancer or advanced
adenomas irrespective of age at diagnosis), they are considered to have a positive family his‐
tory. If a patient is identified as having a positive family history, they should then begin co‐
lonoscopy screening at age 40 (or 10 years before the youngest age of diagnosis), and they
should have an interval follow-up colonoscopy every 5 years. According to these recom‐
mendations, 2nd-degree relatives or relatives diagnosed >60 years of age are not considered
as a conferring a positive family history.
3.6. Polyposis syndromes
While the exact genetic predisposition for the majority of colon cancer remains unknown,
there are several well-known (and identifiable) cancer syndromes that a clinician must take
into account when making colon cancer screening advice. The most common of these is
Familial Adenomatous Polyposis. It affects roughly 1 in 5,000-7,000 individuals and confers
a 100% risk of eventual colorectal cancer, with the average age at diagnosis 40 (Bussey et al.,
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1978). These individuals should begin screening colonoscopy in adolescence (usually started
10-12 years old), and this should be repeated annually. Ultimately these patients should re‐
ceive prophylactic colectomy. Another such polyposis includes Attenuated Adenomatous
Polyposis. As opposed to FAP (which involves hundreds to thousands of polyps diffusely
spread throughout the colon), AAP is an oligopolyposis and typically involves <100 polyps.
These polyps are more often right-sided and with a flat morphology. Patient's typically be‐
gin to have polyps appear in the 4th-5th decade of life and an average age of diagnosis of
cancer at age 55 (Knudsen et al., 2003). Roughly 69% of patients with APP will eventually
develop colon cancer. These patients should begin screening colonoscopy at age 25 and this
should be repeated annually. Less common genetic polyposes a clinician may encounter in‐
volve: MUTYH-Associated Polyposis, Peutz-Jeghers Syndrome, and Juvenile Polyposis Syn‐
drome. MUTYH-Associated Polyposis is an autosomal recessive cancer syndrome
(heterozygotes with one affected allele are at increased risk, but homozygotes show the larg‐
est increase in risk). Variations in phenotype have been described, from hundreds to thou‐
sands of polyps distributed throughout the colon. Lifetime prevalence of colon cancer is
reported at 80% (Jenkins et al., 2006). These individuals should begin annual screening at
age 18-20. Clinicians may also encounter Peutz-Jeghers Syndrome, which is an autosomal
dominant disorder characterized by numerous hamartomatous polyps throughout the co‐
lon. These individuals carry a 39% lifetime risk of colon cancer and should have colonosco‐
py screening every 2-3 years beginning in their late teen years (McGarrity and Amos, 2006).
Finally, pediatric clinicians may encounter Juvenile Polyposis, which is an autosomal domi‐
nant condition characterized by numerous polyps throughout the gastrointestinal tract.
These individuals are often brought to the attention of a physician following an intestinal
obstruction or gastrointestinal bleed as a consequence of the numerous polyps. These pa‐
tients carry a 10-38% lifetime colon cancer risk and should be screened annually beginning
at age 15 (Howe et al., 1998; Jass et al., 1988).
3.7. Non-polyposis syndromes
The most common hereditary colon cancer syndrome is Lynch Syndrome, or Hereditary
Non-Polyposis Colorectal Cancer. This too is an autosomal dominant condition, which is
characterized by numerous, proximal adenomas. Affected individuals carry a 48-68% risk of
colon cancer by age 60, with the majority being diagnosed between age 40-50 (Mecklin et al.,
2007). Even more importantly, adenomas associated with HNPCC are typically more ag‐
gressive and advance to carcinoma quicker than would be otherwise expected. As such,
these individuals should begin screening at age 20, and this should be repeated every 1-3
years.
3.8. CRC risk associated with Inflammatory Bowel Disease
Nearly every clinician is sure to encounter a patient afflicted with Inflammatory Bowel Dis‐
ease (IBD). As such, it is important to recognize that these patients carry an increased risk
for colon cancer, and they cannot be treated as average-risk individuals. The entity is refer‐
red to as Colitis-Associated Cancer, or CAC, and the resultant risk of eventual colon cancer
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is related to the severity of disease (in both Ulcerative Colitis, and Crohn's Disease). The cu‐
mulative risk of colon cancer among patients with ulcerative colitis (U.C.) is thought to be
roughly 2% after 10-years of disease, and up to 18% after 30-years of disease (Eaden et al.,
2001). Although Crohn's Disease (C.D.) classically involves the small intestine, it can also in‐
volve the large bowel, which confers an increased risk of colon cancer as well. Crohn's pa‐
tients with large intestinal involvement carry an 8.3% risk of colon cancer after 30 years of
disease (Canavan et al., 2006). Currently, the recommendation is to begin screening both
U.C. and C.D. patients 8-10 years post-diagnosis, and institute 1-2 year screening intervals.
4. When to stop screening?
As touched on previously, equally important to the initiation of an effective screening pro‐
gram involves the optimal age to finish the screening process. The question could be posed:
“Why stop screening at all if it is an effective means to prevent morbidity and mortality
from colon cancer?” However several factors should be considered including the fact that
colonoscopy is not entirely without risk. The known complications associated with colono‐
scopy (e.g. bleeding, perforation, infection, diverticulitis), occur particularly in the elderly
population. Furthermore, and especially true with regard to colorectal cancer screening,
there exists a potentially long latency period from adenoma to carcinoma which may take
years and even decades in some individuals. Elderly patients with an adenoma seen on
screening may, and oftentimes do, perish as a result of other disease processes. Finally, lim‐
ited resources must also be taken into account. Each and every colonoscopy takes a concert‐
ed effort from a skilled colonoscopist and their support staff, and the required financial
means on the part of the patient and/or government. As such it is necessary to establish evi‐
dence-based guidelines on when patients can safely stop colon cancer screening. The follow‐
ing section will delve further into this topic and the current recommendations for age at
which to stop screening.
4.1. Complications from screening colonoscopy
In general, colonoscopy is a relatively safe, well-tolerated procedure by patients. The majori‐
ty of patients will never experience any complications, even if undergoing multiple colonos‐
copies throughout their lifetime. There are, however, significant and life-threatening
complications that can occur. Although rare, given the enormous number of colonoscopies
performed annually, it is important to be cognizant of the associated complications. In 2010,
an analysis was released tracking complications rates among 18 large studies and involving
over 685,000 colonoscopies (Ko and Dominitz, 2010). The most common complication seen
was lower gastrointestinal bleeding, at roughly 0.1-0.6%. Fortunately, the far majority of
these were not mortal bleeds. However, as most colonoscopies are undertaken in the outpa‐
tient setting, gastrointestinal hemorrhage can develop into a life-threatening event very
quickly in a non-monitored setting. Next most common, bowel perforation posed a risk of
less than 0.3% (Ko and Dominitz, 2010). These most often occur following barotrauma or
mechanical trauma to the bowel wall. Again, although exceedingly rare, a perforated bowel
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1978). These individuals should begin screening colonoscopy in adolescence (usually started
10-12 years old), and this should be repeated annually. Ultimately these patients should re‐
ceive prophylactic colectomy. Another such polyposis includes Attenuated Adenomatous
Polyposis. As opposed to FAP (which involves hundreds to thousands of polyps diffusely
spread throughout the colon), AAP is an oligopolyposis and typically involves <100 polyps.
These polyps are more often right-sided and with a flat morphology. Patient's typically be‐
gin to have polyps appear in the 4th-5th decade of life and an average age of diagnosis of
cancer at age 55 (Knudsen et al., 2003). Roughly 69% of patients with APP will eventually
develop colon cancer. These patients should begin screening colonoscopy at age 25 and this
should be repeated annually. Less common genetic polyposes a clinician may encounter in‐
volve: MUTYH-Associated Polyposis, Peutz-Jeghers Syndrome, and Juvenile Polyposis Syn‐
drome. MUTYH-Associated Polyposis is an autosomal recessive cancer syndrome
(heterozygotes with one affected allele are at increased risk, but homozygotes show the larg‐
est increase in risk). Variations in phenotype have been described, from hundreds to thou‐
sands of polyps distributed throughout the colon. Lifetime prevalence of colon cancer is
reported at 80% (Jenkins et al., 2006). These individuals should begin annual screening at
age 18-20. Clinicians may also encounter Peutz-Jeghers Syndrome, which is an autosomal
dominant disorder characterized by numerous hamartomatous polyps throughout the co‐
lon. These individuals carry a 39% lifetime risk of colon cancer and should have colonosco‐
py screening every 2-3 years beginning in their late teen years (McGarrity and Amos, 2006).
Finally, pediatric clinicians may encounter Juvenile Polyposis, which is an autosomal domi‐
nant condition characterized by numerous polyps throughout the gastrointestinal tract.
These individuals are often brought to the attention of a physician following an intestinal
obstruction or gastrointestinal bleed as a consequence of the numerous polyps. These pa‐
tients carry a 10-38% lifetime colon cancer risk and should be screened annually beginning
at age 15 (Howe et al., 1998; Jass et al., 1988).
3.7. Non-polyposis syndromes
The most common hereditary colon cancer syndrome is Lynch Syndrome, or Hereditary
Non-Polyposis Colorectal Cancer. This too is an autosomal dominant condition, which is
characterized by numerous, proximal adenomas. Affected individuals carry a 48-68% risk of
colon cancer by age 60, with the majority being diagnosed between age 40-50 (Mecklin et al.,
2007). Even more importantly, adenomas associated with HNPCC are typically more ag‐
gressive and advance to carcinoma quicker than would be otherwise expected. As such,
these individuals should begin screening at age 20, and this should be repeated every 1-3
years.
3.8. CRC risk associated with Inflammatory Bowel Disease
Nearly every clinician is sure to encounter a patient afflicted with Inflammatory Bowel Dis‐
ease (IBD). As such, it is important to recognize that these patients carry an increased risk
for colon cancer, and they cannot be treated as average-risk individuals. The entity is refer‐
red to as Colitis-Associated Cancer, or CAC, and the resultant risk of eventual colon cancer
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is related to the severity of disease (in both Ulcerative Colitis, and Crohn's Disease). The cu‐
mulative risk of colon cancer among patients with ulcerative colitis (U.C.) is thought to be
roughly 2% after 10-years of disease, and up to 18% after 30-years of disease (Eaden et al.,
2001). Although Crohn's Disease (C.D.) classically involves the small intestine, it can also in‐
volve the large bowel, which confers an increased risk of colon cancer as well. Crohn's pa‐
tients with large intestinal involvement carry an 8.3% risk of colon cancer after 30 years of
disease (Canavan et al., 2006). Currently, the recommendation is to begin screening both
U.C. and C.D. patients 8-10 years post-diagnosis, and institute 1-2 year screening intervals.
4. When to stop screening?
As touched on previously, equally important to the initiation of an effective screening pro‐
gram involves the optimal age to finish the screening process. The question could be posed:
“Why stop screening at all if it is an effective means to prevent morbidity and mortality
from colon cancer?” However several factors should be considered including the fact that
colonoscopy is not entirely without risk. The known complications associated with colono‐
scopy (e.g. bleeding, perforation, infection, diverticulitis), occur particularly in the elderly
population. Furthermore, and especially true with regard to colorectal cancer screening,
there exists a potentially long latency period from adenoma to carcinoma which may take
years and even decades in some individuals. Elderly patients with an adenoma seen on
screening may, and oftentimes do, perish as a result of other disease processes. Finally, lim‐
ited resources must also be taken into account. Each and every colonoscopy takes a concert‐
ed effort from a skilled colonoscopist and their support staff, and the required financial
means on the part of the patient and/or government. As such it is necessary to establish evi‐
dence-based guidelines on when patients can safely stop colon cancer screening. The follow‐
ing section will delve further into this topic and the current recommendations for age at
which to stop screening.
4.1. Complications from screening colonoscopy
In general, colonoscopy is a relatively safe, well-tolerated procedure by patients. The majori‐
ty of patients will never experience any complications, even if undergoing multiple colonos‐
copies throughout their lifetime. There are, however, significant and life-threatening
complications that can occur. Although rare, given the enormous number of colonoscopies
performed annually, it is important to be cognizant of the associated complications. In 2010,
an analysis was released tracking complications rates among 18 large studies and involving
over 685,000 colonoscopies (Ko and Dominitz, 2010). The most common complication seen
was lower gastrointestinal bleeding, at roughly 0.1-0.6%. Fortunately, the far majority of
these were not mortal bleeds. However, as most colonoscopies are undertaken in the outpa‐
tient setting, gastrointestinal hemorrhage can develop into a life-threatening event very
quickly in a non-monitored setting. Next most common, bowel perforation posed a risk of
less than 0.3% (Ko and Dominitz, 2010). These most often occur following barotrauma or
mechanical trauma to the bowel wall. Again, although exceedingly rare, a perforated bowel
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has the potential to be lethal. A perforation can be clinically evident immediately after the
incident occurs, however, small perforations in the bowel can lead to an insidious course
that can ultimately result in severe peritonitis and rapid clinical decompensation. Diverticu‐
litis is also a well-established complication of colonoscopy, with a rate estimated at
0.04-0.08% (Ko and Dominitz, 2010). There also exists the known entity of post-polypectomy
electrocoagulation syndrome (or post-polypectomy syndrome). Following electrocautery of
the bowel wall, there is risk for a partial or transmural burn of the bowel wall. In cases of a
transmural burn, patients experience symptoms of clinical peritonitis. This rarely proceeds
to actual peritonitis (radiography does not visualize actual perforated bowel with free air in
the peritoneum), and these patients can be managed via supportive care and antibiotics.
However, resultant hospitalization and treatment is not without its own associated risks and
costs, so this cannot be taken lightly either. The incidence of post-polypectomy electrocoagu‐
lation syndrome appears to be roughly 0.003%-0.01% (Ko and Dominitz, 2010). Infection as a
result of colonoscopy is exceedingly rare, and can most times be attributed to poor infection
control procedures involving equipment. Although the risk of transient bacteremia is postu‐
lated to be higher, the actual risk of an infection transmission purely as a result of colonosco‐
py is estimated at roughly 1 per 1.8 million procedures, with Pseudomonas and Salmonella
species being the most commonly identified (Spach et al., 1993). Other case-reportable com‐
plications have included splenic rupture, acute appendicitis, and subcutaneous emphysema
(Hirata et al., 1996; Humphreys et al., 1984; Kamath et al., 2009). Overall mortality from colo‐
noscopy remains controversial due to complicated comorbidities among those in studies
tracking colonoscopy-related mortality. Estimates range from 0%-0.09% (Ko and Dominitz,
2010). Less serious complications include nausea, vomiting, diarrhea and bloating. Fortu‐
nately, these are usually self-limited within several days following the colonoscopy. As evi‐
denced above, colonoscopy does have rare but serious complications. However, it is
important to note that complications are also related to the type of procedure performed
(screening colonoscopy or polypectomy) and the age of those undergoing the procedure.
In assessing the risk of complications from colonoscopies it is important to consider the type
of intervention to be employed during the procedure and the baseline characteristics of the
patient. Many studies have analyzed data pertaining to complications particularly associat‐
ed with different age groups. For example, a retrospective cohort study from 1994-2009 ex‐
amined these risks among over 43,000 patients ages 40-85 (Rutter et al., 2012). They pooled
hemorrhage, perforation, and diverticulitis as serious adverse events. They found an event
rate of 4.7/1000 screening colonoscopies and 6.8/1000 for follow-up colonoscopies. Interest‐
ingly, there were significant differences between age groups. Among ages 40-49 there was a
serious event rate of 4.2/1000, ages 50-64 3.7/1000, ages 65-74 7.9/1000, and for ages 75-84
13.3/1000. Thus the rate of complications clearly increases with age. They also noted an in‐
crease in events following polypectomy vs no intervention, however this proves less clini‐
cally relevant, as a clinician would certainly not forgo polypectomy based on this fact alone.
With the above data, and other studies like it (Gatto et al., 2003), it becomes evident that be‐
yond a certain age, colonoscopies may be causing more harm than good.
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4.2. Timing of progression from adenoma to carcinoma
As mentioned previously, the progression from adenoma to carcinoma may take years and
even decades. Some adenomas may never make the entire progression. The adenoma may
never acquire all the necessary genetic mutations, or simply, an individual may not live long
enough for the adenoma to significantly progress. As such, detecting an asymptomatic pol‐
yp in an elderly individual may have no significance whatsoever. In fact, while the risk of
colonoscopy complications poses a real threat, the adenoma may prove to have no bearing
on a patient's health. Currently, the most recent CDC data estimates that the average life ex‐
pectancy in the United States is 78.7 years (76.2 for males and 81.1 for females) (Centers for
disease control and prevention, 2012). This brings into question the utility of screening eld‐
erly age individuals. At what age will a screening colonoscopy likely provide no benefit to
the average-risk elderly patient?
The following discussion pertains to those at average-risk as identified previously in the
chapter. Individuals with predisposing factors (family history, genetic syndromes, inflam‐
matory disease) are not included in this grouping, and should continue with regularly
scheduled colonoscopies as defined previously. Many of the adenomas identified in these
high-risk groups have demonstrated a more rapid rate of progression to carcinoma, and
thus, they continue to need aggressive screening measures throughout their lifetime.
The incidence of colon cancer rises sharply with advancing age. Many studies have exam‐
ined this relationship over the past decades, and conclusive evidence supports this claim. In
fact, the rate of colon cancer among those over 65 years of age is 254.2/100,000 persons,
while the risk is substantially lower among those under 65, at 18.1/100,000 persons (NIH,
2009). Clearly, the elderly are at highest risk for developing colon cancer. Likewise, the eld‐
erly are also highest at risk for complications of colonoscopy. Extrapolating from the data
previously provided, the complication rate amongst individuals 75-84 is 1330/100,000 peo‐
ple. Therefore, there would be roughly 5 times as many serious complications from colono‐
scopy as there would be actual diagnoses of cancer in the age group 75-84. Further, studies
have been conducted looking at the chances of actually dying from colon cancer if diag‐
nosed late in life. Among those at age 75 (and in the middle quartile of expected life remain‐
ing), they have a 1.9% chance of actually dying from colon cancer (Walter and Covinsky,
2001). By age 85, this risk decreases to 1.6%. Among elderly patients with multiple co-mor‐
bidities, the chance of dying from colon cancer falls to 0.85%. For comparison, a 50-year old
male in the middle quartile of life expectancy has a 2.3% and female a 2.2% chance of even‐
tually dying from colon cancer. While the incidence of colon cancer increases with age, it ap‐
pears the mortality from the disease actually declines (if the cancer develops at the later
age). These elderly patients succumb to an illness other than colon cancer. Additionally,
studies have likewise examined the actual amount of life gained due to screening colonosco‐
py among different age groups. Here too there is a clear association with age. Among
asymptomatic individuals undergoing screening colonoscopy, younger age groups experi‐
ence a much larger benefit in terms of life gained. Among 50-54 year olds undergoing
asymptomatic screening, there is roughly 0.84 years of life years gained (Lin et al., 2006).
However, among individuals 80 years and above, only 0.13 additional years of life are
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has the potential to be lethal. A perforation can be clinically evident immediately after the
incident occurs, however, small perforations in the bowel can lead to an insidious course
that can ultimately result in severe peritonitis and rapid clinical decompensation. Diverticu‐
litis is also a well-established complication of colonoscopy, with a rate estimated at
0.04-0.08% (Ko and Dominitz, 2010). There also exists the known entity of post-polypectomy
electrocoagulation syndrome (or post-polypectomy syndrome). Following electrocautery of
the bowel wall, there is risk for a partial or transmural burn of the bowel wall. In cases of a
transmural burn, patients experience symptoms of clinical peritonitis. This rarely proceeds
to actual peritonitis (radiography does not visualize actual perforated bowel with free air in
the peritoneum), and these patients can be managed via supportive care and antibiotics.
However, resultant hospitalization and treatment is not without its own associated risks and
costs, so this cannot be taken lightly either. The incidence of post-polypectomy electrocoagu‐
lation syndrome appears to be roughly 0.003%-0.01% (Ko and Dominitz, 2010). Infection as a
result of colonoscopy is exceedingly rare, and can most times be attributed to poor infection
control procedures involving equipment. Although the risk of transient bacteremia is postu‐
lated to be higher, the actual risk of an infection transmission purely as a result of colonosco‐
py is estimated at roughly 1 per 1.8 million procedures, with Pseudomonas and Salmonella
species being the most commonly identified (Spach et al., 1993). Other case-reportable com‐
plications have included splenic rupture, acute appendicitis, and subcutaneous emphysema
(Hirata et al., 1996; Humphreys et al., 1984; Kamath et al., 2009). Overall mortality from colo‐
noscopy remains controversial due to complicated comorbidities among those in studies
tracking colonoscopy-related mortality. Estimates range from 0%-0.09% (Ko and Dominitz,
2010). Less serious complications include nausea, vomiting, diarrhea and bloating. Fortu‐
nately, these are usually self-limited within several days following the colonoscopy. As evi‐
denced above, colonoscopy does have rare but serious complications. However, it is
important to note that complications are also related to the type of procedure performed
(screening colonoscopy or polypectomy) and the age of those undergoing the procedure.
In assessing the risk of complications from colonoscopies it is important to consider the type
of intervention to be employed during the procedure and the baseline characteristics of the
patient. Many studies have analyzed data pertaining to complications particularly associat‐
ed with different age groups. For example, a retrospective cohort study from 1994-2009 ex‐
amined these risks among over 43,000 patients ages 40-85 (Rutter et al., 2012). They pooled
hemorrhage, perforation, and diverticulitis as serious adverse events. They found an event
rate of 4.7/1000 screening colonoscopies and 6.8/1000 for follow-up colonoscopies. Interest‐
ingly, there were significant differences between age groups. Among ages 40-49 there was a
serious event rate of 4.2/1000, ages 50-64 3.7/1000, ages 65-74 7.9/1000, and for ages 75-84
13.3/1000. Thus the rate of complications clearly increases with age. They also noted an in‐
crease in events following polypectomy vs no intervention, however this proves less clini‐
cally relevant, as a clinician would certainly not forgo polypectomy based on this fact alone.
With the above data, and other studies like it (Gatto et al., 2003), it becomes evident that be‐
yond a certain age, colonoscopies may be causing more harm than good.
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4.2. Timing of progression from adenoma to carcinoma
As mentioned previously, the progression from adenoma to carcinoma may take years and
even decades. Some adenomas may never make the entire progression. The adenoma may
never acquire all the necessary genetic mutations, or simply, an individual may not live long
enough for the adenoma to significantly progress. As such, detecting an asymptomatic pol‐
yp in an elderly individual may have no significance whatsoever. In fact, while the risk of
colonoscopy complications poses a real threat, the adenoma may prove to have no bearing
on a patient's health. Currently, the most recent CDC data estimates that the average life ex‐
pectancy in the United States is 78.7 years (76.2 for males and 81.1 for females) (Centers for
disease control and prevention, 2012). This brings into question the utility of screening eld‐
erly age individuals. At what age will a screening colonoscopy likely provide no benefit to
the average-risk elderly patient?
The following discussion pertains to those at average-risk as identified previously in the
chapter. Individuals with predisposing factors (family history, genetic syndromes, inflam‐
matory disease) are not included in this grouping, and should continue with regularly
scheduled colonoscopies as defined previously. Many of the adenomas identified in these
high-risk groups have demonstrated a more rapid rate of progression to carcinoma, and
thus, they continue to need aggressive screening measures throughout their lifetime.
The incidence of colon cancer rises sharply with advancing age. Many studies have exam‐
ined this relationship over the past decades, and conclusive evidence supports this claim. In
fact, the rate of colon cancer among those over 65 years of age is 254.2/100,000 persons,
while the risk is substantially lower among those under 65, at 18.1/100,000 persons (NIH,
2009). Clearly, the elderly are at highest risk for developing colon cancer. Likewise, the eld‐
erly are also highest at risk for complications of colonoscopy. Extrapolating from the data
previously provided, the complication rate amongst individuals 75-84 is 1330/100,000 peo‐
ple. Therefore, there would be roughly 5 times as many serious complications from colono‐
scopy as there would be actual diagnoses of cancer in the age group 75-84. Further, studies
have been conducted looking at the chances of actually dying from colon cancer if diag‐
nosed late in life. Among those at age 75 (and in the middle quartile of expected life remain‐
ing), they have a 1.9% chance of actually dying from colon cancer (Walter and Covinsky,
2001). By age 85, this risk decreases to 1.6%. Among elderly patients with multiple co-mor‐
bidities, the chance of dying from colon cancer falls to 0.85%. For comparison, a 50-year old
male in the middle quartile of life expectancy has a 2.3% and female a 2.2% chance of even‐
tually dying from colon cancer. While the incidence of colon cancer increases with age, it ap‐
pears the mortality from the disease actually declines (if the cancer develops at the later
age). These elderly patients succumb to an illness other than colon cancer. Additionally,
studies have likewise examined the actual amount of life gained due to screening colonosco‐
py among different age groups. Here too there is a clear association with age. Among
asymptomatic individuals undergoing screening colonoscopy, younger age groups experi‐
ence a much larger benefit in terms of life gained. Among 50-54 year olds undergoing
asymptomatic screening, there is roughly 0.84 years of life years gained (Lin et al., 2006).
However, among individuals 80 years and above, only 0.13 additional years of life are
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gained. Thus, there is roughly a 6-fold difference in the actual effect of colon cancer screen‐
ing between the two groups. Although younger patients have a much lower chance of de‐
veloping colon cancer, they experience the lowest complication rate and benefit from the
largest amount of life years gained if diagnosed and treated.
4.3. The resource allocation factor
It is also equally important to consider allocation of valuable resources when debating
whether or not to forego colon cancer screening in the elderly. Colonoscopies, while cost-
effective, are expensive. Those uninsured may have to pay thousands of dollars for the pro‐
cedure, and those insured may have to pay copays, deductibles, etc. Moreover, the cost to
society is enormous. Considering there are currently 74,008,000 Americans age 55 and
above, there are millions of colonoscopies completed annually (Wagner et al., 1970). If there
are no established recommendations on when it is appropriate to stop colonoscopy screen‐
ing, millions of dollars will be spent for a procedure that may have minimal impact on the
health of those screened. Moreover, funding that could go toward more cost-effective treat‐
ments or screening programs would be needlessly diverted. Fortunately, the Affordable
Care Act (ACA) recently instated a policy in which Medicare and Medicaid “shall not im‐
pose any cost sharing requirements for evidence-based items or services that have in effect a
rating of ‘A’ or ‘B’ in the current recommendations of the United States Preventive Services
Task Force.” Therefore, the cost of a colonoscopy to the individual may be minimized, how‐
ever the cost to society will only grow. It is important to take into account the number of
providers who can safely and effectively offer colonoscopy screening as well. Studies have
demonstrated that colonoscopies performed by Gastroenterologists vs. non-Gastroenterolo‐
gists are both more cost-effective and more beneficial to the patient (i.e. trained endoscopists
are better at detection) (Hassan et al., 2012). In fact, the American Cancer Society estimates a
savings of roughly $200,000,000 per year if all colonoscopies were performed by Gastroen‐
terologists (currently both Gastroenterologists and non-Gastroenterologists are able to per‐
form colonoscopy). Unfortunately, the number of gastroenterologists available to provide
screening colonoscopies remains limited. Currently, there are roughly 10,400 practicing Gas‐
troenterologists in the United States. As screening compliance increases (and the absolute
number of individuals meeting the indication for screening increases as well), there will be a
severe shortage of practicing Gastroenterologists. As mentioned previously, as of now, there
is a 58.3% compliance rate to colon cancer screening. As this number increases, the limited
supply of Gastroenterologists will ultimately be overwhelmed. Even those who meet indica‐
tions for screening may be unable to obtain a colonoscopy in a timely manner. In effect, ev‐
ery colonoscopy performed on an elderly patient may mean one less colonoscopy for a
young, healthy individual. Simply put, there must be established guidelines followed by all
practitioners to ensure that screening colonoscopies are performed in the most cost-effective
and life-preserving manner. Therefore, it is of paramount importance to take resource allo‐
cation into account when advising patients on whether to proceed with colonoscopy or not.
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4.4. Evidence based approach to ending screening
The USPSTF currently recommends that colon cancer screening via colonoscopy be terminat‐
ed at age 75 (USPSTF, 2008). This recommendation is based upon a Decision Analysis publish‐
ed in 2008. Again, using two simulation models, the authors examined the average life-years
gained and the number of colonoscopies that would be required based upon the age at which
colonoscopy screening was stopped (and assuming a 10-year interval screening method in
average-risk individuals). The authors primarily tested ceasing colonoscopy at age 75 vs 85. In
essence, they found that by stopping screening at age 75, they decreased the number of life-
years gained by only 2-5/1000 people. However, the number of colonoscopies needed de‐
creased by 348-398/1000 people. The ranges given signify the results from both simulation
models. While some may argue that adding 2-5 life-years per 1000 people should take para‐
mount importance, this unfortunately cannot be the case given the limited resources as dis‐
cussed above. Until resources are infinite, it is necessary to funnel finances and medical staff
toward the population that will  most benefit  from screening. Distributing the additional
348-398 colonoscopies to a younger population will result in more life-years gained, lives
saved, and far fewer complications. Therefore, for the time being, it seems that ceasing colono‐
scopy screening at age 75 is both responsible and in the best interest of society.
4.5. Surveillance after late stage cancer diagnosis
Lastly, it is important to recognize that not all colonoscopies will be performed for strictly
screening purposes. Ultimately, the goal of colonoscopy is early diagnosis and curative
treatment by either polypectomy or bowel resection. However, as colon cancer is unfortu‐
nately still such a large cause of mortality in the United States and the screening rate is not
100%, many individuals will still be diagnosed with late-stage and unresectable colon can‐
cer. This then poses the question, what is the utility in surveillance colonoscopy in these in‐
dividuals?
To date, limited data exists concerning this topic. The primary treatment for patients with
diagnosed Stage IV inoperable colon cancer is palliative chemotherapy. Occasionally, che‐
motherapy may be able to shrink the tumor(s) to an operable state, but this is more often not
the case among late-stage diagnoses due to multiple metastases. Studies have analyzed
prognostic indicators among patients with inoperable disease and found that performance
status, ASA-class, CEA level, metastatic load, extent of primary tumor, and chemotherapy
were the only independent variables affecting prognosis in these patients (Stelzner et al.,
2005). While the initial diagnostic colonoscopy can provide valuable tissue data and infor‐
mation regarding depth of invasion, at this time surveillance colonoscopy does not appear
to play a role in the management beyond initial diagnosis. Given that there is no clear bene‐
fit to surveillance colonoscopy after diagnosis of inoperable colon cancer and there are a
multitude of risks associated with the procedure, surveillance colonoscopy is not indicated
in these patients.
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gained. Thus, there is roughly a 6-fold difference in the actual effect of colon cancer screen‐
ing between the two groups. Although younger patients have a much lower chance of de‐
veloping colon cancer, they experience the lowest complication rate and benefit from the
largest amount of life years gained if diagnosed and treated.
4.3. The resource allocation factor
It is also equally important to consider allocation of valuable resources when debating
whether or not to forego colon cancer screening in the elderly. Colonoscopies, while cost-
effective, are expensive. Those uninsured may have to pay thousands of dollars for the pro‐
cedure, and those insured may have to pay copays, deductibles, etc. Moreover, the cost to
society is enormous. Considering there are currently 74,008,000 Americans age 55 and
above, there are millions of colonoscopies completed annually (Wagner et al., 1970). If there
are no established recommendations on when it is appropriate to stop colonoscopy screen‐
ing, millions of dollars will be spent for a procedure that may have minimal impact on the
health of those screened. Moreover, funding that could go toward more cost-effective treat‐
ments or screening programs would be needlessly diverted. Fortunately, the Affordable
Care Act (ACA) recently instated a policy in which Medicare and Medicaid “shall not im‐
pose any cost sharing requirements for evidence-based items or services that have in effect a
rating of ‘A’ or ‘B’ in the current recommendations of the United States Preventive Services
Task Force.” Therefore, the cost of a colonoscopy to the individual may be minimized, how‐
ever the cost to society will only grow. It is important to take into account the number of
providers who can safely and effectively offer colonoscopy screening as well. Studies have
demonstrated that colonoscopies performed by Gastroenterologists vs. non-Gastroenterolo‐
gists are both more cost-effective and more beneficial to the patient (i.e. trained endoscopists
are better at detection) (Hassan et al., 2012). In fact, the American Cancer Society estimates a
savings of roughly $200,000,000 per year if all colonoscopies were performed by Gastroen‐
terologists (currently both Gastroenterologists and non-Gastroenterologists are able to per‐
form colonoscopy). Unfortunately, the number of gastroenterologists available to provide
screening colonoscopies remains limited. Currently, there are roughly 10,400 practicing Gas‐
troenterologists in the United States. As screening compliance increases (and the absolute
number of individuals meeting the indication for screening increases as well), there will be a
severe shortage of practicing Gastroenterologists. As mentioned previously, as of now, there
is a 58.3% compliance rate to colon cancer screening. As this number increases, the limited
supply of Gastroenterologists will ultimately be overwhelmed. Even those who meet indica‐
tions for screening may be unable to obtain a colonoscopy in a timely manner. In effect, ev‐
ery colonoscopy performed on an elderly patient may mean one less colonoscopy for a
young, healthy individual. Simply put, there must be established guidelines followed by all
practitioners to ensure that screening colonoscopies are performed in the most cost-effective
and life-preserving manner. Therefore, it is of paramount importance to take resource allo‐
cation into account when advising patients on whether to proceed with colonoscopy or not.
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4.4. Evidence based approach to ending screening
The USPSTF currently recommends that colon cancer screening via colonoscopy be terminat‐
ed at age 75 (USPSTF, 2008). This recommendation is based upon a Decision Analysis publish‐
ed in 2008. Again, using two simulation models, the authors examined the average life-years
gained and the number of colonoscopies that would be required based upon the age at which
colonoscopy screening was stopped (and assuming a 10-year interval screening method in
average-risk individuals). The authors primarily tested ceasing colonoscopy at age 75 vs 85. In
essence, they found that by stopping screening at age 75, they decreased the number of life-
years gained by only 2-5/1000 people. However, the number of colonoscopies needed de‐
creased by 348-398/1000 people. The ranges given signify the results from both simulation
models. While some may argue that adding 2-5 life-years per 1000 people should take para‐
mount importance, this unfortunately cannot be the case given the limited resources as dis‐
cussed above. Until resources are infinite, it is necessary to funnel finances and medical staff
toward the population that will  most benefit  from screening. Distributing the additional
348-398 colonoscopies to a younger population will result in more life-years gained, lives
saved, and far fewer complications. Therefore, for the time being, it seems that ceasing colono‐
scopy screening at age 75 is both responsible and in the best interest of society.
4.5. Surveillance after late stage cancer diagnosis
Lastly, it is important to recognize that not all colonoscopies will be performed for strictly
screening purposes. Ultimately, the goal of colonoscopy is early diagnosis and curative
treatment by either polypectomy or bowel resection. However, as colon cancer is unfortu‐
nately still such a large cause of mortality in the United States and the screening rate is not
100%, many individuals will still be diagnosed with late-stage and unresectable colon can‐
cer. This then poses the question, what is the utility in surveillance colonoscopy in these in‐
dividuals?
To date, limited data exists concerning this topic. The primary treatment for patients with
diagnosed Stage IV inoperable colon cancer is palliative chemotherapy. Occasionally, che‐
motherapy may be able to shrink the tumor(s) to an operable state, but this is more often not
the case among late-stage diagnoses due to multiple metastases. Studies have analyzed
prognostic indicators among patients with inoperable disease and found that performance
status, ASA-class, CEA level, metastatic load, extent of primary tumor, and chemotherapy
were the only independent variables affecting prognosis in these patients (Stelzner et al.,
2005). While the initial diagnostic colonoscopy can provide valuable tissue data and infor‐
mation regarding depth of invasion, at this time surveillance colonoscopy does not appear
to play a role in the management beyond initial diagnosis. Given that there is no clear bene‐
fit to surveillance colonoscopy after diagnosis of inoperable colon cancer and there are a
multitude of risks associated with the procedure, surveillance colonoscopy is not indicated
in these patients.
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5. Factors that impact effective screening
Colonoscopy is an accurate and effective screening technique that is endorsed by many soci‐
eties including the American Cancer Society, U.S. Multi-society Task Force, American Col‐
lege of Radiology, and American College of Gastroenterology (ACG) (Levin et al., 2008; Rex
et al., 2009; USPSTF, 2008). While it may seem that screening for CRC is a well-established
and accepted standard of care, screening rates for CRC have only recently started to ap‐
proach that of other cancers. Increasing interest in the issue of best practice for CRC screen‐
ing is attributable to updates to screening guidelines as a result of recent studies indicating
significant mortality benefits. In addition to changes in the actual screening guidelines, the
goal of screening has shifted to focus on cancer prevention by removing polyps rather than
simply cancer detection (USPSTF, 2008). Important factors exist that impact the effectiveness
of available screening modalities for CRC, and these originate from physicians, patients, as
well as from society. While current recommendations support initiation of screening at age
50 for all average risk men and women, earlier initiation is advocated for those at higher risk
including African American men and women. Knowledge about these guidelines can im‐
pact screening practice. Consideration must also be given to the modality of CRC screening.
The ACG recommends colonoscopy as the preferred mode of screening, and the gold stand‐
ard given it diagnostic and therapeutic potential (Rex et al., 2009). Studies demonstrate that
most physicians overwhelmingly prefer colonoscopy as the test of choice (Guerra et al.,
2007). In fact, 70% of PCPs strongly believe colonoscopy is the best available colorectal can‐
cer-screening test. Furthermore, a large proportion of physicians are concerned over law‐
suits if they do not offer screening colonoscopies. The fear of facing a lawsuit over
colonoscopy complications can be outweighed by the fear of being sued if the procedure is
not offered at all (McGregor et al., 2010; Varela et al., 2010). While CRC screening saves
lives, the use of colonoscopy and other available options, remains suboptimal. Pinpointing
the reasons why people are not getting screened, either by choice or by circumstance, is es‐
sential in order to increase screening outcomes and compliance. There are unquestionably
many barriers to effective healthcare delivery in the US, let alone being able to appropriately
screen for CRC (Hoffman et al., 2011). Barriers can be sorted into a few main categories:
physician, patient, societal related factors. This section will touch on some of these obstacles.
5.1. The role of the physician in CRC screening
Physician recommendations play a crucial role in the decision to get screened for CRC (Zap‐
ka et al., 2011). A mere discussion of CRC screening at the time of an office visit may be suf‐
ficient and motivate patients to complete CRC screening. Given the prominence of the
physician factor it is important to consider elements that impact physician recommendation
of colonoscopy to their patients. Collegial norms, patient preferences, and published evi‐
dence including guidelines from the ACS and USPSF have been identified as important ele‐
ments. Physicians in the US favor endoscopy and often fail to adequately present
alternatives such as stool testing. One study found that 50% of the patients surveyed did not
receive the test they requested, and most underwent a colonoscopy instead (Hawley et al.,
2012). However, since all screening tests have some benefit, even if they are not on par with
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colonoscopy, physicians need to be sensitive and attuned to patient preferences. Techniques
other than colonoscopy may be more suitable for specific patients, given their individual cir‐
cumstances. For example, a recent study published in Cancer found that wealthy patients
frequently opt for colonoscopy while lower socioeconomic groups tended to choose at home
stool testing over endoscopy (Bandi et al., 2012). Patient preference varies by ethnicity as
well, with African Americans less likely to choose endoscopy than Caucasians (Dimou et al.,
2009). From their trial data, Inadomi and colleagues (Inadomi et al., 2012) predict that if co‐
lonoscopy were the only option offered, fewer patients would be screened. It is evident that
the choice of screening test should take into consideration not only the physician’s, but also
the patient’s perspective because some form of screening still remains superior to no screen‐
ing at all. Considering the evidence above, physicians should recommend one best option to
their patients using evidence-based medicine and taking into account patient specific fac‐
tors. CRC screening guidelines are complicated and offering multiple options still requires
shared decision making in practice (Zapka et al., 2011).
Although Medicare coverage has lessened these concerns, many physicians reported that
health  insurance  remains  very  influential  for  screening  recommendations  (White  et  al.,
2012).  Of note,  individuals  of  lower socioeconomic classes have expressed concerns that
they experience a lack of screening offers from doctors.  This is supported by physicians
who  admit  they  do  not  recommend  colonoscopy,  if  patients  do  not  have  insurance  or
ready access.  Another interesting difference in physician screening recommendation was
the age of the physician, with younger physicians recommending the test more. Although
this  is  merely  speculation,  younger  physicians  may  be  more  comfortable  ordering  this
newer test (Zapka et al., 2011).
In practice, physicians often fail to mention CRC screening because of limited time, compet‐
ing issues, and forgetfulness. At times the many pressing issues that need to be addressed,
preclude the lengthy discussion about available cancer screening tests. Additionally, many
patients only go to a clinic to address urgent issues. These clinics are often overbooked and
the main focus is to stabilize the acute problem. Some patients lack health insurance or are
unwilling to wait for appointments (Guerra et al., 2007). At best, some physicians may rec‐
ommend a follow up health maintenance visit. In addition, one national survey suggested
that the primary care physicians may not adequately discuss all test options available with
average risk patients because they are under the assumption that this will be addressed in
more depth by specialists. Screening rates suffer from lack of coordination between special‐
ists and PCPs (Doubeni et al., 2010). Physician forgetfulness and unfamiliarity with guide‐
lines is a preventable obstacle to screening (White et al., 2012). The screening and
surveillance recommendations differ significantly for a subset of CRC patients with heredi‐
tary syndromes. There is a marked lack of knowledge about screening guidelines for high-
risk populations based on family history and also ethnicity. Primary care physician
recommendations are often inconsistent with published guidelines. Among those most inti‐
mate with guidelines, the gastroenterologists, only a fraction recommended genetic counsel‐
ing, which is also a part of appropriate screening (White et al., 2012).
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5. Factors that impact effective screening
Colonoscopy is an accurate and effective screening technique that is endorsed by many soci‐
eties including the American Cancer Society, U.S. Multi-society Task Force, American Col‐
lege of Radiology, and American College of Gastroenterology (ACG) (Levin et al., 2008; Rex
et al., 2009; USPSTF, 2008). While it may seem that screening for CRC is a well-established
and accepted standard of care, screening rates for CRC have only recently started to ap‐
proach that of other cancers. Increasing interest in the issue of best practice for CRC screen‐
ing is attributable to updates to screening guidelines as a result of recent studies indicating
significant mortality benefits. In addition to changes in the actual screening guidelines, the
goal of screening has shifted to focus on cancer prevention by removing polyps rather than
simply cancer detection (USPSTF, 2008). Important factors exist that impact the effectiveness
of available screening modalities for CRC, and these originate from physicians, patients, as
well as from society. While current recommendations support initiation of screening at age
50 for all average risk men and women, earlier initiation is advocated for those at higher risk
including African American men and women. Knowledge about these guidelines can im‐
pact screening practice. Consideration must also be given to the modality of CRC screening.
The ACG recommends colonoscopy as the preferred mode of screening, and the gold stand‐
ard given it diagnostic and therapeutic potential (Rex et al., 2009). Studies demonstrate that
most physicians overwhelmingly prefer colonoscopy as the test of choice (Guerra et al.,
2007). In fact, 70% of PCPs strongly believe colonoscopy is the best available colorectal can‐
cer-screening test. Furthermore, a large proportion of physicians are concerned over law‐
suits if they do not offer screening colonoscopies. The fear of facing a lawsuit over
colonoscopy complications can be outweighed by the fear of being sued if the procedure is
not offered at all (McGregor et al., 2010; Varela et al., 2010). While CRC screening saves
lives, the use of colonoscopy and other available options, remains suboptimal. Pinpointing
the reasons why people are not getting screened, either by choice or by circumstance, is es‐
sential in order to increase screening outcomes and compliance. There are unquestionably
many barriers to effective healthcare delivery in the US, let alone being able to appropriately
screen for CRC (Hoffman et al., 2011). Barriers can be sorted into a few main categories:
physician, patient, societal related factors. This section will touch on some of these obstacles.
5.1. The role of the physician in CRC screening
Physician recommendations play a crucial role in the decision to get screened for CRC (Zap‐
ka et al., 2011). A mere discussion of CRC screening at the time of an office visit may be suf‐
ficient and motivate patients to complete CRC screening. Given the prominence of the
physician factor it is important to consider elements that impact physician recommendation
of colonoscopy to their patients. Collegial norms, patient preferences, and published evi‐
dence including guidelines from the ACS and USPSF have been identified as important ele‐
ments. Physicians in the US favor endoscopy and often fail to adequately present
alternatives such as stool testing. One study found that 50% of the patients surveyed did not
receive the test they requested, and most underwent a colonoscopy instead (Hawley et al.,
2012). However, since all screening tests have some benefit, even if they are not on par with
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colonoscopy, physicians need to be sensitive and attuned to patient preferences. Techniques
other than colonoscopy may be more suitable for specific patients, given their individual cir‐
cumstances. For example, a recent study published in Cancer found that wealthy patients
frequently opt for colonoscopy while lower socioeconomic groups tended to choose at home
stool testing over endoscopy (Bandi et al., 2012). Patient preference varies by ethnicity as
well, with African Americans less likely to choose endoscopy than Caucasians (Dimou et al.,
2009). From their trial data, Inadomi and colleagues (Inadomi et al., 2012) predict that if co‐
lonoscopy were the only option offered, fewer patients would be screened. It is evident that
the choice of screening test should take into consideration not only the physician’s, but also
the patient’s perspective because some form of screening still remains superior to no screen‐
ing at all. Considering the evidence above, physicians should recommend one best option to
their patients using evidence-based medicine and taking into account patient specific fac‐
tors. CRC screening guidelines are complicated and offering multiple options still requires
shared decision making in practice (Zapka et al., 2011).
Although Medicare coverage has lessened these concerns, many physicians reported that
health  insurance  remains  very  influential  for  screening  recommendations  (White  et  al.,
2012).  Of note,  individuals  of  lower socioeconomic classes have expressed concerns that
they experience a lack of screening offers from doctors.  This is supported by physicians
who  admit  they  do  not  recommend  colonoscopy,  if  patients  do  not  have  insurance  or
ready access.  Another interesting difference in physician screening recommendation was
the age of the physician, with younger physicians recommending the test more. Although
this  is  merely  speculation,  younger  physicians  may  be  more  comfortable  ordering  this
newer test (Zapka et al., 2011).
In practice, physicians often fail to mention CRC screening because of limited time, compet‐
ing issues, and forgetfulness. At times the many pressing issues that need to be addressed,
preclude the lengthy discussion about available cancer screening tests. Additionally, many
patients only go to a clinic to address urgent issues. These clinics are often overbooked and
the main focus is to stabilize the acute problem. Some patients lack health insurance or are
unwilling to wait for appointments (Guerra et al., 2007). At best, some physicians may rec‐
ommend a follow up health maintenance visit. In addition, one national survey suggested
that the primary care physicians may not adequately discuss all test options available with
average risk patients because they are under the assumption that this will be addressed in
more depth by specialists. Screening rates suffer from lack of coordination between special‐
ists and PCPs (Doubeni et al., 2010). Physician forgetfulness and unfamiliarity with guide‐
lines is a preventable obstacle to screening (White et al., 2012). The screening and
surveillance recommendations differ significantly for a subset of CRC patients with heredi‐
tary syndromes. There is a marked lack of knowledge about screening guidelines for high-
risk populations based on family history and also ethnicity. Primary care physician
recommendations are often inconsistent with published guidelines. Among those most inti‐
mate with guidelines, the gastroenterologists, only a fraction recommended genetic counsel‐
ing, which is also a part of appropriate screening (White et al., 2012).
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Studies have suggested that physicians may not be fully aware of patient’s attitudes and val‐
ues towards screening. Physicians underestimated test discomfort and did not recognize the
importance of helping patients make informed decisions for screening. In addition, several
studies have shown that PCPs recommendations are affected by their demography includ‐
ing age, sex and ethnicity. For example, non-Caucasian physicians are less likely to recom‐
mend cancer screening compared to Caucasian doctors. Hispanic physicians in the US were
found to be less likely to recommend CRC screening. In a study in Australia, general practi‐
tioners of Middle Eastern ethnicity estimated CRC incidence to be lower in immigrants com‐
pared to patients born in Australia, which may have resulted in lower recommendations of
CRC screening for immigrants (Koo et al., 2012). Thus in general, primary care physicians
need greater awareness about CRC rates and screening.
While patients cite physician recommendation as the number one motivator for screening, oth‐
er factors might impact compliance. Research demonstrates that providing excessive choices
can be overwhelming subsequently leading to confusion and indecision. Selection of one pre‐
ferred alternative may help simplify the discussion about screening (Inadomi et al., 2012).
Studies that target physician recommendations have been shown to be more effective than
those that focus only on the patient (Guerra et al., 2007). In contrast, others argue that options
are needed because every CRC screening modality has its own strengths and limitations. Ad‐
ditionally, there does not seem to be a clear consensus among patients about preferred meth‐
ods. Thus, an important question arises: would patients be more willing to participate in
screening, if they are given the opportunity to choose? Engaging patients in the decision-mak‐
ing process can improve satisfaction by taking into account each patient’s unique needs. A pa‐
tient-centered approach improves screening compliance (Inadomi et al., 2012).
5.2. Patient-based factors in CRC screening
At the center of the discussion related to screening is the patient’s participation in complet‐
ing the process. While low participation rates in screening related to infrequent or lack of
follow-up is a difficult barrier to overcome, other factors are also important. It is notable that
most of the data about reasons for screening non-compliance comes from direct physician
report (Hoffman et al., 2011). Physicians reported offering screening to all of their high risk
and most of their average risk patients, and most were surprised at the low adherence rates.
Through their interactions with patients, physicians believed barriers to screening were fear
of the test, embarrassment, lack of insurance, and lack of knowledge about cancer and
screening. Interestingly, when patients were asked the same questions, they did not feel that
discomfort or embarrassment kept them from undergoing the procedure. Patients reported
lack of physician recommendation as one of the main factors for not getting tested, along
with lack of symptoms that might suggest a colon neoplasm (Jones et al., 2010). Of course
these studies are limited in terms of the particular patient population sampled and may not
be applicable to all patients; however, it is important to note that patients place great impor‐
tance on the conversation with primary care providers about CRC screening (Fenton et al.,
2011). Furthermore, this is directly linked to patient’s knowledge about CRC and screening.
Misconceptions continue to prevail as barriers to CRC screening, indicating a continued
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need for brief, direct encouragement from providers to educate patients about screening,
particularly in the absence of symptoms or family history of CRC. Physicians can have great
impact on CRC screening, particularly with lifesaving colonoscopy, which is greatly un‐
derutilized in the US.
In a questionnaire investigating the patient barriers to CRC screening, hesitation about
screening was highest among never-screened respondents, intermediate among ever-
screened respondents who were overdue for testing, and lowest among the people adherent
with guidelines suggesting that different obstacles exist within each target group. The only
difference between those groups of patients is prior screening status. These results also dem‐
onstrate that people who have undergone screening are less fearful of the test itself, this
could be attributed to the fact that they have first hand experience instead of false informa‐
tion or misconceptions. Patients who are more educated are likely to be aware of the risks
and benefits of CRC screening (Winterich et al., 2011).
5.2.1. Patient attitudes, beliefs, and knowledge of CRC
Low compliance for CRC screening by patients can be attributed to several factors including
lack of insurance, cost, lack of knowledge of cancer and screening, not seeing a need for test‐
ing, embarrassment, lack of symptoms or health problems, fear of perceived pain, and anxi‐
ety of testing. This is in addition to failure by recommendation from a physician (Jones et al.,
2010). Studies have suggested that many patients dread getting ready for and having the
test and also worry about the test results. Additional research has found that the partici‐
pants did not understand the purpose of screening for cancer, were not able to distinguish
between screening tests from any other tests and did not realize that screening is performed
when a person feels well (Shokar et al., 2005).
Lack of knowledge is a major barrier to screening, particularly for immigrants, ethnic minor‐
ities, and underserved populations because of challenges in effective communication, as will
be discussed later. Studies looking into lack of knowledge about colon cancer screening
identified many other knowledge gaps including low health literacy. Some individuals did
not have a basic understanding of human anatomy and were not able to identify the location
of the colon nor its purpose. A subset of these individuals did not believe colon cancer exist‐
ed. Furthermore, a surprising amount of educated individuals could not accurately describe
the colon’s function, confusing it with the rectum and anus (Francois et al., 2009; Winterich
et al., 2011).
Those that had some fundamental knowledge of colon anatomy lacked an adequate under‐
standing about the causes and risk factors of colon cancer. Many individuals without symp‐
toms or family history do not feel concerned about this disease. Some are under the
impression that causes of colon cancer center around food and thought that bowel cleansing
was a good way to maintain or re-establish health. Others cited that they did not get
screened because they did not smoke, drink, eat unhealthy foods, or participate in anal sex,
all of which they perceived to be high-risk behaviors (Francois et al., 2009).
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Studies have suggested that physicians may not be fully aware of patient’s attitudes and val‐
ues towards screening. Physicians underestimated test discomfort and did not recognize the
importance of helping patients make informed decisions for screening. In addition, several
studies have shown that PCPs recommendations are affected by their demography includ‐
ing age, sex and ethnicity. For example, non-Caucasian physicians are less likely to recom‐
mend cancer screening compared to Caucasian doctors. Hispanic physicians in the US were
found to be less likely to recommend CRC screening. In a study in Australia, general practi‐
tioners of Middle Eastern ethnicity estimated CRC incidence to be lower in immigrants com‐
pared to patients born in Australia, which may have resulted in lower recommendations of
CRC screening for immigrants (Koo et al., 2012). Thus in general, primary care physicians
need greater awareness about CRC rates and screening.
While patients cite physician recommendation as the number one motivator for screening, oth‐
er factors might impact compliance. Research demonstrates that providing excessive choices
can be overwhelming subsequently leading to confusion and indecision. Selection of one pre‐
ferred alternative may help simplify the discussion about screening (Inadomi et al., 2012).
Studies that target physician recommendations have been shown to be more effective than
those that focus only on the patient (Guerra et al., 2007). In contrast, others argue that options
are needed because every CRC screening modality has its own strengths and limitations. Ad‐
ditionally, there does not seem to be a clear consensus among patients about preferred meth‐
ods. Thus, an important question arises: would patients be more willing to participate in
screening, if they are given the opportunity to choose? Engaging patients in the decision-mak‐
ing process can improve satisfaction by taking into account each patient’s unique needs. A pa‐
tient-centered approach improves screening compliance (Inadomi et al., 2012).
5.2. Patient-based factors in CRC screening
At the center of the discussion related to screening is the patient’s participation in complet‐
ing the process. While low participation rates in screening related to infrequent or lack of
follow-up is a difficult barrier to overcome, other factors are also important. It is notable that
most of the data about reasons for screening non-compliance comes from direct physician
report (Hoffman et al., 2011). Physicians reported offering screening to all of their high risk
and most of their average risk patients, and most were surprised at the low adherence rates.
Through their interactions with patients, physicians believed barriers to screening were fear
of the test, embarrassment, lack of insurance, and lack of knowledge about cancer and
screening. Interestingly, when patients were asked the same questions, they did not feel that
discomfort or embarrassment kept them from undergoing the procedure. Patients reported
lack of physician recommendation as one of the main factors for not getting tested, along
with lack of symptoms that might suggest a colon neoplasm (Jones et al., 2010). Of course
these studies are limited in terms of the particular patient population sampled and may not
be applicable to all patients; however, it is important to note that patients place great impor‐
tance on the conversation with primary care providers about CRC screening (Fenton et al.,
2011). Furthermore, this is directly linked to patient’s knowledge about CRC and screening.
Misconceptions continue to prevail as barriers to CRC screening, indicating a continued
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need for brief, direct encouragement from providers to educate patients about screening,
particularly in the absence of symptoms or family history of CRC. Physicians can have great
impact on CRC screening, particularly with lifesaving colonoscopy, which is greatly un‐
derutilized in the US.
In a questionnaire investigating the patient barriers to CRC screening, hesitation about
screening was highest among never-screened respondents, intermediate among ever-
screened respondents who were overdue for testing, and lowest among the people adherent
with guidelines suggesting that different obstacles exist within each target group. The only
difference between those groups of patients is prior screening status. These results also dem‐
onstrate that people who have undergone screening are less fearful of the test itself, this
could be attributed to the fact that they have first hand experience instead of false informa‐
tion or misconceptions. Patients who are more educated are likely to be aware of the risks
and benefits of CRC screening (Winterich et al., 2011).
5.2.1. Patient attitudes, beliefs, and knowledge of CRC
Low compliance for CRC screening by patients can be attributed to several factors including
lack of insurance, cost, lack of knowledge of cancer and screening, not seeing a need for test‐
ing, embarrassment, lack of symptoms or health problems, fear of perceived pain, and anxi‐
ety of testing. This is in addition to failure by recommendation from a physician (Jones et al.,
2010). Studies have suggested that many patients dread getting ready for and having the
test and also worry about the test results. Additional research has found that the partici‐
pants did not understand the purpose of screening for cancer, were not able to distinguish
between screening tests from any other tests and did not realize that screening is performed
when a person feels well (Shokar et al., 2005).
Lack of knowledge is a major barrier to screening, particularly for immigrants, ethnic minor‐
ities, and underserved populations because of challenges in effective communication, as will
be discussed later. Studies looking into lack of knowledge about colon cancer screening
identified many other knowledge gaps including low health literacy. Some individuals did
not have a basic understanding of human anatomy and were not able to identify the location
of the colon nor its purpose. A subset of these individuals did not believe colon cancer exist‐
ed. Furthermore, a surprising amount of educated individuals could not accurately describe
the colon’s function, confusing it with the rectum and anus (Francois et al., 2009; Winterich
et al., 2011).
Those that had some fundamental knowledge of colon anatomy lacked an adequate under‐
standing about the causes and risk factors of colon cancer. Many individuals without symp‐
toms or family history do not feel concerned about this disease. Some are under the
impression that causes of colon cancer center around food and thought that bowel cleansing
was a good way to maintain or re-establish health. Others cited that they did not get
screened because they did not smoke, drink, eat unhealthy foods, or participate in anal sex,
all of which they perceived to be high-risk behaviors (Francois et al., 2009).
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In addition to poor understanding about colon cancer, many misperceptions about colono‐
scopy itself were identified. One study captured the reasons some people did not like colo‐
noscopy including that the preparation was “inconvenient”, “uncomfortable”, and involved
a “compromising position”. Men of all races and levels of educational attainment shared the
male specific gender barrier that they were turned off by the invasive nature of the colono‐
scopy. While males and females have similar screening rates, men expressed more initial
hesitation about screening because of the fear that it threatens their masculinity. Men who
associated their masculinity with these exams experienced them more negatively (Winterich
et al., 2011). Interestingly, Winterich et al. (Winterich et al., 2011) found that as education in‐
creased, men’s negative views of colonoscopy also seemed to increase. Most individuals of a
low-educational attainment generally described the colonoscopy as a “good” test because of
the culturally dominant view that medical care is important (Winterich et al., 2011).
5.2.2. Racial and ethnic disparities in CRC screening
As mentioned earlier, screening rates differ based on race and ethnic groups. The National
Health Interview Survey reported that racial disparities seen with CRC screening are related
to socioeconomic status, however, racial disparities persist despite coverage for CRC screen‐
ing in a Medicare population (Wilkins et al., 2012). Compared to whites, blacks and Hispan‐
ics are less likely to be screened. Overall rates of CRC screening are estimated to be 50% and
it is even lower for minorities. Screening rates vary even within a racial or ethnic group, e.g
among Asians, Koreans and Vietnamese have lower rates of screening; among whites, those
living in Appalachia have lower screening rates. Minority populations and low socioeco‐
nomic status are considered to be factors resulting in low CRC screening rates (Linsky et al.,
2011). Research studies also suggest that immigrants may experience unique barriers such as
language and cultural differences with their health care providers which can lead to poorer
communication about the importance of screening (Goel et al., 2003).
5.2.3. The language divide
Patients who do not speak English are less likely to be screened (Linsky et al., 2011). Accord‐
ing to the 2005-2007 American Community Survey, minorities comprise 26% of the popula‐
tion, and nearly 20% of Americans speak a language other than English at home. By 2050,
minorities could make up about half of the US population, with a similar increase in indi‐
viduals speaking a language other than English at home. Spanish speaking Hispanics are
43% less likely to receive CRC screening. Communication problems when discussing cancer
screening are also documented with Vietnamese Americans (Linsky et al., 2011). Additional‐
ly, for Creole speaking Haitian Americans the language barrier may also be a factor in com‐
municating with physicians (Francois et al., 2009). While patient-physician language
discordance presents a barrier, it is possible to address it through initiatives such as transla‐
tion services so that disparities in screening rates can be reduced.
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5.2.4. Cultural chasms
Cultural beliefs can result in lower screening rates, for example, Italian- Australians, Mace‐
donian-Australians and Greek- Australians were found to believe that nothing can be done
to treat ‘malignant’ cancers and that in fact, treatment of cancers may hasten death (Severino
et al., 2009). They also believe that consumption of ‘unnaturally’ grown foods, eating foods
sprayed with pesticides or experiencing strong emotions may cause cancer. Studies with Af‐
rican Americans have indicated that the lack of CRC knowledge, lack of physician recom‐
mendation, and a distrust of the health care system and providers impede screening; as well
as a fatalistic belief (beliefs that screening and treatments are ‘futile’ since it is in “God’s
hands”) which has also been reported as a barrier for CRC screening (James et al., 2002). A
subset of individuals connected colon cancer with “someone putting a curse on you” (Fran‐
cois et al., 2009). Studies in Latino population suggest that fatalistic attitudes and fear of can‐
cer are barriers to cancer screening and misconceptions about the causes of cancer as well as
perceived discomfort and embarrassment (Walsh et al., 2004).
Among other factors, family recommendations and cultural norms weighed heavily on per‐
ceptions about cancer and colonoscopy. For example, studies with Mexican and Hispanic
communities have cited the need for strategies to distribute the information without causing
any stigma or embarrassment. Privacy is highly valued in Mexican culture and thus individ‐
ualized educational sessions are a good approach. On the other hand, Hispanic communities
prefer group educational workshops. Emphasis on family and being healthy to provide for
the family was effective, as well as convincing women within families of the importance of
screening. Latinos also tend to see doctors only when sick and combine traditional and
home healing with physician prescribed medications. Religion and spirituality seem to im‐
pact the willingness to accept CRC screening, as does low income and less education (Ge‐
trich et al., 2012).
In a study of Haitian immigrants, preventive care was not emphasized by the community.
Haitians make one of the largest immigrant groups in US and have the lowest percentage of
insurance coverage. Instead of having a primary physician they seem to rely on emergency
rooms and do not see a doctor unless there is something wrong, there is not an operating
concept valuing ‘check ups’. Undocumented persons, seek help only in an emergency situa‐
tion and instead rely on home remedies. These individuals expressed that they simply did
not want to know if there was something wrong with them, because finding one problem
might lead to other ones (Francois et al., 2009).
5.2.5. Health literacy and educational outreach in CRC screening
Efforts to empower patients to become involved in their own care have proven to be effec‐
tive. Health literacy campaigns in New York City have improved CRC screening rates.
Community education is required to promote screening and public education campaigns are
shown to be effective. For example Mr. Polyp ads, a public service announcement from the
American Cancer Society, led many to ask their doctors about colonoscopies (Guerra et al.,
2007). Population based interventions aimed at increasing the demand for screening include,
reminders and incentives, mass and small media, group and one-on-one education. Bilin‐
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In addition to poor understanding about colon cancer, many misperceptions about colono‐
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associated their masculinity with these exams experienced them more negatively (Winterich
et al., 2011). Interestingly, Winterich et al. (Winterich et al., 2011) found that as education in‐
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Patients who do not speak English are less likely to be screened (Linsky et al., 2011). Accord‐
ing to the 2005-2007 American Community Survey, minorities comprise 26% of the popula‐
tion, and nearly 20% of Americans speak a language other than English at home. By 2050,
minorities could make up about half of the US population, with a similar increase in indi‐
viduals speaking a language other than English at home. Spanish speaking Hispanics are
43% less likely to receive CRC screening. Communication problems when discussing cancer
screening are also documented with Vietnamese Americans (Linsky et al., 2011). Additional‐
ly, for Creole speaking Haitian Americans the language barrier may also be a factor in com‐
municating with physicians (Francois et al., 2009). While patient-physician language
discordance presents a barrier, it is possible to address it through initiatives such as transla‐
tion services so that disparities in screening rates can be reduced.
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any stigma or embarrassment. Privacy is highly valued in Mexican culture and thus individ‐
ualized educational sessions are a good approach. On the other hand, Hispanic communities
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Haitians make one of the largest immigrant groups in US and have the lowest percentage of
insurance coverage. Instead of having a primary physician they seem to rely on emergency
rooms and do not see a doctor unless there is something wrong, there is not an operating
concept valuing ‘check ups’. Undocumented persons, seek help only in an emergency situa‐
tion and instead rely on home remedies. These individuals expressed that they simply did
not want to know if there was something wrong with them, because finding one problem
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Community education is required to promote screening and public education campaigns are
shown to be effective. For example Mr. Polyp ads, a public service announcement from the
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gual verbal communication and ‘word of mouth’ are also potentially very effective modali‐
ties. Blumenthal et al. (Blumenthal et al., 2010) tested three interventions intended to
increase the rate of CRC screening among African Americans. They concluded that group
education doubled screening rates and reduced out of pocket expenses. Furthermore, differ‐
ences in attitudes and perceived barriers among ethnic and minority population may need
culturally tailored interventions. Focus groups with Hispanics identified fear of finding can‐
cer and fear of embarrassment from the examination, as screening obstacles. With this infor‐
mation, Varela et al. (Varela et al., 2010) developed targeted educational materials to
promote colonoscopies among Hispanics. Similar educational materials could tap into faith-
based programs like the successful Witness Project for breast cancer.
5.2.6. Patient navigators and customized CRC screening
As previously mentioned, ethnic and cultural differences can pose a great barrier to effective
cancer screening. Patient advocates who help coordinate care provide an option for tackling
screening disparities. Termed patient navigators, these individuals are laypersons from the
community who help patients navigate the intricacies of the health care system (Lasser et al.,
2011). They can better address the unique needs of a patient and are responsible for almost
anything such as helping patients get insurance, finding transportation to doctors’ appoint‐
ments, healthcare education, and emotional support. For example, patients that require in‐
terpreters are found to be less compliant with screening recommendations. Providing
patients with a healthcare ambassador who speaks their preferred language has proven to
be a simple yet extremely powerful intervention. In a randomized controlled trial, recently
published in the Archives of Internal Medicine, researchers found quantifiable benefits from
assigning black and non-English speaking patients with a healthcare navigator. These pa‐
tients had a greater likelihood of being screened by FOBT than control subjects (33.6% vs
20.0%; P<.001) and were also more likely to undergo colonoscopy (26.4% vs 13.0%; P,.001).
Moreover, these patients had more adenomas detected (8.1% vs 3.9%; P<.06) and more cases
of CRC prevented (Lasser et al., 2011). This study highlights the importance of a multidisci‐
plinary approach to medicine. The impact of patient navigators, especially on urban and ra‐
cial minorities, is demonstrated by numerous studies (Chen et al., 2008; Lasser et al., 2011;
Lasser et al., 2009; Ma et al., 2009; Myers et al., 2008; Nash et al., 2006). A recent study found
patient navigators to be effective for Creole or Portuguese speaking patients. This model can
be observed in practice in Boston where Partners in Health routinely trains paramedical per‐
sonnel to assist in providing customized care for patients with HIV and TB in Haiti and
Rwanda.
The benefit of a team approach to healthcare is further evidenced by studies demonstrating
that the use of nurse practitioners and physicians assistants further streamlines healthcare
delivery and improves screening compliance. Moreover, telephone counseling and printed
materials can help improve follow up and overall quality of life in colorectal cancer survi‐
vors. Clouston et al. (Clouston et al., 2012) performed a study to evaluate use of a website
and telephones on CRC screening rates and concluded that both increased compliance sig‐
nificantly. However, a strong and trusting family physician-patient relationship must be
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maintained; otherwise, patients will experience a fundamental disconnect in the patient-
physician relationship that may discourage screening. The team-based approach does not
look to replace the physician, but can enhance patient-physician discourse.
Customized programs targeted to specific individuals may help improve patient participa‐
tion rates. Tailored screening guidelines have been advocated for certain groups based on
noted prevalence and anatomic location of colonic lesions in these populations. For example,
women are known to have an increased risk of right-sided polyps and cancer (Chu et al.,
2011), while African Americans tend to develop colorectal cancer at an earlier age (Agrawal
et al., 2005). The recommendation for tailored screening guidelines as suggested by the ACG
have the potential to help address existing disparities in CRC but must be balanced by ease
of implementation as well as healthcare financing concerns.
5.3. Public policies, outreach, and CRC screening
Although screening rates for CRC remain suboptimal, there has been an overall upward
trend. Endorsement from various recommending organizations helped promote awareness
of CRC screening in the medical community. Supported by population-based studies, gas‐
troenterology organizations have promoted screening with colonoscopy as the best screen‐
ing test. The healthcare policy to support CRC screening through Medicare reimbursement
was impactful in developing further acceptance. Medicare’s decision to support screening
colonoscopy had a significant impact on the popularity of this modality as other payers fol‐
lowed suit. With insurance companies willing to pay, doctors were more inclined to recom‐
mend screening and free to choose their preferred modality, colonoscopy. In fact,
gastroenterologists report they are now performing many more colonoscopies than before.
Some spend 50% to 80% of their time performing this one procedure, a dramatic increase
from before (Ransohoff, 2005).
Public perception and support has greatly impacted the implementation of screening, espe‐
cially colonoscopy. All of the aforementioned factors are geared at gaining strong popular
support, a necessary ingredient for any widespread screening practice. For example, pros‐
tate cancer screening became widely practiced on the basis of popular support, even without
evidence of mortality reduction. Arguably the most influential aspect of colon cancer and
screening awareness was the increasing presence of colonoscopy in the media. Famous peo‐
ple affected by colon cancer include Ronald Reagan, Audrey Hepburn, and Daryl Strawber‐
ry to name a few. Public interest in colonoscopy reached a turning point in March of 2000,
the first colon cancer awareness month. This initiative was spearheaded by news icon Katie
Couric, who advocated for CRC screening on the national stage by televising her own colo‐
noscopy after her husband’s death (Cram et al., 2003). Similar appearances of colonoscopy
in the media impacted CRC screening practices in the United States. Most recently, Dr. Oz
underwent a colonoscopy on his eponymous television show. An editorial featured in the
New York Times entitled “Going the distance-the case for true colorectal-cancer screening”
garnered further support for colonoscopies stating that sigmoidoscopy, that only screens
part of the colon, is comparable to mammography for only one breast. Numerous editorials
and front page articles have featured colonoscopies (Ransohoff, 2005). For example a news‐
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gual verbal communication and ‘word of mouth’ are also potentially very effective modali‐
ties. Blumenthal et al. (Blumenthal et al., 2010) tested three interventions intended to
increase the rate of CRC screening among African Americans. They concluded that group
education doubled screening rates and reduced out of pocket expenses. Furthermore, differ‐
ences in attitudes and perceived barriers among ethnic and minority population may need
culturally tailored interventions. Focus groups with Hispanics identified fear of finding can‐
cer and fear of embarrassment from the examination, as screening obstacles. With this infor‐
mation, Varela et al. (Varela et al., 2010) developed targeted educational materials to
promote colonoscopies among Hispanics. Similar educational materials could tap into faith-
based programs like the successful Witness Project for breast cancer.
5.2.6. Patient navigators and customized CRC screening
As previously mentioned, ethnic and cultural differences can pose a great barrier to effective
cancer screening. Patient advocates who help coordinate care provide an option for tackling
screening disparities. Termed patient navigators, these individuals are laypersons from the
community who help patients navigate the intricacies of the health care system (Lasser et al.,
2011). They can better address the unique needs of a patient and are responsible for almost
anything such as helping patients get insurance, finding transportation to doctors’ appoint‐
ments, healthcare education, and emotional support. For example, patients that require in‐
terpreters are found to be less compliant with screening recommendations. Providing
patients with a healthcare ambassador who speaks their preferred language has proven to
be a simple yet extremely powerful intervention. In a randomized controlled trial, recently
published in the Archives of Internal Medicine, researchers found quantifiable benefits from
assigning black and non-English speaking patients with a healthcare navigator. These pa‐
tients had a greater likelihood of being screened by FOBT than control subjects (33.6% vs
20.0%; P<.001) and were also more likely to undergo colonoscopy (26.4% vs 13.0%; P,.001).
Moreover, these patients had more adenomas detected (8.1% vs 3.9%; P<.06) and more cases
of CRC prevented (Lasser et al., 2011). This study highlights the importance of a multidisci‐
plinary approach to medicine. The impact of patient navigators, especially on urban and ra‐
cial minorities, is demonstrated by numerous studies (Chen et al., 2008; Lasser et al., 2011;
Lasser et al., 2009; Ma et al., 2009; Myers et al., 2008; Nash et al., 2006). A recent study found
patient navigators to be effective for Creole or Portuguese speaking patients. This model can
be observed in practice in Boston where Partners in Health routinely trains paramedical per‐
sonnel to assist in providing customized care for patients with HIV and TB in Haiti and
Rwanda.
The benefit of a team approach to healthcare is further evidenced by studies demonstrating
that the use of nurse practitioners and physicians assistants further streamlines healthcare
delivery and improves screening compliance. Moreover, telephone counseling and printed
materials can help improve follow up and overall quality of life in colorectal cancer survi‐
vors. Clouston et al. (Clouston et al., 2012) performed a study to evaluate use of a website
and telephones on CRC screening rates and concluded that both increased compliance sig‐
nificantly. However, a strong and trusting family physician-patient relationship must be
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maintained; otherwise, patients will experience a fundamental disconnect in the patient-
physician relationship that may discourage screening. The team-based approach does not
look to replace the physician, but can enhance patient-physician discourse.
Customized programs targeted to specific individuals may help improve patient participa‐
tion rates. Tailored screening guidelines have been advocated for certain groups based on
noted prevalence and anatomic location of colonic lesions in these populations. For example,
women are known to have an increased risk of right-sided polyps and cancer (Chu et al.,
2011), while African Americans tend to develop colorectal cancer at an earlier age (Agrawal
et al., 2005). The recommendation for tailored screening guidelines as suggested by the ACG
have the potential to help address existing disparities in CRC but must be balanced by ease
of implementation as well as healthcare financing concerns.
5.3. Public policies, outreach, and CRC screening
Although screening rates for CRC remain suboptimal, there has been an overall upward
trend. Endorsement from various recommending organizations helped promote awareness
of CRC screening in the medical community. Supported by population-based studies, gas‐
troenterology organizations have promoted screening with colonoscopy as the best screen‐
ing test. The healthcare policy to support CRC screening through Medicare reimbursement
was impactful in developing further acceptance. Medicare’s decision to support screening
colonoscopy had a significant impact on the popularity of this modality as other payers fol‐
lowed suit. With insurance companies willing to pay, doctors were more inclined to recom‐
mend screening and free to choose their preferred modality, colonoscopy. In fact,
gastroenterologists report they are now performing many more colonoscopies than before.
Some spend 50% to 80% of their time performing this one procedure, a dramatic increase
from before (Ransohoff, 2005).
Public perception and support has greatly impacted the implementation of screening, espe‐
cially colonoscopy. All of the aforementioned factors are geared at gaining strong popular
support, a necessary ingredient for any widespread screening practice. For example, pros‐
tate cancer screening became widely practiced on the basis of popular support, even without
evidence of mortality reduction. Arguably the most influential aspect of colon cancer and
screening awareness was the increasing presence of colonoscopy in the media. Famous peo‐
ple affected by colon cancer include Ronald Reagan, Audrey Hepburn, and Daryl Strawber‐
ry to name a few. Public interest in colonoscopy reached a turning point in March of 2000,
the first colon cancer awareness month. This initiative was spearheaded by news icon Katie
Couric, who advocated for CRC screening on the national stage by televising her own colo‐
noscopy after her husband’s death (Cram et al., 2003). Similar appearances of colonoscopy
in the media impacted CRC screening practices in the United States. Most recently, Dr. Oz
underwent a colonoscopy on his eponymous television show. An editorial featured in the
New York Times entitled “Going the distance-the case for true colorectal-cancer screening”
garnered further support for colonoscopies stating that sigmoidoscopy, that only screens
part of the colon, is comparable to mammography for only one breast. Numerous editorials
and front page articles have featured colonoscopies (Ransohoff, 2005). For example a news‐
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paper ad made the assertion, “your golden years deserve the gold standard of colon cancer
screening” (American College of Gastroenterology [ACG], 2012). Additional marketing on
the web has helped improve awareness among the public who increasingly use the web for
health information (Cohen and Adams, 2011).
5.3.1. Healthcare access
For patients to consider screening, it is important that to have insurance coverage, access to
healthcare or both. Only 24% of uninsured Americans, who do not have a usual source of
health care and are eligible, participate in CRC screening (Shapiro et al., 2012). Patients with
higher incomes are likely to have health insurance and tend to have a consistent source of
care. A recent systemic review reported that lower socioeconomic status was correlated with
a higher incidence and mortality rate (Wilkins et al., 2012). Subramanian et al. (Subramanian
et al., 2010) argue that when budgets are tight, options other than colonoscopies are better
for screening, basing this on the premise that some form of screening is better than no
screening at all. This study asserts that state and federal agencies have screening programs
for the uninsured and underinsured that may not be able to support colonoscopy in their
limited budget. However efficacy of the guaiac based fecal blood test depends on 100% com‐
pliance. This is often not practical and the study’s authors admit that colonoscopy is still a
better screening test if annual testing is not feasible.
In addition to financial access, geographic access can pose a problem for individuals in rural
areas. In New York City and other urban centers, most hospitals and many private practices
will offer colonoscopy; however, this is not the case in every part of the country. Several
studies have found lower screening rates in rural versus nonrural areas (Wilkins et al.,
2012). Geographic distance is a factor and individuals are less likely to be screened if the
nearest colonoscopy-offering center is over an hour away. The rural countries in the study
by Wilkins et al. (Wilkins et al., 2012) had higher poverty rates, lower educational level, lim‐
ited access to doctors, and less insurance coverage.
5.3.2. National programs
The benefits of a team approach to healthcare is further evidenced by national programs
that help promote patient awareness and education about CRC screening. Health policy ini‐
tiatives need to underscore the importance of screening programs to improve quality of can‐
cer screening. Cancer registries may be of use to identify and monitor the incidence, stage of
cancer and screening rate across regions. A CRC screening registry similar to Breast Cancer
Surveillance Consortium could be established to monitor rates of screening, overuse, quality
and complications. An ideal monitoring system should be able to estimate rates of screening
regardless of patient’s insurance status and demographic characteristics, assess use, appro‐
priateness and outcomes. Efforts should be made to support expansion, analysis and collab‐
oration of existing data sources and databases such as Clinical Outcome Research Initiative
(CORI) endoscopy data base, the Cancer Research Network (CRN) and the Computed To‐
mography Colonography Registry.
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5.3.3. Communication via current technologies
The use of systems strategies can improve physician delivery of healthcare. Systems strat‐
egies employ patient and physician screening reminders, performance reports of screening
rates, and electronic medical records (Yabroff et al., 2011). Given time constraints, remem‐
bering to perform all routine screenings for every patient is difficult. The increasing use of
electronic medical records (EMR) has helped physicians overcome this obstacle. Pop-up re‐
minders can help minimize forgetfulness, as well as the added pressure of remembering in‐
dividualized guidelines. These electronic prompts have the additional advantage of
flexibility, which allows for screening to account for the patient’s personal and family histo‐
ry. In one retrospective survey, the physicians that utilized this technology, which automati‐
cally provided appointments for CRC screening at a certain age, had the highest screening
rates (Fenton et al., 2011).
In addition to physician prompts, organized screening programs make use of patient re‐
minders to improve screening compliance. These programs reach out to all members of the
population due for CRC screening via mailed reminders (Levin et al., 2011). In addition to
outreach mailings, the Task Force on Community Preventive Services of the Centers for Dis‐
ease Control and Prevention recommend performance reports for doctors. Monetary incen‐
tive from insurance companies for completing age-appropriate screening is effective.
Additionally, better reimbursements are needed to encourage spending time on preventive
medicine (Guerra et al., 2007). Brouwers (Brouwers et al., 2011) conducted a systemic review
that included 66 randomized controlled studies and a cluster of randomized controlled tri‐
als. They concluded that client reminders, small media and provider audit and feedback ap‐
pear to increase screening rates significantly. Despite evidence that systems strategies are
effective, relatively few physicians report using a comprehensive plan to promote cancer
screening (Yabroff et al., 2011).
5.3.4. Health insurance coverage for colonoscopy
Ensuring health insurance coverage and usual source of care will most likely increase use
among those who have never been screened. Following Medicare’s example, private insur‐
ance coverage of CRC screening will be a step towards resolving the cost issue for physi‐
cians and patients. Asking patients to pay thousands of out of pocket expenses to undergo a
colonoscopy, will not help increase the rates of this life saving procedure. In a step to in‐
crease testing accessibility and affordability, the Affordable Care Act will ask insurers to
cover screening colonoscopies. This will include not only colonoscopy, but the use of anes‐
thesia (e.g. propofol) as opposed to conscious sedation (e.g., midazolam, fentanyl). Provid‐
ing increased options for sedation is likely to remove the patient barrier related to
discomfort and make it more likely that individuals will comply with colonoscopy as a life-
saving screening modality (Liu et al., 2012).
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paper ad made the assertion, “your golden years deserve the gold standard of colon cancer
screening” (American College of Gastroenterology [ACG], 2012). Additional marketing on
the web has helped improve awareness among the public who increasingly use the web for
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5.3.1. Healthcare access
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limited budget. However efficacy of the guaiac based fecal blood test depends on 100% com‐
pliance. This is often not practical and the study’s authors admit that colonoscopy is still a
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areas. In New York City and other urban centers, most hospitals and many private practices
will offer colonoscopy; however, this is not the case in every part of the country. Several
studies have found lower screening rates in rural versus nonrural areas (Wilkins et al.,
2012). Geographic distance is a factor and individuals are less likely to be screened if the
nearest colonoscopy-offering center is over an hour away. The rural countries in the study
by Wilkins et al. (Wilkins et al., 2012) had higher poverty rates, lower educational level, lim‐
ited access to doctors, and less insurance coverage.
5.3.2. National programs
The benefits of a team approach to healthcare is further evidenced by national programs
that help promote patient awareness and education about CRC screening. Health policy ini‐
tiatives need to underscore the importance of screening programs to improve quality of can‐
cer screening. Cancer registries may be of use to identify and monitor the incidence, stage of
cancer and screening rate across regions. A CRC screening registry similar to Breast Cancer
Surveillance Consortium could be established to monitor rates of screening, overuse, quality
and complications. An ideal monitoring system should be able to estimate rates of screening
regardless of patient’s insurance status and demographic characteristics, assess use, appro‐
priateness and outcomes. Efforts should be made to support expansion, analysis and collab‐
oration of existing data sources and databases such as Clinical Outcome Research Initiative
(CORI) endoscopy data base, the Cancer Research Network (CRN) and the Computed To‐
mography Colonography Registry.
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effective, relatively few physicians report using a comprehensive plan to promote cancer
screening (Yabroff et al., 2011).
5.3.4. Health insurance coverage for colonoscopy
Ensuring health insurance coverage and usual source of care will most likely increase use
among those who have never been screened. Following Medicare’s example, private insur‐
ance coverage of CRC screening will be a step towards resolving the cost issue for physi‐
cians and patients. Asking patients to pay thousands of out of pocket expenses to undergo a
colonoscopy, will not help increase the rates of this life saving procedure. In a step to in‐
crease testing accessibility and affordability, the Affordable Care Act will ask insurers to
cover screening colonoscopies. This will include not only colonoscopy, but the use of anes‐
thesia (e.g. propofol) as opposed to conscious sedation (e.g., midazolam, fentanyl). Provid‐
ing increased options for sedation is likely to remove the patient barrier related to
discomfort and make it more likely that individuals will comply with colonoscopy as a life-
saving screening modality (Liu et al., 2012).




This chapter has summarized the current body of knowledge related to colorectal cancer
screening and surveillance recommendations in the context of addressing risk stratification,
when to start and stop screening, as well as factors that impact screening rates. Overall,
screening, detection, and removal of precancerous lesions allow for the prevention of CRC.
It is notable that although strong evidence now exists for the mortality benefits of CRC
screening, significant disparities remain in the disease thus giving rise to opportunities to
address physician, patient, as well as societal factors that can improve screening rates.
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1. Introduction
René Descartes (1596-1650) in the published Discourse on Method, wrote: “…And because
the actions of life often brook no delay, it is certainly very true that, when it is not in our
power to determine the truest opinions, we ought to follow the most probable ones, and
even when we see no difference in probability among this group of truths or that one, never‐
theless, we have to decide on some for ourselves and then to consider them, not as some‐
thing doubtful with regard to the practical matter at hand, but as manifestly true and very
certain, because the reason which made us choose them has these qualities”. [1] Colonosco‐
py (COL) issues this doubt.
Everybody known the effect of COL on colorectal cancer (CRC) until 2009, when an observa‐
tional case–control study did not identify a reasonable explanation for COL: much less effec‐
tive in preventing death from colorectal cancer (CRC) of the right colon compared with the
left colon [2]. Moreover to prevent one cancer death, 1,250 colonoscopies need to be per‐
formed, but perforation of the colon occurs at a rate of about 1 in 1000 procedures [3].
Since polyps often take 10 to 15 years to transform into cancer, in someone at average risk of
colorectal cancer, guidelines recommend 10 years after a normal screening COL before the
next COL. [4,5]. By removing premalignant adenomas and detecting early cancer, COL
should lower colorectal cancer mortality. Although gastroenterologists strongly believe that
© 2013 Vannelli et al.; licensee InTech. This is an open access article distributed under the terms of the
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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COL lowers colorectal cancer mortality, evidence in support of this belief is indirect. Robert
S. Sandler in 2010 wrote: “The mortality from colorectal cancer has actually been decreasing
steadily since 1980, long before widespread use of COL or any other screening, and before
use of effective adjuvant therapy for cancer” [6].
However the high cost of biological therapy for advanced CRC, and the high risk of CRC in
low-income population are likely to affect the cost-effectiveness of COL in the future [7,8].
In  Italy  CRC rank  third  for  incidence  among male  (second among female)  and  second
among the most frequent causes of tumour death for both men and women [9]. The cur‐
rent  trend  of  the  incidence  shows  a  slow-down  among  male  patients  and  stabilization
among women. Mortality seems to be in decrease in particular in the population under
50 years old. In Southern Italy and in the Italian islands the incidence is lower (like mor‐
tality), but its trend is less favourable than in central-northern Italy. In the Southern Italy
trends on the increase are reported both among men and women. The success of Color‐
ectal  cancer  screening  (CCS)  is  the  success  of  COL.  However  there  are  critical  points:
complications  of  COL programmes;  low coverage;  low compliance;  overload  on  endos‐
copy facilities.  Faecal  occult  blood screening (FOBT)  for  CRC in  men and women aged
50 to 74 is the Italian and European Union recommendation [10]. CCS is widely accepted
as a public  health policy in Italy [11].  On the contrary few regions have adopted wide‐
spread CCS programmes, although some are inching their way to that goal [12]. The rea‐
son,  is  the  burden  that  extensive  CCS  places  on  COL  services  [13].  Behind  every  CCS
test,  no matter what kind, is  the potential  need for a COL, who can detect and remove
adenomas, and detect asymptomatic cancers [14-19].
The social and economical impact of CRC is such, to warrant the decisions of the Italian gov‐
ernment to implement the screening as a form of prevention. According to the Italian gov‐
ernment agreements, on September 30th 2010, the Italian Regions should have implemented
the Plan of National Prevention and transformed it into Plan of Regional Prevention: April
24th 2010 agreement between Government, Regions and Autonomous Provinces of Trento
and Bolzano: “… the regions are committed to implement by September 30, 2010, the Re‐
gional Plan of Prevention to carry out the interventions established by the National Plan of
Prevention …” [20].
Two authorities coordinate activities and research projects for both general and specific,
population. The Italian Network of Cancer Registries (AIRTUM), and the National Centre
for Disease Prevention and Control (Ccm) [21,22].
AIRTUM, called AIRT until  2006, was born in 1997, in 2005, AIRTUM created a central‐
ized database where data from Cancer Registries are stored and, after checked for quali‐
ty and completeness, used for collaborative studies on cancer epidemiology in Italy [14].
Cancer registration in Italy began in the 1970s with a steady increase in experiences and
coverage  of  an  increasing  proportion  of  the  Italian  resident  population.  The  density  of
registries is greater in northern Italy, especially in the North-east, compared with Central
and Southern Italy (Figure 1).
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Figure 1. Italian Network of Cancer Registries: red actived, white not yet actived.
On the other hand, especially in the South of Italy, cancer registration has remarkably ex‐
panded in recent years with several new registries, which provide a more detailed and de‐
scriptive dataset of the oncologic illnesses in this area of Italy. Figure 1 shows the proportion
of the resident population covered by cancer registries according to region and geographic
macroareas (Northwest, Northeast, Centre, and South). Regional coverage varies from 0% in
several southern regions (Puglia, Basilicata, Abruzzi, Molise), as well as Val d’Aosta, to
100% (e.g., Umbria, Friuli Venetia Giulia, Trento, and Bolzano). Nevertheless, Southern Italy
reported an increase in cancer reporting. Today more than a third of the Italian population
lives in an area with an active cancer registry. This proportion differs between areas (37% in
the Northwest, 68% in the Northeast, 26% in the Centre, and 18% in South). Overall, AIR‐
TUM Registries involve more than 19.000.000 subjects, or 34% of the entire Italian resident
population. The importance of AIRTUM, is supported by the growing number of accredited
registries contributing to the centralized dataset, thus improving representation at the na‐
tional level. Furthermore, the presence of historic registries, operating since the 1980s, has
helped calculate 20-year incidence trends, and stable, robust prevalence estimates. Ccm is to
liaise between the Ministry of health on the one side, and regional governments on the other
as regards surveillance, prevention and promptly responding to emergencies [23-25]. Over
the years, Ccm has acquired a specific identity, which makes it unique within the frame‐
work of Italian public health; its main features are: analyze health hazards implementation
in prevention secondary and tertiary prevention. The Centre is a bridge between the world
of research and health facilities on the one hand, and the best practices and entities being
developed on the other, by activating institutional partnerships and professional collabora‐
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COL lowers colorectal cancer mortality, evidence in support of this belief is indirect. Robert
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On the other hand, especially in the South of Italy, cancer registration has remarkably ex‐
panded in recent years with several new registries, which provide a more detailed and de‐
scriptive dataset of the oncologic illnesses in this area of Italy. Figure 1 shows the proportion
of the resident population covered by cancer registries according to region and geographic
macroareas (Northwest, Northeast, Centre, and South). Regional coverage varies from 0% in
several southern regions (Puglia, Basilicata, Abruzzi, Molise), as well as Val d’Aosta, to
100% (e.g., Umbria, Friuli Venetia Giulia, Trento, and Bolzano). Nevertheless, Southern Italy
reported an increase in cancer reporting. Today more than a third of the Italian population
lives in an area with an active cancer registry. This proportion differs between areas (37% in
the Northwest, 68% in the Northeast, 26% in the Centre, and 18% in South). Overall, AIR‐
TUM Registries involve more than 19.000.000 subjects, or 34% of the entire Italian resident
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liaise between the Ministry of health on the one side, and regional governments on the other
as regards surveillance, prevention and promptly responding to emergencies [23-25]. Over
the years, Ccm has acquired a specific identity, which makes it unique within the frame‐
work of Italian public health; its main features are: analyze health hazards implementation
in prevention secondary and tertiary prevention. The Centre is a bridge between the world
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tions: its aim is to build an Italian prevention network. The goal of Ccm is to optimise the
national prevention Plan checking surveillance plans and active prevention with the Re‐
gions.(Figure 2).
Figure 2. Regional colorectal cancer screening: red actived, white not yet actived, red and white partial actived.
The cooperation with these two authorities introduced design standards and evaluation cri‐
teria, as part of an active collaboration relationship between AIRTUM, CCM and the part‐
ners with which it has agreements, both in the design and monitoring phase of programmes
and projects of CCS.
At the present days, no studies are ongoing to define the cause-effect relationship between
costs, CCS programme, and COL.
In this paper we show how both the choice of specific constraints on output weights (CCS
programme) can affect the measurement of COL efficiency using the "Data Envelopment
Analysis" (DEA).
In their originating study, Charnes, Cooper, and Rhodes on 1978, described DEA as a
“mathematical programming model applied to observational data [that] provides a new
way of obtaining empirical estimates of relations - such as the production functions and/or
efficient production possibility surfaces – that are cornerstones of modern economics” [27].
DEA is a relatively new “data oriented” approach for evaluating the performance of a set of
peer entities called Decision Making Units (DMUs) which convert multiple inputs into mul‐
tiple outputs.
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DEA is applied by the management control to evaluate the relative efficiency of human re‐
sources, the results are related to the cost of diagnostic procedures, standardized by the
case-mix, and both scatter plot and cluster analysis are produced to find out related area of
performance and to plan a strategy for the continuous quality improvement. The objective
of this study therefore, is to propose one model of study of the costs in the strategy of CCS
supporting the benefits of COL using DEA model.
2. Materials and methods
The absence in the literature of previous experience or analogous models can makes difficult
to create a logistic model. At the present days, there are many studies to define the cause-
effect relationship between costs, and CCS programme, or between costs and COL. The ob‐
jective of this study is to propose one model of study of the costs in the strategy of CCS
supporting the benefits of COL using DEA model. Since the incidence of colorectal cancer
shows a geographical variability, we considered the epidemiological data in the light of the
different Italian cancer records, which are often referred to provincial or regional results and
we compared them with the screening tests available in each Region.
In the first part of the paper, we calculated the global population in Italy and the number of
current colorectal cancer cases using the historical archive of ISTAT (Italian National Insti‐
tute of Statistics). The ISTAT produces and distributes information that describes the social,
economic and environmental conditions of the Country, and the changes taking place with‐
in it, in strict compliance with legal provisions on confidentiality. As the main producer of
national statistics, it provides data and releases information to European statistical authori‐
ties and international organizations. We then evaluated the economical impact considering
every single available regional result obtained from the archives of Age.Na.S. (Italian Agen‐
cies for Regional Health Care Services), AIRTUM, and CCM, and comparing them with the
available Italian data obtained from the Italian Ministry of Health and the statistical registers
of INAIL (Italian institute for insurance against industrial accident) and INPS (Italian Insti‐
tute of social insurance). The Age.Na.S. is a public agency founded in 1993. In the Italian
healthcare service the Agency plays as a technical body supporting the Ministry of Labour,
Health and Social Services and Regions. The Agency also coordinates health research pro‐
grams financed by the Ministry of Labour, Health and Social Services or by the Regions. The
National Fund against Accidents created on 1883, took the name of INAIL on 1933. INAIL
took up the management of compulsory insurance against occupational diseases in the in‐
dustrial and agricultural sector, diseases caused by X-rays and radioactive substances; com‐
pulsory insurance has also been extended to "housewives". It produces and distributes
information on occupational diseases. The INPS, established in 1933, is the large Italian pub‐
lic body that pays out old-age pensions to workers, after receiving contributions from them
throughout their working lives, and manages the types of assistance provided for by the
“social state”, sickness, maternity and unemployment benefits, invalidity payments and so‐
cial payments for citizens who are in need. INPS is one of the biggest public body in Europe,
produces and distributes information that describes National Health Service.
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In view of the geography of the Italian territory and the distribution of the population we
analyzed the data considering three macro-areas which include different regions, i.e. the re‐
gions of Northern Italy: Piedmont, Emilia Romagna, Liguria, Friuli Venetia Giulia, Veneto,
Trenton Alto-Adige, Lombardy and Valle d’Aosta; the regions of Central Italy: Tuscany,
Umbria, Latium, Marche, Abruzzi, Molise and Sardinia; the regions of Southern Italy: Cam‐
pania, Puglia, Basilicata, Calabria and Sicily.
For each Region we considered the following indicators in order to assess a possible plan of
screening campaign of colorectal cancers: global population, mean age and population older
than 65 years; relationship between Gross Domestic Product (GDP) and per capita income;
incidence of colorectal cancer and possible screening campaign on the territory; index of pa‐
tients’ emigration and reimbursement through Diagnostic Related Group (DRG) of the path‐
ology as a ratio versus the unit value represented by Italy as a system.
The second part of the paper is the object of the article: the implement of particular method‐
ologies in order to determine which COL is cost-effective in the mass CCS programme. In
this chapter a method for efficiency measurement in CCS programme has been described.
First an overview of efficiency measurements applicable is given. Calculation methods is de‐
scribed and examples of inputs and outputs are provided.
A method to measure efficiency is proposed. This method proves to be particularly suc‐
cessful  in  cost-efficiency  analysis,  when  the  performance  indicators  are  numerous  and
hard  to  aggregate.  The  results  show  that  there  are  two  cost-effective  strategies  after  a
positive FOBT: COL.
We performed an explorative study to efficiency measurement in CCS. To construct an effi‐
ciency measure or measures for the CCS programme, literature has been searched for differ‐
ent types of efficiency measures used in healthcare. Hence a selection of criteria and
methods is made which tend to be suitable to evaluate which COL is cost-effective in the
mass CCS programme.
Besides Italian CCS programme were carried out to gain understanding of the care process
for CRC patients. The proper knowledge of the process it is useful to choose suitable per‐
formance indicators.
3. Results
Out of a population of 60.387.000 inhabitants (data updated at 2010), the incidence of color‐
ectal cancers was almost of 49.000 cases, with a prevalence of over 310.000 cases and mortali‐
ty higher than 18.000 cases (data updated at 2006). The analysis of the abovementioned three
macro-areas is characterized by strong differences both in general and in particular terms.
There are considerable imbalances between the Northern, Central and Southern areas con‐
sidering their input, output and outcome.
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Data in terms of distribution of population, mean age and population older than 65 years
are distributed in the different macro-areas according to the distribution recorded by the
Italian Institute of Statistics which depicts particular realities partially due to the industrial
development and the local health level. We can differentiate in detail the following data for




























Liguria 1.615.064 47,3 26,7 1,03 104,16
82,5
1 plan 11,19 1
Friuli-Venetia
Giulia
1.230.936 45,4 22,7 1,11 140,17
95,52
Global regional plan 6,4 1,22
Veneto 4.885.548 42,9 19,3 1,15 124,02
83,94
17 plans 5,31 1,17
Trenton Alto-
Adige










Valle d’Aosta 127.065 43,6 20,3 1,32 82,83
60,04
Global regional plan 22,17 1
ITALY 60.387.000 42,8 19,9 1 107,8
69,64
L.D. 138 2004 art. 2
bis
Sof > 50 years
- - 1
Table 1. Macro-area: Northern Italy
Piedmont is a Region with a large-size population with mean age and rate of elderly popula‐
tion higher than the Italian average. It has at its disposal a bit more resources than the Italian
average and its screening campaign covers only some provinces; the incidence of the disease
is lower than the Italian average; the emigration index is low and the refund of the health
expenditure is a little bit higher than the national average. Emilia Romagna is a large-size
population with mean age and rate of elderly persons higher than the Italian average. It has
at its disposal more resources than the national average and its screening campaign covers
all the provinces, the incidence of the disease is higher than the Italian average; the emigra‐
tion index is low and the refund of the health expenditure is a little bit higher than the na‐
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We performed an explorative study to efficiency measurement in CCS. To construct an effi‐
ciency measure or measures for the CCS programme, literature has been searched for differ‐
ent types of efficiency measures used in healthcare. Hence a selection of criteria and
methods is made which tend to be suitable to evaluate which COL is cost-effective in the
mass CCS programme.
Besides Italian CCS programme were carried out to gain understanding of the care process
for CRC patients. The proper knowledge of the process it is useful to choose suitable per‐
formance indicators.
3. Results
Out of a population of 60.387.000 inhabitants (data updated at 2010), the incidence of color‐
ectal cancers was almost of 49.000 cases, with a prevalence of over 310.000 cases and mortali‐
ty higher than 18.000 cases (data updated at 2006). The analysis of the abovementioned three
macro-areas is characterized by strong differences both in general and in particular terms.
There are considerable imbalances between the Northern, Central and Southern areas con‐
sidering their input, output and outcome.
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Table 1. Macro-area: Northern Italy
Piedmont is a Region with a large-size population with mean age and rate of elderly popula‐
tion higher than the Italian average. It has at its disposal a bit more resources than the Italian
average and its screening campaign covers only some provinces; the incidence of the disease
is lower than the Italian average; the emigration index is low and the refund of the health
expenditure is a little bit higher than the national average. Emilia Romagna is a large-size
population with mean age and rate of elderly persons higher than the Italian average. It has
at its disposal more resources than the national average and its screening campaign covers
all the provinces, the incidence of the disease is higher than the Italian average; the emigra‐
tion index is low and the refund of the health expenditure is a little bit higher than the na‐
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tional average. Liguria has a middle-size population with mean age and rate of elderly
definitely higher than the Italian average. It has at its disposal a little bit more resources than
the Italian average and its screening campaign covers only one province; the incidence of
the disease is lower than the National average; its emigration index is high and the refund of
the health expenditure is on the average. Friuli Venetia Giulia Region has a middle-size pop‐
ulation with mean age and rate of elderly persons higher than the Italian average. It has at
its disposal more resources than the Italian average and its screening campaign covers all
the provinces with a regional plan; the incidence of the disease is higher than the national
average; its emigration index is low and the refund of the health expenditure is higher than
the national average.
Veneto Region has a large-size population with mean age and rate of elderly in line with
the Italian average. It  has at its disposal more resources than the Italian average and its
screening campaign covers all  the provinces;  the incidence of  the disease is  higher than
the national  average,  its  emigration index is  low and the refund of  the health expendi‐
ture  is  higher  than  the  national  average.  Trenton  Alto  Adige  Region  has  a  middle-size
population with mean age and rate of elderly persons lower than the Italian average. It
has at its disposal more resources than the national average and its screening campaign
covers the whole region,  the incidence of  the disease is  higher than the Italian average;
its emigration index is high and the refund of the health expenditure is in line with the
national  average.  Lombardy has a  large-size  population with mean age higher  than the
average and a rate of elderly slightly lower than the Italian average. It has at its disposal
more resources than the national average and its screening campaign covers all its prov‐
inces, the incidence of the disease is slightly higher than the Italian average, it has a low
emigration index and the refund of  health expenditure  is  lower than the national  aver‐
age. Valle d’Aosta Region has a small-size population with mean age and rate of elderly
persons higher than the national  average.  It  has at  its  disposal  more resources than the
national  average,  its  screening campaign covers  the  whole  Region,  the  incidence  of  the
disease is lower than the national average; it has a high emigration index and the refund
of health expenditure is in line with the national average.
Tuscany Region has a large-size population with mean age and rate of elderly persons high‐
er than the Italian average. It has at its disposal more resources than the Italian average and
its screening campaign covers the whole territory; the incidence of the disease is lower than
the national average; its emigration index is mean and the refund of health expenditure is
lower than the national average. Umbria Region has a small-size population with mean age
and a rate of elderly persons higher than the Italian average. It has at its disposal fewer re‐
sources than the Italian average and its screening campaign covers the whole Region; the in‐
cidence of the disease is higher than the national average; the emigration index is high and
the refund of health expenditure is higher than the national average.
Lazio Region has a large-size population with mean age and a rate of elderly persons lower
than the Italian average. It has at its disposal more resources than the Italian average and its
screening campaign covers only some provinces; the incidence of the disease is lower than
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the national average; its emigration index is intermediate and the refund of health expendi‐




























Lazio 5.626.710 42,6 19,2 1,22 89,06
52,57
4 plans 6,64 0,89
Marche 1.569.578 44,3 22,6 1,00 109,89
67,70
2007 pilot project 10,75 1
Abruzzi 1.334.675 43,4 21,3 0,81 113,25
42,75
6 plans 10,2 1
Molise 320.795 43,6 22,0 0,72 113,29
43,16
Global Regional plan 20,62 1
Sardinia 1.671.001 42,2 17,8 0,80 101,42
54,12
1 plan 4,24 1
ITALY 60.387.000 42,8 19,9 1 107,8
69,64
L.D. 138 2004 art. 2
bis Sof > 50 years
- - 1
Table 2. Macro-area: Central Italy
Marche Region has a middle-size population with mean age and rate of elderly persons
higher than the Italian average. It has at its disposal resources in line with the national aver‐
age and implements no screening campaign; the incidence of the disease is higher than the
national average; its emigration index is high and the refund of health expenditure is in line
with the national average.
Abruzzi has a middle-size population with mean age and rate of elderly persons higher than
the Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease is higher than
the national average; its emigration index is high and the refund of health expenditure is in
line with the national average.
Molise Region has a small-size population with mean age and rate of elderly higher than the
Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers the whole Region; its emigration index is high and the refund of
health expenditure is in line with the national average.
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tional average. Liguria has a middle-size population with mean age and rate of elderly
definitely higher than the Italian average. It has at its disposal a little bit more resources than
the Italian average and its screening campaign covers only one province; the incidence of
the disease is lower than the National average; its emigration index is high and the refund of
the health expenditure is on the average. Friuli Venetia Giulia Region has a middle-size pop‐
ulation with mean age and rate of elderly persons higher than the Italian average. It has at
its disposal more resources than the Italian average and its screening campaign covers all
the provinces with a regional plan; the incidence of the disease is higher than the national
average; its emigration index is low and the refund of the health expenditure is higher than
the national average.
Veneto Region has a large-size population with mean age and rate of elderly in line with
the Italian average. It  has at its disposal more resources than the Italian average and its
screening campaign covers all  the provinces;  the incidence of  the disease is  higher than
the national  average,  its  emigration index is  low and the refund of  the health expendi‐
ture  is  higher  than  the  national  average.  Trenton  Alto  Adige  Region  has  a  middle-size
population with mean age and rate of elderly persons lower than the Italian average. It
has at its disposal more resources than the national average and its screening campaign
covers the whole region,  the incidence of  the disease is  higher than the Italian average;
its emigration index is high and the refund of the health expenditure is in line with the
national  average.  Lombardy has a  large-size  population with mean age higher  than the
average and a rate of elderly slightly lower than the Italian average. It has at its disposal
more resources than the national average and its screening campaign covers all its prov‐
inces, the incidence of the disease is slightly higher than the Italian average, it has a low
emigration index and the refund of  health expenditure  is  lower than the national  aver‐
age. Valle d’Aosta Region has a small-size population with mean age and rate of elderly
persons higher than the national  average.  It  has at  its  disposal  more resources than the
national  average,  its  screening campaign covers  the  whole  Region,  the  incidence  of  the
disease is lower than the national average; it has a high emigration index and the refund
of health expenditure is in line with the national average.
Tuscany Region has a large-size population with mean age and rate of elderly persons high‐
er than the Italian average. It has at its disposal more resources than the Italian average and
its screening campaign covers the whole territory; the incidence of the disease is lower than
the national average; its emigration index is mean and the refund of health expenditure is
lower than the national average. Umbria Region has a small-size population with mean age
and a rate of elderly persons higher than the Italian average. It has at its disposal fewer re‐
sources than the Italian average and its screening campaign covers the whole Region; the in‐
cidence of the disease is higher than the national average; the emigration index is high and
the refund of health expenditure is higher than the national average.
Lazio Region has a large-size population with mean age and a rate of elderly persons lower
than the Italian average. It has at its disposal more resources than the Italian average and its
screening campaign covers only some provinces; the incidence of the disease is lower than
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the national average; its emigration index is intermediate and the refund of health expendi‐




























Lazio 5.626.710 42,6 19,2 1,22 89,06
52,57
4 plans 6,64 0,89
Marche 1.569.578 44,3 22,6 1,00 109,89
67,70
2007 pilot project 10,75 1
Abruzzi 1.334.675 43,4 21,3 0,81 113,25
42,75
6 plans 10,2 1
Molise 320.795 43,6 22,0 0,72 113,29
43,16
Global Regional plan 20,62 1
Sardinia 1.671.001 42,2 17,8 0,80 101,42
54,12
1 plan 4,24 1
ITALY 60.387.000 42,8 19,9 1 107,8
69,64
L.D. 138 2004 art. 2
bis Sof > 50 years
- - 1
Table 2. Macro-area: Central Italy
Marche Region has a middle-size population with mean age and rate of elderly persons
higher than the Italian average. It has at its disposal resources in line with the national aver‐
age and implements no screening campaign; the incidence of the disease is higher than the
national average; its emigration index is high and the refund of health expenditure is in line
with the national average.
Abruzzi has a middle-size population with mean age and rate of elderly persons higher than
the Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease is higher than
the national average; its emigration index is high and the refund of health expenditure is in
line with the national average.
Molise Region has a small-size population with mean age and rate of elderly higher than the
Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers the whole Region; its emigration index is high and the refund of
health expenditure is in line with the national average.
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Sardinia Region has a middle-size population with mean age and rate of elderly lower than
the Italian average. It has at its disposal resources in line with the national average and its
screening campaign covers only one province; the incidence of the disease is lower than the
national average, its emigration index is low and the refund of health expenditure is in line


















Campania 5.812.962 39,0 15,4 0,64 60,09
41,07
4 plans 7,55 0,89
Puglia 4.079.702 40,7 17,4 0,66 68,89
35,98
- - 7,64 1





Calabria 2.008.709 41,1 18,4 0,65 83,08
35,93
4 plans 14,82 1
Sicily 5.037,799 40,7 18,0 0,66 71,15
45,33
- - 6,09 1
ITALY 60.387.000 42,8 19,9 1 107,8
69,64
L.D. 138 2004 art. 2
bis Sof > 50 years
- - 1
Table 3. Macro-area: Southern Italy
Campania Region has a large-size population with mean age and rate of elderly lower than
the Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease is lower than
the national average; its emigration index is intermediate and the refund of health expendi‐
ture is slightly lower than the national average.
Puglia Region has a large population with mean age and rate of elderly lower than the Ital‐
ian average. It has at is disposal fewer resources than the national average and it has no
screening campaign; the incidence of the disease is lower than the national average and its
emigration index is intermediate. The refund of health expenditure is in line with the nation‐
al average.
Basilicata has a small-sized population with mean age and rate of elderly higher than the
Italian average. It has at its disposal fewer resources than the national average and the
screening campaign was discontinued in 2007, the incidence of the disease is lower than the
national average, its emigration index is high and the refund of health expenditure is in line
with the national average.
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Calabria has a middle-sized population with mean age and rate of elderly lower than the
Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease in lower than
the national average; its emigration index is high and the refund of health expenditure is in
line with the national average.
Sicily has a large population with mean age and rate of elderly lower than the Italian aver‐
age. It has at its disposal fewer resources than the national average and has no screening
campaign; the incidence of the disease is lower than the national average, its emigration in‐
dex is intermediate and the refund of health expenditure is in line with the national average.
4. Discussion
The average cost of colo-rectal cancer treatments in Italy has been estimated to be approxi‐
mately € 9.149,00 per patient per year including chemotherapy [27]. Some authors estimate
that for the city of Ferrara the overall cost related to the introduction of a CCS programme
was approximately € 1.400.000,00 (from October 2005 until March 2007 with more than
99.000 individuals invited) with a large proportion of these costs related to the implementa‐
tion and management of the programme [28]. FOBT plus COL, increase cost relative to
cheapest strategy. As a consequence of screening, some individuals with low risk receive a
recommendation for a follow-up COL. However follow-up colonoscopies will increase the
cost consequences of introducing screening, but not the expected colorectal cancer treatment
costs. The Italian Observatory on screening Practices has been collecting data on CCS since
2004 [29]. In 2007 there were 71 CRC screening programmes in Italy, covering 46,6% of the
total eligible population, with a higher coverage in the North (71,6%), and in the Centre
(52,1%) than in the South (7%). The majority of programmes (65) used the guaiac FOBT
(gFOBT) as first-line test. Only seven programmes used the flexible sigmoidoscopy (FS), of
which three used a combination of FS and gFOBT. The quality and efficacy of the screening
programmes are evaluated using ad hoc indicators developed by the Italian Group for Col‐
orectal Screening (GISCoR) [28]. In 2007, on average 79,1% of the eligible population was in‐
vited for FOBT screening, with only Lombardy, Umbria, and most of the programmes in
Emilia Romagna reaching the 90% target. Among the invited individuals, 46,3% underwent
FOBT with significant variations across (from 26,5% in Lazio to 65% in Veneto) and within
regions (from 11 to 80%). Among the people invited for the first time, the average percent‐
age of individuals with a positive test was 5,6%, while among people who were recalled it
was 4%. The probability of having a positive result was higher for men than for women and
increased with age. Among people with a positive test, only 78,7% underwent a COL [2].
The South and Centre had a lower rate of COL attendance than the North. Men were slight‐
ly more likely to undertake a COL after a positive FOBT than women, mainly because of the
uncomfortable feeling and concern of women having a male physician performing the tests.
The risk of bowel perforation and bleeding during COL was negligible. For FS, on average
66,5% of the eligible population was invited with large variations across programmes. Only
27,7% of those invited underwent FS with a slightly higher proportion among men than
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Sardinia Region has a middle-size population with mean age and rate of elderly lower than
the Italian average. It has at its disposal resources in line with the national average and its
screening campaign covers only one province; the incidence of the disease is lower than the
national average, its emigration index is low and the refund of health expenditure is in line


















Campania 5.812.962 39,0 15,4 0,64 60,09
41,07
4 plans 7,55 0,89
Puglia 4.079.702 40,7 17,4 0,66 68,89
35,98
- - 7,64 1





Calabria 2.008.709 41,1 18,4 0,65 83,08
35,93
4 plans 14,82 1
Sicily 5.037,799 40,7 18,0 0,66 71,15
45,33
- - 6,09 1
ITALY 60.387.000 42,8 19,9 1 107,8
69,64
L.D. 138 2004 art. 2
bis Sof > 50 years
- - 1
Table 3. Macro-area: Southern Italy
Campania Region has a large-size population with mean age and rate of elderly lower than
the Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease is lower than
the national average; its emigration index is intermediate and the refund of health expendi‐
ture is slightly lower than the national average.
Puglia Region has a large population with mean age and rate of elderly lower than the Ital‐
ian average. It has at is disposal fewer resources than the national average and it has no
screening campaign; the incidence of the disease is lower than the national average and its
emigration index is intermediate. The refund of health expenditure is in line with the nation‐
al average.
Basilicata has a small-sized population with mean age and rate of elderly higher than the
Italian average. It has at its disposal fewer resources than the national average and the
screening campaign was discontinued in 2007, the incidence of the disease is lower than the
national average, its emigration index is high and the refund of health expenditure is in line
with the national average.
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Calabria has a middle-sized population with mean age and rate of elderly lower than the
Italian average. It has at its disposal fewer resources than the national average and its
screening campaign covers only some provinces; the incidence of the disease in lower than
the national average; its emigration index is high and the refund of health expenditure is in
line with the national average.
Sicily has a large population with mean age and rate of elderly lower than the Italian aver‐
age. It has at its disposal fewer resources than the national average and has no screening
campaign; the incidence of the disease is lower than the national average, its emigration in‐
dex is intermediate and the refund of health expenditure is in line with the national average.
4. Discussion
The average cost of colo-rectal cancer treatments in Italy has been estimated to be approxi‐
mately € 9.149,00 per patient per year including chemotherapy [27]. Some authors estimate
that for the city of Ferrara the overall cost related to the introduction of a CCS programme
was approximately € 1.400.000,00 (from October 2005 until March 2007 with more than
99.000 individuals invited) with a large proportion of these costs related to the implementa‐
tion and management of the programme [28]. FOBT plus COL, increase cost relative to
cheapest strategy. As a consequence of screening, some individuals with low risk receive a
recommendation for a follow-up COL. However follow-up colonoscopies will increase the
cost consequences of introducing screening, but not the expected colorectal cancer treatment
costs. The Italian Observatory on screening Practices has been collecting data on CCS since
2004 [29]. In 2007 there were 71 CRC screening programmes in Italy, covering 46,6% of the
total eligible population, with a higher coverage in the North (71,6%), and in the Centre
(52,1%) than in the South (7%). The majority of programmes (65) used the guaiac FOBT
(gFOBT) as first-line test. Only seven programmes used the flexible sigmoidoscopy (FS), of
which three used a combination of FS and gFOBT. The quality and efficacy of the screening
programmes are evaluated using ad hoc indicators developed by the Italian Group for Col‐
orectal Screening (GISCoR) [28]. In 2007, on average 79,1% of the eligible population was in‐
vited for FOBT screening, with only Lombardy, Umbria, and most of the programmes in
Emilia Romagna reaching the 90% target. Among the invited individuals, 46,3% underwent
FOBT with significant variations across (from 26,5% in Lazio to 65% in Veneto) and within
regions (from 11 to 80%). Among the people invited for the first time, the average percent‐
age of individuals with a positive test was 5,6%, while among people who were recalled it
was 4%. The probability of having a positive result was higher for men than for women and
increased with age. Among people with a positive test, only 78,7% underwent a COL [2].
The South and Centre had a lower rate of COL attendance than the North. Men were slight‐
ly more likely to undertake a COL after a positive FOBT than women, mainly because of the
uncomfortable feeling and concern of women having a male physician performing the tests.
The risk of bowel perforation and bleeding during COL was negligible. For FS, on average
66,5% of the eligible population was invited with large variations across programmes. Only
27,7% of those invited underwent FS with a slightly higher proportion among men than
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women. The response rate was higher whenever FS was combined with FOBT [30]. The per‐
centage of FS successfully completed was 88%, with again a higher level among men than
women; 14,3% of men and 7,6% of women were sent for a COL for further analysis and 90%
of these attended the test. In 2007 overall FOBT and FS detected 20.796 adenoma of which,
2.449 were carcinomas. An additional 295 carcinomas were diagnosed in individuals who
underwent further follow-up tests. Most of the adenomas identified were in Stage I, (54.5%),
followed by increased widely Stages III and IV (24,9%), and then in Stage II (20,7%). The crit‐
ical points are: complications of COL (40 programs) with average perforation rate of 0,08%
(2,5% operative COL) and average bleeding rate of 0,55%; low coverage and delay in South‐
ern Italy; low compliance; overload on endoscopy facilities.
The role of screening is an extremely topical question even though in the past it was already
subject of discussion and until few years ago it was considered to fall within the competence
of the central government [31]. Only in the last years we have observed a different interest
especially in Italy due to the changed political conditions. Does a convergence really exist
between federalism, screening and standard cost? The process which links the federal struc‐
ture of the nation with the screening is a thin red line which began with the promulgation of
the Constitution and over the years it has been fully implemented with Act No. 42 of year
2009 with enforcement of Article 119 of the Constitution which guarantees autonomy of rev‐
enues and expenditure of municipalities, provinces, towns and regions and assure princi‐
ples of support and social cohesion [32]. In particular, it assures the funding of the essential
levels of health care (which includes the practice of screening) referring to a benchmark of
cost and requirements [32]. In year 2001 an agreement was made between Government and
Regions for the guidelines about prevention, diagnosis and assistance in oncology, including
indications for the screenings, and the promulgation of Decree of the President of the Coun‐
cil of Ministry No. 26 of November 29th 2001, which defines the Essential Levels of Care
(LEA) including the plans of screening for the early diagnosis of colorectal, breast, cervix
cancers [33]. Within the 2001 financial budget (law N. 388, 2000) it was decided that target
population screening was free of charge [34]. In 2004 the Health Minister redistributed over‐
all € 7.000.000, a minimum of € 50.000 per region, for reducing the gaps in cancer screenings
and activating the CCS programme (€ 1.750.000 specifically for CCS). This agreement made
these plans to be a right for women and men. The debate about the allocation of resources in
regimen of federalism is very lively, in particular regarding the costs of Health Care System.
We remind that the allocation of the funds to the Health Care System for the prevention of
diseases remained constant at 5% for some years [35]. The criterion of the historical expendi‐
ture will be replaced by the standard cost. The standard cost is the tool to assure the LEA
funding and consists of the expenditure for the following items: staff, equipment, consuma‐
bles and general costs of the health performances of the production unit [36]. Moreover, a
“direct” cost of production is predicted, i.e. a percentage to cover the general functioning
costs of the equipment of the production unit [37]. The characteristics of the colorectal can‐
cers show a strong geographical variability: chronic trend, increase in the incidence and a
still too high mortality rate. The increase in the prevalence should be allotted partially to the
ageing of the population, but mostly to the diffusion and implementation of screening plans.
The cost of the screening campaign is defined by the following factors: first costs of tests,
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staff, confirmation procedure (selection of population at risk to reduce costs); second assess‐
ment of efficacy: sensitivity, specificity, productive value; third non-invasive method: it is
addressed to probably healthy subjects; latter possibility of intervention: the disease or con‐
dition to be diagnosed should be susceptible of therapy.
In the first years 2000 the Italian Government, in view of the severe unbalanced offer of
screening plans, established to allocate further financial resources (52 million euro between
2004 and 2006) for interventions promoting the re-balancing of the offer and the quality of
the screening plan of cervix and breast cancers and the diffusion of the screening of colorec‐
tal cancer [33]. Even though in year 2008 in oncology the plans of screening of colorectal can‐
cers had a significant increase exceeding the threshold of 50%, unfortunately they are not
always able to achieve acceptable levels of efficacy. According to “The screening plans in
Italy 2009”, the screening campaigns for colorectal cancers carried out in the last years,
showed some critical aspects: we observed a progressive increase in the compliance of the
first years versus a progressive stabilization or decrease in the compliance afterwards [20].
There are extremely strong differences between Northern, Central and Southern Italy. How‐
ever, the rate of detection of cancers by using faecal occult blood and endoscopy has always
been lower than the acceptable minimum.
In fact, many differences are reported in relation with the ratio between regional and per
capita income resulting into a three-speed Italy. This is mirrored also by the incidence of col‐
orectal cancer, which exhibits a different distribution where the highest rate is in the North‐
ern Italy and the minimum rate in the Southern Italy. According to the data of the National
Screening Observatory, they are spread not uniformly throughout the territory. According
to “The screening plans in Italy 2009”, the real extension of colorectal screening plans (faecal
occult blood plus endoscopy) for the macro-areas evidenced some critical aspects [20]. We
passed from 5% in 2004 to 12% in 2005, then to 30% in 2006, which stabilized at 37% in
2007/2008 as global Italian data. Even though there were significant differences with a posi‐
tive presence in the Northern Italy versus a delay in the Central Italy and an insufficient
presence in the Southern Italy, these data showed a similar annual tendency for each macro-
area. However, the rate of identification of cancers by using faecal occult blood and endos‐
copy has always been lower than the acceptable minimum. After an initial enthusiasm, we
observed a progressive decrease in the percentage of compliance with the plan in both mac‐
ro-areas. Regarding the emigration index, there are notable differences within the three mac‐
ro-areas, which influence the general index. The value shows that the regions of Northern
Italy have more attraction power versus the regions of Southern Italy, whereas the regions
of Central Italy have not particularly high emigration indices.
This latter parameter: the DRG index shows clear imbalances within all regions and there‐
fore it is not a useful element to discriminate the different macro-areas.
The lack of homogeneity on the territory, moreover, is still marked with evident consequen‐
ces on mortality and morbidity [38]. The implementation of federalism poses a question: if
these large differences already exist, will the situation be improved or will the disparity be‐
come even stronger? On April 29, 2010, the agreement between Government, Regions and
Autonomous Provinces of Trento and Bolzano was undersigned. According to this agree‐
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women. The response rate was higher whenever FS was combined with FOBT [30]. The per‐
centage of FS successfully completed was 88%, with again a higher level among men than
women; 14,3% of men and 7,6% of women were sent for a COL for further analysis and 90%
of these attended the test. In 2007 overall FOBT and FS detected 20.796 adenoma of which,
2.449 were carcinomas. An additional 295 carcinomas were diagnosed in individuals who
underwent further follow-up tests. Most of the adenomas identified were in Stage I, (54.5%),
followed by increased widely Stages III and IV (24,9%), and then in Stage II (20,7%). The crit‐
ical points are: complications of COL (40 programs) with average perforation rate of 0,08%
(2,5% operative COL) and average bleeding rate of 0,55%; low coverage and delay in South‐
ern Italy; low compliance; overload on endoscopy facilities.
The role of screening is an extremely topical question even though in the past it was already
subject of discussion and until few years ago it was considered to fall within the competence
of the central government [31]. Only in the last years we have observed a different interest
especially in Italy due to the changed political conditions. Does a convergence really exist
between federalism, screening and standard cost? The process which links the federal struc‐
ture of the nation with the screening is a thin red line which began with the promulgation of
the Constitution and over the years it has been fully implemented with Act No. 42 of year
2009 with enforcement of Article 119 of the Constitution which guarantees autonomy of rev‐
enues and expenditure of municipalities, provinces, towns and regions and assure princi‐
ples of support and social cohesion [32]. In particular, it assures the funding of the essential
levels of health care (which includes the practice of screening) referring to a benchmark of
cost and requirements [32]. In year 2001 an agreement was made between Government and
Regions for the guidelines about prevention, diagnosis and assistance in oncology, including
indications for the screenings, and the promulgation of Decree of the President of the Coun‐
cil of Ministry No. 26 of November 29th 2001, which defines the Essential Levels of Care
(LEA) including the plans of screening for the early diagnosis of colorectal, breast, cervix
cancers [33]. Within the 2001 financial budget (law N. 388, 2000) it was decided that target
population screening was free of charge [34]. In 2004 the Health Minister redistributed over‐
all € 7.000.000, a minimum of € 50.000 per region, for reducing the gaps in cancer screenings
and activating the CCS programme (€ 1.750.000 specifically for CCS). This agreement made
these plans to be a right for women and men. The debate about the allocation of resources in
regimen of federalism is very lively, in particular regarding the costs of Health Care System.
We remind that the allocation of the funds to the Health Care System for the prevention of
diseases remained constant at 5% for some years [35]. The criterion of the historical expendi‐
ture will be replaced by the standard cost. The standard cost is the tool to assure the LEA
funding and consists of the expenditure for the following items: staff, equipment, consuma‐
bles and general costs of the health performances of the production unit [36]. Moreover, a
“direct” cost of production is predicted, i.e. a percentage to cover the general functioning
costs of the equipment of the production unit [37]. The characteristics of the colorectal can‐
cers show a strong geographical variability: chronic trend, increase in the incidence and a
still too high mortality rate. The increase in the prevalence should be allotted partially to the
ageing of the population, but mostly to the diffusion and implementation of screening plans.
The cost of the screening campaign is defined by the following factors: first costs of tests,
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staff, confirmation procedure (selection of population at risk to reduce costs); second assess‐
ment of efficacy: sensitivity, specificity, productive value; third non-invasive method: it is
addressed to probably healthy subjects; latter possibility of intervention: the disease or con‐
dition to be diagnosed should be susceptible of therapy.
In the first years 2000 the Italian Government, in view of the severe unbalanced offer of
screening plans, established to allocate further financial resources (52 million euro between
2004 and 2006) for interventions promoting the re-balancing of the offer and the quality of
the screening plan of cervix and breast cancers and the diffusion of the screening of colorec‐
tal cancer [33]. Even though in year 2008 in oncology the plans of screening of colorectal can‐
cers had a significant increase exceeding the threshold of 50%, unfortunately they are not
always able to achieve acceptable levels of efficacy. According to “The screening plans in
Italy 2009”, the screening campaigns for colorectal cancers carried out in the last years,
showed some critical aspects: we observed a progressive increase in the compliance of the
first years versus a progressive stabilization or decrease in the compliance afterwards [20].
There are extremely strong differences between Northern, Central and Southern Italy. How‐
ever, the rate of detection of cancers by using faecal occult blood and endoscopy has always
been lower than the acceptable minimum.
In fact, many differences are reported in relation with the ratio between regional and per
capita income resulting into a three-speed Italy. This is mirrored also by the incidence of col‐
orectal cancer, which exhibits a different distribution where the highest rate is in the North‐
ern Italy and the minimum rate in the Southern Italy. According to the data of the National
Screening Observatory, they are spread not uniformly throughout the territory. According
to “The screening plans in Italy 2009”, the real extension of colorectal screening plans (faecal
occult blood plus endoscopy) for the macro-areas evidenced some critical aspects [20]. We
passed from 5% in 2004 to 12% in 2005, then to 30% in 2006, which stabilized at 37% in
2007/2008 as global Italian data. Even though there were significant differences with a posi‐
tive presence in the Northern Italy versus a delay in the Central Italy and an insufficient
presence in the Southern Italy, these data showed a similar annual tendency for each macro-
area. However, the rate of identification of cancers by using faecal occult blood and endos‐
copy has always been lower than the acceptable minimum. After an initial enthusiasm, we
observed a progressive decrease in the percentage of compliance with the plan in both mac‐
ro-areas. Regarding the emigration index, there are notable differences within the three mac‐
ro-areas, which influence the general index. The value shows that the regions of Northern
Italy have more attraction power versus the regions of Southern Italy, whereas the regions
of Central Italy have not particularly high emigration indices.
This latter parameter: the DRG index shows clear imbalances within all regions and there‐
fore it is not a useful element to discriminate the different macro-areas.
The lack of homogeneity on the territory, moreover, is still marked with evident consequen‐
ces on mortality and morbidity [38]. The implementation of federalism poses a question: if
these large differences already exist, will the situation be improved or will the disparity be‐
come even stronger? On April 29, 2010, the agreement between Government, Regions and
Autonomous Provinces of Trento and Bolzano was undersigned. According to this agree‐
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ment the regions are committed to implement by September 2010, the Regional Plan of Pre‐
vention to carry out the interventions established by the National Plan of Prevention: among
the macro-areas of interventions there are oncologic screening programs [39]. The critical
points are: complications of COL (40 programmes) with average perforation rate of 0.08%
(2,5% operative COL) and average bleeding rate of 0,55%; low coverage and delay in South‐
ern Italy; low compliance; overload on endoscopy facilities.
The critical limit to implement the screening campaigns of colorectal cancers is the allocation
of own resources to Regions and local bodies and the overcoming of the dichotomy between
legislative and administrative (on the territory) competences and derived finance (transfer
from Government to territory) [40]. Up to now the Government has been engaged in fund‐
ing screening campaigns, from now on the Regions will be in charge of it [41]. Unfortunately
since there is not yet an assessment of the costs of this procedure, the “promotion cam‐
paign”, so far implemented, is risking to be reduced [42].
The concept of standard cost versus the historical cost is playing a crucial role in the fiscal
federalism. The standard cost will contribute, in fact, to establish the “official” needs of each
local body and therefore the contingent equalizing transfer to which it will have the right to
in case of insufficient fiscal capacity [43].
Which approach should be used to calculate the standard costs of the federal finance?
There are two models among those currently used: micro-analytical (standard cost of each
supplied performance) and macro-analytical (standard cost of easily measurable variables:
demographic structure, epidemiological and social characteristics). The first approach is not
very consistent with the purposes of the federalist reform (valid only as control mean) while
the second model establishes a budget of expenditure resulting from merely political choices
and not from the real needs of the population. What is the solution? To calculate the neces‐
sary resources the fundamental element to refer to is the efficiency [44-46]. The efficiency
measures the economical employment of resources in the productive process. It is defined as
the ratio between performances (screening) and resources (budget) according to the formu‐
la: efficiency= output/input [47,48].
A better approach, but for some aspects much more complex, could be the one of DEA [49].
Farrell (1957) in his preliminary work “The measurement of productive efficiency” intro‐
duced not only the well-known allocation between technique and price or allocative efficien‐
cy, but he also proposed a key to measure the comparative efficiency of the productive units
which use various inputs to produce different outputs [50]. The efficiency of each unit
would be equal to the ratio between real and potential output [51]. More than two decades
after Charnes, Cooper and Rhodes (CCR), the idea of Farrell was developed and it was dem‐
onstrated that a linear mathematical program could be used to choose the most effective
productive unit. The method, known as Data Envelopment Analysis, has been extensively
used to measure the efficiency in many economical areas [52].
The analyses are non-parametric and its characteristic is that it can evaluate the relative effi‐
ciency of decisional units, and the like, through linear programming techniques without
specifying whether the relative importance of the different factors of production or that of
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the prices [53]. In this sense the results of non-parametric methods are objective, because
they do not require prior specifications. On the other hand, however, their disadvantage is
that they do not admit errors being deterministic methods; the results could be therefore in‐
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Now the system of weights adopted strongly influences the efficiency, therefore through
an algorithm of Charnes,  Cooper and Rhodes (CCR),  we try to find the optimal system
of weights (among the proposed ones) in order to maximize the efficiency of the respon‐
sibility centre and the comparable ideal responsibility centre [54].  This suggests that the
standard cost  can be calculated in  two ways:  maximizing the numerator  and fixing the
denominator (output-oriented method – screening) or, vice versa, keeping the numerator
and minimizing the denominator (input-oriented method – prevention budget) [55].  The
difference  is  important  since  it  determines  the  form of  efficiency that  we are  assessing.
Output-effective  means there  is  no other  unit  that  develops a  larger  screening with the
same budget for the prevention [56].
A productive unit is called input-effective if there is no other unit able to obtain the same
screening using a lower budget (DMUs).
This methodology assesses the efficiency as the ratio between quality of the screening and
available budget. Some weights are obviously introduced to include demographic and
health characteristics of the Region. Now for each unit we can obtain the optimal budget to
be allocated to the Region for the screening campaign. In this way by adding the sum of ev‐
ery single regional budget, the necessary budget of national expenditure can be obtained to
carry out an effective and really sustainable screening campaign.
In view of the above mentioned results, we can assume an equivalent model (Table 4).
The following example of three Regions (large, middle, and small) illustrate how DEA
works.
Each Region has exactly 10 COL (the only input), and we are be able to measure a Region
CCR programme based on two outputs: number of patients subject to screening, and num‐
ber of found cancers. The data for these Regions is as follows:
Region “large”: 100 COL, 1000 number of recruited patients, 20 number of found cancers;
Region “medium”: 100 COL, 400 number of recruited patients, 50 number of found cancers;
Region “small”: 100 COL, 200 number of recruited patients, 150 number of found cancers.
Now, the key to DEA is to determine whether we can create a virtual Region that is better
than one or more of the real Regions. Any such dominated Region will be an inefficient Re‐
gion. Consider trying to create a virtual Region that is better than Region “large”. Such a Re‐
gion would use no more inputs than a Region “large”, and produce at least as much output.
Clearly, no combination of Regions “medium” and “small” can possibly do that. Region
The Future of Colonoscopy: The Use of Data Envelopment Analysis (DEA) for Colorectal Cancer Screening...
http://dx.doi.org/10.5772/52310
85
ment the regions are committed to implement by September 2010, the Regional Plan of Pre‐
vention to carry out the interventions established by the National Plan of Prevention: among
the macro-areas of interventions there are oncologic screening programs [39]. The critical
points are: complications of COL (40 programmes) with average perforation rate of 0.08%
(2,5% operative COL) and average bleeding rate of 0,55%; low coverage and delay in South‐
ern Italy; low compliance; overload on endoscopy facilities.
The critical limit to implement the screening campaigns of colorectal cancers is the allocation
of own resources to Regions and local bodies and the overcoming of the dichotomy between
legislative and administrative (on the territory) competences and derived finance (transfer
from Government to territory) [40]. Up to now the Government has been engaged in fund‐
ing screening campaigns, from now on the Regions will be in charge of it [41]. Unfortunately
since there is not yet an assessment of the costs of this procedure, the “promotion cam‐
paign”, so far implemented, is risking to be reduced [42].
The concept of standard cost versus the historical cost is playing a crucial role in the fiscal
federalism. The standard cost will contribute, in fact, to establish the “official” needs of each
local body and therefore the contingent equalizing transfer to which it will have the right to
in case of insufficient fiscal capacity [43].
Which approach should be used to calculate the standard costs of the federal finance?
There are two models among those currently used: micro-analytical (standard cost of each
supplied performance) and macro-analytical (standard cost of easily measurable variables:
demographic structure, epidemiological and social characteristics). The first approach is not
very consistent with the purposes of the federalist reform (valid only as control mean) while
the second model establishes a budget of expenditure resulting from merely political choices
and not from the real needs of the population. What is the solution? To calculate the neces‐
sary resources the fundamental element to refer to is the efficiency [44-46]. The efficiency
measures the economical employment of resources in the productive process. It is defined as
the ratio between performances (screening) and resources (budget) according to the formu‐
la: efficiency= output/input [47,48].
A better approach, but for some aspects much more complex, could be the one of DEA [49].
Farrell (1957) in his preliminary work “The measurement of productive efficiency” intro‐
duced not only the well-known allocation between technique and price or allocative efficien‐
cy, but he also proposed a key to measure the comparative efficiency of the productive units
which use various inputs to produce different outputs [50]. The efficiency of each unit
would be equal to the ratio between real and potential output [51]. More than two decades
after Charnes, Cooper and Rhodes (CCR), the idea of Farrell was developed and it was dem‐
onstrated that a linear mathematical program could be used to choose the most effective
productive unit. The method, known as Data Envelopment Analysis, has been extensively
used to measure the efficiency in many economical areas [52].
The analyses are non-parametric and its characteristic is that it can evaluate the relative effi‐
ciency of decisional units, and the like, through linear programming techniques without
specifying whether the relative importance of the different factors of production or that of
Colonoscopy and Colorectal Cancer Screening - Future Directions84
the prices [53]. In this sense the results of non-parametric methods are objective, because
they do not require prior specifications. On the other hand, however, their disadvantage is
that they do not admit errors being deterministic methods; the results could be therefore in‐








ur yr0  / ∑ vi xi0
Now the system of weights adopted strongly influences the efficiency, therefore through
an algorithm of Charnes,  Cooper and Rhodes (CCR),  we try to find the optimal system
of weights (among the proposed ones) in order to maximize the efficiency of the respon‐
sibility centre and the comparable ideal responsibility centre [54].  This suggests that the
standard cost  can be calculated in  two ways:  maximizing the numerator  and fixing the
denominator (output-oriented method – screening) or, vice versa, keeping the numerator
and minimizing the denominator (input-oriented method – prevention budget) [55].  The
difference  is  important  since  it  determines  the  form of  efficiency that  we are  assessing.
Output-effective  means there  is  no other  unit  that  develops a  larger  screening with the
same budget for the prevention [56].
A productive unit is called input-effective if there is no other unit able to obtain the same
screening using a lower budget (DMUs).
This methodology assesses the efficiency as the ratio between quality of the screening and
available budget. Some weights are obviously introduced to include demographic and
health characteristics of the Region. Now for each unit we can obtain the optimal budget to
be allocated to the Region for the screening campaign. In this way by adding the sum of ev‐
ery single regional budget, the necessary budget of national expenditure can be obtained to
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than one or more of the real Regions. Any such dominated Region will be an inefficient Re‐
gion. Consider trying to create a virtual Region that is better than Region “large”. Such a Re‐
gion would use no more inputs than a Region “large”, and produce at least as much output.
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“large” is therefore deemed to be efficient. Region “small” is in the same situation. Howev‐
er, consider Region “medium”. If we take half of Region “large” and combine it with half of
Region “small”, then we create a Region that processes different outputs (600 number of re‐
cruited patients, 85 number of found cancers) with just input (100 COL). This dominates
“medium” (we would much rather have the virtual Region we created than Region “medi‐
um”). Region “medium” is therefore inefficient. Another way to see this is that we can scale
down the inputs to “medium” (number of COL) and still have at least as much output. If we
assume (and we do), that inputs are linearly scalable, then we estimate that we can get by
with 63 COL. We do that by taking 0.34 times Region “small” plus 0.29 times Region “medi‐
um”. The result uses 63 COL and produces at least as much as Region “medium” does. We
say that Region “medium”’s efficiency rating is 0.63. Regions “small” and “large” have an







Equivalent number of hours of physicians of general medicine
Equivalent number of hours of endoscopists
Equivalent number of hours of anaesthetists
Equivalent number of hours of nurses
Equivalent number of hours of executives
Equivalent number of hours of lab physician
Number of evaluations
Number of endoscopies
Number of histological exams
Equivalent number of hours of pathologists
Equivalent number of hours of technicians of pathologic anatomy
Number of histological analyses
Output
Number of recruited patients
Number of patients subject to screening
Number of found cancers
Table 4. Example of sustainable screening campaign.
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After the definition of the population size and the observed input and output to assess the
screening unit (DMUs), it is possible to calculate the index of efficiency by using the above-
mentioned formula. This index can be referred to the single Regions or to the system Italy as
a whole.
In many states, a larger question may be whether the overwhelming use of COL as the
screening method is the appropriate choice.
Determination of the appropriateness of an indication for COL has been advanced as a
means to help rationalize the use of endoscopic resources. Current guidelines regarding the
appropriateness of COL are relatively inefficient in excluding a clinically meaningful CRC
risk for patients, in whom COL is generally not indicated, raising serious concerns about
their applicability to clinical practice.
A tailored navigation approach, which determines the particular concerns and barriers of an
eligible individual and matches them with the strengths and weaknesses of each strategy to
find the one most suitable, may be the optimal way to maximize the number of people who
can benefit from COL.
In the end, a test can only provide benefit if it is actually done [57].
5. Conclusions
Nowadays the Italian National Health Service is distributed on extremely diversified region‐
al realities. Needs and inefficiencies of production are inseparably correlated in the health
expenditure of the Regions. In the future the issues that are now more critical will have to be
adjusted: to implement screening plans, supply the Regions with the objectives related to
common LEAs in view of the regional differences. According to the “National Centre for the
Prevention and Control of the Diseases” (institution of coordination between Ministry of
Health and Regions for the activities of surveillance, prevention and prompt response to the
emergencies), it is necessary to “design the interventions of secondary prevention not as
performances but rather as “paths” (profiles of care) offered to the citizen within various or‐
ganizing activities on the territory aiming at the efficiency in the practice”. Only in this way
the efficiencies can be optimized and the necessary budget minimized for each Region for
the screening campaigns. In order to avoid the funding of squandering, a formula of analyti‐
cal calculation of the needs will be necessary [58]. A further problem in the future will be to
make homogeneous the different kinds of screening currently in use on the territory to as‐
sure a higher allocative efficiency and COL will clearly has a future, which will expand even
if the technology stands still. For a screening programme to be successful, multiple events
have to occur, beginning with awareness and recommendation from the primary-care physi‐
cian, patient acceptance, financial coverage, risk stratification, screening test, timely diagno‐
sis, timely treatment, and appropriate follow-up. If any one of these steps is faulty or is not
of high quality, the screening will fail. In this scenario we had to consider the COL as a
means than an aim. In this regard DEA, which is an innovative methodology easy to be ap‐
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screening unit (DMUs), it is possible to calculate the index of efficiency by using the above-
mentioned formula. This index can be referred to the single Regions or to the system Italy as
a whole.
In many states, a larger question may be whether the overwhelming use of COL as the
screening method is the appropriate choice.
Determination of the appropriateness of an indication for COL has been advanced as a
means to help rationalize the use of endoscopic resources. Current guidelines regarding the
appropriateness of COL are relatively inefficient in excluding a clinically meaningful CRC
risk for patients, in whom COL is generally not indicated, raising serious concerns about
their applicability to clinical practice.
A tailored navigation approach, which determines the particular concerns and barriers of an
eligible individual and matches them with the strengths and weaknesses of each strategy to
find the one most suitable, may be the optimal way to maximize the number of people who
can benefit from COL.
In the end, a test can only provide benefit if it is actually done [57].
5. Conclusions
Nowadays the Italian National Health Service is distributed on extremely diversified region‐
al realities. Needs and inefficiencies of production are inseparably correlated in the health
expenditure of the Regions. In the future the issues that are now more critical will have to be
adjusted: to implement screening plans, supply the Regions with the objectives related to
common LEAs in view of the regional differences. According to the “National Centre for the
Prevention and Control of the Diseases” (institution of coordination between Ministry of
Health and Regions for the activities of surveillance, prevention and prompt response to the
emergencies), it is necessary to “design the interventions of secondary prevention not as
performances but rather as “paths” (profiles of care) offered to the citizen within various or‐
ganizing activities on the territory aiming at the efficiency in the practice”. Only in this way
the efficiencies can be optimized and the necessary budget minimized for each Region for
the screening campaigns. In order to avoid the funding of squandering, a formula of analyti‐
cal calculation of the needs will be necessary [58]. A further problem in the future will be to
make homogeneous the different kinds of screening currently in use on the territory to as‐
sure a higher allocative efficiency and COL will clearly has a future, which will expand even
if the technology stands still. For a screening programme to be successful, multiple events
have to occur, beginning with awareness and recommendation from the primary-care physi‐
cian, patient acceptance, financial coverage, risk stratification, screening test, timely diagno‐
sis, timely treatment, and appropriate follow-up. If any one of these steps is faulty or is not
of high quality, the screening will fail. In this scenario we had to consider the COL as a
means than an aim. In this regard DEA, which is an innovative methodology easy to be ap‐
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plied especially in the health care with diversified systems as ours, can be a useful tool to
calculate the regional needs in order to carry out screening campaigns.
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Wolff and Shinya published their experience with therapeutic colonoscopy in September 1969
in JAMA [2], three months after they had commenced to perform diagnostic fiber colonoscopy.
Since then, this has become an increasingly significant arm of minimally invasive colorectal
surgery, complementing, even possibly replacing procedures that were once performed using
“open” surgical techniques. [1-3]
Following the introduction of the fiber-optic colonoscopy for diagnostic evaluation of the
lower gastrointestinal tract, enabling all parts of the colon to the assessed under direct vision
and instrumentation as reported by Deyhle and Demling in 1971, and Sakai in 1972, [4-5]
mastery of these techniques by Williams and colleagues have enabled therapeutic interven‐
tions to be performed endoscopically. [6]
Propelling this “endoscopic therapy” movement is the increasing evidence of the “adenoma-
carcinoma” polyp-cancer sequence introduced by Morson and Bussey from 1968 to 1970. [7]
This fundamental concept has enabled a form of prevention of colorectal cancer by endoscopic
removal of precursor lesions and is the basis of colonoscopic screening for colorectal cancer,
resulting in the effective cessation to their progression to cancer.
2. Polypectomy in the colon
Winawer and colleagues in 1993 provided strong evidence that the prevention of colorectal
cancer can be achieved by colonoscopic polypectomy. [9] Data and statistics from the National
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Polyp Study Workgroup demonstrated that the incidence of colorectal cancer is reduced by
colonoscopic polypectomy and provided evidence for the adherence to the principle of
searching and subsequent removal of adenomatous polyps in the colon and rectum. They
reported on the 6-year follow-up of 1,418 patients after repeated colonoscopy to clear all
polyps. While this study did not have a true control arm, the background age and sex specific
incidence of colorectal cancer was used as a control group. The removal of all polyps seen
during endoscopy prevented the development of 75% of carcinomas. The Veterans Affairs
Study conducted by Muller and Sonnenberg published in 1995 found that only 50% of cancers
were prevented, but the study was limited, for not all patients had received total colonoscopy
in that study. [10] Hurlstone and colleagues postulate that one possible factor responsible for
polyp surveillance failing to prevent all colorectal cancers within these studies may be due to
the lack of Western experience of flat and depressed lesions within the colon. [11]
The evolution of colonoscopic polypectomies was between the 1950s and 1970s. As neither
radiographic imaging via barium studies; nor macroscopic appearance of the polyps gave any
definite information about its nature or behavior, histologic assessment was thereby deemed
necessary to establish the diagnosis of these polyps and thereafter, their prognosis. Hellwig
and Barbosa reported that forceps biopsy gave samples that were inadequate for the exclusion
of the presence of malignancy. [12] Also there was no complete removal of the lesion, which
is necessary for a full histological study.
In the 1970s, the largest series of colonoscopic polypectomies performed were reported by
Wolff and Shinya in 1973. [13] They reported their undertaking of a program to remove colonic
polyps endoscopically. Shinya was also responsible for the conception of “snare polypectomy”
and with Hiroshi Ichikawa, developed various polypectomy techniques in the 1970s. This was
performed after achieving 1600 uncomplicated diagnostic colonoscopies. They removed 303
polyps ranging from 0.5 to 5.0cm in diameter with minimal complication. Major bleeding
requiring transfusion was encountered in one patient, and minor bleeding in four others. The
other series published were much smaller and were descriptive, mainly by Friend and
Ottenjahn in 1972, Dehyle, Demling, Fruhmorgen, Testas and Williams et al in 1973. Morgen‐
thal et al thus concluded in a review published in 2007 that colonoscopic polypectomy may be
the most significant of all developments in therapeutic endoscopy. [8]
Already in the early development of colonoscopic polypectomy, several problems were
encountered and along with them, limitations with this technique. In 1974, Williams and
colleagues reviewed their series of 300 polypectomies in 169 patients. Fundamental principles
such as adequate bowel preparation to ensure minimally obstructed view of the polyp to be
snared, and to ensure no residual fluid present to dissipate the energy current have been
described right from the introduction of colonoscopic polypectomy and are still adhered to
today.
2.1. Electrocautery in snare polypectomy and hot biopsy
Williams et al described the use of a diathermy snare loop technique for excision of polyps up
to 4.5 cm in diameter. The “hot-biopsy” technique was also introduced and they reported their
results in 107 smaller polyps. Their results compared favorably to surgical polypectomies.
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They reported a single “closed” perforation that was managed conservatively, and 2 patients
who experienced major hemorrhage. [14]
For small sessile polyps, the snare loop was passed over the head of the polyps and tightened at
the base. For pedunculated polyps, the snare was closed halfway down the stalk. This was
positioned “high” enough to minimize the risk of heat necrosis of the bowel wall, but “low”
enough to include areas of mucosal change suspicious of early malignant invasion of the stalk. [14]
Figure 1. Principle of “current density” in diathermy electrocoagulation – heating effect in the stalk of the polyp (after
Curtiss 1973)
The technique of diathermy snare polypectomy was based on the theory of diathermy currents
described by Curtiss in 1973. The electrical precautions described then are also still observed
today. These are to tighten the snare and elevate the polyp away from the bowel in the direc‐
tion that the current passes into the smallest possible area of tissue within the stalk, enabling
localized heating at the area of highest “current density” (Fig 1). [15] As this is applicable to
pedunculated polyps with inherent stalks, Williams and colleagues [14] described the techni‐
que of creating a “pseudo-pedicle” in small sessile polyps by lifting the snared polyp forcible.
Heat necrosis is avoided by ensuring that the polyp head, upon being lifted up, did not come into
contact with the opposite bowel wall during the application of the current. These principles were
extended for the same authors described the “hot-biopsy” techniques by which polyps up to
7mm were simultaneously biopsies and also destroyed by the application of a strong coagulat‐
ing current down the closed jaws of the biopsy forceps. The tissue within the jaws is not heated
and therefore preserved, as the current bypasses this area of conductive material.
Figure 2. Technique of “hot biopsy” with the use of diathermy forceps – principle of selective coagulation necrosis at
the base of the polyp.
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other series published were much smaller and were descriptive, mainly by Friend and
Ottenjahn in 1972, Dehyle, Demling, Fruhmorgen, Testas and Williams et al in 1973. Morgen‐
thal et al thus concluded in a review published in 2007 that colonoscopic polypectomy may be
the most significant of all developments in therapeutic endoscopy. [8]
Already in the early development of colonoscopic polypectomy, several problems were
encountered and along with them, limitations with this technique. In 1974, Williams and
colleagues reviewed their series of 300 polypectomies in 169 patients. Fundamental principles
such as adequate bowel preparation to ensure minimally obstructed view of the polyp to be
snared, and to ensure no residual fluid present to dissipate the energy current have been
described right from the introduction of colonoscopic polypectomy and are still adhered to
today.
2.1. Electrocautery in snare polypectomy and hot biopsy
Williams et al described the use of a diathermy snare loop technique for excision of polyps up
to 4.5 cm in diameter. The “hot-biopsy” technique was also introduced and they reported their
results in 107 smaller polyps. Their results compared favorably to surgical polypectomies.
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They reported a single “closed” perforation that was managed conservatively, and 2 patients
who experienced major hemorrhage. [14]
For small sessile polyps, the snare loop was passed over the head of the polyps and tightened at
the base. For pedunculated polyps, the snare was closed halfway down the stalk. This was
positioned “high” enough to minimize the risk of heat necrosis of the bowel wall, but “low”
enough to include areas of mucosal change suspicious of early malignant invasion of the stalk. [14]
Figure 1. Principle of “current density” in diathermy electrocoagulation – heating effect in the stalk of the polyp (after
Curtiss 1973)
The technique of diathermy snare polypectomy was based on the theory of diathermy currents
described by Curtiss in 1973. The electrical precautions described then are also still observed
today. These are to tighten the snare and elevate the polyp away from the bowel in the direc‐
tion that the current passes into the smallest possible area of tissue within the stalk, enabling
localized heating at the area of highest “current density” (Fig 1). [15] As this is applicable to
pedunculated polyps with inherent stalks, Williams and colleagues [14] described the techni‐
que of creating a “pseudo-pedicle” in small sessile polyps by lifting the snared polyp forcible.
Heat necrosis is avoided by ensuring that the polyp head, upon being lifted up, did not come into
contact with the opposite bowel wall during the application of the current. These principles were
extended for the same authors described the “hot-biopsy” techniques by which polyps up to
7mm were simultaneously biopsies and also destroyed by the application of a strong coagulat‐
ing current down the closed jaws of the biopsy forceps. The tissue within the jaws is not heated
and therefore preserved, as the current bypasses this area of conductive material.
Figure 2. Technique of “hot biopsy” with the use of diathermy forceps – principle of selective coagulation necrosis at
the base of the polyp.
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Since then, the role of therapeutic colonoscopic polypectomy have grown exponentially as the
technical problems of polypectomy and electrosurgery, in comparison to open surgical
polypectomy, are more easily mastered and taught. More importantly, these techniques can
be learnt not just by the surgeons, but also the gastroenterologists.
2.2. Impact of polypectomy — Review of the technique and histologic outcomes
In the 1980s to 1990s, Williams and Bedenne performed a literature review on what they called
“the polyp problem” and carried out a critique of their current practice. They concluded that
since the introduction of the adenoma-carcinoma sequence in 1973, there have been no
evidence in the literature to disprove this concept that majority of colorectal cancers develop
from previous adenomas. Even then, they concluded with the current management of
colorectal polyps was “transparently worthwhile” for the ease of the removal of symptomatic
or threatening polyps avoids the morbidity of surgery and unnecessary operation. [15]
The concept of the “flat adenoma” was also reviewed, and has been described as precursors
of carcinomas especially in inherited colorectal cancers. Jass and colleagues [17] described that
this may account for 10% of patients whose carcinoma develop in a “de novo” fashion. These
are usually found in the right sided colon and characteristically present as a “firm pale button
only 5-15mm in diameter”’ that could be missed at endoscopy, especially if bowel preparation
of the caecal and right sided colon is inadequate. [18]During this time, colonoscopic techniques
were reviewed. [19-20] It was reported that small polyps up to 5-6mm can be conveniently
managed with the hot-biopsy technique. Combined with rapid electrocoagulation technique,
the histological yield has been reported to be over 95%. There must be some visible eletrocoa‐
gulation during this procedure to avoid recurrences of the polyp as simple “cold-biopsy”
without electrocoagulation resulted in up to 29% remnant viable tissue. There is however, a
significant incidence of complications, namely perforation when coagulation is overdone in
the proximal colon. [21-23]
The use of a bipolar electrode, although initially demonstrated promise in localizing heat
necrosis to the area within the jaws of the biopsy forceps, was not predictably effective in polyp
destruction. This is because the tissue grasped between the jaws were heated and thereby
destroyed by the electrical current passing between the jaws, resulting in inability to interpret
the histology. [24]For polyps larger than 5-6mm in diameter, Williams et al concluded that it
was safer to use conventional snare polypectomy. [16] Retrieval of the specimen was by
aspiration into a filtered polyp suction trap commercially available since the late 1980s. [25]
For polyps larger than 1cm (medium to large sized), the principles of sclerotherapy injection
with adrenaline in saline for short stalks prior to snaring or after bleeding have been widely
practiced. Although some have reported that polyps 3cm or greater in size can be excised by
snare polypectomy without employing the injection techniques. [26]
2.3. Advent of endoscopic mucosal resection & submucosa dissection
It is hence, of no surprise when the techniques of submucosal injection with various fluids
(ranged from isotonic to hypertonic saline; 50% glucose with epinephrine +/- indigocarmine)
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to enable a safer and more reliable removal of relatively large or flat lesions were popularized
in the last twenty years as Endoscopic Mucosal Resection (EMR). [28] In general, for lesions
larger than 2cm, several endoscopists recognize the challenge in performing an en bloc
resection, hence piecemeal resection was routinely performed. These had then become
accepted as a relatively quick and easy procedure to perform. [29-30] The disadvantages of the
lack of a precise histological evaluation and risk of local recurrence were reported and widely
accepted. The default staging of the resection automatically becomes Rx as compared to R0 if
an adequate en bloc resection had been performed. Hence there was a challenge to perform a
single step non piece-meal mucosectomy for large flat lesions.The first such successful
procedure in the colorectum for a lesions larger than 2cm was performed by the co-author
(H.Y.) and published in 1999. He performed single step resection of a 40mm flat-elevated tumor
in the rectum using sodium hyaluronate which enabled a prominent and longer lasting mucosa
protrusion. [79-80]
In a recent analysis of 58 lateral spreading tumours (>10 mm in diameter with a low vertical
axis extending laterally along the luminal wall) 36 lesions required piecemeal resection due to
their maximum diameter exceeding 20 mm, and the majority of recurrences (8/10) detected
occurred in this group. These recurrences were successfully managed by further EMR. [11] Re-
treatment of recurrent tumors after such piecemeal EMRs were postulated to have added
difficulty as the local fibrosis prevented an adequate mucosal lift, hence increasing the risk of
perforation and inadequate resection. Hurlstone and colleagues reported their method of
addressing these issues. The problem of recurrence that piecemeal or incomplete resection
poses may be tackled by utilizing endoscopic submucosal resection (ESD) which has recently
been developed by Japanese groups for the endoluminal resection of Paris 0-II lesions of the
stomach, gastro-esophageal junction and esophagus using a gastroscope with a distal trans‐
parent cap attachment. The technique allows en bloc knife dissection after sodium hyaluronic
acid or glycerol submucosal infiltration for lesions > 20 mm in diameter. [11]
2.4. Endoscopic microsurgery
In 1987, Buess and colleagues extended the application of endoscopy in the arena of minimally
invasive surgery, pushing back their boundaries by introducing the transanal endoscopic
microsurgery (TEM) procedure. This enabled two-handed use of surgical instrumentation and
suturing techniques via a jumbo proctoscope to enable air insufflation of the rectum and
sigmoid colon. He reported the ability to resect large and full thickness lesions up to the
distance of 25cm from the anal verge. However, large sessile tumours in the proximal colon
will still require surgical management if endoscopic snaring is too risky or if it fails. [31] This
eventually resulted in the evolution of the ESD technique, an amulgamation of both endoscopic
and surgical principles.
2.5. Strategy of endoscopic treatment for colorectal tumours — Endoscopic submucosal
dissection: Technique
ESD is a new endoluminal therapeutic technique involving the use of cutting devices to permit
a larger resection of the tissue over the muscularis propria. The major advantages of the
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from previous adenomas. Even then, they concluded with the current management of
colorectal polyps was “transparently worthwhile” for the ease of the removal of symptomatic
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The concept of the “flat adenoma” was also reviewed, and has been described as precursors
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this may account for 10% of patients whose carcinoma develop in a “de novo” fashion. These
are usually found in the right sided colon and characteristically present as a “firm pale button
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the histological yield has been reported to be over 95%. There must be some visible eletrocoa‐
gulation during this procedure to avoid recurrences of the polyp as simple “cold-biopsy”
without electrocoagulation resulted in up to 29% remnant viable tissue. There is however, a
significant incidence of complications, namely perforation when coagulation is overdone in
the proximal colon. [21-23]
The use of a bipolar electrode, although initially demonstrated promise in localizing heat
necrosis to the area within the jaws of the biopsy forceps, was not predictably effective in polyp
destruction. This is because the tissue grasped between the jaws were heated and thereby
destroyed by the electrical current passing between the jaws, resulting in inability to interpret
the histology. [24]For polyps larger than 5-6mm in diameter, Williams et al concluded that it
was safer to use conventional snare polypectomy. [16] Retrieval of the specimen was by
aspiration into a filtered polyp suction trap commercially available since the late 1980s. [25]
For polyps larger than 1cm (medium to large sized), the principles of sclerotherapy injection
with adrenaline in saline for short stalks prior to snaring or after bleeding have been widely
practiced. Although some have reported that polyps 3cm or greater in size can be excised by
snare polypectomy without employing the injection techniques. [26]
2.3. Advent of endoscopic mucosal resection & submucosa dissection
It is hence, of no surprise when the techniques of submucosal injection with various fluids
(ranged from isotonic to hypertonic saline; 50% glucose with epinephrine +/- indigocarmine)
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to enable a safer and more reliable removal of relatively large or flat lesions were popularized
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larger than 2cm, several endoscopists recognize the challenge in performing an en bloc
resection, hence piecemeal resection was routinely performed. These had then become
accepted as a relatively quick and easy procedure to perform. [29-30] The disadvantages of the
lack of a precise histological evaluation and risk of local recurrence were reported and widely
accepted. The default staging of the resection automatically becomes Rx as compared to R0 if
an adequate en bloc resection had been performed. Hence there was a challenge to perform a
single step non piece-meal mucosectomy for large flat lesions.The first such successful
procedure in the colorectum for a lesions larger than 2cm was performed by the co-author
(H.Y.) and published in 1999. He performed single step resection of a 40mm flat-elevated tumor
in the rectum using sodium hyaluronate which enabled a prominent and longer lasting mucosa
protrusion. [79-80]
In a recent analysis of 58 lateral spreading tumours (>10 mm in diameter with a low vertical
axis extending laterally along the luminal wall) 36 lesions required piecemeal resection due to
their maximum diameter exceeding 20 mm, and the majority of recurrences (8/10) detected
occurred in this group. These recurrences were successfully managed by further EMR. [11] Re-
treatment of recurrent tumors after such piecemeal EMRs were postulated to have added
difficulty as the local fibrosis prevented an adequate mucosal lift, hence increasing the risk of
perforation and inadequate resection. Hurlstone and colleagues reported their method of
addressing these issues. The problem of recurrence that piecemeal or incomplete resection
poses may be tackled by utilizing endoscopic submucosal resection (ESD) which has recently
been developed by Japanese groups for the endoluminal resection of Paris 0-II lesions of the
stomach, gastro-esophageal junction and esophagus using a gastroscope with a distal trans‐
parent cap attachment. The technique allows en bloc knife dissection after sodium hyaluronic
acid or glycerol submucosal infiltration for lesions > 20 mm in diameter. [11]
2.4. Endoscopic microsurgery
In 1987, Buess and colleagues extended the application of endoscopy in the arena of minimally
invasive surgery, pushing back their boundaries by introducing the transanal endoscopic
microsurgery (TEM) procedure. This enabled two-handed use of surgical instrumentation and
suturing techniques via a jumbo proctoscope to enable air insufflation of the rectum and
sigmoid colon. He reported the ability to resect large and full thickness lesions up to the
distance of 25cm from the anal verge. However, large sessile tumours in the proximal colon
will still require surgical management if endoscopic snaring is too risky or if it fails. [31] This
eventually resulted in the evolution of the ESD technique, an amulgamation of both endoscopic
and surgical principles.
2.5. Strategy of endoscopic treatment for colorectal tumours — Endoscopic submucosal
dissection: Technique
ESD is a new endoluminal therapeutic technique involving the use of cutting devices to permit
a larger resection of the tissue over the muscularis propria. The major advantages of the
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technique in comparison with polypectomy and endoscopic mucosal resection are controllable
resection size and shape, and en bloc resection of a large lesion or one with ulcerative features.
[33-34] Naohisa Yahagi surmised this technique as a “fairly new arrival in the field of endos‐
copy”, but had redefined the whole concept of minimally invasive endoscopic resection for
gastrointestinal neoplasms. [35]The technique of endoscopic submucosal dissection (ESD) has
extended its applications for en bloc resection of large ulcerative lesions in the stomach for the
treatment of early gastric cancer to that of resection of superficial neoplasms of the colon and
the rectum for the treatment of early colorectal cancer. [36-39]
ESD has the advantage of permitting en bloc and histologically complete resection. On the
other hand, ESD has some disadvantages such as a long operating time, a high frequency of
complications, and the need for a high level of technical skill [39-41].
Figure 3. (a): mucosal incision made 3-5mm outside the tumour edge with Endocut mode. 3(b) Submucosal dissection
performed using the ST hood as means of elevation and counter-traction.
The most important aspects of this technique are to incise the mucosa surrounding the lesion
(Figure 3a), and to dissect completely the submucosa beneath that lesion (Figure 3b) to achieve
reliable en bloc resection regardless of the size or location of the tumor
2.6. Principles of ESD
The technique of endoscopic resection is less invasive than surgical resection [34,39-40]. Its
limitation lies in its inability to perform lymph node dissection, hence cure can only be achieved
in localized tumors without metastases. [35,39] The risk of lymph node metastases strongly
correlates with the depth of invasion of the tumor, the histopathologic type of the lesion and
the presence of lymphovascular involvement. [42-46] Hence, the precise staging of the lesion
pre-procedure with pit pattern diagnosis using the technique of magnifying endoscopy is
strongly recommended for the appropriate selection of tumors for endoscopic resection
[47-48].
Detailed pathological examination of the resected specimen is paramount to document the
complete resection of the neoplasms, allowing appropriate decisions regarding the need for
further surgical intervention. Curative endoscopic resection is defined by confirmation of
negative resection margins, differentiated histopathologic type, depth of submucosal invasion
to be <1,000 um and no lymphatic or vascular involvement. En bloc resection of the entire lesion
is necessary to obtain such information.
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ESD has demonstrated superiority to EMR for a more reliable en bloc resection of a targeted
area of mucosa can be achieved. It has also shown to provide a higher complete resection rate
with local recurrence rate as compared to piecemeal EMR. [32,49-51]. It enables the control of
the size as well as the shape of the lesion to be resected, those with ulcerative findings can also
be resected en bloc, leading to a potential cure of the target lesions without resection of that
portion of the gastrointestinal tract or organ.
2.7. Indication for colorectal ESD
The characterization and endoscopic staging of each lesion is paramount in determining the
suitability and thereby success of this procedure. In general, ESD can be applied to almost all
lesions provided that they are within the mucosa and superficial submucosal layer of the
colorectal wall. Absolute indications for ESD have been reported to be those that “cannot be
resected en bloc by standard available procedures; those that require precise histological
evaluation on account of a significant malignant potential. Hurlstone and colleagues describe
these to be laterally spreading tumors of the nongranulating types (LST-NG). The use of the
snare EMR technique for en bloc resection of larger lesions with features pf LST-NG type,
pseudo-depressed type and lesions with type Vi pit pattern with suspicion of carcinoma
infiltrating into the submucosal layer (sm), or large elevated tumors are deemed difficult.
Other indications described in literature are those with biopsy-induced submucosal fibrotic
scars, lesions located at challenging areas: on haustrae and difficult colonic angulations, and
large lesions (>20mm), and small rectal carcinoid tumor when en bloc resection by conventional
methods were deemed impossible. [52-53] Sporadic localized tumors occurring in the back‐
ground of chronic inflammation such as those seen in inflammatory bowel disease namely
ulcerative colitis; and residual early carcinoma post endoscopic resection are also indications
for ESD. The success in such cases is dependent on the operability of endoscope, and the skill
of the endoscopists - factors that should always be considered in the practice of ESD.
In the past decade, efforts to establish an East-West consensus on the clinicopathological
importance of the macroscopic morphology of the colorectal polyp, incorporating the exo‐
phytic protruding polyps as well as those that are flat and depressed, have resulted in the
introduction of multiple classifications. These are namely, the Paris classification and the
modified Kudo criteria. The Cho criterion is used to differentiate tumor stage and nodal disease
status by using high-frequency endoscopic ultrasonography. All are used to establish the
exclusion criteria of ESD, which are: T2/N1 disease, transfixed type IIC component (constant
concavity of the lesion regardless of air insufflations or deflation as defined by Kudo). Presence
of systemic disease (hepatic metastases) or local nodal metastasis at index computer tomog‐
raphy imaging of abdomen and pelvis excludes ESD as a curative procedure. [58-9]
More recently in Japan, the indications for colorectal ESD have been established by the
Colorectal ESD Standardization Implementation Working Group (Table 1). The development
of various devices, endoscopes, and accessories for colorectal ESD have increased the safety
of colorectal ESD, established its procedures, and simplified its techniques. Consequently,
colorectal ESD has been gradually introduced in many institutions, both within Japan and in
Asian countries. [59]
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technique in comparison with polypectomy and endoscopic mucosal resection are controllable
resection size and shape, and en bloc resection of a large lesion or one with ulcerative features.
[33-34] Naohisa Yahagi surmised this technique as a “fairly new arrival in the field of endos‐
copy”, but had redefined the whole concept of minimally invasive endoscopic resection for
gastrointestinal neoplasms. [35]The technique of endoscopic submucosal dissection (ESD) has
extended its applications for en bloc resection of large ulcerative lesions in the stomach for the
treatment of early gastric cancer to that of resection of superficial neoplasms of the colon and
the rectum for the treatment of early colorectal cancer. [36-39]
ESD has the advantage of permitting en bloc and histologically complete resection. On the
other hand, ESD has some disadvantages such as a long operating time, a high frequency of
complications, and the need for a high level of technical skill [39-41].
Figure 3. (a): mucosal incision made 3-5mm outside the tumour edge with Endocut mode. 3(b) Submucosal dissection
performed using the ST hood as means of elevation and counter-traction.
The most important aspects of this technique are to incise the mucosa surrounding the lesion
(Figure 3a), and to dissect completely the submucosa beneath that lesion (Figure 3b) to achieve
reliable en bloc resection regardless of the size or location of the tumor
2.6. Principles of ESD
The technique of endoscopic resection is less invasive than surgical resection [34,39-40]. Its
limitation lies in its inability to perform lymph node dissection, hence cure can only be achieved
in localized tumors without metastases. [35,39] The risk of lymph node metastases strongly
correlates with the depth of invasion of the tumor, the histopathologic type of the lesion and
the presence of lymphovascular involvement. [42-46] Hence, the precise staging of the lesion
pre-procedure with pit pattern diagnosis using the technique of magnifying endoscopy is
strongly recommended for the appropriate selection of tumors for endoscopic resection
[47-48].
Detailed pathological examination of the resected specimen is paramount to document the
complete resection of the neoplasms, allowing appropriate decisions regarding the need for
further surgical intervention. Curative endoscopic resection is defined by confirmation of
negative resection margins, differentiated histopathologic type, depth of submucosal invasion
to be <1,000 um and no lymphatic or vascular involvement. En bloc resection of the entire lesion
is necessary to obtain such information.
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with local recurrence rate as compared to piecemeal EMR. [32,49-51]. It enables the control of
the size as well as the shape of the lesion to be resected, those with ulcerative findings can also
be resected en bloc, leading to a potential cure of the target lesions without resection of that
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suitability and thereby success of this procedure. In general, ESD can be applied to almost all
lesions provided that they are within the mucosa and superficial submucosal layer of the
colorectal wall. Absolute indications for ESD have been reported to be those that “cannot be
resected en bloc by standard available procedures; those that require precise histological
evaluation on account of a significant malignant potential. Hurlstone and colleagues describe
these to be laterally spreading tumors of the nongranulating types (LST-NG). The use of the
snare EMR technique for en bloc resection of larger lesions with features pf LST-NG type,
pseudo-depressed type and lesions with type Vi pit pattern with suspicion of carcinoma
infiltrating into the submucosal layer (sm), or large elevated tumors are deemed difficult.
Other indications described in literature are those with biopsy-induced submucosal fibrotic
scars, lesions located at challenging areas: on haustrae and difficult colonic angulations, and
large lesions (>20mm), and small rectal carcinoid tumor when en bloc resection by conventional
methods were deemed impossible. [52-53] Sporadic localized tumors occurring in the back‐
ground of chronic inflammation such as those seen in inflammatory bowel disease namely
ulcerative colitis; and residual early carcinoma post endoscopic resection are also indications
for ESD. The success in such cases is dependent on the operability of endoscope, and the skill
of the endoscopists - factors that should always be considered in the practice of ESD.
In the past decade, efforts to establish an East-West consensus on the clinicopathological
importance of the macroscopic morphology of the colorectal polyp, incorporating the exo‐
phytic protruding polyps as well as those that are flat and depressed, have resulted in the
introduction of multiple classifications. These are namely, the Paris classification and the
modified Kudo criteria. The Cho criterion is used to differentiate tumor stage and nodal disease
status by using high-frequency endoscopic ultrasonography. All are used to establish the
exclusion criteria of ESD, which are: T2/N1 disease, transfixed type IIC component (constant
concavity of the lesion regardless of air insufflations or deflation as defined by Kudo). Presence
of systemic disease (hepatic metastases) or local nodal metastasis at index computer tomog‐
raphy imaging of abdomen and pelvis excludes ESD as a curative procedure. [58-9]
More recently in Japan, the indications for colorectal ESD have been established by the
Colorectal ESD Standardization Implementation Working Group (Table 1). The development
of various devices, endoscopes, and accessories for colorectal ESD have increased the safety
of colorectal ESD, established its procedures, and simplified its techniques. Consequently,
colorectal ESD has been gradually introduced in many institutions, both within Japan and in
Asian countries. [59]
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Indications for Colorectal ESD - Standardization Implementation Working Group
Lesions larger than 20mm in diameter in which en
bloc resection using snare EMR is difficult, although it
is indicative for endoscopic treatment
Non granular LST, particularly those of
pseudodepressed type
Lesions with V1 type pit pattern
Carcinoma with submucosal infiltration
Large depressed type lesion
Large lesions with elevated type suspected to be
cancer (including granular LST that consisted of large
nodules)
Mucosal lesions with fibrosis caused by prolapse due
to biopsy of peristalsis of the lesions
Sporadic localized tumors in chronic inflammation
such as ulcerative colitis
Local residual early cancer after endoscopic resection
Table 1. Indications of ESD for colorectal neoplasms. The Colorectal ESD Standardization Implementation Working
Group, a subordinate organization of the Gastroenterological Endoscopy Promotion Liaison Conference has proposed
the Indication Criteria for Colorectal ESD (Tanaka S, Oka S, Chayama K. Colorectal endoscopic submucosal dissection:
present status and future perspective, including its differentiation from endoscopic mucosal resection. J. Gastroenterol.
2008; 43: 641–51 (Review).
2.8. Assessment of tumour extent
Mucosal neoplasms in the colon and rectum typically have clear margins, which become even
more prominent after submucosal injection and/or with the assistance of chromo-endoscopy.
Thus in most cases, placing marks around the tumour prior to dissection is not necessary.
Chromo-endoscopy with indigo carmine spray with or without the use of crystal violet dye,
is useful to enhance the borders of the tumors. Newer imaging techniques, such as narrow
band imaging (NBI) and flexible spectral imaging color enhancement (FICE) or Fuji Intelligent
Color Enhancement (FICE ®) (Fujifilm Corp., Tokyo, Japan) are also useful to determine the
borders of these tumors.
2.9. Preparation and set-up
This aspect of the procedure is important in ensuring optimal conditions during a technically
challenging procedure. Optimal vision of the operating field is essential. A well-prepared
bowel can also limit the contamination and degree of peritonitis should a perforation occur.
2.9.1. Endoscopes
Thinner endoscopes are preferred for precise control of the tip. Some authors select a single
channel upper endoscope for ESD for rectosigmoid and distal left sided lesions. In our case
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series performed in a local institution, we used a specifically designed colonoscope
(EC-450RD5; Fujifilm Corp., Tokyo, Japan; Fig. 4) for ESD in the colon and rectum. It is a single-
channel scope with tip size (9.8mm) with a regular shaft size (12.8mm). This enables the usage
of the retroflexed approach in any part of the colon and rectum as the tip is thin and short with
good angulation ability. A relatively large accessory channel of 3.2 mm and a water jet function
with good targeting direction make this scope suitable for ESD. The water jet allows the
operator to wash out blood or mucus at the target area from their tips. A mixture of water with
simethicon is used as a standard preparation solution for there is marked reduction in adherent
residue and enables easier luminal lavage during ESD.
It is paramount to understand that maneuverability of the endoscope is the key factor in
successful ESD and this should not be compromised. Hence, some authors report that in the
cases of colorectal neoplasms, the application of the upper GI endoscopes is preferable to that
of a slim single-channel endoscope. This is especially so when retroflexed manipulation is
necessary as an endoscope with a small diameter allows smoother maneuverability in the
retroflexed position. Such a position is recommended for large-sized lesions with its oral edge
straddling a fold.
Figure 4. Colonoscope for ESD (EC-450RD5; Fujifilm Corp.). a The bending section of the endoscope tip is thin and
short with good angulation capability. b A large accessory channel and a water jet channel are situated close to each
other. c Water jet function of the scope. d Good targeting direction of the water jet to the tip of an accessory device.
When a lesion for ESD is located in an unstable part of the colon and paradoxical movements
with a standard colonoscope hamper the reliable performance of the ESD procedure, we select
a double-balloon colonoscope (EC-450BI5, Fujifilm, Japan; Fig. 5). The double-balloon colo‐
noscope provides precise control of the endoscope tip, even in this situation (Fig. 6). The
principle of DBE is well described by the co-author (H.Y.), and this has enabled optimal
maneuverability and stability of the endoscope tip especially in the colon with its inherent
anatomic variability in comparison to the oesophagus or stomach. Ohya and colleagues [54]
highlighted these in their brief article on the use of a balloon over-tube as an endoscopic
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Carcinoma with submucosal infiltration
Large depressed type lesion
Large lesions with elevated type suspected to be
cancer (including granular LST that consisted of large
nodules)
Mucosal lesions with fibrosis caused by prolapse due
to biopsy of peristalsis of the lesions
Sporadic localized tumors in chronic inflammation
such as ulcerative colitis
Local residual early cancer after endoscopic resection
Table 1. Indications of ESD for colorectal neoplasms. The Colorectal ESD Standardization Implementation Working
Group, a subordinate organization of the Gastroenterological Endoscopy Promotion Liaison Conference has proposed
the Indication Criteria for Colorectal ESD (Tanaka S, Oka S, Chayama K. Colorectal endoscopic submucosal dissection:
present status and future perspective, including its differentiation from endoscopic mucosal resection. J. Gastroenterol.
2008; 43: 641–51 (Review).
2.8. Assessment of tumour extent
Mucosal neoplasms in the colon and rectum typically have clear margins, which become even
more prominent after submucosal injection and/or with the assistance of chromo-endoscopy.
Thus in most cases, placing marks around the tumour prior to dissection is not necessary.
Chromo-endoscopy with indigo carmine spray with or without the use of crystal violet dye,
is useful to enhance the borders of the tumors. Newer imaging techniques, such as narrow
band imaging (NBI) and flexible spectral imaging color enhancement (FICE) or Fuji Intelligent
Color Enhancement (FICE ®) (Fujifilm Corp., Tokyo, Japan) are also useful to determine the
borders of these tumors.
2.9. Preparation and set-up
This aspect of the procedure is important in ensuring optimal conditions during a technically
challenging procedure. Optimal vision of the operating field is essential. A well-prepared
bowel can also limit the contamination and degree of peritonitis should a perforation occur.
2.9.1. Endoscopes
Thinner endoscopes are preferred for precise control of the tip. Some authors select a single
channel upper endoscope for ESD for rectosigmoid and distal left sided lesions. In our case
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series performed in a local institution, we used a specifically designed colonoscope
(EC-450RD5; Fujifilm Corp., Tokyo, Japan; Fig. 4) for ESD in the colon and rectum. It is a single-
channel scope with tip size (9.8mm) with a regular shaft size (12.8mm). This enables the usage
of the retroflexed approach in any part of the colon and rectum as the tip is thin and short with
good angulation ability. A relatively large accessory channel of 3.2 mm and a water jet function
with good targeting direction make this scope suitable for ESD. The water jet allows the
operator to wash out blood or mucus at the target area from their tips. A mixture of water with
simethicon is used as a standard preparation solution for there is marked reduction in adherent
residue and enables easier luminal lavage during ESD.
It is paramount to understand that maneuverability of the endoscope is the key factor in
successful ESD and this should not be compromised. Hence, some authors report that in the
cases of colorectal neoplasms, the application of the upper GI endoscopes is preferable to that
of a slim single-channel endoscope. This is especially so when retroflexed manipulation is
necessary as an endoscope with a small diameter allows smoother maneuverability in the
retroflexed position. Such a position is recommended for large-sized lesions with its oral edge
straddling a fold.
Figure 4. Colonoscope for ESD (EC-450RD5; Fujifilm Corp.). a The bending section of the endoscope tip is thin and
short with good angulation capability. b A large accessory channel and a water jet channel are situated close to each
other. c Water jet function of the scope. d Good targeting direction of the water jet to the tip of an accessory device.
When a lesion for ESD is located in an unstable part of the colon and paradoxical movements
with a standard colonoscope hamper the reliable performance of the ESD procedure, we select
a double-balloon colonoscope (EC-450BI5, Fujifilm, Japan; Fig. 5). The double-balloon colo‐
noscope provides precise control of the endoscope tip, even in this situation (Fig. 6). The
principle of DBE is well described by the co-author (H.Y.), and this has enabled optimal
maneuverability and stability of the endoscope tip especially in the colon with its inherent
anatomic variability in comparison to the oesophagus or stomach. Ohya and colleagues [54]
highlighted these in their brief article on the use of a balloon over-tube as an endoscopic
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channel and platform for colorectal ESD in cases whereby access was difficult due to the colon
being a longer tubular structure, with folds and formation of loops during intubation resulting
in paradoxical movements. These authors report that the use of the balloon over-tube enabled
optimal traction on the intestinal wall, and provided a shorter direct access to the lesion.
Figure 5. Double-balloon colonoscope (EC-450BI5, Fujifilm Corp.). a Soft balloons are equipped at the tip of the endo‐
scope and the tip of the overtube. b A balloon controller to inflate or deflate the balloons.
Figure 6. Illustrations demonstrating the sequential maneuvers of the instruments in the double-balloon method: (a)
ante grade and (b) retrograde approach. Blue – paradoxical movements with standard colonoscope. Green – Precise
control of endoscope tip provided by the double balloon (DB) colonoscope.
2.9.2. Accessories
Several kinds of electrosurgical knives have been developed for ESD. Among the currently
available knives, we use a FlushKnife® (1.5mm; DK2618JN15; Fujifilm Corp., Tokyo, Japan)
for ESD in the colon for our series. A FlushKnife® is a special needle knife featuring the water
jet function through the knife sheath. The water jet function can be used to cleanse the surface
of the mucosa and the needle itself. It can also be used for fluid injections directly into the
submucosal layer through the FlushKnife® after mucosal incision. This improves is efficacy
as it can be used for both injection and dissection. ESD can be performed immediately after
the injection without changing the devices. The appropriate length of the needle can be selected
from among 1, 1.5, 2, 2.5 and 3 mm sizes, based on the specific situation. (Fig 7)
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Figure 7. Flush knife (DK2618JN10–30; Fujifilm Corp.). a The appropriate length of the needle can be selected from
among 1, 1.5, 2, 2.5 and 3 mm sizes. b Water jet function through the knife sheath.
2.9.3. Hood
A transparent hood attached to the tip of the endoscope is useful to open the incised wound
and to maintain a good endoscopic view during the procedure. It also allows precise control
of the knife by stabilizing the target with its tip. Use of a hood is substituted for the triangulation
used during surgical procedures, which is difficult to apply in endoscopic procedures. We
mainly use a transparent hood with a small-caliber tip (ST hood; DH-15GR, DH-16CR; Fujifilm,
Japan; Fig 8) for colonic ESD. The ST hood has an aperture small enough to make it easy to
widen an incised wound using the edge of the hood, and to allow more accurate adjustment
of the depth of incision by the knife point. Using the ST hood, it is easy to create a submucosal
tunnel proceeding with submucosal dissection by inserting the tip of the hood into the
submucosal layer, which is a useful strategy for effective ESD.
c 
Figure 8. ST hood (DH-15GR, DH-16CR; Fujifilm Corp.). a Two sizes of the hood, DH-15GR for a thin endoscope tip and
DH-16CR for a standard colonoscope tip) are available. b ST hood attached to the endoscope. c varying widths and
heights for various locations and tissues
2.9.4. Electrosurgical current generator
The current and frequency of the electrosurgical current generator is of great importance to
enable a reliable incision with effective control of bleeding and minimum tissue damage. We
mainly use the ERBE VIO 300 D (Erbe, Tubingen, Germany). It is set to ‘Endo Cut I’ mode for
mucosal incision, and to ‘swift coagulation’ or ‘dry cut’ mode for submucosal dissection. Table
2 is an example of the settings that was used in our case series.
Evolution and Strategy of Endoscopic Treatment for Colorectal Tumours
http://dx.doi.org/10.5772/53342
105
channel and platform for colorectal ESD in cases whereby access was difficult due to the colon
being a longer tubular structure, with folds and formation of loops during intubation resulting
in paradoxical movements. These authors report that the use of the balloon over-tube enabled
optimal traction on the intestinal wall, and provided a shorter direct access to the lesion.
Figure 5. Double-balloon colonoscope (EC-450BI5, Fujifilm Corp.). a Soft balloons are equipped at the tip of the endo‐
scope and the tip of the overtube. b A balloon controller to inflate or deflate the balloons.
Figure 6. Illustrations demonstrating the sequential maneuvers of the instruments in the double-balloon method: (a)
ante grade and (b) retrograde approach. Blue – paradoxical movements with standard colonoscope. Green – Precise
control of endoscope tip provided by the double balloon (DB) colonoscope.
2.9.2. Accessories
Several kinds of electrosurgical knives have been developed for ESD. Among the currently
available knives, we use a FlushKnife® (1.5mm; DK2618JN15; Fujifilm Corp., Tokyo, Japan)
for ESD in the colon for our series. A FlushKnife® is a special needle knife featuring the water
jet function through the knife sheath. The water jet function can be used to cleanse the surface
of the mucosa and the needle itself. It can also be used for fluid injections directly into the
submucosal layer through the FlushKnife® after mucosal incision. This improves is efficacy
as it can be used for both injection and dissection. ESD can be performed immediately after
the injection without changing the devices. The appropriate length of the needle can be selected
from among 1, 1.5, 2, 2.5 and 3 mm sizes, based on the specific situation. (Fig 7)
Colonoscopy and Colorectal Cancer Screening - Future Directions104
Figure 7. Flush knife (DK2618JN10–30; Fujifilm Corp.). a The appropriate length of the needle can be selected from
among 1, 1.5, 2, 2.5 and 3 mm sizes. b Water jet function through the knife sheath.
2.9.3. Hood
A transparent hood attached to the tip of the endoscope is useful to open the incised wound
and to maintain a good endoscopic view during the procedure. It also allows precise control
of the knife by stabilizing the target with its tip. Use of a hood is substituted for the triangulation
used during surgical procedures, which is difficult to apply in endoscopic procedures. We
mainly use a transparent hood with a small-caliber tip (ST hood; DH-15GR, DH-16CR; Fujifilm,
Japan; Fig 8) for colonic ESD. The ST hood has an aperture small enough to make it easy to
widen an incised wound using the edge of the hood, and to allow more accurate adjustment
of the depth of incision by the knife point. Using the ST hood, it is easy to create a submucosal
tunnel proceeding with submucosal dissection by inserting the tip of the hood into the
submucosal layer, which is a useful strategy for effective ESD.
c 
Figure 8. ST hood (DH-15GR, DH-16CR; Fujifilm Corp.). a Two sizes of the hood, DH-15GR for a thin endoscope tip and
DH-16CR for a standard colonoscope tip) are available. b ST hood attached to the endoscope. c varying widths and
heights for various locations and tissues
2.9.4. Electrosurgical current generator
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mainly use the ERBE VIO 300 D (Erbe, Tubingen, Germany). It is set to ‘Endo Cut I’ mode for
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Device Cut Mode Coagulation Mode




Submucosal Dissection Flush knife Dry Cut E6 30 W Swift Coag E4 30 W
Hemostasis Flush knife
Hemostatic Forceps
Spray Coag E2 5 W
Soft Coag E6 80 W
Table 2. ERBE VIO 300D settings for ESD procedures (W: watts)
Minor bleeding and small blood vessels can be managed using the knife. However, more
reliable hemostasis for a larger vessel can be achieved using hemostatic forceps (HDB2422W;
Pentax, Tokyo, Japan). The generator is set to soft coagulation mode for the hemostatic forceps.
Effective control of bleeding during the procedure is a vital factor for successful ESD.
3. ESD technique
ESD for colorectal tumors has been considered more technically demanding as compared to
that in the stomach. This can be attributed to these following reasons: (1) thinner and softer
colonic wall, (2) endoscopic control is difficult in specific parts of the colon due to paradoxical
movement; (3) limitations to the retroflexed approach due to the narrow caliber of the colon;
(4) tumours located on or behind a prominent colonic folds, peristalsis, and (5) higher risk of
diffuse peritonitis requiring emergency surgical intervention as compared to perforation of
the upper gastrointestinal tract. [34]
Several devices have been applied to ESD in the colon and rectum with the principle to use a
dissecting technique that allows direct visualization of the submucosal tissue, and to use long-
lasting injecting fluid. [79-80]
3.1. Technical method
3.1.1. Approach strategy and technique for mucosal incisions and submucosal dissection
Success of the ESD procedure lies with the maneuverability and stability of the endoscope.
Hence, the insertion must be done in a controlled manner to avoid loop formation if possible.
Authors have reported that rotation is a key movement. Upon reaching the tumor, the lumen
of the intestine is filled with a mixture of water and simethicon to ensure adequate visualiza‐
tion. Chromoendoscopy with indigo carmine is performed to characterize the surface details
and extent of the lesion. The borders of the lesion should be clearly visualized. [34]
A good strategy with prior considerations to the angle of approach to the lesion, taking into
account the direction of gravity in relation its location is recommended. This can be assessed
by observing the direction of the course of the jet stream of water from the water-jet. The
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position of the patient should be selected to locate the lesion at the top of the colonic lumen
with regard to gravity. This enables sufficient opening of the mucosal incision and good
visualization of the submucosal tissue during the procedure. Hence, minimal sedation for
patient comfort is recommended if possible to allow patients to move positions more readily
and report any undue discomfort during the procedure. In cases of unfavorable events such
as bleeding and perforation, this positioning is beneficial to avoid or minimize further
complications. In this position, bowel contents will not spill or leak into the intraperitoneal
cavity and also, in situations of bleeding, blood will flow in the opposite direction (anti-gravity)
to that of the lesion and not pool at the area of dissection. For example, if the bleeding point is
at the top of the lumen, hemostasis can be performed reliably with accurate identification of
the bleeding point because blood flows away from the bleeding point by gravity.
Even in cases of perforation, if the perforation occurs at the top of the lumen with regard to
gravity, identification and closing of the perforation is easier, maintaining a good view of the
site of perforation. Air, not contaminated intestinal fluid, will flow out from the lumen to the
abdominal cavity before closing the perforation, which is important to prevent diffuse
peritonitis.
The mucosal incision is made only in the area to be dissected. This is made with a short
FlushKnife (1.5 mm; DK2618JN15; Fujifilm Corp., Tokyo, Japan) after sufficient protrusion of
the mucosa is obtained with injection of suitable fluid. The Endo Cut mode is used for the
mucosal incision. ESD can be performed safely with a FlushKnife as long as adequate thick‐
ening of the submucosal layer is present. This maintains a safety margin away from the muscle
layer. The dissection should be done parallel to the muscular layer, by sliding the knife from
the centre of the tumor toward the mucosal incision on the side, while hooking submucosal
fibers with the knife. There are several other types of knives available commercially and several
other techniques have been described in literature but these are not described here.
Several newer strategies have been introduced over the last couple of years. As shown in Figure
9(a) [SAFEKnife Horizontal®. DK2518DH1 Fujifilm Corp, Tokyo Japan] newer knives have
been designed to enable a different axis of cutting. These are introduced during the submucosal
dissection itself during the procedure with the aim to achieve maximal safety and efficacy.
The mucosal incision is made only in the area to be dissected and then dissection of the
submucosa from the incised part is promptly started. Circumferential marking around the
tumor with the tip of the electrosurgical knife is recommended for lesions in the upper
gastrointestinal tract but not for intestinal neoplasms as the colonic wall is thin enough to be
perforated in the process.
The development and subsequent maintenance of sufficient mucosal elevation is paramount
for safe mucosal incisions and submucosal dissection. For these purposes, 0.4% sodium
hyaluronate solution (MucoUp®; Seikagaku Corp, Tokyo, Japan) is the best injection fluid for
ESD. [79-80]. The authors have found that the submucosal injection of sodium hyaluronate
(0.4%) – commercially known as MucoUp®, (Johnson and Johnson Medical Co., Tokyo, Japan)
enables the creation of a long-lasting mucosal protrusion that usually lasts more than 1 hour,
providing the longest lasting fluid cushion, [49,79-80] and higher successful en-bloc resection
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hyaluronate solution (MucoUp®; Seikagaku Corp, Tokyo, Japan) is the best injection fluid for
ESD. [79-80]. The authors have found that the submucosal injection of sodium hyaluronate
(0.4%) – commercially known as MucoUp®, (Johnson and Johnson Medical Co., Tokyo, Japan)
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and lower perforation complication rates have been reported using HA, particularly for
colorectal ESD [31,44,47,53-54]. However, in view of its high cost and unavailability locally
(US $49.50–128.00/mL in the United States), we have created our own solution using (Fig 10a-
b) 4 vials of Optovisc Eyedrops® (Ashford, FP Marketing) (Fig 10a) to make up 40mls of




Figure 9. (a): SAFEKnife H ® that cuts in the horizontal plane and (b) SAFEKnife V ® that cuts in the vertical plane –
invented by Dr H Yamamoto, manufactured by Fujifilm Corp Japan – 9(c) SAFEKnife V ® has a sandwichlike structure
with a central electrode plate placed between 2 insulated plates enablising a safe and effective dieesction of the sub‐
mucosal layers with a vertical approach
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Figure 10. (a): one vial of Optovisc® (b): Indigo Carmine Solution
This solution is injected into the submucosal layer just outside where the mucosal incision is
intended.
3.1.2. Mucosal incision
The mucosal incision is made with a short FlushKnife® (1.5 mm; DK2618JN15; Fujifilm Corp.,
Tokyo, Japan) after sufficient protrusion of the mucosa is obtained. Only the needle part should
be used for the incision, keeping the tip of the sheath touching the surface of the mucosa
without pushing the sheath into the submucosal layer. The Endo Cut mode is used for the
mucosal incision, at 30 watts. (Table 2)
There is no need for complete marginal cutting of the mucosa before the submucosal dissection.
Some authors report that after exposure of the submucosal layer, with the visualization of the
blue-stained submucosal connective tissue, further submucosal injection from the exposed
submucosal layers may be used to elevate the layer that is to be cut. If the blue submucosal
layers is not seen, this may indicate that the muscularis mucosae layers is incompletely cut and
the incising line should be traced again until the blue submucosal layer is seen.
3.1.3. Submucosal dissection
ESD can be performed safely with a FlushKnife® as long as adequate thickening of the
submucosal layer is present. This maintains a safety margin away from the muscle layer. The
dissection should be done parallel to the muscular layer, by sliding the knife from the centre
of the tumor toward the mucosal incision on the side, while hooking submucosal fibers with
the knife. The submucosal fibres stained blue (indigo-carmine) are very soft and dissected
easily with gentle application of the FlushKnife ® using the forced or swift coagulation mode.
The knife length may be kept at the same length (<2mm) for both the mucosal incision and
submucosal dissection.
A recent “tunneling” method has been introduced to dissect the submucosal layer, starting at
the proximal edge of the colorectal tumour, followed by the distal edge.[34] Submucosal
dissection is continued to make a tunnel in the submucosal layer by inserting the tip of the
endoscope with a transparent hood under the mucosal tumor. This is continued to reach the
mucosal incision at the proximal edge. After penetration of the tunnel, which began from both
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A recent “tunneling” method has been introduced to dissect the submucosal layer, starting at
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dissection is continued to make a tunnel in the submucosal layer by inserting the tip of the
endoscope with a transparent hood under the mucosal tumor. This is continued to reach the
mucosal incision at the proximal edge. After penetration of the tunnel, which began from both
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ends, it is widened laterally. The mucosa on both sides of the tumour is then incised laterally
and dissected submucosally to complete the dissection. (Fig.11). This tunneling technique
enables the endoscope tip to be stabilized, hence a more precise control of the Flushknife® is
achieved. This technique also enables a good safety margin for further dissection by stretching
the submucosal tissue. Adjusting the approach angle of the knife to be tangential to the wall
also is easy with this method because an adjusting force with the endoscope tip can be applied
in either direction by pushing the mucosa up or pushing the muscle wall down with the tip of
the hood (Fig 11b). This method is particularly useful for large lesions, lesions with fibrosis,
and lesions located on a curved wall.
Figure 11. ESD using a tunneling method. a A large granular laterally spreading tumor (LST) in the rectum. b Distal
edge of the tumor after submucosal injection of sodium hyaluronate solution. c Penetration of the tunnel in the sub‐
mucosal layer. d Mucosal defect after the completion of ESD; © Photographs courtesy of H Yamamoto 2010
3.2. Handling of the resected specimen and histopathological assessment
The resected specimen is carefully retrieved per anally without tearing. A small specimen may
be retrieved via suction into the soft hood/cap. A Roth net or other retrieval devices may be
Figure 12. En bloc resection of the entire lesion (68 × 62 mm in diameter). Histopathologic examination confirmed
complete curative resection (adenocarcinoma in adenoma, no invasion to submucosa, no lymphatic or vascular in‐
volvement); © Photographs courtesy of H Yamamoto 2010
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used for moderate-sized lesions but with larger lesions, an over-tube may be required. The
shape and orientation of the specimen is dutifully recorded, and the specimen pinned out on
a Styrofoam or corkboard with the oral and anal sides indicated. The preservation of fresh
material is ensured by freezing in liquid nitrogen, embedded in OCT prior to freezing, The
slice is cut from the middle without warming up to allow a frozen section to be used for further
analysis. We recommend the use of formalin soaked needles to fix the specimen, which should
be tension-free as there is 20 to 50% shrinkage of the specimen soaked in formalin.
The ESD specimens are regarded as complex specimens and undergo a standardized process‐
ing during both macroscopic and microscopic assessment of the specimens. They are photo‐
graphed with a styrofoam backing board, with the oral side of the specimen “O” at 12 o’clock
position, and the anal side “A” at the 6 o’clock position to ensure that the orientation of the
specimens are known. (Fig 12)
Figure 13. Mounting of a specimen on a Styrofoam board
Since 2009 to 2011, the specimen has been processed as shown below: The principle is to enable
a fairly precise assessment of margin involvement. Currently, there are 2 methods of section‐
ing, each having their advantages and disadvantages. The first is described below whereby
each transverse section should be submitted separately. The smaller fragments from the lateral
edges should be submitted no more than 2 pieces per block. This has been performed since
January 2009. The disadvantage of this method is that rounded irregular edges of such
specimen are inadvertently shaved off during each 2mm sectioning and these margins cannot
be assessed accurately when the sections happen to be tangential to the edge. The second
method of sectioning aims to overcome the above problem. The axis of sectioning is perpen‐
dicular to the tangential line drawn at the edge. (Fig 14) This will enable more accurate margin
assessment although tissue loss at the apex of each “segment” is inevitable. Inking of the
margins is necessary and different colour should be used to represent the respective margins
as required.
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Figure 11. ESD using a tunneling method. a A large granular laterally spreading tumor (LST) in the rectum. b Distal
edge of the tumor after submucosal injection of sodium hyaluronate solution. c Penetration of the tunnel in the sub‐
mucosal layer. d Mucosal defect after the completion of ESD; © Photographs courtesy of H Yamamoto 2010
3.2. Handling of the resected specimen and histopathological assessment
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Figure 12. En bloc resection of the entire lesion (68 × 62 mm in diameter). Histopathologic examination confirmed
complete curative resection (adenocarcinoma in adenoma, no invasion to submucosa, no lymphatic or vascular in‐
volvement); © Photographs courtesy of H Yamamoto 2010
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3.3. Standard operating procedures — Endoscopic Submucosal Dissections (ESD)
Currently all ESD specimens are regarded as complex specimens by the histopathology
laboratory. They are photographed with the styrofoam backing board so that the orientation
of the specimen is known. The principle of processing the ESD is to be able to tell the clinician
fairly precisely where the margin is involved. An example of how the ESD specimen should
be grossed and submitted is given below.









Figure 14. Pictorial diagram of how the specimen is sectioned and labeled
Each transverse section is submitted separately and the smaller fragments from the lateral
edges should be submitted no more than 2 pieces per block. It is understood that some ESD
specimen may have a rather irregular shape. In this situation, the pathologist or assistant
trimmer should discuss with the consultant in charge how the specimen should best be
processed so that the margins can be mapped back during microscopy.
An example of how the blocking should be represented in the photograph of the specimen is
given below. This will be attached to the back of the report and filed. (Fig 14).
The completeness of the ESD is determined through precise histological evaluation. [56] Any
intramucosal carcinoma for which the resection margins are free of tumor is considered
radically curative. This is also true for cases where there is submucosal invasion that is limited
to 1000 μm or less, or that the invasive front comprises of only highly or well-differentiated
tumor. High risk factors for lymph node metastases are generally absent; hence further surgery
is deemed unnecessary. [59]
Surgery is recommended for lesions with a high risk of local recurrence or lymph node
metastases as seen in these following circumstances: lesions with 1) positive vertical (deep)
margin; 2) those with submucosal invasion >1000 μm, 3) presence of vascular infiltration, 4)
poorly or undifferentiated cancer front and 5) lesions with budding seen at the deepest part
of invasion.
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The clinical course after a smooth and uneventful colorectal ESD is usually favorable. Soft food
may be started a day after the treatment, presuming no symptoms, and oral intake is then
gradually built up. These patients may be discharged from the hospital within 5 days of the
treatment, irrespective of resection size. This is to allow identification of delayed complications
such as bleeding or perforation. A few days of bowel rest and intravenous administration of
antibiotics are recommended for patients who have had a perforation treated with immediate



























Figure 16. Example of how the margins can be mapped in correlation with microscopy is given below to enable the
clinician to be given appropriate information about the margins of concern.
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Figure 16. Example of how the margins can be mapped in correlation with microscopy is given below to enable the
clinician to be given appropriate information about the margins of concern.
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Immediate surgical intervention is required for those who develop signs of general peritonitis.
Patients who have localized peritonitis should be evaluated with radiologic investigation and
clinical assessment, as this may be a result of post polypectomy syndrome. Patients who have
had esophageal, gastric, or duodenal ESD, a follow-up endoscopic assessment is performed
to check the healing process and identify exposed blood vessels with subsequent therapy.
However, no such post-procedural examination is necessary after colorectal ESD, as the risk
for delayed bleeding is relatively low. In such cases, patients are discharged from the ward
within 1 week without checking ulcer healing. They will need to undergo follow-up endos‐
copies 2 months after the initial ESD to confirm healing and exclude recurrence.
In the recent years, various devices and peripheral equipment, as well as newer techniques,
have been described by Japanese endoscopists. Colorectal ESD has henceforth become both
safer and simpler. The Colorectal ESD Standardization Implementation Working Group in
Japan reported the details and results of a nationwide questionnaire survey on the current
situation of colorectal ESD in Japan. [61] They analyzed colorectal ESD performed from
January 2000 to September 2008 by 194 of the 391 (28.8% of the total number of those institutions
that responded). They reported the prevalence of colorectal ESD in Japan, the total number of
colorectal ESD procedures performed during the stipulated period and compared it to the
number performed in the last 1 year. They also investigated if those endoscopists that perform
colorectal ESDs were performing gastric ESD; whether restrictions were placed upon those
operators performing the ESD. Technical differences and equipment preferences were also
analyzed.
Outcomes analysis was also performed. It was concluded that there was no observed rela‐
tionship between the number of cases performed and the time required to complete an en bloc
resection. However, operational difficulty was not documented in these comparisons.
The rate of complete en bloc resection of colorectal ESD for all the institutions was 83.8%. When
stratified according to number of cases performed, the rate of complete en bloc resection of the
institutions where 100 or more colorectal ESD had been performed was 90.2%; that of institu‐
tions where 50–99 colorectal ESD had been performed was 83.5%; that of those where 25–49
colorectal ESD had been performed was 85.3%; and that of those where 1–24 colorectal ESD
had been performed was 82.2%.
Reported overall incidence of perforation as 4.8% from this survey, a value less than 5.9%
reported by Tsuda el al in 2006. Reported rates from other series range from 4 to 10%, higher
when compared with EMR (0.3 – 0.5%) [36,61-67]. Small perforations recognized during the
procedure can be successfully sealed with endoscopic clips. [56,69,70], larger perforations
require urgent salvage surgery to prevent peritonitis and its subsequent complications. [71] It
can thus be postulated that the safety of colorectal ESD has increased over the recent years.
The overall incidence of hemorrhage was 1.9%. It is the most common complication of EMR
and ESD, with rates reported ranging from 1% to 45%, with an average rate of 10% in larger
series. [75-77] Most bleeding episodes are observed during the procedure or within the first
24 hours. [71] Delayed bleeding has been reported in up to 13.9% of patients. [72-73]
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Hemostasis may be more difficult to achieve during the procedure as large elevated lesions,
lesions that have been resected before and have developed fibrosis, and carcinomatous lesions
develop strong neovascularization. Based on their survey, the authors recommended that to
acquire a safe colorectal ESD technique, more than a certain number of cases should be
performed. However, this “magic number” was not revealed. More importantly, there was no
death occurring during this period of assessment in Japan. Table 3 demonstrates the safety and
effectiveness of colorectal ESD and in these reports, ESD was performed or colorectal lesions
with a median size of 29-37mm with an average procedure time of 90-120min. Niimi et al
reports in a study of 310 consecutive patients who underwent ESD for colorectal epithelial
neoplasms, overall survival rates were 97.1% at 3 years and 95.3% at 5 years during a median
follow up of 38.7 months (range 12.8-104.2 months). Impressively, the disease specific survival
rates were 100% at 3 years, leading the co-author (H.Y) to conclude that in expert hands,
colorectal ESD is efficacious and safe.
Table 3. Summary of outcomes of colorectal ESD
4. Conclusion
ESD has emerged as an important therapeutic modality for superficial colorectal tumors,
providing a high en bloc resection rate with lower morbidity as compared to surgical ap‐
proaches. Both premalignant and early malignant tumors including depressed lesions and
those with fibrosis can now be resected with adequate histological assessment. The nature of
this procedure for colorectal lesions, with its inherent difficulties, must be recognized and
hence a great degree of both skill and patience is required. Colorectal ESD has a higher risk of
complication as compared to gastric or esophageal ESD and consequently, requires both a
thorough knowledge and specific training to achieve satisfactory performance.
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1. Introduction
Adenomatous polyps are non-invasive tumours of epithelial cells arising from the mucosa
with the potential to become malignant. The adenoma-carcinoma sequence is well known
and it is accepted that more than 95% of colon adenocarcinomas arise from adenoma [1].
The World Health Organisation (WHO) classifies adenomas into tubular (<20% villous ar‐
chitecture), tubulovillous and villous (80% villous architecture), with approximately 87% of
adenomas being tubular, 8% tubulovillous and 5% villous [2].
Figure 1. Polyp in colon
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Only 5% of adenomas are in danger of becoming malignant. The probability of high grade
dysplasia and carcinomatous transformation increases with polyp size, a villous component,
when there are many polyps or the age at diagnosis is more than 60 years [2]. The neoplasia
is considered to be advanced when polyp size is 1 cm or more, there is a villous component
or a high degree of dysplasia. Mixed polyps also have the ability to become malignant, as
does hyperplastic polyposis syndrome. More than 25% of advanced polyps are located in
the area proximal to the splenic flexure [3].
2. Epidemiology
The prevalence of cancerous polyps in series of endoscopically removed polyps is between
0.2% and 11% [4-6].Currently, screening programs allow the detection and treatment of a
great number of adenomas and malignant polyps, and this contributes to a reduction of the
mortality by colorectal cancer (CRC) [1,7]. In an asymptomatic population of people over 50
years old who underwent direct colonoscopy, there was a 0.8% prevalence of adenocarcino‐
ma of which 50% were carcinoma “in situ” or in stage I [8,9]. During screening programmes,
adenocarcinomas have been detected in between 3% - 4.6% of those who undergo colono‐
scopy following a positive immunological faecal occult blood test result [10,11].
3. Histology
Carcinoma "in situ", intramucosal carcinoma, high displasia or intraepithelial carcinoma is the
stage at which there is no involvement of the muscularis mucosa. In general, this tumour stage
does not cause metastasis. It is classified as pTis or Stage 0 in the TNM staging system.These
terms are defined as non-invasive high grade neoplasia in the Vienna classification [12].Carci‐
noma in situ or severe displasia or intraepithelial carcinoma corresponds to a carcinoma that
is restricted to the epithelial layer without invasion into the lamina propria. Intramucosal car‐
cinoma is a carcinoma characterized by the invasion into the lamina propria.
When the carcinoma spreads to the submucosa, the polyp is considered to have become ma‐
lignant, being able to spread to lymph nodes or distant sites. The tumours that affect the
submucosa are classified as T1 and correspond to Stage I of the TNM staging system. This
term is defined as submucosal carcinoma in the classification of Vienna [12].
The term pseudoinvasion refers to the presence of glandular epithelium of the mucosa be‐
neath the muscularis mucosa in colonic polyps. These lesions have no malignant potential
and should be management in a similar way to adenomas [13]. However, an inexperienced
pathologist can mistake this phenomenon for invasive carcinoma. Pseudoinvasion usually
occurs in large polyps (>1 cm), especially those with long stalks, and is most commonly
found in polyps of the sigmoid colon. Islands of adenomatous epithelium are displaced
through the muscularis mucosa and are found within the submucosa of the stalk. The dis‐
placed glandular tissue usually has rounded not infiltrative, contours, carries with it a small
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amount of lamina propria, and is cytologically identical to the overlying adenomatous com‐
ponent. Hemorrhage and hemosiderin depositions, are commonly seen and are a clue to di‐
agnosis. In addition, inflammation and granulation tissue, can be found.Cystic dilatation of
the displaced glands with mucin distention is also not uncommon in pseudoinvasion be‐
cause mucin produced by the entrapped glands has no means of reaching the lumen. Occa‐
sionally, rupture of dilated glands occurs with acellularmucin extravasation and there is a
subsequent inflammatory response. Distinction from mucinous (colloid) carcinoma is im‐
portant and can be difficult. Specifically, in mucinous carcinoma, the mucin pools contain
malignant cells, a feature lacking in pseudoinvasion.
For these reasons, it is highly recommended that level sections and second opinions, are ob‐
tained in cases of polyps with potential pseudoinvasion [14].
All adenomas have some degree of dysplasia. However, low and high grade dysplasias are
artificial subdivisions of a spectrum. There is no definition of “high-grade”. Indeed, the
WHO book on tumors of the digestive system, does not contain a list of criteria for high-
grade dysplasia in adenomas [15,16]. However in general, high-grade dysplasia entails more
substantial changes and includes carcinoma "in situ". Among these changes we consider ar‐
chitectural alteration, often resembling the glandular arrangement of adenomas and cyto‐
logic abnormalities, principally cellular and nuclear pleomorphism, nuclear
hyperchromatism, loss of nuclear polarity, and marked stratification of nuclei. Other au‐
thors have considered as features of high grade displasia: loss of normal glandular architec‐
ture, hyperchromatic cells with multilayered irregular nuclei and loss of mucin, high
nuclear/cytoplasmic ratio, marked nuclear atypia with prominent nuclei and focal cribri‐
form patterns. Not all these features are necessarily present to the same degree in all dys‐
plastic epithelia, while low-grade dysplasia manifests these same changes but to a lesser
degree [15,16].
4. Prognostic factors
Many factors have been associated with a higher probability of residual disease or recurrent
carcinoma.
4.1. Morphology
Morphology is described as polypoid (pedunculated or sessil) and nonpolypoid (flat or ul‐
cerated) subtypes according to the Paris classification [17]. The type of polyp and its mor‐
phology can guide the endoscopist towards its potential malignancy [2,18,19]. These
features include the size, the presence of depressed ulceration, irregular contours, deformi‐
ty, a short and immobile stalk and the inability to elevate a sessile polyp when a submucosal
bleb is formed. In such suspicious lesions, as well as in flat or depressed lesions, diagnosis
can be carried out using chromoendoscopy and magnification techniques that can highlight
abnormalities of glandular cytoarchitecture and reveal information concerning the extent of
submucosal invasion [20,21].
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The term pseudoinvasion refers to the presence of glandular epithelium of the mucosa be‐
neath the muscularis mucosa in colonic polyps. These lesions have no malignant potential
and should be management in a similar way to adenomas [13]. However, an inexperienced
pathologist can mistake this phenomenon for invasive carcinoma. Pseudoinvasion usually
occurs in large polyps (>1 cm), especially those with long stalks, and is most commonly
found in polyps of the sigmoid colon. Islands of adenomatous epithelium are displaced
through the muscularis mucosa and are found within the submucosa of the stalk. The dis‐
placed glandular tissue usually has rounded not infiltrative, contours, carries with it a small
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amount of lamina propria, and is cytologically identical to the overlying adenomatous com‐
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nuclear/cytoplasmic ratio, marked nuclear atypia with prominent nuclei and focal cribri‐
form patterns. Not all these features are necessarily present to the same degree in all dys‐
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degree [15,16].
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phology can guide the endoscopist towards its potential malignancy [2,18,19]. These
features include the size, the presence of depressed ulceration, irregular contours, deformi‐
ty, a short and immobile stalk and the inability to elevate a sessile polyp when a submucosal
bleb is formed. In such suspicious lesions, as well as in flat or depressed lesions, diagnosis
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abnormalities of glandular cytoarchitecture and reveal information concerning the extent of
submucosal invasion [20,21].
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Figure 2. Polyps in colon: Pedunculated polyp 0-Ip (A), sessile polyp 0-Is (B y C), flat polyp 0-IIb (D y F), superficial ele‐
vated with central depres ion 0-IIa + IIc (E) and excavated polyp 0-IIc (G y H).
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Kudo et al. [22] developed the pit pattern classification for colon polyps with six classes of
surface pattern depicted by magnifying endoscopy after indigo carmine staining. Class 5 of
this pit-pattern classification or an unstructured surface has been shown to correlate well
with a diagnosis of malignancy, and can provide important additional information prior to
endoscopic treatment. However, endoscopic ultrasound using high frequency transendosco‐
picminiprobes currently appears to be the most accurate method for defining submucosal or
further bowel wall invasion, enabling direct referral for surgical intervention in those cases
with deeper infiltration who are at the greatest risk of lymphatic spread [23].
4.2. Type of resection
The success of treatment of a malignant polyp depends on the complete resection by poly‐
pectomy or surgical intervention. When en-bloc removal of a polyp is performed, it is possi‐
ble to assess the depth of infiltration of the tumour cells and whether the margin is affected.
Pedunculated malignant polyps are easily removed using a loop snare. However, this tech‐
nique frequently results in piecemeal removal when applied to sessile and flat malignant
polyps. Nevertheless, around one-third of malignant polyps are removed in this way [24].
En-bloc removal is advantageous because it allows full histological evaluation of the com‐
plete resection and is associated with lower recurrence rates than piecemeal removal [25].
Endoscopic submucosal dissection (ESD) has been found to be particularly useful for the re‐
moval of sessile or flat adenomatous lesions. It has an advantage over other endoscopic
techniques in that it allows en-bloc removal of large (>2 cm) colonic lesions. In ESD an elec‐
trosurgical cutting device is used to carefully dissect the deeper layers of the submucosa to
remove neoplastic lesions in the mucosa. In a meta-analysis it was found that ESD en-bloc
resection is achieved in 84.9% of lesions, and clear vertical and lateral margins are achieved
in 75.3% of cases [26].
4.3. Level of invasion of adenocarcinoma into the polyp and polypectomy resection
margin
Haggitt et al. [27] have assigned levels of invasion to each malignant polyp. In this study,
level 1 described invasive adenocarcinoma limited to the polyp head, level 2 included in‐
volvement of the neck, level 3 corresponded to adenocarcinoma cells in the stalk, and level 4
to invasion, adenocarcinoma cells infiltrating the submucosa at the level of the adjacent
bowel wall. In this system, invasive adenocarcinoma in a sessile polyp by definition had lev‐
el 4 invasion. However, precise histological evaluation of Haggitt's level may be difficult.
Properly marked and orientated specimens are essential.
More recently, some authors have proposed an additional histological classification system
based on the grade of cell differentiation at the lesion margins and on the size and depth of
invasion of the submucosa. Submucosal invasion has been classified into three types based
on the depth of invasion. When less than one-third of the submucosa is invaded the stage is
sm1, and if more than two-thirds is invaded the stage is sm3, while stage sm2 is intermedi‐
ate with invasion of cancer into the middle third. It has been shown that penetration of can‐
cerous cells is associated with a risk of lymphatic spread [29-32]. Research based on large
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Kudo et al. [22] developed the pit pattern classification for colon polyps with six classes of
surface pattern depicted by magnifying endoscopy after indigo carmine staining. Class 5 of
this pit-pattern classification or an unstructured surface has been shown to correlate well
with a diagnosis of malignancy, and can provide important additional information prior to
endoscopic treatment. However, endoscopic ultrasound using high frequency transendosco‐
picminiprobes currently appears to be the most accurate method for defining submucosal or
further bowel wall invasion, enabling direct referral for surgical intervention in those cases
with deeper infiltration who are at the greatest risk of lymphatic spread [23].
4.2. Type of resection
The success of treatment of a malignant polyp depends on the complete resection by poly‐
pectomy or surgical intervention. When en-bloc removal of a polyp is performed, it is possi‐
ble to assess the depth of infiltration of the tumour cells and whether the margin is affected.
Pedunculated malignant polyps are easily removed using a loop snare. However, this tech‐
nique frequently results in piecemeal removal when applied to sessile and flat malignant
polyps. Nevertheless, around one-third of malignant polyps are removed in this way [24].
En-bloc removal is advantageous because it allows full histological evaluation of the com‐
plete resection and is associated with lower recurrence rates than piecemeal removal [25].
Endoscopic submucosal dissection (ESD) has been found to be particularly useful for the re‐
moval of sessile or flat adenomatous lesions. It has an advantage over other endoscopic
techniques in that it allows en-bloc removal of large (>2 cm) colonic lesions. In ESD an elec‐
trosurgical cutting device is used to carefully dissect the deeper layers of the submucosa to
remove neoplastic lesions in the mucosa. In a meta-analysis it was found that ESD en-bloc
resection is achieved in 84.9% of lesions, and clear vertical and lateral margins are achieved
in 75.3% of cases [26].
4.3. Level of invasion of adenocarcinoma into the polyp and polypectomy resection
margin
Haggitt et al. [27] have assigned levels of invasion to each malignant polyp. In this study,
level 1 described invasive adenocarcinoma limited to the polyp head, level 2 included in‐
volvement of the neck, level 3 corresponded to adenocarcinoma cells in the stalk, and level 4
to invasion, adenocarcinoma cells infiltrating the submucosa at the level of the adjacent
bowel wall. In this system, invasive adenocarcinoma in a sessile polyp by definition had lev‐
el 4 invasion. However, precise histological evaluation of Haggitt's level may be difficult.
Properly marked and orientated specimens are essential.
More recently, some authors have proposed an additional histological classification system
based on the grade of cell differentiation at the lesion margins and on the size and depth of
invasion of the submucosa. Submucosal invasion has been classified into three types based
on the depth of invasion. When less than one-third of the submucosa is invaded the stage is
sm1, and if more than two-thirds is invaded the stage is sm3, while stage sm2 is intermedi‐
ate with invasion of cancer into the middle third. It has been shown that penetration of can‐
cerous cells is associated with a risk of lymphatic spread [29-32]. Research based on large
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patient series has shown a 1-3% risk for lymph node metastases in sm1 cancers, 8% in sm2
cancers and 23% in sm3 cancers [29].
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Figure 3. Resection of a pedunculated polyp with an endoscopic snare (A-D).
In sessile polyps, it is essential that the pathologist identifies the stalk or the depth of the
diathermy burn. The risk of relapse ranges from 0% to 2% in malignant polyps with a mar‐
gin of resection greater than 1 mm. If the resection margin is involved, or is less than 1 mm,
the percentage of relapse ranges between 21% and 33% [30]. Most authors believe that a re‐
section margin of more than 1 mm is safe and that in such cases the probability of residual
disease or recurrent carcinoma is low [4,5,30,31].
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Figure 4. Elevation of a superficial elevated polyp (0‐IIb) with Indigo 
CarmineFigure 4. Elevation of a superficial elevated polyp (0-IIb) with Indigo Carmine
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4.4. Stage of differentiation
Four grades were considered [32]:
Grade 1: Corresponded to a well-differentiated intestinal-type adenocarcinoma with well-
formed glands and open lumina or with more than 95% glandular differentiation.
Grade 2: Moderately differentiated intestinal-type adenocarcinoma containing solid nests
showing only focal glands or with 50-95% glandular differentiation.
Grade 3: Carcinoma is poorly differentiated intestinal–type. Signet ring cell or mucinous ad‐
enocarcinoma, composed of hyperchromatic cells arranged into solid sheets and forming ab‐
sorptive glands, with 5% to 50% glandular differentiation.
Grade 4: Undifferentiated tumours which have less than 5% glandular differentiation.
Undifferentiated carcinoma: Medullary carcinomas with high microsatellite instability.
The prognosis correlates with the histological grade [32]. For example, Grade 3 of differen‐
tiation is seen in 5.7 to 9.2% of patients and the risk of residual lesions or relapse in these
cases is of the order of 36-38% [30].
4.5. Lymphatic invasion
Lymphatic invasion is defined as tumour cells within a true endothelial-lined channel in the
absence of red blood cells [33]. The risk of lymphatic spread has been estimated by histologi‐
cal study of resected specimens. Since lymphatics do not penetrate much beyond the muscu‐
laris mucosae, focal cancer that has not invaded through this layer appears to present little
or no risk of lymph node spread [34]. The near absence of lymphatics within the mucosa has
been proposed as the reason for the observed lack of malignant potential (lymph node meta‐
stasis) observed in polyps showing only intramucosal carcinoma. However, this theory has
been challenged by studies using more sensitive techniques to detect lymphatic vessels.
Studies using the relatively new antibody D2-40, which stains lymphatic but not blood ves‐
sel endothelium, have shown that lymphatic present in the stalk and mucosa of adenomas
and undergo proliferation, are early invasive cancers. Lymphatic channels are often present
near nests of infiltrating tumours in malignant polyps [35,36].
Detecting lymphatic invasion by expert pathologists using light microscopy is difficult.
There are no recognized guidelines for establishing the presence of lymphatic invasion (for
example, the number of sections or immunostains needed to identify lymphatic vessels). For
example, in a study in which five pathologists assessed the lymphatic invasion of 140 malig‐
nant polyps, they agreed (4 out of 5 observers) on only 17 cases [37].The intra and inter-ob‐
server variability in the interpretation of samples received among even the most expert
histopathologists can be high and often leads to diagnostic uncertainties [37]. The use of im‐
munohistochemistry for D2-40 may help identify lymphatic channels. However, its use is
not yet routine, and technical issues such as loss of a suspicious focus in level sections limits
the usefulness of special stains in this setting. The presence of lymphatic invasion has been
proposed by some researchers as an indication for colectomy. However, few malignant pol‐
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patient series has shown a 1-3% risk for lymph node metastases in sm1 cancers, 8% in sm2
cancers and 23% in sm3 cancers [29].
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sorptive glands, with 5% to 50% glandular differentiation.
Grade 4: Undifferentiated tumours which have less than 5% glandular differentiation.
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The prognosis correlates with the histological grade [32]. For example, Grade 3 of differen‐
tiation is seen in 5.7 to 9.2% of patients and the risk of residual lesions or relapse in these
cases is of the order of 36-38% [30].
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cal study of resected specimens. Since lymphatics do not penetrate much beyond the muscu‐
laris mucosae, focal cancer that has not invaded through this layer appears to present little
or no risk of lymph node spread [34]. The near absence of lymphatics within the mucosa has
been proposed as the reason for the observed lack of malignant potential (lymph node meta‐
stasis) observed in polyps showing only intramucosal carcinoma. However, this theory has
been challenged by studies using more sensitive techniques to detect lymphatic vessels.
Studies using the relatively new antibody D2-40, which stains lymphatic but not blood ves‐
sel endothelium, have shown that lymphatic present in the stalk and mucosa of adenomas
and undergo proliferation, are early invasive cancers. Lymphatic channels are often present
near nests of infiltrating tumours in malignant polyps [35,36].
Detecting lymphatic invasion by expert pathologists using light microscopy is difficult.
There are no recognized guidelines for establishing the presence of lymphatic invasion (for
example, the number of sections or immunostains needed to identify lymphatic vessels). For
example, in a study in which five pathologists assessed the lymphatic invasion of 140 malig‐
nant polyps, they agreed (4 out of 5 observers) on only 17 cases [37].The intra and inter-ob‐
server variability in the interpretation of samples received among even the most expert
histopathologists can be high and often leads to diagnostic uncertainties [37]. The use of im‐
munohistochemistry for D2-40 may help identify lymphatic channels. However, its use is
not yet routine, and technical issues such as loss of a suspicious focus in level sections limits
the usefulness of special stains in this setting. The presence of lymphatic invasion has been
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yps with lymphatic invasion have been reported, and most of them have had positive mar‐
gins, grade 3 invasive adenocarcinoma (as defined above), or both [5].
4.6. Vascular invasion
The presence of vascular invasion is defined as cancer in an endothelial-lined channel sur‐
rounded by a smooth muscle wall [35]. However, it is difficult to recognise it. Vascular
markers (CD31, CD34 and factor VIII) may help. These markers strongly stain blood vessel
endothelium, and to a lesser extent lymphatic endothelium [14].The prevalence of venous
invasion in malignant polyps varies greatly, ranging from 3.5% to 39% [37].Often venous in‐
vasion is associated with lymphatic invasion and/or tumours which have a resection margin
of less than 2 mm and/or are poorly differentiated. In contrast, Talbot et al. [38] observed
that venous invasion was not associated with poorer prognosis.
4.7. Risk of residual disease or recurrent carcinoma in favourable and unfavourable
histology
Favourable histology is defined as grade 1 or 2 differentiated adenocarcinoma in which car‐
cinoma cells are at least 1 mm from a clearly visualized margin, resection is carried out en
bloc and there is an absence of vascular or lymphatic invasion.
Unfavourable histology is defined as polyps with biopsy margin ≤1 mm, tumour within the
cauterized region constitutes a positive margin, piecemeal removal, poorly differentiated tu‐
mour (grade 3) or lymphatic or vascular invasion.In these cases, surgical resection is indicat‐
ed because of the increased risk of lymph node metastasis or residual disease [14]. On the
other hand, in the absence of unfavourable features, polypectomy is considered curative.
Sometimes, specimens do not lend themselves to proper analysis for any reason (piecemeal
removal or poor orientation) result in a default decision to resect.
In 1995, Volk et al [5] reviewed 20 studies in which 858 malignant polyps were analysed.
They observed residual disease or recurrent carcinoma in 89 patients (10%). However, there
were relapses or tumours in the area of the resection in only 8 (1%) patients with favourable
histological criteria. Subsequent studies have also reported an incidence of less than 1%
[37,39]. Only one study described incidence higher than 5% in malignant polyps with fa‐
vourable histology [40] and the study itself has been widely criticized from subsequent re‐
views [5]. By contrast, in malignant polyps with unfavourable histology, the risk of relapse
or residual lesions ranges between 10% and 39% [5,14,29,39].
4.8. Marking with India Ink
In 1975, Ponsky and King [41] published the first case in which marking with India ink was
used with the purpose of locating the polyp during the surgical procedure. Sometimes to lo‐
cate the base of the polyp after polypectomy or during surgery is extremely difficult.
All the endoscopicallyunresectable polyps in patients in whom surgery would be consid‐
ered, should be tattooed. Endoscopicallyresectable polyps that could have become malig‐
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nant should also be tattooed. Among the criteria that should hint the endoscopist about the
presence of malignancy in the polyps is size, an irregular surface or a flat or excavated mor‐
phology [2,18,42,43].
The size of the polyp is an important factor that indicates malignancy [42,44-46]. The proba‐
bility of dysplasia could be up to 38,5% in those larger than 1 cm [47].The flat or ulcerated
lesions have a higher risk of high-grade dysplasia or carcinoma [22,48-50]. The probability of
cancer or severe dysplasia increases from 4% in small flat lesions, up to 6% in small polyps,
16% in large polyps and 29% in long, flat lesions, and up to 75% in depressed lesions [51].
However, tattooing in suspicious polyps at first colonoscopy, in our experience is still low,
17.6%. We study a retrospective series that include 74 patients. Our endoscopists usually
marked large polyps, polyps resected in a fragmented manner and polyps with proximal lo‐
cation. However, in a multivariate analysis only proximal location was significant associated
with marking. It is known that flat polyps, with a greater potential for malignancy, are most
frequently located in the right colon [37,39]. In our series, 16.2% of the polyps were proxi‐
mal; of these, 58.3% were marked; on the other hand, only 9.7% of the distal polyps were
marked. The factors that could have a greater influence when it comes to marking proximal
polyps more frequently was their potential to become malignant in this location and the dif‐
ficulty of finding the polypectomy scar in subsequent controls or in surgery.
We agree with other authors [52-57] that tattooing is one of the best methods for tumor
location, either if the patient is following-up by colonoscopy or is undergoing for surgical
resection [42,58].
5. Treatment
Prior to removal of the polyp, it is difficult to know whether the polyp is malignant or not.
Some features, as we have mentioned earlier, can give some indication of the degree of ma‐
lignancy. Regardless of the morphological characteristics, a polyp is normally removed
when detected.
Polypectomy should be performed en bloc, since this is essential to establish and define fa‐
vourable or unfavourable histological criteria. In just a few cases, only polyp biopsies are
performed, such a lack of coagulation data, polyp could be difficult to remove at that point
in time, or the patient being on antiplatelet drugs or anticoagulants.
The indication for a malignant polyp with sessile morphology, regardless of favourable his‐
tological criteria, is surgery [10], especially in patients younger than 50 years old, who tend
to present fewer surgical complications [59]. Surgical treatment is recommended for malig‐
nant polyps with pedunculated morphology which have unfavourable histological criteria
(partial polyp resection, poorly differentiated carcinoma, vascular or lymphatic invasion, or
lesions ≤1 mm from the polypectomy) [10]. On the other hand, for malignant polyps with
pedunculated morphology but with favourable histological criteria, polypectomy is consid‐
ered to be curative (Figure 7). Non-invasive high grade neoplasia regardless of their mor‐
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resection [42,58].
5. Treatment
Prior to removal of the polyp, it is difficult to know whether the polyp is malignant or not.
Some features, as we have mentioned earlier, can give some indication of the degree of ma‐
lignancy. Regardless of the morphological characteristics, a polyp is normally removed
when detected.
Polypectomy should be performed en bloc, since this is essential to establish and define fa‐
vourable or unfavourable histological criteria. In just a few cases, only polyp biopsies are
performed, such a lack of coagulation data, polyp could be difficult to remove at that point
in time, or the patient being on antiplatelet drugs or anticoagulants.
The indication for a malignant polyp with sessile morphology, regardless of favourable his‐
tological criteria, is surgery [10], especially in patients younger than 50 years old, who tend
to present fewer surgical complications [59]. Surgical treatment is recommended for malig‐
nant polyps with pedunculated morphology which have unfavourable histological criteria
(partial polyp resection, poorly differentiated carcinoma, vascular or lymphatic invasion, or
lesions ≤1 mm from the polypectomy) [10]. On the other hand, for malignant polyps with
pedunculated morphology but with favourable histological criteria, polypectomy is consid‐
ered to be curative (Figure 7). Non-invasive high grade neoplasia regardless of their mor‐
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phology, are considered to be cured with polypectomy. Indeed, according to some authors,
polyps harbouring "in situ" or "intramucosal" cancer should not be regarded or treated as
malignant polyps [59].
Figure 5. Endoscopic Mucosal Resection in a 0-IIa + Is polyp in 




Figure 5. Endoscopic Mucosal Resection in a 0-IIa + Is polyp in colon (A-E), with control of the base after one month (F).
However, until now in many pathology reports were not reported histological criteria. For
example at the University of Minnesota between 1987 and 2000, 83% of the reports are not
angiolymphatic vessel invasion, 69% not reported the depth of invasion by cancer cells and
22% no stated the degree of tumour differentiation [60]. Beside the agreement among experi‐
enced pathologists was poor with respect to histological grade of differentiated carcinoma
and angiolymphatic vessel invasion [60].
Endoscopic submucosal dissection (ESD) has emerged as a possible technique to successful‐
ly resect malignant colonic polyps en bloc [26,61]. The technique makes it possible to treat
and cure large (>2 cm) sessile and flat polyps enabling pathological evaluation in most pa‐
tients, also can be an alternative to surgery for older patients and for those suffering from
associated conditions that contraindicate surgery.




Figure 6. Polypectomy of pediculated polyp 0-Ip. Submucosal
injection was performed using indigo carmine (A,B), polypectomy
was made with electrosurgical knives (C), After polypectomy, a
large non bleeding vessel was visualized (D) and cauterized using
coagulation forceps (E) and obliterated with an endoclip(F) to
reduce the risk of delayed bleeding
Figure 6. Polypectomy of pediculated polyp 0-Ip. Submucosal injection was performed using indigo carmine (A,B),
polypectomy was made with electrosurgical knives (C), After polypectomy, a large non bleeding vessel was visualized
(D) and cauterized using coagulation f rceps (E) and obliterated with an endoclip (F) to reduce the risk of delayed
bleeding
An exception to these guidelines is patients with malignant polyps, with sessile or flat mor‐
phology, that are located in the rectum. The occurence of distant metastases is correlated to
T-stage and, after radical resection of T1 tumours, the 5-year rate of metastases is about 10%
[62], similar to other locations of malignant polyps. About 50% of the local recurrences fol‐
lowing local resection are curable if the patients are included in an intensive follow-up pro‐
gramme. Local resection should be offered to patients whenever the individually calculated
risk of short-term mortality after major surgery exceeds twice the additional risk of local re‐
currence added by local procedures. An adequate preoperative evaluation of the patient's
general health is essential before deciding the modality of treatment for the individual T1
rectum cancer patient.
In recent years, various serum markers been identified in an effort to establish which pa‐
tients could benefit from surgical treatment and from a more strict follow up. These markers
include metalloproteinase 7, vascular adhesion proteins, vascular endothelial growth factors
and cytokeratins [63-66]. The majority of markers have been studied in patients operated on
for colon cancer with infiltration of the lamina propria (equivalent to or higher than T2), so
these results cannot readily be extrapolated to malignant colorectal polyps.
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* Biopsy margin ≤ 1 mm, piecemeal removal, poorly differentiated tumour, lymphatic or vascular invasion
Figure 7. Therapeutic algorithm of pedunculated (0-Ip) polyps.
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6. Follow-up
In cases of non-invasive high grade neoplasia and malignant polyps with pedunculated
morphology and favourable histological criteria, it is recommended that a colonoscopy be
carried out three months after taking the biopsy [1,43].If this is normal, a further check-up is
advised after one year, three years and five year [43]. Some authors suggest that if the re‐
sults within three months are negative, subsequent monitoring should be the same as that
offered to patients with non-malignant adenomas [35,44]. However, recent studies estimate
that 11.8% of patients who have undergone polypectomy will develop a metachronic ad‐
vanced adenoma and 0.6% an invasive carcinoma. Associated risk factors include age, num‐
ber of polyps (5 or more), size (greater than 1 cm), villous architecture, proximal location,
and being male. Smoking, body mass index, family history of CRC, and degree of dysplasia
were not found to be associated with higher risks of advanced adenoma or cancer [45].
There have been reports of cases of malignant pedunculated polyps with unfavourable his‐
tological criteria which, despite no findings of residual carcinoma in the intestine wall or
lymph node involvement, are found on follow up to have distant metastasis, even five years
after surgery [4,5].
7. Conclusion
En brief, the adenoma-carcinoma sequence is well known and polypectomy has proven to
reduce the incidence of CRC. However, the success of treatment depends on the complete
resection and the future follow up of the base of polypectomy.
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1. Introduction
Endoscopic resection of colorectal polyps is a well-recognised therapy for the prevention of
colorectal carcinoma. Roughly 10% of resected polyps contain foci of carcinoma and are of‐
ten termed malignant polyps or polyp cancers. Their incidence is increasing in line with the
increasing use of colonoscopy.[1] A proportion of these will have progressed to nodal dis‐
ease before presentation and a further oncological resection should be considered for high
risk patients.[2]
The risk of nodal disease at presentation can be stratified by histology but definitive staging
information can currently only be obtained by oncological resection, a procedure which can
cause significant morbidity and mortality, especially in the elderly. This is of particular rele‐
vance as the majority of patients do not have nodal disease, even for the most dangerous
categories of polyp.[3] There is a real risk of causing excess morbidity by over treating the
majority in order to adequately treat the minority.
2. Malignant polyps
Not all polyps are created equal. The adenoma carcinoma sequence has long been recog‐
nised as the natural history of colorectal carcinoma and it is therefore logical that some ade‐
nomas will be discovered with foci of malignancy within them.
For those confined to the mucosa, polyps showing foci of potentially malignant cells are of‐
ten termed carcinoma in situ. The lack of lymphatics in the mucosa prevents distant spread
and, as these lesions are neither regarded as malignant or treated as malignancies, the term
high grade mucosal neoplasm is now preferred. [4]
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The definition of colorectal carcinoma is dysplasia crossing the muscularis mucosa, so when
high grade dysplasia in these polyps crosses this barrier the lesion is termed a malignant
polyp. A malignant polyp is essentially a macroscopically benign lesion that contains malig‐
nant foci on further examination. When the totality of the polyp is comprised of malignancy
the term polypoid carcinoma is often used.
T1 lesions are therapeutically significant as they are the first lesions where nodal and distant
metastases must be considered. The management of these polyps is based on the belief that
the risk of spread can be stratified according to the histology of the resected polyp.[5] In the
past authors used various criteria to define favourable or unfavourable histology and guide
management.[1,2,6,7] For a large part, this has involved dividing patients into two groups.
A “low risk” group, who are safe without further treatment and a “high risk group”, for
whom surgery should be considered.[8,9] Unfortunately published studies disagree about
the factors that are most significant.[3,10-12]
3. Factors affecting risk of nodal disease
3.1. Morphology
The Paris classification[13] of gastro-intestinal tumours recognises that adenomas may be
polypoid or non polypoid. Non polypoid (0-II, 0-III ) lesions are not usually removed endo‐
scopically as they are more challenging to remove and are recognised to have high malig‐
nant potential.
0-I: Polypoid 0-Ip: Pedunculated
0-Is: Sessile




Table 1. Paris Classification of Superficial Tumours of the Colon and Rectum.[13]
Polypoid lesions can be pedunculated (Type 0-1p) or sessile (Type 0-1s). Due to their shape
malignant sessile polyps are harder to remove with clear margins and have more ready ac‐
cess to the deeper portions of the submucosa. They are therefore more likely to be classified
as high risk. Seitz et al[9] presented a series of 114 endoscopically removed malignant pol‐
yps. Overall 46% of these polyps were sessile, but 65% of “high risk” (ie. requiring surgical
removal) polyps were sessile. Conversely only 23% of “low risk” polyps were sessile.
An earlier literature series of 741 malignant polyps reported that 58.3% of sessile polyps had
“high risk features” (Grade 3-4, vascular or lymphatic invasion, positive resection margin)
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whereas only 10% of pedunculated polyps were similarly classified.[11] One meta-analysis
reported positive resection margins in 56.8% of sessile lesions verses 18.7% in polypoid le‐
sions (P < 0.0001).
Size and tubular or villous architecture are also well known to affect the malignant potential
of polyps. However, in a similar fashion to flat or depressed areas of dysplasia, very large
polyps are seldom excised endoscopically and are not relevant to the current topic.
3.2. Grading
Polyps are defined by dysplasia and the varying degree displayed by different polyps is
thought to explain a large degree of their different metastatic potential.[14]
Negative for Intraepithelial neoplasia.
Indefinite for Intraepithelial neoplasia.
Low-grade Intraepithelial neoplasia. Adenoma/dysplasia
High-grade neoplasia (intraepithelial or intramucosal) Adenoma/dysplasia (4-1
Noninvasive carcinoma (4-2)
Suspicious for invasive carcinoma (4-3)
Intramucosal carcinoma (lamina propria invasion) (4-4)
Submucosal carcinoma
Table 2. Revised Vienna classification of epithelial neoplasla for esophagus, stomach, and colon. [13]
The revised Vienna classification is widely used to define the degree of dysplasia colorectal
polyp. By definition malignant polyps are 4-4. For colorectal carcinomas the WHO classifica‐
tion recognises 4 grades of differentiation, with G1 representing well differentiated, through
moderate (G2) and poorly differentiated (G3) to undifferentiated (G4). G1-2 are convention‐
ally regarded as low grade and G3-4 as high grade.
In a meta-analysis of published series, Hassan et al.[1] reported a 3.9 (1.9-8.4) odds ratio for no‐
dal metastasis with regard to high vs low grade malignant polyps. The odds ratio for mortality
was reported as 9.2 (4.7-18.2). Determining the exact risk from high grade dysplasia is compli‐
cated by their relative rarity. One study of 80 malignant polyps found only 2 poorly differenti‐
ated polyps.[12] In a meta-analysis 7.2% of 1612 malignant polys were high grade.[1]
It is interesting to note that despite poor differentiation being recognised as an important
determinant of nodal disease, no universally accepted definition exists. Indeed in studies
where the prevalence of highly dysplastic lesions was lower, the risk of nodal disease in
these polyps was increased. (See Table 3). This suggests that poor differentiation, when a
rigorous definition is used is an extremely important predictor of nodal disease. Those stud‐
ies that did not find the degree of dysplasia to be significant are hampered by the very small
number of highly dysplastic lesions in their sample.
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% (No. of Cases)
Yamamoto et al 2004 301 0.1 (4) -
Tominaga et al 2005 155 1.3 (2) 50.0 (1)
Kurokawa et al 2005 180 1.1 (2) 50.0 (1)
Whitlow et al 1997 59 1.7 (1) 0 (0)
Haggitt et al 1985 64 3.1 (2) 0 (0)
Geraghty et al 1991 81 2.5 (2) -
Suzuki et al 2003 65 3.1 (2) 100 (2)
Sakuragi et al 2003 278 2.5 (7) 57.1 (4)
Seitz et al 2004 116 3.4 (4) -
Wang et al 2005 159 4.4 (7) 85.7 (6)
Morson et al 1984 61 5 (3) -
Cooper et al 1995 140 5.7 (8) -
Netzer et al 1998 62 8.1 (5) 40.0 (2)
Hackelsberger et al 1995 87 11.5 (10) -
Hassan et al 2005 380 14.7 (56) 23.2 (13)
Nascimbeni et al 2002 344 34.0 (117) -
Nascimbeni et al 2004 144 39.6 (57) -
Table 3. Incidence of G3 Poorly Differentiated T1 Colorectal Carcinoma and Incidence of Nodal Involvement. In those
studied with a higher incidence of G3 carcinoma, incidence of nodal disease in those carcinomas falls. From[3]
3.3. Depth of invasion
Haggitt’s classification is based on the greatest anatomical depth of invasion in pedunculat‐
ed polyps.[5] Haggitt 0 lesions are confined to the mucosa. Haggitt grades 1-3 breach the
submucosa within the polyp, and they are confined to the head, neck and stalk of the polyp
respectively. Only Haggitt 4 lesions invade past the stalk into the submucosa of the wall.
Most authors would agree that only Haggit 4 lesions require further treatment. If adequately
excised, Haggitt 0-3 lesions have a risk of recurrence (<1%) which is lower than the predict‐
ed mortality of an oncological resection.[15,16] Conversely, for level 4 lessions, Haggitt re‐
ported nodal disease rates of almost 13%.
All sessile lesions are Haggitt 4 by definition, but other authors have treated selected sessile
lesions with polypectomy alone to good effect. Kudo produced a refinement for sessile pol‐
yps by dividing the submucosa into thirds.[13] This has become known as the Kikuchi clas‐
sification. [2] Lesions confined to the superficial third of the submucosa (called Sm1)
demonstrated very low rates of nodal disease and many authors recommend no further
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treatment after polypectomy for Sm1. In the absence of other risk factors most would agree
for Sm2 lesions as well.[7]
The Kikuchi classification has been widely accepted for the assessment of T1 colorectal tu‐
mours but can be difficult to perform on endoscopy specimens as the muscularis propria is
not usually included in the specimen.[2]
Difficulty is also encountered when the muscularis muscosa cannot be identified. A large col‐
laborative Japanese study used Haggit level 2 (i.e. the border between the head and neck of
the polyp) as a baseline for pedunculated polyps. Provided that there was no lymphatic in‐
vasion, they found no nodal disease if the depth of invasion from here was <3mm. For ses‐
sile polyps the superficial aspect of the lesion was used and again no nodal disease
discovered if the invasion was <1mm, regardless of other lymphatic invasion. [17] Other Jap‐
anese studies have also found good correlation between quantitative measures of submucos‐
al invasion and risk of lymph node metastasis.[18,19]
Although the study included operative specimens as well as endocsopically removed malig‐
nant polyps, Ueno[14] showed that the width of tumour invasion is also an important factor.
3.4. Incomplete or piecemeal resection
Involved resection margins have been shown to be strongly associated with poor outcomes.
These patients have higher mortality, local recurrence and rates of residual disease. In one,
all be it small, study 75% of incompletely resected polyps were associated with an adverse
outcome.[20] It should be noted that even when incomplete resection is reported, absence of
residual disease in the surgical specimen is the rule (94% in one study) rather than the ex‐
ception[21]. This is likely due to diathermy electrofulguration of the remnant.
The European recommendations state that tumour cells within 1mm of the margin repre‐
sents a positive margin[22], with some authors arguing then >2mm represents the true safe
margin[21].
Incomplete removal is failure of primary therapy and requires further resection. Piecemeal
removal of the polyp prevents proper histological assessment and surgery is mandated in all
cases. For this reason endoscopic mucosal resection by the strip biopsy method is discour‐
aged for the removal of potentially malignant lesions.
3.5. Lymphatic and vascular invasion
Lymphatic invasion has been sighted by some authors as an important predictor of nodal
disease. Controversy exists however as reported cases are rare and usually associated with
poorly differentiated tumours or incomplete resection. Inter-observer variability and the
ease of mistaking retraction artefact for lymphatic invasion also make interpretation diffi‐
cult.[6,12]
Lymphatic invasion is usually associated with other high risk factors and in those cases with
adverse outcomes, almost invariably so. Many authors would regard its status as an inde‐
pendent risk factor is unclear.[20] However a large multi-centre retrospective study from Ja‐
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pan found lymphatic involvement to be highly significant for nodal metastases (odds ratio
4.69 P<0.0001) in a multivariate analysis of risk factors.[17] They also found that in a small
number of cases adverse outcomes were seen from cases of lymphatic invasion, despite in‐
vasion being confined to the head of the polyp (Haggit 1).
Vascular invasion is also considered difficult to identify, but where present, it is strongly as‐
sociated with nodal disease. Yasuda[18] studied T1 rectal tumours, including specimens
from primary resections and resections after polypectomy. The odds ratio for the nodal
metastasis with reference to the presence or absence of vascular invasion was 12.023 (3.751–
116.751 p=0.001). Another study of sessile T1 colorectal carcinomas found that vascular inva‐
sion was a significant factor in both univariate and multivariate analysis. However they ad‐
mit that the small number of cases of vascular invasion were found in lesions with deeper
Sm3 invasion.[23]
An odds ratio of 7 (2.6–19.2) for lymph node metastasis was reported in the only meta-anal‐
ysis looking specifically at malignant polyps and the presence of vascular invasion.[1] How‐
ever, the same analysis demonstrated no such increased risk in polyps that would otherwise
be considered low risk. It may well be that vascular invasion carries no special significance
in itself and should not be emphasised in decision making.
3.6. Tumour budding
Tumour budding is the presence of microscopic islands of tumour cells out ahead of the
main front of tumour invasion. At present there is no defined agree standard to reporting
the phenomenon but several authors have found it to be highly significant. Yasuda reported
an odds ratio of 11.11 (3.64–146.03)[18] for predicting nodal disease but until further study
occurs it is difficult to make firm recommendations.
3.7. Location
T1 rectal tumours seem to be particularly likely to cause nodal disease, especially when lo‐
cated in the lower third.[15,23] However at this stage there have been no studies looking at
this relationship specifically in malignant polyps.
4. “The low risk polyp”
Several authors, starting with Morson in 1984[24], have developed the concept of the low
risk polyp. That is, a polyp which can be safely treated with polypectomy alone, as there is
minimal risk of nodal disease. The concept has been incorporated into the American College
of Gastroenterology guide lines[25]. They recommend no further treatment if:
The polyp is considered to be completely excised by the endoscopist and is submitted in toto
for pathological examination.
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In the pathology laboratory, the polyp is fixed and sectioned so that it is possible to accurate‐
ly determine the depth of invasion, grade of differentiation, and completeness of excision of
the carcinoma.
The cancer is not poorly differentiated.
There is no vascular or lymphatic involvement.
The margin of excision is not involved. Invasion of the stalk of a pedunculated polyp, by
itself, is not an unfavourable prognostic finding, as long as the cancer does not extend to the
margin of stalk resection.
The European recommendations, while noting the potential of tumour budding and lym‐
phatic and vascular invasion as prognostic factors, decline to provide a guideline as they
have not been statistically significant in all cases.[22]
Another perspective is given by Nicholls,[7] who instead offered an algorithmic approach.
He differentiates between colonic and rectal polyps. For rectal lesions judged to be adenoma
prior to resection he recommends that all poorly differentiated lesions be removed. For co‐
lonic polyps he suggested further resection solely for Haggit 4 polyps (including by defini‐
tion all sessile polyps) with a depth of invasion >1000 µm.
Systematic review of studies which selected low risk polyps using methodology broadly
similar to the American criteria has demonstrated very low rates of nodal recurrence. (See
Table 4). Mortality from oncological resection varies greatly by age and co-morbidity but is
usually quoted around 3-5%.[26-28] Therefore, for these lesions, the safest course of action is
surveillance rather than further resection.[8,29]
It should be noted that these criteria take no account of the depth of invasion and that these
guidelines would encourage the removal of some lesions that have been safely treated by
endoscopy. It may be that they are documenting many of the same characteristics but in a
different way. It is not hard to imagine that Sm3 lesions are less likely to be excised with
clear margins and are more likely to show poor differentiation. Indeed a large study of sur‐
gically resected sessile T1 colorectal tumours found Sm3 invasion in 68% of G3+4 tumours
and on 33% in G1+2 (P=0.001). This study also found tumour grade not to be significant on
multivariate analysis.[23]
Given Japanese experience it maybe be better to refine the criteria for a low risk polyp as
any polyp lacking all of these features:
High grade (G3-4) lesions.
Incomplete resection or other factors preventing adequate histological assessment of the le‐
sion.
Piecemeal resection
Depth of invasion greater than 2mm from muscularis mucosa
Width of invasion greater than 4mm.
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The utility of including lymphatic invasion, vascular invasion or tumour budding is unclear
at this time. Further work should be done to examine the risk from polyps of the lower third






Unfavourable outcome in low
risk group
Bernard et al. 1988 19 3 0
Christie 1988 88 6 0
Conte et al. 1987 30 4 0
Cooper et al. 1995 140 16 0
Cranley et al. 1986 39 10 0
Cunningham et al. 1994 36 2 0
Eckardt et al. 1988 61 11 0
Fried et al. 1984 22 0 0
Geraghty et al. 1991 80 5 0
Hackelsberger et al. 1995 86 8 0
Kikuchi et al. 1995 78 9 0
Kyzer et al. 1992 42 1 0
Morson et al. 1984 60 2 0
Netzer et al. 1998 70 16 0
Rossini et al. 1988 66 4 0
Shatney et al. 1975 28 1 0
Speroni et al. 1988 30 2 0
Sugihara et al. 1989 25 3 0
Volk et al. 1995 47 10 0
Whitlow et al. 1997 59 4 0
Seitz et al. 2004 114 16 0
Total 1,227 135 0
Table 4. Incidence of Adverse Outcome in Low Risk Polyps. Low risk = Low risk = excision complete with resection
margins of at least 2 mm, no Grade 3 carcinoma, and no vascular invasion. (From Sitz et al. 2004)
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5. “The high risk polyp”
Polyps that do not meet the low risk criteria should be considered for surgical removal even
if there has been total excision of the primary lesion. Indeed, it is unusual to find residual
tumour in the surgical specimen, especially if the lesion had clear histological margins.[6]
The justification for surgery is the desire for regional control as the risk of nodal disease is
much higher in these patients and oncological resection is required to obtain regional con‐
trol in a similar manner to other colorectal malignancies. The dilemma is that only a minori‐
ty of these patients have nodal disease requiring control and these patients are only reliably
identified after resection. Especially in elderly, the decision to resect has the possibility to
cause considerable harm without producing a benefit to the patient.
5.1. “First do no harm...”
It is an old surgical adage that surgery is only indicated if the natural history of the cure is
better than the natural history of the disease. In situations of uncertainly like this it is useful
to examine the possible outcomes of proposed courses of action in order to see were the sur‐
vival advantage lies.
The outcomes of the decision to operate will be a function of the risk of nodal disease and
the risk of operative mortality and morbidity. We feel it is useful to consider these decisions










Survival as for stage IV disease (Roughly
5%)
Curative procedure, without operative mortality
(Roughly 100%)
Table 5. 2x2 Table of outcomes from the decision regarding further resection of high risk malignant polyps.
5.2. Nodal disease and oncological resection
We see no reason to regard these patients as any different from patients who had proceded
straight to oncological resection and post operatively were staged either IIIa to IIIc (TNM
v5). In the SEER data from 1998 to 2000 there is a huge difference between those with regard
to five year survival (73% vs. 28% respectively). Clearly this stage differentiation has huge
implications for the advisability of surgery. It has been suggested that T1-2N2 tumours have
a better survival that T3-4N2 tumours and the TNMv6 classification has been changed to re‐
flect this. Newer SEER data shows five year survival of 87.7% for T1-2N1 disease and 75%
for T1-2N2 disease. [30]
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To our knowledge there is no current method of estimating the extent of nodal disease from
polypectomy histology.
5.3. Nodal disease and no further resection
For those patients with nodal disease who do not have it resected the prognosis is likely to
be compromised. Intensive surveillance is likely to detect continued disease progression.
The role of chemotherapy and or radiotherapy has not been clearly defined in this group but
is likely to be palliative in nature.
5.4. Absence of Nodal disease
The survival of patients after endoscopic removal of T1 lesions and no nodal disease is ex‐
cellent. The mortality in these groups will be limited to the operative mortality from further
resection.
5.5. Risk of Nodal disease
Various figures have been quoted in the text for the risk of nodal disease in high risk pa‐
tients. This can partly be explained by the differing criteria used to define risk by various
authors. Further stratification within the “high risk group” may become apparent with fur‐
ther study.
The St Mark’s Lymph Node Positivity Model[31] can be used to predict the individual risk
of nodal metastasis after local resection of rectal tumours. However it makes no distinction
within T1 tumours. Such assessment of individual risk factors to produce a personalised risk
is not possible based on the current evidence. Further studies using multivariate analysis
will be required to tease out the importance of individual risk factors.
For our analysis we have chosen to present data based on Sm depth as this has shown to be
a reproducible predictor of nodal disease. Both Kikuchi and Nascimbeni reported rates of
roughly 5, 10 and 25% for Sm 1, 2 and 3 respectively.[23,32]
Risk Factor Incidence of nodal disease
Depth of invasion Haggit 1.2.3 = <1%[9]
Kikuchi SM1 = 5%
Kikuchi Sm2 = 10%
Kicuchi Sm3 = 25%[23, 32]
Poorly differentiated 25-100%. Not found to be important in multivariate
analysis.[14, 17]
Lympho-vascular Invasion 41% Poor reproducibility.[18]
Incomplete resection 75%[20]
Table 6. Incidence of nodal disease by risk factor
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5.6. The risk of further resection
Oncological resection of colorectal lesions is performed via segmental resection of the affect‐
ed potion of the bowel and its draining lymph node basin. Harvesting these nodes gains lo‐
cal control and definatively stages the disease. It is a major undertaking with considerable
risks. In the case of very low rectal tumours an abdomino-perinal excision of rectum (APER)
results in permanent stoma formation.
In  the  UK at  least,  operative  mortality  has  fallen in  recent  years.  30  day mortality  was
6.8% in 1999, falling to 3.7% in 2009/10.[33,34] Rates from Scandinavia (4.8%)[26] and the
US (3.1%)[27] are broadly similar.  This remains considerably higher than the rate of no‐
dal  disease  in  the  low risk  malignant  polyps.  The 90  day mortality  rate,  considered by
some authors to be a more accurate measure of operative mortality is higher still, is 5.6%
in the UK.[34]
This baseline rate is affected by both tumour and patient factors. Patients over the age of 80
are over ten times more likely to die than those under 50 (15% vs 1.2% 30 day mortality).
[28,33] Comparing ASA1 and ASA4 patients, the odds ratio for death at 30 days is 14.06. Pa‐
tients with rectal tumours do better than those with colonic tumours, though this seems to
be due to high mortality for patients undergoing subtotal or total colectomy. Female sex, af‐
fluence, high volume surgical centres and elective rather than emergency surgery all also
have a beneficial effect.[33]
On  top  of  mortality,  anastomotic  leaks,  wound  complications,  cardiovascular  complica‐
tions, defecatory disorders and the psychological impact of stoma formation must also be
considered when deciding whether  or  not  to  resect.  Morbidity rates  of  up to 35% have
been reported in the past.[15] These seem to affect laparoscopic surgery as much as open
resections, but hospital discharge and return to work occurs sooner following laparoscop‐
ic procedures. [35,36]
A more accurate individualised operative risk can be estimated from risk scoring systems.
CR-POSSUM uses patient and operative parameters to estimate operative risk on an indi‐
vidual basis and has been well validated.[37,38] Cardiopulmonary exercise testing is also
useful in predicting complications and the length of hospital stay. Both these tools can be of
great use to the surgeon and patient when used thoughtfully during surgical planning. [39]
5.7. The special case of rectal tumours
There has been considerable interest in recent years in local resection of early rectal tumours
to avoid stoma formation. This is relevant as malignant polyps in the rectum are a variety of
early rectal tumour. Transanal Endoscopic Microsurgery (TEMS) allows full thickness exci‐
sion of rectal lesions below the peritoneal fold, with excellent rates of local recurrence.[15]
Its ability to harvest local lymph nodes is limited, and as such it is not generally a suitable
second procedure for high risk lesions. It may have a role as secondary procedure for incom‐
pletely removed polyps which otherwise show favourable features. In its guidance the
ACPGBI recommended full classical resection of rectal tumours that show the high risk fea‐
tures described earlier.[40]
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The anatomical location of the draining nodes in rectal lesions has also encouraged more ex‐
tensive use of imaging to predict local nodal metastases. Endoanal Ultrasound and MRI
both have the ability to detect enlarged local nodes; however distinguishing between the
commonly found reactive nodes and metastases can be difficult. Micrometastases have also
been detected in radiologically normal nodes. The use of new contrast agents may improve
accuracy but currently histological examination remains the gold standard for detecting no‐
dal disease. [15]
For locally excised T1 and T2 tumours adjuvant chemoradiotherapy has been used with suc‐
cess to prevent local recurrence if further surgery is not deemed appropriate. The role of ad‐
juvant therapy in malignant polyps is unexplored at this time.
5.8. Calculating the survival advantage
As the nodal status of these patients is unknown prior to surgery, mortality is a composite of
the mortality of those with and without nodal disease. The contribution from each group
will be in proportion to the risk of nodal disease.
cM = R.NM + (1-R).nM
Where cM= Composite mortality
R =Risk of nodal disease
NM =Mortality of those with nodal disease
nM =Mortality of those without nodal disease
The best course of action can be discerned by calculating the difference between cM with
and without surgery. Tables 7-9 contain sample composite survival figures and number
needed to treat at five years for various stages of malignant polyp.
Using this method we can see that for a patient with a Sm3 lesion (25% of nodal disease) and
a predicted operative mortality of 2% there will be an absolute risk reduction of mortality at
5 years of 16% (NNT 6.25) if 5 year survival of node positive patients is 75% and a 4.5% re‐
duction (NNT 21.05) if 5 year survival of node positive patients is 27%. In stage IIIa (75%
five year survival) disease the absolute risk is reduced by 10% (NNT 1), but this disappears
for stage IIIc. There has been considerable debate regarding the need to resect Sm2 lesions.
In this model the benefit from resection disappears once operative mortality reaches 5% for
IIIa lesions and 10% for IIIc lesions. Clearly careful though needs to be given to risk when
choosing to operate on these patients.
Obviously  this  model  makes  no  account  of  operative  morbidity.  For  patients  with  IIIc
disease  and  Sm3  lesions  there  is  a  survival  advantage  to  operating;  however  the  deci‐
sion  to  subject  40  patients  to  major  surgery  to  save  1  life  at  five  years  needs  careful
consideration.
Colonoscopy and Colorectal Cancer Screening - Future Directions152
Patient A Patient B Patient C Patient D
Age 55 55 80 60
Lesion Kikuchi Sm3 Haggit level 1 Kikuchi Sm2 Kikuchi Sm1
Risk of nodal disease 25% <1% 10% 5%
Operative Mortality 1% 1% 10% 5%
Compsite Survival without further
resection
81.00 "/>99% 90.50 95.25
Compsite survival with resection 94.20 99% 88.50 94.00
Survival advantage 13.20 - - -
Table 7. Examples of using composite survival to inform decision making in patients with malignant polyps
6. Conclusion
This problem has been known and debated for over 30 years.[41] As the role of endoscopy
has grown and developed, guidelines have been formulated to help clinicians make benefi‐
cial choices. Unfortunately the small scale and heterogeneity for published work had pre‐
vented any guidelines from gaining universal acceptance. The focus on tumour grade in the
American guidance has been challenged by work from Japan that emphasises the impor‐
tance of quantitative measures of the depth of invasion. Japanese work has also shown lym‐
phatic invasion, vascular invasion and tumour budding to be of high prognostic
significance, but concerns about reproducibility have prevented their universal adoption. It
is also unclear which observed prognostic factors are truly significant and which are co-
founding. None of the prognostic factors identified are highly specific and clinicians must
still make difficult decisions based on the balance of risk.
The solution to this problem will surely come from improved pre-operative staging. En‐
do-anal  ultra  sound and targeted contrast  MRI  have both  shown promise  for  rectal  tu‐
mours.  Sentinel  node  mapping  in  the  colon  has  also  been  investigated  but  remains
experimental. [42]
Until highly accurate pre-operative staging of nodal disease is possible effort must be made
to refine the classification of malignant polyps to identify the truly significant prognostic
factors. It is the opinion of the authors that an individualised prediction model comparing
operative surgical risk and risk of progressive disease should be used to counsel patients re‐
garding future strategies. Creation of a national or international database would facil;itate
better predictive models.
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duction (NNT 21.05) if 5 year survival of node positive patients is 27%. In stage IIIa (75%
five year survival) disease the absolute risk is reduced by 10% (NNT 1), but this disappears
for stage IIIc. There has been considerable debate regarding the need to resect Sm2 lesions.
In this model the benefit from resection disappears once operative mortality reaches 5% for
IIIa lesions and 10% for IIIc lesions. Clearly careful though needs to be given to risk when
choosing to operate on these patients.
Obviously  this  model  makes  no  account  of  operative  morbidity.  For  patients  with  IIIc
disease  and  Sm3  lesions  there  is  a  survival  advantage  to  operating;  however  the  deci‐
sion  to  subject  40  patients  to  major  surgery  to  save  1  life  at  five  years  needs  careful
consideration.
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Patient A Patient B Patient C Patient D
Age 55 55 80 60
Lesion Kikuchi Sm3 Haggit level 1 Kikuchi Sm2 Kikuchi Sm1
Risk of nodal disease 25% <1% 10% 5%
Operative Mortality 1% 1% 10% 5%
Compsite Survival without further
resection
81.00 "/>99% 90.50 95.25
Compsite survival with resection 94.20 99% 88.50 94.00
Survival advantage 13.20 - - -
Table 7. Examples of using composite survival to inform decision making in patients with malignant polyps
6. Conclusion
This problem has been known and debated for over 30 years.[41] As the role of endoscopy
has grown and developed, guidelines have been formulated to help clinicians make benefi‐
cial choices. Unfortunately the small scale and heterogeneity for published work had pre‐
vented any guidelines from gaining universal acceptance. The focus on tumour grade in the
American guidance has been challenged by work from Japan that emphasises the impor‐
tance of quantitative measures of the depth of invasion. Japanese work has also shown lym‐
phatic invasion, vascular invasion and tumour budding to be of high prognostic
significance, but concerns about reproducibility have prevented their universal adoption. It
is also unclear which observed prognostic factors are truly significant and which are co-
founding. None of the prognostic factors identified are highly specific and clinicians must
still make difficult decisions based on the balance of risk.
The solution to this problem will surely come from improved pre-operative staging. En‐
do-anal  ultra  sound and targeted contrast  MRI  have both  shown promise  for  rectal  tu‐
mours.  Sentinel  node  mapping  in  the  colon  has  also  been  investigated  but  remains
experimental. [42]
Until highly accurate pre-operative staging of nodal disease is possible effort must be made
to refine the classification of malignant polyps to identify the truly significant prognostic
factors. It is the opinion of the authors that an individualised prediction model comparing
operative surgical risk and risk of progressive disease should be used to counsel patients re‐
garding future strategies. Creation of a national or international database would facil;itate
better predictive models.
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5
No Resectio /% 95.25 95.25 95.25 95.25 95.25
Resection/% 98.45 97.50 94.65 89.90 85.15
Survival Advantage/% 3.20 2.25 - - -
NNT 31.25 44.44 - - -
10
No Resection/% 90.50 90.50 90.50 90.50 90.50
Resection/% 97.90 97.00 94.30 89.80 85.30
Survival Advantage/% 7.40 6.50 3.80 - -
NNT 13.51 15.38 26.32 - -
15
No Resection/% 85.75 85.75 85.75 85.75 85.75
Resection/% 97.35 96.50 93.95 89.70 85.45
Survival Advantage/% 11.60 10.75 8.20 3.95 -
NNT 8.62 9.30 12.20 25.32 -
20
No Resection/% 81.00 81.00 81.00 81.00 81.00
Resection/% 96.80 96.00 93.60 89.60 84.00
Survival Advantage/% 15.80 15.00 12.60 8.60 3.00
NNT 6.33 6.67 7.94 11.63 33.33
25
No Resection/% 76.25 76.25 76.25 76.25 76.25
Resection/% 96.25 95.50 93.25 89.50 85.75
Survival Advantage/% 20.00 19.25 17.00 13.25 9.50
NNT 5.00 5.19 5.88 7.55 10.53
30
No Resection/% 71.50 71.50 71.50 71.50 71.50
Resection/% 95.70 95.00 92.90 89.40 85.90
Survival Advantage/% 24.20 23.50 21.40 17.90 14.40
NNT 0.04 0.04 0.05 0.06 0.07
Table 8. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival for
node positive patients is 88% after resection.
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Table 9. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival is 75%
after resection.
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No Resection/% 95.25 95.25 95.25 95.25 95.25
Resection/% 95.30 94.35 91.50 86.75 82.00
Survival Advantage/% 0.05 - - - -
NNT 2000.00 - - - -
10
No Resection/% 90.50 90.50 90.50 90.50 90.50
Resection/% 91.60 90.70 88.00 83.50 79.00
Survival Advantage/% 1.10 0.20 - - -
NNT 90.91 500.00 - - -
15
No Resection/% 85.75 85.75 85.75 85.75 85.75
Resection/% 87.90 87.05 84.50 80.25 76.00
Survival Advantage/% 2.15 1.30 - - -
NNT 46.51 76.92 - - -
20
No Resection/% 81.00 81.00 81.00 81.00 81.00
Resection/% 84.20 83.40 81.00 77.00 73.00
Survival Advantage/% 3.20 2.40 0.00 - -
NNT 31.25 41.67 - - -
25
No Resection/% 76.25 76.25 76.25 76.25 76.25
Resection/% 80.50 79.75 77.50 73.75 70.00
Survival Advantage/% 4.25 3.50 1.25 - -
NNT 23.53 28.57 80.00 - -
30
No Resection/% 71.50 71.50 71.50 71.50 71.50
Resection/% 76.80 76.10 74.00 70.50 67.00
Survival Advantage/% 5.30 4.60 2.50 - -
NNT 18.87 21.74 40.00 - -
Table 10. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival in
node positive patients is 27% after resection.
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1. Introduction
Observation of the mucosal crypt patterns using chromoendoscopy with magnification has
been reported to be the most reliable method for determining whether a colorectal cancer
(CRC) is early or advanced tumour. Moreover, brand-new endoscopic system have the capa‐
bility to enhance visibility by the capillary pattern, which may prove to be reliable for detec‐
tion of deep submucosal invasive CRC.
Early CRC is defined as a tumour whose invasion is limited to the mucosa or submucosa.
The endoscopic mucosal resection and endoscopic mucosal dissection (EMR/ESD) have be‐
come useful for early CRC. However, EMR/ESD is applicable only to intramucosal carcino‐
ma, and additional surgery is required if the resected lesion reveals submucosal invasion by
pathological diagnosis. Therefore, endoscopist and surgical pathologist considered that it
would be very useful to predict the depth of invasion of submucosal invasive CRC before
EMR/ESD. On the other hand, desmoplastic reaction (DR) which is characterized by the
infiltration of eosinophilic myofibroblasts in the stroma of invasive carcinoma is suggested to
be a prognostic marker in CRC patients.
Here we describe that detection of DR in pre-treatment biopsy specimens is useful for pre‐
dicting the depth of submucosal invasion and evaluation of submucosal depth with head in‐
vasion or stalk invasion in post EMR/ESD specimen is useful for predicting the lymph node
metastasis and discuss relevant issues in arriving at the correct differential diagnosis based
on histological findings for gastrointestinal endoscopist and surgical pathologist.
© 2013 Tomita et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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2. Correlations between lymph node metastasis and early colorectal
carcinoma
The endoscopic mucosal resection and endoscopic submucosal dissection (EMR/ESD) have
become useful for early CRC which is defined as a T1 stage tumour whose invasion is limit‐
ed to the mucosa or submucosa according to the T categories for colorectal cancer of the
American Joint Committee on Cancer (AJCC) staging system (Table 1).
Tx: No description of the tumor's extent is possible because of incomplete information.
Tis: The cancer is in the earliest stage (in situ). It involves only the mucosa. It has not grown beyond the muscularis
mucosa (inner muscle layer).
T1: The cancer has grown through the muscularis mucosa and extends into the submucosa.
T2: The cancer has grown through the submucosa and extends into the muscularis propria (thick outer muscle layer).
T3: The cancer has grown through the muscularis propria and into the outermost layers of the colon or rectum but not
through them. It has not reached any nearby organs or tissues.
T4a: The cancer has grown through the serosa (also known as the visceral peritoneum), the outermost lining of the
intestines.
T4b:The cancer has grown through the wall of the colon or rectum and is attached to or invades into nearby tissues or
organs.
Table 1. T categories for colorectal cancer of the AJCC staging system.
The endoscopic mucosal dissection (EMR: endoscopic mucosal resection and ESD: endo‐
scopic submucosal dissection) of intramucosal carcinoma is accepted as curative, as there is
almost negative of lymph node metastasis. [1-4]. However, the reported prevalence rates of
lymph node metastasis range from 6 to 12% of all patients with submucosal invasive color‐
ectal carcinoma (SICC) [3-6]. Therefore, the endoscopic mucosal dissected cases of SICC
with lymph node metastasis, and after EMR/ESD, surgical resection accompanied with
lymph node dissection is necessary.
It has been known that we should be considered be additional resection is required due
to the risk of lymph node metastasis following findings (1) massive submucosal invasion:
(2)  lymphatic/vessel  invasion;  or  (3)  poorly  differentiated  component  in  resected
EMR/ESD specimens [7, 8]. There has been no standard method of measurement of sub‐
mucosal invasion depth. Therefore, Japanese Society for Cancer of the Colon and Rectum
has  recently  demonstrated definite  for  method of  measurement  of  submucosal  invasion
depth.
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3. Ip type (pedunculated lesion) and non-Ip type (nonpedunculated
lesion) of early colorectal carcinoma
Macroscopic type (endoscopic finding) was assessed according to the macroscopic clas‐
sification of early stomach carcinoma, with minor modifications. In shortly, SICCs were div‐
ided into two lesions: pedunculated (Ip type) (Figure. 1, Figure. 2(a)) and nonpedunculated
(Non-Ip type) (Figure. 1b, Figure. 2(b)). Nonpedunculated lesion were subclassified as semi‐
pedunculated lesion (Isp type) and sessile lesion (Is type). Respectively. Ip type (pedunculat‐
ed lesion) has typically head with stalk (Figure. 1, Figure 2).
Figure 1. Schema of macroscopic (endoscopic) classification of SICCs: pedunculated(Ip type) and nonpedunculat‐
ed(Non-Ip type). Arrowhead: muscularis mucosae.: 0 µm
(a) (b) 
Figure 2. Histological appearance of pedunculated(Ip type) (a) and nonpedunculated(Non-Ip type) (b) on Hematoxy‐
lin and Eosin staining section.
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The method used for measurement of submucosal invasion depth (Figure. 3)
Figure 3. Algorithm of measurement of submucosal invasion depth.
Firstly, EMR/ESD resected specimens are divided into pedunculated(Ip type) and nonpe‐
dunculated(Non-Ip type). For pedunculated SICC, level 2 according to Haggitt’s classificati‐
on [9] was used as the baseline (so-called Haggitt’s line), and submucosal invasion depth
was measured as the vertical distance from this line to the deepest site of invasion. The base‐
line to distinguish between head invasion, (Figure. 4(a)) and stalk invasion, (Figure. 4(b)). In
head invasion, submucosal invasion depth was regarded as 0 µm. When the deepest portion
of invasion was located below the baseline, the case was defined as a stalk invasion and the
vertical distance from this line to the deepest portion of invasion was utilized as submucosal
invasion depth.
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On the other hand, nonpedunculated and when the muscularis mucosae could be identified
in hematoxylin and eosin stain, the muscularis mucosae was used as baseline and the verti‐
cal distance from this line to the deepest site of invasion represented submucosal invasion
depth, (Figure. 4(c))., however, when the muscularis mucosae could not be identified, the su‐

































Figure 4. Schema of measurement of submucosal invasion depth. Ip type with head invasion (a) and stalk invasion (b),

































Figure 5. Histological findings with depth of submucosal invasion (µm). Ip type with head invasion: 0 µm (a) and stalk
invasion: X µm (b), non-Ip type with musucular mucosae: Y µm (c) and without musucular mucosae: Z µm (d) on Hem‐
atoxylin and Eos  staini g section
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4. Correlations between lymph node metastasis and depth of submucosal
invasive colorectal carcinoma
The Japanese collaborative retrospectively study for 865 SICCs. This nationwide survey not on‐
ly represents a first for Japan, but reviewing the literature using PubMed revealed no similar
surveys from anywhere in the world at that time [3] This study reported that pedunculated (Ip
type) SICC, rate of lymph node metastasis was never in head invasion cases and stalk invasion
cases with submucosal invasion depth < 3000 µm if lymphatic invasion was negative (Table 2).
And, For nonpedunculated (non-Ip type) SICC, rate of lymph node metastasis was also 0%
if submucosal invasion depth was <1000 µm (Table 3). In multivariate analysis, SM depth
<1000µm (P <0.006), sprouting (P <0.002), and lymphatic invasion (P<0.0001) represented
significant risk factors, with odds ratios of 5.404, 2.276, and 4.691, respectively. Several priv‐
iously reports suggested that prognosis in patients with early colorectal carcinoma based on
Haggitt’s classification, finding that level 4 which is carcinoma invading the submucosa of
the bowel wall below the stalk of the polyp but above the muscularis propria, represented
the most important factor for lymph node metastasis [9, 10]. Therefore, these results re‐
vealed that submucosal invasion could be an important of predicting lymph node metastasis
potential.
Histological type at the
deepest portion
LNM (+) Ly (+) V (+) Sp (+) wel, mod por
SM depth (µm) (%) (%) (%) (%) (%) (%)
X=0 (n=53) 3 (5.7) 15 (28.3) 9 (17.0) 15 (28.3) 51 (96.2) 2 (3.8)
0 <X<500 (n=10) 0 (0) 2 (20.0) 0 (0) 3 (33.3) 10 (100) 0 (0)
500≤X<1000 (n=7) 0 (0) 1 (14.3) 0 (0) 2 (28.6) 7 (100) 0 (0)
1000≤X<1500 (n=11) 1 (9.1) 2 (18.2) 3 (27.3) 7 (63.6) 11 (100) 0 (0)
1500≤X<2000 (n = 7) 1 (14.3) 4 (57.1) 0 (0) 5 (71.4) 7 (100) 0 (0)
2000 ≤X<2500 (n= 10) 1 (10.0) 4 (40.0) 3 (30.0) 1 (10.0) 9 (90.0) 1 (10.0)
2500≤X< 3000 (n= 4) 0 (0) 0 (0) 2 (50) 1 (25.0) 4 (100) 0 (0)
3000 ≤X<3500 (n= 9) 2 (22.2) 4 (44.4) 3 (33.3) 5 (55.6) 8 (88.9) 1 (11.1)
3500 ≤X (n= 30) 2 (6.7) 9 (30.0) 10 (33.3) 10 (33.3) 28 (93.3) 2 (6.7)
SICC, submucosal invasive colorectal carcinoma; SM depth, depth of submucosal invasion of SICC; LNM, lymph node
metastasis; Ly, lymphatic invasion; V, venous invasion; Sp, sprouting; wel, well-differentiated adenocarcinoma; mod,
moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma
Table 2. Relationship between clinicopathological factors and the rate of lymph node metastasis according to SM
depth in pedunculated (Ip type) SICC (adapted from [3])





LNM (+) Ly (+) V (+) Sp (+) wel, mod por Identified
Not
identified
SM depth (µm) (%) (%) (%) (%) (%) (%) (%) (%)
0 <X<500
(n=65)
0 (0) 5 (7.7) 3 (4.6) 9 (13.8) 64 (98.5) 1 (1.5) 64 (98.5) 1 (1.5)
500≤X<1000
(n=58)
0 (0) 12 (20.7) 7 (12.1) 7 (12.1) 58 (100) 0 (0) 51 (87.9) 7 (12.1)
1000≤X<1500
(n=52)
6 (11.5) 16 (30.8) 12 (23.1) 16 (30.8) 51 (98.1) 1 (1.9) 36 (69.2) 16 (30.8)
1500≤X<2000
(n = 82)
10 (12.2) 27 (32.9) 16 (19.5) 37 (45.1) 82 (100) 0 (0) 48 (58.5) 34 (41.5)
2000 ≤X<2500
(n= 84)
13 (15.5) 28 (33.3) 21 (25.0) 42 (50.0) 78 (92.9) 6 (7.1) 31 (36.9) 53 (63.1)
2500≤X< 3000
(n= 71)
8 (11.3) 29 (40.8) 16 (22.5) 38 (53.5) 71 (100) 0 (0) 20 (28.2) 51 (71.8)
3000 ≤X<3500
(n= 72)
5 (6.9) 26 (36.1) 15 (20.8) 35 (48.6) 69 (95.8) 3 (4.2) 16 (22.2) 56 (77.8)
3500 ≤X
(n= 240)
35 (14.6) 92 (38.3) 74 (30.8) 133 (55.4) 237 (98.8) 3 (1.2) 48 (20.0) 192 (80.0)
Table 3. Relationship between clinicopathological factors and the rate of lymph node metastasis according to SM
depth in nonpedunculated (non-Ip type) SICC (adapted from [3])
Suprisingly, Japanese collaborative retrospectively nationwide survey shows both of Ip type
(pedunculated lesion) and non-Ip type (nonpedunculated lesion) of early colorectal carcino‐
ma with rate of lymph node metastasis was also 0% if submucosal invasion depth was <1000
µm (Table 4). It is easy to measure one southern micrometer using by small ruler under mi‐
croscopy for surgical pathologist. When if submucosal invasion depth was 1000 µm ≤, surgi‐
cal pathologist should be advice to gastrointestinal endoscopist. And recently Japanese
large-scale multicenter retrospectively study for 384 (head invasion: 240, stalk invasion: 144)
pedunculated (Ip type) SICCs demonstrated that incidence of lymph node metastasis was
3.5%. the incidence of lymph node metastasis was 0.0% inpatients with head invasion, as‐
compared with 6.2% in patients with stalk invasion (Tabel 4). Pedunculated type early inva‐
sive colorectal cancers pathologically diagnosed as head invasion can be only treated by
endoscopic resection.
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pedunculated (Ip type) SICCs demonstrated that incidence of lymph node metastasis was
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SM depth X (µm) Ip type Non-Ip type
n pN positive (%) n pN positive (%)
head invasion (X=0) 53 3(5.7)*
0 < X < 500 10 0(0) 65 0(0)
500 ≤ X < 1000 7 0(0) 58 0(0)
1000 ≤ X < 1500 11 1(9.1)* 52 6(11.5)
1500 ≤ X < 2000 7 1(14.3)* 82 10(12.2)
2000 ≤ X < 2500 10 1(10.0)* 84 13(15.3)
2500 ≤ X < 3000 4 0(0) 71 8(11.3)
3000 ≤ X < 3500 9 2(22.2) 72 5(6.9)
3500 ≤ X 30 2(6.7) 240 35(14.6)
Ip type: pedunculated lesion. Non-Ip type: nonpedunculated lesion
*: vessels invasion
Table 4. Relationship between clinicopathological factors and the rate of the lymph node metastasis according to SM
depth (summarized of Table 2 and 3, adapted from [11]. English translated version]
Head invasion Stalk invasion Total
Lymph node metastasis n (%) 0 ⁄101 (0) 8 ⁄129 (6.2) 8 ⁄230 (3.5)
95% CI (%) 0.00–3.60P 2.70–11.90 1.50–6.70
*P = 0.02
Recurrence n (%) 0 ⁄219 (0) 1 ⁄121 (0.8) 1 ⁄340 (0.3)
95% CI (%) 0.00–1.70 0.02–4.50 0.01–1.60
**P = 0.72
Lymphovascular invasion†, n (%) 35 ⁄240 (15) 55 ⁄144 (38) 90 ⁄384 (23)
Lymphatic invasion, n (%) 21 (9) 33 (23) 54 (14)
Venous invasion, n (%) 16 (7) 37 (26) 53 (14)
Poorly differentiated component, n (%) 26 ⁄240 (11) 26 ⁄144 (18) 52 ⁄384 (14)
Lymphatic and ⁄or venous invasion. CI, confidence interval
Table 5. Histopathological characteristics of 384 cases of pedunculated type early invasive colorectal cancer (adapted
from [12])
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5. The treatment of colorectal carcinoma with submucosal invasion state
after endoscopic resection
Many new treatment methods have been developed over the last few decades. The Japanese
Society for Cancer of the Colon and Rectum guidelines 2010 for the treatment of colorectal
cancer (JSCCR Guidelines 2010 [13]) have been prepared to show standard treatment strat‐
egies for submucosal invasive colorectal cancer (Figure. 6).
Figure 6. Guide line for the treatment of colorectal carcinoma with submucosal invasion state after endoscopic resec-
tion. (adapted from JSCCR Guidelines 2010 [13] with minor modifications );; Pap: papillary adenocarcinoma, Tub: tub‐
ular adenocarcinoma, Por: poorly differentiated adenocarcinoma, Sig: signet-ring cell carcinoma, Muc: mucinous
adenocarcinoma, SM: submucosal invasion, Budding: tumor budding. The tumor budding denotes that at the invasion
front of colorectal adenocarcinomas tumour cells, and the potential of tumour budding as a prognostic factor
(G1:Grade 1 to G3: Grade 3) for routine surgical pathology [14,15])




Figure 7. Endoscopic, stereomicroscopic, macroscopic findings of the early colorectal carcinoma. Endoscopic finding of
the pedunculated(Non-Ip) type (a), several pits are arranged irregularly in the stereomicroscopic view (b), macroscopic
appearance of SICC, post formalin-fixed. Most of the endoscopic detectable lesions were the irregular elevated type
macroscopically. (White bar: mucosal invasion, Red bar: submucosal invasion) (c),
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6. Detection of desmoplastic reaction in biopsy specimens of colorectal
cancer
Early CRC, including submucosal invasive colorectal carcinoma (SICC), is defined as a tumor
whose invasion is limited to the mucosa or submucosa. The endoscopic resection (EMR/ESD)
have been useful for early CRC. However, endoscopic resection is applicable only to intramu‐
cosal carcinoma (Tis stage tumor), and additional surgery is required if the resected specimen
reveals submucosal invasion by pathological diagnosis. However, the study of Japanese Soci‐
ety for Cancer of the Colon and Recum have recently demonstrated that the depth of submu‐
cosal invasion is closely correlated with the prevalence of lymph node metastasis in patients
with SICC (See. Correlations between lymph node metastasis and early colorectal Carcinoma).
Therefore, gastrointestinal endoscopist and surgical pathologist considered that it would be
very useful to predict the depth of invasion of SICC before endoscopic resection for case se‐
lection. New endoscopic systems are possible to predict submocosal invasion depth without
biopsy. However, these developed systems have not been used in everywhere. On the other
hand, the stromal change associated with carcinoma invasion has been called desmoplastic
reaction (DR), desmoplasia, and cancer-associated fibroblast. Reported incidence of the DR
is suggested to be a prognostic marker in CRC patients [16, 17]. Recently, JSCCR studies
have been assessed the DR in pretreatment biopsy specimens of SICRC to predict the sub‐
mucosal depth in retorospective and prospective study.
The DR is characterized by modifications in the composition of stromal cells and extracellu‐
lar matrix (ECM) components with eosinophilic change [18, 19] (Figure. 8). The main pro‐
ducers of many ECM compounds and represent the major cellular component including DR
that often show differentiated phenotype with expression of the smooth muscle actin, plate‐
let derived growth factor receptor- type I collagen [18, 20, 21].
The presence and histological findings of DR in biopsy specimens were evaluated by pathol‐
ogists at each respective institute and the criteria for assessment of DR established in con‐
sensus meeting among JSCCR members including us. (Table 6).
Figure 8. Histological appearance of desmoplastic reaction (DR). Note the growth of eosinophilic spindle cells
(myofibroblasts.*) with submucosal invasive carcinoma component on Hematoxylin and Eosin staining section.
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1) Existence of carcinoma is required for detection of DR.
2) The histological findings of infiltrating carcinoma do not signify the presence of DR.
3) DR contains areas of collagen fiber accumulation and myofibroblast proliferation, but inflammatory infiltration does
not signify the presence of DR.
4) All histological findings were determined by HE stain alone; detection of DR does notrequire the use of any special
stains.
DR, desmoplastic reaction.
Table 6. Criteria for detection of desmoplastic reaction (adapted from [22])
A retorospective study for detection of desmoplastic reaction in biopsy specimens of early
colorectal cancer reported that 359 patients with SICRCs, who had undergone surgical or en‐
doscopic mucosal resection, were analysed [23]. For pedunculated (Ip type) SICRCs was not
significantly related to submucosal depth. However, for nonpedunculated (non-Ip type) the
prevalence of DR in pretreatment biopsy specimens was significantly related to submucosal
depth. When nonpedunculated(non-Ip type) SICRCs were further divided using a specific
cut off value of 1000 µm for submucosal depth, the positivity ratio of DR in pretreatment
biopsy specimens was significantly higher in SICRCs with an submucosal depth of 1000 µm
than in cases where the submucosal depth was <1000 µm (Table 7). Detection of DR in pre‐
treatment biopsy specimens is useful for the prediction of submucosal depth in nonpedun‐
culated (non-Ip) SICRCs,
Depth of submucosal invasion (µm) Pedunculated SICRC Nonpedunculated SICRC
DR (-) (%) DR (+) (%) DR (-) (%) DR (+) (%)
X<1000 3 (37.5) 5 (62.5) 30 (65.2) 16 (34.8)
1000 ≤ X < 2000 1 (50.0) 1 (50.0) 25 (56.8) 19 (43.2)
2000 ≤ X < 3000 5 (100) 0 (0.0) 22 (27.5) 58 (72.5)
3000 ≤ X < 4000 3 (33.3) 6 (66.7) 20 (29.9) 47 (70.1)
4000 ≤ X < 5000 0 (0.0) 1 (100) 11 (31.4) 24 (68.6)
5000 ≤ X < 6000 1 (100) 0 (0.0) 10 (43.5) 13 (56.5)
6000 ≤ X < 7000 2 (100) 0 (0.0) 5 (55.6) 4 (44.4)
7000 ≤ X < 8000 0 (0.0) 2 (100) 0 (0.0) 4 (100)
8000 ≤ X < 9000 0 (0.0) 0 (0.0) 4 (44.4) 5 (55.6)
9000 ≤ X < 10000 0 (0.0) 0 (0.0) 0 (0.0) 4 (100)
10000 ≤X 1 (50.0) 1 (50.0) 2 (33.3) 4 (66.7
Table 7. Relationship between depth of submucosal invasion and DR in biopsy specimens of patients with SICRCs -
retorospective study - (adapted from [23])
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After retorospective study [22], same study group confirmed verification of patients SICRC
with 112 nonpedunculated (non-Ip type) cases. Finally, nonpedunculated (non-Ip type) case
of the prevalence of DR was significantly correlated with submucosal depth. The sensitivity
and specificity of detection of DR for prediction of pSM2 (tumor invasion <1000 µm) in non‐
pedunculated SICRC were 68.6% and 92.0%, respectively.
Additionally, receiver operating characteristic (ROC), analysis confirmed 950 µm as the best
diagnostic cut-off value of submucosal depth for DR detection, and 50 µm, which is the dif‐
ference between the value of 950 µm as determined by cut off value (COV) and 1000 µm, the
defining value of pSM2, is an acceptable measurement error range.
In statistics and diagnostic testing, positive predictive value (PPV) is the proportion of pa‐
tients with positive test results who are correctly diagnosed, on the other hand, negative
predictive value (NPV) is negative test results. Both of PPV and NPV are critical measure of
the performance of a diagnostic method. In this studies revealed that PPV:0.93, NPV:0.59 in
pedunculated and PPV:0.95, NPV:0.59 in nonpedunculated type. These results provide a ba‐
sis for assessment of DR as a good indicator of pSM2. (Table 8).
Depth of submucosal invasion Number of patients DR–negative DR–positive
pSM2 54 17 37
pM+ pSM1 27 24 3
pSM2, SM invasion ≧1000 µm; pM + pSM1, SM invasion < 1000 µm.
Sensitivity: (37/37+ 17) x 100 = 68.5%.
Specificity: (24/24+ 3) x 100 = 88.9%.
DR, desmoplastic reaction.
Depth of submucosal invasion Number of patients DR–negative DR–positive
pSM2 51 16 35
pM+ pSM1 25 23 2
pSM2, SM invasion ≧1000 µm; pM + pSM1, SM invasion < 1000 µm.
Sensitivity: (35/35+ 16) x100 = 68.6%.
Specificity: (23/23+ 2) x 100 = 92.0%.
DR, desmoplastic reaction.
Table 8. Relationship between depth of submucosal invasion and DR in biopsy specimens of patients with
pedunculated (upper part) and nonpedunculated (lower part) type - prospective study - (adapted from [22])
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7. Conclusion
In this issue, we have discussed the a critical role of pathological assessment for T1 stage color‐
ectal cancer, several problems related to the pathological diagnosis of early CRC at increased
risk of lymph node metastasis and submucosal invasion. A new endoscopic systems which
may prove to be reliable for detection of deep submucosal invasive CRC. Moreover, current en‐
doscopic resection (EMR/ESD) have become useful for early CRC, but, these resection is appli‐
cable only to intramucosal carcinoma, and additional surgery is required if the resected lesion
reveals submucosal invasion by pathological diagnosis, because prevalence rates of lymph
node metastasis about 10% of all patients with submucosal invasive colorectal carcinoma.
We believe that curative endoscopic management for early CRC may be need to accurately
pathological diagnosis of submucosal depth. Assessment of DR in pretreatment biopsy
specimen nonpedunculated (non-Ip type) and submucosal depth with head invasion or
stalk invasion in pedunculated (Ip type) for post endoscopic resection (EMR/ESD) specimen
may be useful for the clinicopathological diagnosis of colorectal carcinoma with invasion in‐
to the submucosal layer.
Acknowledgment
The authors would like to thank member of Japanese Society for Cancer of the Colon and
Recum; Professor Ajioka (Division of Molecular and Functional Pathology, Department of
Cellular Function, Graduate School of Medical and Dental Sciences, Niigata University), Dr
Ueno (Department of Surgery, National Defense Medical College, Saitama, Professer Oh‐
kura (Department of Pathology, Kyorin University School of Medicine), Professor Kashida
(Department of Gastroenterology and Hepatology, Faculty of Medicine, Kinki University),
Professor Togashi (Department of Gastroenterology, Fukushima Prefectural Aizu General
Hospital), Professor Yao (Department of Human Pathology, Juntendo University School of
Medicine) Dr Wada (Department of Pathology, Juntendo Shizuoka Hospital of Juntendo
University School of Medicine), Professor Watanabe (Department of Surgical Oncology The
University of Tokyo), Dr Ochiai (Pathology Division, Research Center for Innovative Oncol‐
ogy, National Cancer Center Hospital East), Professor Sugai (Diagnostic Pathology, Iwate
Medical University, Morioka), Professor Sugihara (Surgical Oncology, Tokyo Medical and
Dental University). And we also thank Dr Fujii (Center for Gastrointestinal Endoscopy, Kyo‐
to-Katsura Hospital) for his insightful comments. Moreover, the authors greatly thank Ms C.
Sato -Matsuyama, A. Shimizu, M. Katayama, (Department of Surgical and Molecular Pathol‐
ogy, DOKKYO Medical University School of Medicine) for technical assistance and to Ms. S.
Kidachi, A. Kikuchi (Department of Surgical and Molecular Pathology, DOKKYO Medical
University School of Medicine) for secretarial assistance in preparing the manuscript.
This work was partially supported by the Grant-in-Aid for Scientific Research (C: No 18659101,
23590410) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
Japan and DOKKYO Medical University Young Investigator Award (2009, 2011, 2012).
Desmoplastic Reaction in Biopsy Specimens of T1 Stage Colorectal Cancer Plays a Critical Role in Defining the Level...
http://dx.doi.org/10.5772/51900
173
After retorospective study [22], same study group confirmed verification of patients SICRC
with 112 nonpedunculated (non-Ip type) cases. Finally, nonpedunculated (non-Ip type) case
of the prevalence of DR was significantly correlated with submucosal depth. The sensitivity
and specificity of detection of DR for prediction of pSM2 (tumor invasion <1000 µm) in non‐
pedunculated SICRC were 68.6% and 92.0%, respectively.
Additionally, receiver operating characteristic (ROC), analysis confirmed 950 µm as the best
diagnostic cut-off value of submucosal depth for DR detection, and 50 µm, which is the dif‐
ference between the value of 950 µm as determined by cut off value (COV) and 1000 µm, the
defining value of pSM2, is an acceptable measurement error range.
In statistics and diagnostic testing, positive predictive value (PPV) is the proportion of pa‐
tients with positive test results who are correctly diagnosed, on the other hand, negative
predictive value (NPV) is negative test results. Both of PPV and NPV are critical measure of
the performance of a diagnostic method. In this studies revealed that PPV:0.93, NPV:0.59 in
pedunculated and PPV:0.95, NPV:0.59 in nonpedunculated type. These results provide a ba‐
sis for assessment of DR as a good indicator of pSM2. (Table 8).
Depth of submucosal invasion Number of patients DR–negative DR–positive
pSM2 54 17 37
pM+ pSM1 27 24 3
pSM2, SM invasion ≧1000 µm; pM + pSM1, SM invasion < 1000 µm.
Sensitivity: (37/37+ 17) x 100 = 68.5%.
Specificity: (24/24+ 3) x 100 = 88.9%.
DR, desmoplastic reaction.
Depth of submucosal invasion Number of patients DR–negative DR–positive
pSM2 51 16 35
pM+ pSM1 25 23 2
pSM2, SM invasion ≧1000 µm; pM + pSM1, SM invasion < 1000 µm.
Sensitivity: (35/35+ 16) x100 = 68.6%.
Specificity: (23/23+ 2) x 100 = 92.0%.
DR, desmoplastic reaction.
Table 8. Relationship between depth of submucosal invasion and DR in biopsy specimens of patients with
pedunculated (upper part) and nonpedunculated (lower part) type - prospective study - (adapted from [22])
Colonoscopy and Colorectal Cancer Screening - Future Directions172
7. Conclusion
In this issue, we have discussed the a critical role of pathological assessment for T1 stage color‐
ectal cancer, several problems related to the pathological diagnosis of early CRC at increased
risk of lymph node metastasis and submucosal invasion. A new endoscopic systems which
may prove to be reliable for detection of deep submucosal invasive CRC. Moreover, current en‐
doscopic resection (EMR/ESD) have become useful for early CRC, but, these resection is appli‐
cable only to intramucosal carcinoma, and additional surgery is required if the resected lesion
reveals submucosal invasion by pathological diagnosis, because prevalence rates of lymph
node metastasis about 10% of all patients with submucosal invasive colorectal carcinoma.
We believe that curative endoscopic management for early CRC may be need to accurately
pathological diagnosis of submucosal depth. Assessment of DR in pretreatment biopsy
specimen nonpedunculated (non-Ip type) and submucosal depth with head invasion or
stalk invasion in pedunculated (Ip type) for post endoscopic resection (EMR/ESD) specimen
may be useful for the clinicopathological diagnosis of colorectal carcinoma with invasion in‐
to the submucosal layer.
Acknowledgment
The authors would like to thank member of Japanese Society for Cancer of the Colon and
Recum; Professor Ajioka (Division of Molecular and Functional Pathology, Department of
Cellular Function, Graduate School of Medical and Dental Sciences, Niigata University), Dr
Ueno (Department of Surgery, National Defense Medical College, Saitama, Professer Oh‐
kura (Department of Pathology, Kyorin University School of Medicine), Professor Kashida
(Department of Gastroenterology and Hepatology, Faculty of Medicine, Kinki University),
Professor Togashi (Department of Gastroenterology, Fukushima Prefectural Aizu General
Hospital), Professor Yao (Department of Human Pathology, Juntendo University School of
Medicine) Dr Wada (Department of Pathology, Juntendo Shizuoka Hospital of Juntendo
University School of Medicine), Professor Watanabe (Department of Surgical Oncology The
University of Tokyo), Dr Ochiai (Pathology Division, Research Center for Innovative Oncol‐
ogy, National Cancer Center Hospital East), Professor Sugai (Diagnostic Pathology, Iwate
Medical University, Morioka), Professor Sugihara (Surgical Oncology, Tokyo Medical and
Dental University). And we also thank Dr Fujii (Center for Gastrointestinal Endoscopy, Kyo‐
to-Katsura Hospital) for his insightful comments. Moreover, the authors greatly thank Ms C.
Sato -Matsuyama, A. Shimizu, M. Katayama, (Department of Surgical and Molecular Pathol‐
ogy, DOKKYO Medical University School of Medicine) for technical assistance and to Ms. S.
Kidachi, A. Kikuchi (Department of Surgical and Molecular Pathology, DOKKYO Medical
University School of Medicine) for secretarial assistance in preparing the manuscript.
This work was partially supported by the Grant-in-Aid for Scientific Research (C: No 18659101,
23590410) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
Japan and DOKKYO Medical University Young Investigator Award (2009, 2011, 2012).




Shigeki Tomita, Kazuhito Ichikawa and Takahiro Fujimori
*Address all correspondence to: sstomita@dokkyomed.ac.jp
Department of Surgical and Molecular Pathology, DOKKYO Medical University School of
Medicine, Tochigi, Japan
References
[1] Morson. BC, Whiteway JE, Jones EA, Macrae FA, Williams CB. Histopathology and
prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut
1984;25(5): 437-444.
[2] Fujimori T, Kawamata H, Kashida H. Precancerous lesions of the colorectum. Journal
of gastroenterology 2001;36(9): 587-594.
[3] Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, Kumamoto T, Ishi‐
guro S, Kato Y, Shimoda T, Iwashita A, Ajioka Y, Watanabe H, Watanabe T, Muto T,
Nagasako K. Correlations between lymph node metastasis and depth of submucosal
invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative
study. Journal of gastroenterology 2004;39(6): 534-543..
[4] Al Natour RH, Saund MS, Sanchez VM, Whang EE, Sharma AM, Huang Q, Boosalis
VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis in colon
carcinoids and can be used to select patients for endoscopic resection. Journal of gas‐
trointestinal surgery 2012;16(3): 595-602.
[5] Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the
colon and rectum. The American journal of surgical pathology 1983;7(7): 613-623.
[6] Minamoto T, Mai M, Ogino T, Sawaguchi K, Ohta T, Fujimoto T, Takahashi Y. Early
invasive colorectal carcinomas metastatic to the lymph node with attention to their
nonpolypoid development. The American journal of gastroenterology 1993;88(7):
1035-1039.
[7] Coverlizza S, Risio M, Ferrari A, Fenoglio-Preiser CM, Rossini FP. Colorectal adeno‐
mas containing invasive carcinoma: pathologic assessment of lymph node metastatic
potential. Cancer 1989;64(9): 1937-1947.
[8] Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, Schönegg R, Maurer C,
Hüsler J, Halter F, Schmassmann A. Risk factor assessment of endoscopically re‐
moved malignant polyps. Gut 1998;43(5): 669-674.
Colonoscopy and Colorectal Cancer Screening - Future Directions174
[9] Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal car‐
cinomas arising in adenomas: implications for lesions removed by endoscopic poly‐
pectomy. Gastroenterology 1985;89(2): 328-36.
[10] Pollard CW, Nivatvongs S, Rojanasakul A, Reiman HM, Dozois RR. The fate of pa‐
tients following polypectomy alone for polyps containing invasive carcinoma. Dis‐
eases of the colon and rectum 1992;35(10): 933-937.
[11] Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of
the Colon and Rectum (JSCCR) guidelines 2005 for the treatment of colorectal cancer.
In Japanease, Tokyo, Kanehara: 2005.
[12] Matsuda T, Fukuzawa M, Uraoka T, Nishi M, Yamaguchi Y, Kobayashi N, Ikematsu
H, Saito Y, Nakajima T, Fujii T, Murakami Y, Shimoda T, Kushima R, Fujimori T.
Risk of lymph node metastasis in patients with pedunculated type early invasive col‐
orectal cancer: a retrospective multicenter study. Cancer science 2011;102(9):
1693-1697
[13] Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo
I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A,
Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N,
Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T,
Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the
Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. International journal of clinical
oncology 2012;17(1): 1-29.
[14] Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50(1): 151-162.
[15] Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to
estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40(2):
127-132.
[16] Nakada I, Tasaki T, Ubukata H, Goto Y, Watanabe Y, Sato S, Tabuchi T, Tsuchiya A,
Soma T. Desmoplastic response in biopsy specimens of early colorectal carcinoma is
predictive of deep submucosal invasion. Diseases of the colon and rectum 1998;41(7):
896-900.
[17] Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Seki‐
moto M, Matsuura N, Monden M. Stromal myofibroblasts predict disease recurrence
for colorectal cancer. Clinical cancer research 2007;13(7): 2082-2090.
[18] Ban S, Shimizu M. Muscularis mucosae in desmoplastic stroma formation of early in‐
vasive rectal adenocarcinoma. World journal of gastroenterology 2009;15(39):
4976-4979.
[19] Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, Dia‐
mandis EP. Proteomic signatures of the desmoplastic invasion front reveal collagen




Shigeki Tomita, Kazuhito Ichikawa and Takahiro Fujimori
*Address all correspondence to: sstomita@dokkyomed.ac.jp
Department of Surgical and Molecular Pathology, DOKKYO Medical University School of
Medicine, Tochigi, Japan
References
[1] Morson. BC, Whiteway JE, Jones EA, Macrae FA, Williams CB. Histopathology and
prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut
1984;25(5): 437-444.
[2] Fujimori T, Kawamata H, Kashida H. Precancerous lesions of the colorectum. Journal
of gastroenterology 2001;36(9): 587-594.
[3] Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, Kumamoto T, Ishi‐
guro S, Kato Y, Shimoda T, Iwashita A, Ajioka Y, Watanabe H, Watanabe T, Muto T,
Nagasako K. Correlations between lymph node metastasis and depth of submucosal
invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative
study. Journal of gastroenterology 2004;39(6): 534-543..
[4] Al Natour RH, Saund MS, Sanchez VM, Whang EE, Sharma AM, Huang Q, Boosalis
VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis in colon
carcinoids and can be used to select patients for endoscopic resection. Journal of gas‐
trointestinal surgery 2012;16(3): 595-602.
[5] Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the
colon and rectum. The American journal of surgical pathology 1983;7(7): 613-623.
[6] Minamoto T, Mai M, Ogino T, Sawaguchi K, Ohta T, Fujimoto T, Takahashi Y. Early
invasive colorectal carcinomas metastatic to the lymph node with attention to their
nonpolypoid development. The American journal of gastroenterology 1993;88(7):
1035-1039.
[7] Coverlizza S, Risio M, Ferrari A, Fenoglio-Preiser CM, Rossini FP. Colorectal adeno‐
mas containing invasive carcinoma: pathologic assessment of lymph node metastatic
potential. Cancer 1989;64(9): 1937-1947.
[8] Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, Schönegg R, Maurer C,
Hüsler J, Halter F, Schmassmann A. Risk factor assessment of endoscopically re‐
moved malignant polyps. Gut 1998;43(5): 669-674.
Colonoscopy and Colorectal Cancer Screening - Future Directions174
[9] Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal car‐
cinomas arising in adenomas: implications for lesions removed by endoscopic poly‐
pectomy. Gastroenterology 1985;89(2): 328-36.
[10] Pollard CW, Nivatvongs S, Rojanasakul A, Reiman HM, Dozois RR. The fate of pa‐
tients following polypectomy alone for polyps containing invasive carcinoma. Dis‐
eases of the colon and rectum 1992;35(10): 933-937.
[11] Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of
the Colon and Rectum (JSCCR) guidelines 2005 for the treatment of colorectal cancer.
In Japanease, Tokyo, Kanehara: 2005.
[12] Matsuda T, Fukuzawa M, Uraoka T, Nishi M, Yamaguchi Y, Kobayashi N, Ikematsu
H, Saito Y, Nakajima T, Fujii T, Murakami Y, Shimoda T, Kushima R, Fujimori T.
Risk of lymph node metastasis in patients with pedunculated type early invasive col‐
orectal cancer: a retrospective multicenter study. Cancer science 2011;102(9):
1693-1697
[13] Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo
I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A,
Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N,
Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T,
Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the
Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. International journal of clinical
oncology 2012;17(1): 1-29.
[14] Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50(1): 151-162.
[15] Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to
estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40(2):
127-132.
[16] Nakada I, Tasaki T, Ubukata H, Goto Y, Watanabe Y, Sato S, Tabuchi T, Tsuchiya A,
Soma T. Desmoplastic response in biopsy specimens of early colorectal carcinoma is
predictive of deep submucosal invasion. Diseases of the colon and rectum 1998;41(7):
896-900.
[17] Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Seki‐
moto M, Matsuura N, Monden M. Stromal myofibroblasts predict disease recurrence
for colorectal cancer. Clinical cancer research 2007;13(7): 2082-2090.
[18] Ban S, Shimizu M. Muscularis mucosae in desmoplastic stroma formation of early in‐
vasive rectal adenocarcinoma. World journal of gastroenterology 2009;15(39):
4976-4979.
[19] Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, Dia‐
mandis EP. Proteomic signatures of the desmoplastic invasion front reveal collagen
Desmoplastic Reaction in Biopsy Specimens of T1 Stage Colorectal Cancer Plays a Critical Role in Defining the Level...
http://dx.doi.org/10.5772/51900
175
type XII as a marker of myofibroblastic differentiation during colorectal cancer meta‐
stasis. Oncotarget. 2012;3(3): 267-285.
[20] De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of
invasive cancer growth. International journal of cancer 2008;123(10): 2229-2238.
[21] Kimura R, Fujimori T, Ichikawa K, Ajioka Y, Ueno H, Ohkura Y, Kashida H, Togashi
K, Yao T, Wada R, Watanabe T, Ochiai A, Sugai T, Sugihara K, Igarashi Y. Desmo‐
plastic reaction in biopsy specimens of early colorectal cancer: A Japanese prospec‐
tive multicenter study. Pathology international 2012;62(8): 525-531.
[22] Schmid SA, Dietrich A, Schulte S, Gaumann A, Kunz-Schughart LA. Fibroblastic re‐
action and vascular maturation in human colon cancers. International journal of radi‐
ation biology 2009;85(11): 1013-1025.
[23] Hirose M, Fukui H, Igarashi Y, Fujimori Y, Katake Y, Sekikawa A, Ichikawa K, Tomi‐
ta S, Imura J, Ajioka Y, Ueno H, Hase K, Ohkura Y, Kashida H, Togashi K, Nishigami
T, Matsui T, Yao T, Wada R, Matsuda K, Watanabe T, Ochiai A, Sugai T, Sugihara K,
Fujimori T. Detection of desmoplastic reaction in biopsy specimens is useful for pre‐
dicting the depth of invasion of early colorectal cancer: a Japanese collaborative
study. Journal of gastroenterology 2010;45(12): 1212-1218.
Colonoscopy and Colorectal Cancer Screening - Future Directions176
Chapter 8
In vivo Optical Diagnosis of Polyp Histology: Can We
Omit Pathological Examination of Diminutive Polyps?
Marco Bustamante-Balén
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53205
1. Introduction
In the United States colorectal cancer (CRC) is the third more commonly diagnosed cancer in
both sexes and it is also the third leading cause of cancer death among men and women [1].
In Europe CRC is the second leading cause of cancer death in both sexes [2]. These figures
mean a heavy economic burden for any health system. The national cost of a year of CRC care
in the United States has been estimated to be between $4.5 and $9.6 billion [3]. In Spain €180.6
million of annual loses in work productivity because of CRC have been reported [4].
Adenomatous polyps are the precursors of CRC in most of the cases. Through a progressive
accumulation of mutations and following some of the described carcinogenetic pathways
[5], a benign adenomatous polyp develops into an advanced adenoma with high-grade dys‐
plasia (HGD) and then progresses to invasive cancer (Figure 1). Invasive cancers confined to
the wall of the colon (TNM stages I and II) are curable by surgery while more advanced can‐
cers are treated by a combination of surgery and chemotherapy.
Detecting cancer at an early stage or, even better, diagnosing and resecting adenomas before
a carcinoma has developed improves outcomes. This was first confirmed in the initial report
of the National Polyp Study [6] which showed a reduction in the incidence of colorectal can‐
cer of around 76% in patients in which a polypectomy had been performed. Recently, the
same group has described in the same cohort of patients a reduction in mortality of 53% in
the long term [7]. This is the rationale for population-based screening programs, designed to
detect advanced adenomas and CRC at an early and curable stage. For instance, recently the
results of a nationwide screening colonoscopy program in Germany have been reported of a
nationwide screening colonoscopy program in Germany, showing that 69.6% of diagnosed
CRC were stages I and II [8]. Therefore, screening for CRC with removal of adenomas and
surveillance colonoscopy of patients who have been treated for adenomas or CCR is recom‐
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mended by Professional Societies and authorities [9-11]. Surveillance intervals after resec‐
tion of one or more adenomas are planned based primarily in the number, size and presence
of advanced histological features [12]. Polyps larger than 10 mm, with villous component (>
25%) or with high-grade dysplasia are considered advanced adenomas and have a greater
tendency to malignancy [13]. Detection and resection of these advanced adenomas is the
main objective of the surveillance programs [14,15]. Therefore, submitting all resected pol‐
yps to pathologic evaluation is the standard of care.
Figure 1. Development of CRC from normal tissue to adenocarcinoma
However, most of the adenomas diagnosed in colonoscopies are 5 mm or less (diminutive
polyps). In symptomatic patients the proportion of adenomas larger than 10 mm is between
5 and 15% [16-18]. A report from our group using chromoendoscopy to improve the adeno‐
ma detection rate showed that 73% of adenomas were < 5 mm [19]. This is also the situation
in screening colonoscopy, with reported proportions of adenomas < 5 mm of around 80%
[20]. A significant proportion of diminutive polyps, between 23% and 40%, are not even ade‐
nomas [21-24]. Overall, the prevalence of advanced histology in diminutive polyps seems
low, although there is some heterogeneity in the literature due to different inclusion criteria
(screening versus symptomatic patients; patients only with polyps less than a specific size,
etc.), differences in the performed analysis (per-patient, per-polyp) and probably also due to
the variability in the pathologic interpretation of dysplasia and proportion of villous compo‐
nent (table 1).
A recent systematic review with stringent inclusion criteria (average-risk asymptomatic
population, clear definition of advanced adenoma, definition of the method adopted to as‐
sess polyp size, reported prevalence of advanced adenomas according to polyp size, and at
least 500 subjects included) showed that the prevalence of advanced lesions among patients
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whose largest polyp was diminutive (≤ 5 mm), small (6-9 mm) and large (≥ 10 mm) was
0.9%, 4.9% and 73.5% respectively [27]. The most recent study on this topic, a retrospective
review of data from three prospective clinical trials has shown that the prevalence of ad‐
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Table 1. Absolute prevalence of advanced adenomas according to the largest polyp size. AA: advanced adenoma;
HGD: high-grade dysplasia; NA: non-applicable
Moreover, it remains unclear the practical role of advanced histological features in assessing
the individual risk of CRC and in planning the management of patients with colonic polyps.
First, there is a substantial interobserver variability in the diagnosis of the villous compo‐
nent and even HGD, with kappa index ranging from 0.35 to 0.48 and 0.38 to 0.69 respective‐
ly [28,29]. This problem may be even greater in polyps less than 10 mm [30]. Second, it is not
clear that villous component or HGD are independent predictors of the subsequent develop‐
ment of advanced adenomas during follow-up. In the case of villous component the pub‐
lished studies do not separately identify patients whose most advanced polyp is a tubulo-
villous or villous adenoma < 10 mm in size, therefore the risk of this subgroup of polyps
cannot be accurately assessed [31]. High grade dysplasia has not been shown to be an inde‐
pendent risk factor for metachronous advanced neoplasm in the NCI Pooling Project after
adjustments for size and histology [32].
Taking all these data as a whole it appears clear that the standard practice of submitting all
diminutive polyps found in colonoscopy to pathological assessment may have little clinical
impact on the management of patients, and may result in substantial costs. Waiting for the
pathological report may induce a delay in informing the patient and in recommending the
next colonoscopy surveillance interval. In this context, some authors are recommending a
“resect and discard” strategy to be applied to diminutive polyps found anywhere in the col‐
orectum. Following this strategy the histology of a diminutive polyp would be assessed by
an appropriate endoscopic method, the assessment would be recorded by means of a high-
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resolution photograph and the polyp then would be resected and discarded. The endoscopic
assessment of histology would be used to make an immediate recommendation regarding
the next colonoscopy surveillance interval. Finally, when multiple diminutive rectosigmoid
hyperplastic polyps are suspected endoscopically, histology can be established by real-time
endoscopic assessment and documented by photography without the need of resection and
pathological evaluation [33].
2. Endoscopic assessment of polyp histology
The key factor in adopting the “resect and discard” strategy is the endoscopic evaluation of
polyp histology, since this information is necessary to plan the next surveillance interval.
Moreover, the presence of suspicious endoscopic features may prompt a polyp to be submit‐
ted to pathologic assessment. Therefore, a reliable endoscopic method of evaluating histolo‐
gy is needed.
In recent years several imaging-enhancing technologies have emerged as an adjuvant for di‐
agnosing and evaluating colorectal lesions [34]. High-resolution and magnification endo‐
scopes allow enlarging the image and discriminating details. These endoscopes are often
used in combination with chromoendoscopy, which involves the topical application of dyes
at the time of endoscopy to enhance tissue characterization. Narrow-band imaging (NBI) is a
technology that applies narrow-bandwidth filters to white light endoscopy allowing dis‐
crimination of mucosal vascular net. Fuji Intelligent Color Enhancement (FICE) and i-Scan
are based on the same physical principles as NBI but are not depending on optical filters but
on a postprocessing image system. All these technologies have been evaluated in the predic‐
tion of histology of colon polyps.
2.1. High-resolution/magnification endoscopy and chromoendoscopy
The usefulness of this technology in assessing histology is based on the pit-pattern classifica‐
tion proposed by Kudo which is intended to differentiate between non-neoplastic, neoplas‐
tic and malignant polyps. Following this classification patterns I and II correspond to non-
neoplastic lesions and patterns III to V to neoplastic ones. Type V suggests malignant
transformation [35].
Several large case series evaluate the utility of pit-pattern analysis to differentiate neoplastic
from non-neoplastic lesions. Generally speaking, positive predictive values (PPV) for neo‐
plastic lesion range between 70 to 100% and negative predictive values (NPV) between 70
and 99%. Studies with the largest number of lesions show an overall accuracy of 80-95%
[36-38]. One study focused in diminutive lesions, reported an overall accuracy of 95% [39].
There are also some randomized controlled trials comparing magnification plus chromoen‐
doscopy to conventional chromoendoscopy. Konishi et al. [40] showed an accuracy of mag‐
nification colonoscopy in distinguishing non-neoplastic from neoplastic lesions < 10 mm in
size of 92% vs 68% for conventional chromoendoscopy. Emura el al. [41] using a similar de‐
sign showing an overall accuracy of 95% vs 84%. These figures were similar whenthe sub‐
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group of lesions ≤ 5 mm was analyzed. Conventional colonoscopy, chromoendoscopy and
magnification chromoendoscopy were compared in the study by Fu et al. [42], and the latter
was found to have the highest accuracy (95.6%).
Magnification chromoendoscopy has also been evaluated in the prediction of malignant his‐
tology and invasive depth of cancer with variable results. Overall, it seems that its sensitivi‐
ty and accuracy are lower. For instance, Bianco et al. [43] showed that endoscopic
differentiation between invasive and noninvasive neoplasm had a PPV of 79% and a NPV of
95%. Hurlstone et al. reported an accuracy of 78% and a specificity of 50% [44]. Some au‐
thors use a modification of the Kudo classification with different subtypes of the type V pat‐
tern that may be quite cumbersome to use [45].
In conclusion, high-magnification chromoendoscopy allows the prediction of histology even
in small and diminutive lesions, but is better differentiating nonneoplastic from neoplastic
lesions than differentiating invasive from noninvasive neoplasms. Moreover, it must be kept
in mind that overall accuracy is not 100%, despite the fact that a technology with a NPV of
95% for adenomatous histology fulfils the PIVI criteria for leaving suspected rectosigmoid
hyperplastic polyps ≤ 5 mm in size in place [33].
2.2. Narrow-band imaging
2.2.1. Predicting histology by means of vascular features
Angiogenesis is a main step in the progression of neoplasms; therefore the diagnosis based
on vascular  morphological  changes seems ideal  for  early detection and diagnosis  of  co‐
lon neoplasms. NBI enhances the visibility of the capillary network on the surface layer of
the mucosa.
Normal mucosa displays a regular hexagonal or honeycomb-like pattern of capillary vessels
around the crypt of the gland. This capillary meshwork, named meshed capillary (MC), is
invisible or faintly visible (Figure 2a). In the neoplastic lesion, vessels grow thicker, with
increasing diameter size, disruption and rise of vessel density as the lesion progresses. There‐
fore, recognizing the lesion becomes easier because it appears as a brownish area (Figure 2b).
Figure 2. NBI image of normal mucosa (a) and a diminutive adenoma (b)
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resolution photograph and the polyp then would be resected and discarded. The endoscopic
assessment of histology would be used to make an immediate recommendation regarding
the next colonoscopy surveillance interval. Finally, when multiple diminutive rectosigmoid
hyperplastic polyps are suspected endoscopically, histology can be established by real-time
endoscopic assessment and documented by photography without the need of resection and
pathological evaluation [33].
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polyp histology, since this information is necessary to plan the next surveillance interval.
Moreover, the presence of suspicious endoscopic features may prompt a polyp to be submit‐
ted to pathologic assessment. Therefore, a reliable endoscopic method of evaluating histolo‐
gy is needed.
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scopes allow enlarging the image and discriminating details. These endoscopes are often
used in combination with chromoendoscopy, which involves the topical application of dyes
at the time of endoscopy to enhance tissue characterization. Narrow-band imaging (NBI) is a
technology that applies narrow-bandwidth filters to white light endoscopy allowing dis‐
crimination of mucosal vascular net. Fuji Intelligent Color Enhancement (FICE) and i-Scan
are based on the same physical principles as NBI but are not depending on optical filters but
on a postprocessing image system. All these technologies have been evaluated in the predic‐
tion of histology of colon polyps.
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The usefulness of this technology in assessing histology is based on the pit-pattern classifica‐
tion proposed by Kudo which is intended to differentiate between non-neoplastic, neoplas‐
tic and malignant polyps. Following this classification patterns I and II correspond to non-
neoplastic lesions and patterns III to V to neoplastic ones. Type V suggests malignant
transformation [35].
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plastic lesion range between 70 to 100% and negative predictive values (NPV) between 70
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There are also some randomized controlled trials comparing magnification plus chromoen‐
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nification colonoscopy in distinguishing non-neoplastic from neoplastic lesions < 10 mm in
size of 92% vs 68% for conventional chromoendoscopy. Emura el al. [41] using a similar de‐
sign showing an overall accuracy of 95% vs 84%. These figures were similar whenthe sub‐
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group of lesions ≤ 5 mm was analyzed. Conventional colonoscopy, chromoendoscopy and
magnification chromoendoscopy were compared in the study by Fu et al. [42], and the latter
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tern that may be quite cumbersome to use [45].
In conclusion, high-magnification chromoendoscopy allows the prediction of histology even
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lesions than differentiating invasive from noninvasive neoplasms. Moreover, it must be kept
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lon neoplasms. NBI enhances the visibility of the capillary network on the surface layer of
the mucosa.
Normal mucosa displays a regular hexagonal or honeycomb-like pattern of capillary vessels
around the crypt of the gland. This capillary meshwork, named meshed capillary (MC), is
invisible or faintly visible (Figure 2a). In the neoplastic lesion, vessels grow thicker, with
increasing diameter size, disruption and rise of vessel density as the lesion progresses. There‐
fore, recognizing the lesion becomes easier because it appears as a brownish area (Figure 2b).
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Several studies have evaluated the performance of NBI in characterizing colorectal lesions,
focusing in the characteristics of the vascular capillary network. Generally speaking, NBI
sensitivity and specificity for diagnosing neoplastic lesions ranges between 77% and 99%
and 59 – 100% respectively (table 2). This heterogeneity may be explained by the use of dif‐
ferent descriptions of vascular networks. Examples are, brown blob or dense vascular net‐
work to predict neoplasia [46-48]; fine capillary network, dark dots, light rounds, tubular or
gyrus like [49]; microvessel thickness (invisible, thin, thick) and microvessel irregularity (in‐
visible, regular, mildly irregular, severely irregular) [50]; vascular patter intensity (weaker,
the same or darker than the surrounding mucosa) [51]; fine vascular network or dilated
corkscrew type vessels and abnormal branching patterns [52]; and finally, capillary pattern
(CP type I: invisible or faintly visible, CP type II: capillaries elongated and thicker and CP
type III: capillaries of irregular sizes, thicker and branched) [53-55].Other causes of heteroge‐
neity are the use of magnification or high-resolution endoscopes since the results with the
latter are not as encouraging (see section 2.2.5) [46,49,56], and finally, better results are re‐
ported by experts.
2.2.2. Predicting histology by means of pit pattern evaluation
Most of the published studies, mainly from Japan, use optical magnification in combination
with NBI, and the performance of pit pattern analysis with NBI ha salso been assessed (table
3). Sensitivity for neoplastic lesion ranges between 86 and 100%, while specificity ranges be‐
tween 84 and 100%. Some studies have compared NBI with chromoendoscopy showing sim‐
ilar diagnostic accuracy, suggesting that NBI could replace chromoendoscopy in the
diagnostic evaluation of colon lesions [46, 47, 52]. However, the original pit pattern classifi‐
cation was not designed for NBI, and has not been validated for this purpose. NBI funda‐
mentals are different that those of chromoendoscopy. The latter uses dyes that lie inside the
pits or stain their edges depending on the stain used while NBI highlights the capillary
plexus that surrounds the opening of each pit. Machida et al. [57] described the use of NBI
with magnification for pit pattern classification, showing that NBI was superior to conven‐
tional colonoscopy for pit pattern delineation but inferior to chromoendoscopy. The correla‐
tion between pit pattern analysis using chromoendoscopy and NBI is far from perfect
especially for the pattern with the upmost clinical importance, type V. A study compared
the pit pattern analysis obtained by NBI with stereoscopic examination and showed that the
correlation was only 57% for type VN[58]. East et al. [51] found a kappa score of only 0.23
between both types of pit pattern evaluation. Better results were obtained by Hirata et al.
[48] (78% of agreement for pit pattern VI and 100% for VN).
Author Mag Patients/
Lesions






Su [47] Yes 78/110 96 87 93 92 92
Tischendorf [52] Yes 99/200 94 89 94 89 92
East [51] a Yes 30/33 77-91 50-60 - - 69-81
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Lesions






Chiu [46] a Yes/No 133/180 87-95 88-72 96-92 67-80 87-90
Sano [53] Yes 92/150 96 92 97 90 95
Hirata [50] Yes 163/189 99 90 99 90 98
Hirata [48] Yes 99/148 99 94 99 94 99
Rastogi [49] No 40/123 96 86 90 95 92
Kanao [55] Yes 223/289 95 100 100 20 99
Henry [54] No 42/126 93 88 909 91 91
Ignjatovic [56] Yes/No 48/80 93-74 59-56 - - 76-85
Table 2. Vascular pattern analysis with NBI for prediction of adenomatous histology. Mag: use of optical
magnification; PPV: positive predictive value; NPV: negative predictive value; DA: diagnostic accuracy. aTwo observers.
Values for each observer are shown.
Author Mag Patients/
Lesions






Machida [57] Yes 34/43 100 75 91 100 93
East [51] a Yes 20/33 86-77 80-60 - - 84-72
Tischendorf [52] Yes 99/200 90 89 93 84 90
Van den Broek [59] Yes 100/208 90 70 69 90 78
Table 3. Pit pattern analysis with NBI for prediction of adenomatous histology aTwo observers. Values for each
observer are shown. Mag: use of optical magnification; PPV: positive predictive value; NPV: negative predictive value;
AC: diagnostic accuracy.
A systematic review which included 6 reports published until 2008 comparing NBI (pit pat‐
tern and vascular assessment) and chromoendoscopy showed a pooled sensitivity, specifici‐
ty and overall accuracy of 92%, 86% and 89% respectively [60].
2.2.3. Predicting submucosal invasion
NBI has also been evaluated to diagnose early colorectal neoplasia and submucosal inva‐
sion. Katagiri et al. [61] used the capillary pattern classification in colon adenomas. Those
showing CP type III harbored HGD or invasive cancer. In a recent report this group further
developed this classification expanding CP type III in group IIIA (visible microvascular ar‐
chitecture and high microvessel density with lack of uniformity, branching and curtailed ir‐
regularity) and group IIIB (nearly avascular or loose microvascular area). This detailed
classification allowed differentiation between lesions with Sm1 submucosal invasion from
Sm2-Sm3 with a sensitivity, specificity and diagnostic accuracy of 84.8%, 88.7% and 87.7%
respectively [62]. Hirata et al.[50] found that the accuracy of diagnosis of submucosal mas‐
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sive invasion on the basis of thick and severely irregular vascular pattern was 100%. Kanao
et al. [55] used a combination of capillary pattern and pit pattern and showed that lesions
with irregular microvessels with variable sizes and distribution, and pit absence with avas‐
cular areas harbored more often massive submucosal invasion.
2.2.4. NBI compared with other diagnostic modalities
NBI has been compared with other image enhancing technologies, most frequently with
chromoendoscopy. Overall, the diagnostic accuracy of NBI is better than that of convention‐
al colonoscopy and equivalent to that of chromoendoscopy (figure 3) [46,47,52], especially if
vascular assessment rather than pit pattern is used [51].
Figure 3. Invasive carcinoma in a depressed lesion observed with white light (a), NBI (b), and chromoendoscopy (c)
Four recent studies perform an evaluation of endoscopic trimodal imaging (high-resolution
endoscopy, autofluorescence imaging and NBI) for colonic polyp characterization. Three
studies from the same group show a poor diagnostic accuracy for NBI without magnifica‐
tion and autofluorescence with similar sensitivity but worse specificity [59,63,64]. Ignjatovic
et al. [56] reported that NBI with magnification appeared to have the best accuracy, albeit
modest and not adequate for in vivo diagnosis.
2.2.5. NBI without optical magnification
Most of the studies on prediction of histology using NBI have been carried out in Japan us‐
ing Olympus equipments with optical magnification (Lucera), a feature not included in
high-resolution systems (Exera) available in the USA and in continental Europe. Most of the
capillary pattern descriptions or classifications have been designed using optical magnifica‐
tion, therefore are not directly applicable to high-resolution examinations. That is also the
case for the Kudo´s pit pattern classification.
The results of NBI without optical magnification in predicting histology are variable with
authors showing an accuracy similar to that of optical magnification NBI and authors ob‐
taining worse results [56]. Again, different definitions for a vascular pattern typical of ade‐
noma (table 4) may account for these discrepancies. None of these classifications have been
appropriately validated and its reproducibility in different clinical settings is unknown.
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Author Predictive of adenoma Predictive of hyperplastic
Rastogi [49, 65,
66]
Round/oval pattern (dark outer and a lighter
central area)
Tubulogyrus pattern
Fine capillary network alone but absent mucosal
pattern
Circular pattern with dots (central dark area
surrounded by a lighter area)
Rex [67] Overall brown color
Short thick blood vessels
Tubular or oval pits, variable size pits
Central brown depression
Straight blood vessels around pits forming
rectangles, pentagons, etc.
Bland, featureless appearance
Pattern of black dots surrounded by white
Thin blood vessels coursing across polyp surface, and
not surrounding pits
Rogart [68] Modified Kudo´s classification Vascular color intensity (light, medium, dark)
Sikka [69] Neoplastic pit pattern (elongation of crypts,
cerebriform pattern)
Increased vascular markins
Non-neoplastic pit pattern (circular pit pattern)
No vascular markins
Table 4. Prediction of histology using NBI without magnification
The group of the Indiana University has very recently designed a simple classification for
determination of polyp histology (NICE classification) and has validated it for its use by ex‐
perienced and non-experienced examinators (table 5) [70]. Further studies are needed to
evaluate the reproducibility of this classification in real-time endoscopy.
2.2.6. Prediction of histology of diminutive polyps
Some authors have evaluated de diagnostic accuracy of NBI on diminutive polyps showing
similar results to those on polyps of any size. In a study by Rex [67] the sensitivity of NBI in
diagnosing adenomas was 92%, specificity 87%, PPV was 88%, NPV 91% and accuracy 89%.
Grading the confidence on the endoscopic diagnosis in high and low, high confidence pre‐
dictions of adenomas were correct in 92% of polyps and in 91% of ≤ 5 mm polyps. The
equivalent figures for hyperplastic prediction were 95%. The same group evaluated the per‐
formance of NBI in real time for distal colorectal polyps, and showed a sensitivity of 96%, a
specificity of 99.4%, and NPV and PPV of 99.4% and 96% respectively [71]. The authors con‐
cluded that NBI is sufficiently accurate to allow distal hyperplastic polyps to be left in place
without resection and small, distal adenomas to be discarded without pathologic assess‐
ment. In the study of Henry et al. [54] the sensitivity for predicting histology was 87%, spe‐
cificity was 93%, PPV was 89%, NPV was 91% and overall accuracy was 90%. Paggy et al.
[72] found similar results both in the whole group of < 10 mm polyps and in diminutive pol‐
yps. Other authors have not showed as good results [56,73]. The most recent report using
the NICE classification found an accuracy of 89%, sensitivity of 98% and a NPV of 95%. In
conclusion, diagnostic accuracy of endoscopic prediction of histology of diminutive polyps
seems equivalent to that of larger polyps, at least in expert hands.
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high-resolution systems (Exera) available in the USA and in continental Europe. Most of the
capillary pattern descriptions or classifications have been designed using optical magnifica‐
tion, therefore are not directly applicable to high-resolution examinations. That is also the
case for the Kudo´s pit pattern classification.
The results of NBI without optical magnification in predicting histology are variable with
authors showing an accuracy similar to that of optical magnification NBI and authors ob‐
taining worse results [56]. Again, different definitions for a vascular pattern typical of ade‐
noma (table 4) may account for these discrepancies. None of these classifications have been
appropriately validated and its reproducibility in different clinical settings is unknown.
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NICE criterion Type 1 Type 2
Color Same or lighter than background Browner relative to background
Vessels None, or isolated lacy vessels coursing across
the lesion
Brown vessels surrounding white
structures
Surface pattern Dark or white spots of uniform size, or
homogeneous abscence of pattern
Oval, tubular, or branched white
structures surrounded by brown
vessels
Most likely pathology Hyperplastic Adenoma
Table 5. The NBI International colorectal endoscopic (NICE) classification
2.2.7. Learning NBI. Does expertise matters?
Most of the published studies have been performed by experts endoscopists, both in Japan
and in Western countries. Reliable information about reproducibility of this results is lack‐
ing. Moreover, the overall accuracy in prediction of histology es markedly influenced by
expertise in NBI interpretation, as has been shown in a study performed in a non academic
setting in which sensitivity for high-confidence prediction was 77% and specificity 78% [73].
Experts have been shown to perform better than non-experts and with a higher interobserv‐
er agreement [74]. Fortunately, NBI interpretation of histology can be easily learned. Several
studies have shown significant improvements in diagnostic accuracy and in interobserver
agreement after following a computer-based training module [75] or a short teaching ses‐
sion [76].
2.3. Fujinon intelligent color enhancement system (FICE) and i-Scan
FICE also narrowes the bandwidth of light components using a computed spectral estima‐
tion technology that aritmetically processes the reflected photons to reconstitute virtual im‐
ages for a choice of different wavelenghts [77]. Therefore, it no depends on optical filters to
modify the image. There are less studies using FICE or i-Scan than NBI but its accuracy
seems broadly similar.
In the study by Pohl et al. [77] FICE (with set 4 activated) was used to identify the pit pattern
and the vascular pattern intensity in a similar way to NBI. The sensitivity and specificity of
FICE for the prediction of adenoma was 93.2% and 61.2%, figures similar to those of chro‐
moendoscopy. Parra et al. [78] showed that FICE performance in predicting histology was
inferior to that of chromoendoscopy with magnification. Kim et al. [80] reported that FICE
with magnification was better than without magnification especially for diminutive polyps
[79]. Regarding i-Scan, a study compared this technology with NBI for histology prediction
of diminutive polyps and showed a similar performance with good agreement between the
two modalities (kappa index > 0.7).
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3. Conclusion
New image-enhancing technologies may allow in vivo histological assessment of colorectal
polyps, avoiding the need to pathological evaluation of all resected polyps. This would rep‐
resent substantial savings and a more direct planning of surveillance intervals [81]. Howev‐
er, there are several steps to achieve before the resect and discard strategy is widely
implemented. First a more simple, reproducible and validated way of characterize colon le‐
sions is needed, especially in community practice. Learning the technique is also crucial be‐
cause when learning curve is achieved NBI performs significantly better [68]. Moreover,
implementing PIVI guidelines [33] implies accepting a 10% rate of false negative when in
vivo assessing histology of rectal polyps. Endoscopists may feel more comfortable with a
much lower rate before leaving polyps behind. Finally, if in vivo histology is applied in dai‐
ly practice this represents a turning point in the management of colon polyps, which must
be supported by Professional Societies.
In vivo histology seems here to stay, but we are still at the beginning of the way. Improve‐
ment in equipments and development of new technologies will help the medical community
to take this step forward.
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Oval, tubular, or branched white
structures surrounded by brown
vessels
Most likely pathology Hyperplastic Adenoma
Table 5. The NBI International colorectal endoscopic (NICE) classification
2.2.7. Learning NBI. Does expertise matters?
Most of the published studies have been performed by experts endoscopists, both in Japan
and in Western countries. Reliable information about reproducibility of this results is lack‐
ing. Moreover, the overall accuracy in prediction of histology es markedly influenced by
expertise in NBI interpretation, as has been shown in a study performed in a non academic
setting in which sensitivity for high-confidence prediction was 77% and specificity 78% [73].
Experts have been shown to perform better than non-experts and with a higher interobserv‐
er agreement [74]. Fortunately, NBI interpretation of histology can be easily learned. Several
studies have shown significant improvements in diagnostic accuracy and in interobserver
agreement after following a computer-based training module [75] or a short teaching ses‐
sion [76].
2.3. Fujinon intelligent color enhancement system (FICE) and i-Scan
FICE also narrowes the bandwidth of light components using a computed spectral estima‐
tion technology that aritmetically processes the reflected photons to reconstitute virtual im‐
ages for a choice of different wavelenghts [77]. Therefore, it no depends on optical filters to
modify the image. There are less studies using FICE or i-Scan than NBI but its accuracy
seems broadly similar.
In the study by Pohl et al. [77] FICE (with set 4 activated) was used to identify the pit pattern
and the vascular pattern intensity in a similar way to NBI. The sensitivity and specificity of
FICE for the prediction of adenoma was 93.2% and 61.2%, figures similar to those of chro‐
moendoscopy. Parra et al. [78] showed that FICE performance in predicting histology was
inferior to that of chromoendoscopy with magnification. Kim et al. [80] reported that FICE
with magnification was better than without magnification especially for diminutive polyps
[79]. Regarding i-Scan, a study compared this technology with NBI for histology prediction
of diminutive polyps and showed a similar performance with good agreement between the
two modalities (kappa index > 0.7).
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3. Conclusion
New image-enhancing technologies may allow in vivo histological assessment of colorectal
polyps, avoiding the need to pathological evaluation of all resected polyps. This would rep‐
resent substantial savings and a more direct planning of surveillance intervals [81]. Howev‐
er, there are several steps to achieve before the resect and discard strategy is widely
implemented. First a more simple, reproducible and validated way of characterize colon le‐
sions is needed, especially in community practice. Learning the technique is also crucial be‐
cause when learning curve is achieved NBI performs significantly better [68]. Moreover,
implementing PIVI guidelines [33] implies accepting a 10% rate of false negative when in
vivo assessing histology of rectal polyps. Endoscopists may feel more comfortable with a
much lower rate before leaving polyps behind. Finally, if in vivo histology is applied in dai‐
ly practice this represents a turning point in the management of colon polyps, which must
be supported by Professional Societies.
In vivo histology seems here to stay, but we are still at the beginning of the way. Improve‐
ment in equipments and development of new technologies will help the medical community
to take this step forward.
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1. Introduction
“Complication, in medicine, is an unfavorable evolution of a disease, a health condition or a therapy.
The disease can become worse in its severity or show a higher number of signs, symptoms, or new
pathological changes, become widespread throughout the body or affect other organ systems. A new
disease may also appear as a complication to a previous existing disease. A medical treatment, such as
drugs or surgery may produce adverse effects and/or produce new health problem(s) by itself. There‐
fore, a complication may be iatrogenic, i.e., literally brought forth by the physician. Medical knowl‐
edge about a disease, procedure or treatment usually entails a list of the most common complications,
so that they can be foreseen, prevented or recognized more easily and speedily.
Depending on the degree of vulnerability, susceptibility, age, health status, immune system condition,
etc. complications may arise more easily. Complications affect adversely the prognosis of a disease.
Non-invasive and minimally invasive medical procedures usually favor fewer complications in com‐
parison to invasive ones.” [1]
A currently popular focus in the gastroenterology and endoscopic literature is the quality of
colonoscopy with regard to colorectal cancer screening [2]. This includes the collection of
evidence regarding the use of colonoscopy as a tool for screening programs, defining and
establishing quality indicators and minimum requirements that endoscopists involved in
colorectal cancer screening programs should meet, and providing evidence about proce‐
dures that may improve the quality of colonoscopy. Those who have decades of experience
performing colonoscopy will be quite familiar with the myriad of complications associated
with the procedure, either through their reading of the gastrointestinal endoscopy literature,
from personal experience or the experience of colleagues. That being said, three major cate‐
© 2013 Miskovitz; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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gories of complications associated with colonoscopy are widely recognized. They are seda‐
tion-related complications, hemorrhage associated with colonic polypectomy and
colonoscopy-related colonic perforation. Sedation-related complications are usually cardio‐
vascular and/or pulmonary and include oxygen desaturation, respiratory arrest, alterations
in heart rate (bradycardia and tachycardia), cardiac arrhythmias, myocardial infarction,
stroke, seizures (at times attributed to the method of preparation) and shock. Hemorrhage is
most often associated with snare electrocautery polypectomy but may also occur during the
performance of diagnostic colonoscopy with or without biopsies. Two general subcategories
of hemorrhage exist: hemorrhage immediately following the performance of polypectomy
or delayed hemorrhage occurring up to several weeks after the therapeutic procedure. Co‐
lonic perforation resulting from colonoscopy may occur due to mechanical forces exerted
against the colonic wall (colonoscope tip or shaft, biopsy forceps, dilatation of a stricture),
barotrauma as a result of intraluminal air or carbon dioxide insufflation, or as a result of a
therapeutic procedure such as polypectomy, foreign body extraction, or stent placement to
name a few. A thorough understanding of these complications, their incidence and treat‐
ment, is part of the training of all those learning to perform colonoscopy and forms the basis
for the physician obtaining informed consent (an explanation of the risks and benefits of the
procedure) from the patient. This chapter will systematically review our current under‐
standing of these complication categories and the methods of minimizing the likelihood of
developing these complications. The latest treatments of specific complications will be re‐
viewed with the intent of aiding the physician endoscopist’s understanding of the principles
of risk management as regards to performing colonoscopy.
“Primum non nocere” is the Latin phrase that means "First, do no harm". Non-maleficence,
which is derived from this maxim, is one of the principal precepts of medical ethics taught
to all medical students in medical school and is a fundamental principle for the provision of
medical services world-wide. Another way to state it is that "given an existing problem, it
may be better not to do something, or even to do nothing, than to risk causing more harm
than good." It reminds the physician and other health care providers that they must consid‐
er the possible harm that any intervention might do. It is invoked when debating the use of
an intervention that carries an obvious risk of harm but a less certain chance of benefit. This
ancient principle should be kept in mind when contemplating colonoscopy and the possible
complications of the procedure.
1.1. Informed consent for colonoscopy
The doctrine of informed consent (and its antithesis, informed refusal) for colonoscopy in‐
volves an assessment of the competence of the patient by the physician, disclosure of, in an
understandable way, the information necessary to allow the patient to make an informed
decision (risks and benefits considered) regarding the role of colonoscopy in his care, and
the documentation of these proceedings in the medical record [3]. It is an intrinsic part of the
doctor-patient relationship and an ethical obligation on the part of the physician in the clini‐
cal practice of medicine. In the United States, the doctrine of medical informed consent is
most famously traced back to a 1914 New York court decision centered about the observa‐
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tion that since most surgical operations involve some use of force, there must be consent on
the part of the patient. Because the nature of surgery is outside the experience of most pa‐
tients, the consent must be granted only after the patient is properly informed of the risks
and benefits. The most famous description of informed consent is a quote from New York
Justice Benjamin Cardozo who, in 1914, stated that:
"Every human being of adult years and sound mind has a right to determine what shall be done with
his own body; and a surgeon who performs an operation without his patient's consent commits an
assault for which he is liable in damages" [4]. 
This advice is still applicable in the 21st century! Most important in considering the compli‐
cations of colonoscopy is the need to meticulously document the obtaining of informed con‐
sent from the patient and the procedural technique, findings and outcome including any
complications [5].
2. Sedation-related complications of colonoscopy
Sedation-related complications of colonoscopy are usually cardiovascular, pulmonary and oc‐
casionally neurological. The risk of these events occurring is associated with advancing age,
higher American Society of Anesthesiologists Physical Status Classification System scores
(ASA score—with category 6 not being applicable), and the patient’s co-morbidities [6-8].
ASA Physical Status Classification System (I-VI)
ASA-I A normal healthy patient.
ASA-II A patient with mild systemic disease.
ASA-III A patient with severe systemic disease.
ASA-IV A patient with severe systemic disease that is a constant threat to life.
ASA-V A moribund patient who is not expected to survive without the operation.
ASA-VI A declared brain-dead patient whose organs are being removed for donor purposes.
ASA-E Emergency operation of any variety (used to modify one of the above classifications,
i.e., ASA III-E)
In general, patients’ inpatient status, trainee participation and the routine use of supplemen‐
tal oxygen (the latter by possibly masking hypercapnea and hypoventilation) are associated
with a higher risk of unplanned cardiopulmonary events [9]. The monitoring period for the
“event rate” should likely include the 30 days post procedure [10].
2.1. Hypoxemia
Hypoxemia, which is usually transient but often anxiety provoking for the colonoscopist, is
a common occurrence during sedation for colonoscopy and has lead to the often “routine”
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practice by colonoscopists and attending anesthesiologists and nurse anesthetists of provid‐
ing patients with supplemental oxygen [9] delivered by nasal cannula and on occasion by a
venturi air-entrapment mask (the latter providing a fixed and predictable oxygen concentra‐
tion despite a variable respiration pattern). Prolonged hypoxemia associated with colono‐
scopy is rare. The etiology of hypoxemia is often multifactorial but not to be overlooked is
the amount of air (or carbon dioxide) insufflated into the colon for adequate luminal disten‐
tion and in some cases the passing of this gas into the small bowel through an incompetent
ileocecal valve thereby affecting diaphragmatic function. This has lead most endoscopists to
periodically monitor the degree of abdominal distention (“softness”) by direct palpation of
the abdomen either routinely during the procedure or when there are drops in the moni‐
tored oxygen saturation.
2.2. Hypercapnea
Capnography monitor use is widespread in hospitals but these devices are less commonly
used in the gastrointestinal endoscopy suite and other ambulatory settings where propofol
is often used. In 2012 the American Society of Anesthesiologists (ASA) advised its member
to use such carbon dioxide monitoring devices that detect changes in the amount of carbon
dioxide the patient is exhaling during monitored anesthesia care for upper gastrointestinal
endoscopies [11]. The new policy states:
“Monitoring for exhaled carbon dioxide should be considered during endoscopic procedures in which
sedation is provided with propofol alone or in combination with opioids and/or benzodiazepines, and
especially during these procedures on the upper gastrointestinal tract. Careful attention to airway
management must be provided during endoscopic retrograde cholangiopancreatography (ERCP) pro‐
cedures performed in the prone position where ventilatory monitoring, airway maintenance and re‐
suscitation may be especially difficult.”
It has only been a matter of time since this recommendation has found application in the
monitoring of sedated patients undergoing colonoscopy. The new policy has met with
mixed reviews in the gastrointestinal endoscopy and anesthesiology communities but most
have agreed that there is little downside to such monitoring.
It is important to emphasize that at least one individual with training in advanced cardiac
life support (tracheal intubation, defibrillation, use of resuscitation medications, ACLS cer‐
tification) that is capable of establishing an airway and providing positive-pressure ventila‐
tion should be present during colonoscopy sedation. Ability for communication with “back
up” local paramedics or life support personnel should be confirmed.
2.3. Hypotension
The etiology of hypotension during colonoscopy is also multifactorial (pre-procedure anti‐
hypertensive medications, sedatives and analgesics used during the performance of the pro‐
cedure, arrhythmias, pre-procedure cardiac performance status, etc.) but the state of
hydration of the patient after (usually a polyethylene glycol containing) bowel preparation
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may reign supreme among the factors to consider. Intravenous replacement with crystalloid
solutions should be considered during such events and in anticipation of such events in ap‐
propriately screened patients.
2.4. Arrhythmia
Cardiac arrhythmias including bradycardia, less often tachycardia, atrial premature contrac‐
tions, paroxysms of atrial fibrillation, and ventricular premature contractions have been
documented during procedural sedation. Most resolve with the intravenous administration
of fluids or increased sedation. With regard to bradycardia there is asymptomatic bradycar‐
dia (heart rate less than 60 bpm) and symptomatic bradycardia defined as a heart rate less
than 60/min that elicits signs and symptoms. In symptomatic bradycardia the heart rate will
usually be less than 50/min. Symptomatic bradycardia exists when the following 3 criteria
are present: 1.) The heart rate is slow; 2.) The patient has symptoms; and 3.) The symptoms
are due to the slow heart rate. Atropine is the first drug of choice for symptomatic bradycar‐
dia [12]. The dose in the bradycardia ACLS algorithm is 0.5 mg IV push which may be re‐
peated up to a total dose of 3 mg. (Anesthesiologists often choose glycopyrrolate [Robinul®]
as an alternative to atropine.) Dopamine is a second line drug for symptomatic bradycardia
when atropine is not effective. The dosage is 2-10 micrograms/kg/min infusion. Epinephrine
can be used as an equal alternative to dopamine when atropine is not effective. The dosage
is 2-10 micrograms/min. Rare cases of ventricular tachycardia and cardiac arrest during ven‐
tricular fibrillation have been reported necessitating the need for continuous EKG monitor‐
ing, the availability of ACLS trained personnel, as well as obtaining a history of cardiac or
pulmonary disease prior to initiating the procedure.
2.5. Pulmonary embolism
Although the prevalence of coexistent pulmonary embolism at the time of colon cancer de‐
tection has been estimated to be as high as 2% (with the concurrent prevalence of deep ve‐
nous thrombosis being as high as 8%) there are no accepted statistics for the incidence of
pulmonary embolism complicating diagnostic or therapeutic colonoscopy [13].
2.6. TIA/stroke
The risk of stroke in patients with AF whose anticoagulation is adjusted for endoscopies is
low, but almost tenfold higher in patients with complex clinical situations [14]. Age, history
of stroke, hypertension, hyperlipidemia, and family history of vascular disease may increase
the risk of suffering a stroke during or immediately after undergoing a gastrointestinal en‐
doscopic procedure. Comprehensive guidelines for the management of anticoagulation and
antiplatelet therapy in patients undergoing gastrointestinal endoscopic procedures includ‐
ing colonoscopy have recently been published [15] and should serve as a reference and
guide when dealing with such patients.
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Recent myocardial infarction has traditionally precluded the performance of elective colono‐
scopy for at least several months but recently this issue has been closely addressed in the
literature [16]. Colonoscopy performed in patients who have experienced a recent myocar‐
dial infarction is associated with a higher rate of minor, transient, and primarily cardiovas‐
cular complications when compared with control patients but is relatively infrequently
associated with major complications. In certain circumstances, despite the higher risk, colo‐
noscopy may be beneficial in this setting, particularly given the higher frequency of ische‐
mic colitis in this patient population. The occurrence of cardiac ischemia (and concomitant
cardiac rhythm disturbances) in patients undergoing colonoscopy who have known cardiac
disease or cardiac risk factors has recently been quantified [17]. Holter EKG recordings and
measurement of cTnI troponin I levels showed a high incidence of new but silent ischemic
and arrhythmic EKG changes during colonoscopy and do a lesser extent those patients with
one or more risk factors for heart disease. Two patients with known heart disease died with‐
in 30 days of colonoscopy.
3. Colonic hemorrhage associated with polypectomy
Although hemorrhage can occur during diagnostic colonoscopy (particularly when “cold”
or “hot” forceps biopsy techniques are used) it most often complicates polypectomy occur‐
ring immediately or being delayed for several weeks after the procedure [18]. The overall
incidence of hemorrhage has been reported to be in the range of 1 to 6 per 1,000 colonoscop‐
ies [19,6] (this being a useful figure to quote when obtaining informed consent from the pa‐
tient) with the number of polyps [20], polyp size [19] recent anticoagulant use [22,23] and
even polyp histology(!) [6,24,25] being modifying factors! The effects of aspirin, nonsteroidal
anti-inflammatory drugs and clopidogrel both alone and in combination on this complica‐
tion of colonoscopy have also been addressed [26,27].
Patients requiring colonoscopy with or without biopsy and/or polypectomy are often taking
antithrombotic agents including anticoagulants such as warfarin, heparin, and low molecular
weight  heparin,  and antiplatelet  agents  such as  aspirin,  non-steroidal  anti-inflammatory
drugs, thienopyridines such as clopidrogel and ticlopidine, and glycoprotein IIb/IIIa receptor
inhibitors. The indications for the use of these medications include atrial fibrillation, acute cor‐
onary syndrome, deep venous thrombosis, hypercoagulable states and indwelling endopros‐
theses such as coronary artery stents. When hemorrhage does occur in patients taking these
agents it is most commonly from the gastrointestinal tract [28]. Risk stratification for these pa‐
tients can generally be relegated to two categories. Low risk procedures include diagnostic co‐
lonoscopy including mucosal biopsy [29,30] and high-risk procedures include colonoscopy
with polypectomy and the dilatation of either benign or malignant colonic strictures (guide‐
lines extrapolated in part from experience reported in the upper gastrointestinal endoscopy lit‐
erature)  [31-33].  A comprehensive review of  the types  of  antithrombotic  therapies,  their
implications for patients undergoing colonoscopy, and recommendations and a management
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algorithm for such patients using these agents has recently been published [34]. Newer antico‐
agulants, for which current guidelines regarding their being held for endoscopic procedures,
are lacking and these agents are reaching the market at an increasing rate. They include dana‐
paroid, a low molecular weight heparinoid consisting of a mixture of heparin sulfate, derma‐
tan sulfate, and chondroitin sulfate [35,36] which was recently removed from the US market
due to shortages; the direct thrombin inhibitors recombinant hirudin (lepirudin), argatroban,
desirudin and bivalirudin [37-39]; the recently available orally active direct thrombin inhibi‐
tor dabigatran etexlate [40]; and the factor Xa inhibitors idraparinux, rivaroxaban, and apixa‐
ban [41]. There is no doubt that as these agents are used they will affect practice standards with
regard to colonoscopy and polypectomy.
Acute postpolypectomy bleeding is often immediately localizable by or apparent on colono‐
scopy and amenable to endoscopic therapy using clips, ligatures, cautery or argon plasma
coagulation [42,43] or nonendoscopic techniques such as angiographic embolizaton or sur‐
gery [44]. Recent endoscopic clip application devices have undergone redesign and im‐
provements to optimize their clinical effectiveness [45]. The site of delayed postpolypectomy
colonic hemorrhage can be identified by colonoscopy, by red cell nuclear scintigraphy
and/or by selective angiography [46] and dealt with in a similar fashion.
A variety of procedural techniques have been proposed to minimize the risk of hemorrhage
complicating polypectomy. These include the avoidance of the use of the “hot biopsy” tech‐
nique [47], the use of clips or detachable snares [48,49] and possibly the use of epinephrine
injections to the base of the polyp prior to initiating the polypectomy [50,51]. Proper techni‐
que for the removal of pendunculated polyps includes planning for the application of pres‐
sure by regrasping the pedicle with the snare if immediate bleeding occurs, the injection of
epinephrine 1:10,000 to 1:20,000 dilution into the bleeding site, the application of cautery
(with thermal probes, bipolar cautery [BICAP], the argon plasma coagulator, or the tip of the
polypectomy snare), the use of hemoclips, and/or the use of loops and band ligators on the
pedicle. Similar techniques may be used in those with delayed bleeding who seem to be ac‐
tively bleeding. Up to 50 percent of patients with delayed hemorrhage may require blood
transfusion [23].
4. Colonic perforation associated with polypectomy
Perforation of the colon is the most dreaded complication of colonoscopy and polypectomy
and this risk, albeit small, should be cited in the process of obtaining informed consent form
the patient for the procedure.
Abdominal pain, abdominal distention, +/- abdominal tenderness, hiccoughs, loss of bowel
sounds indicative of ileus, and late developing peritoneal signs are the hallmarks of perfora‐
tion following colonoscopy. As physical examination, chest x-ray and abdominal flat and
upright x-ray alone or in combination may not be diagnostic of colonic perforation patients
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suspected of having this complication should undergo CT scanning of the abdomen and pel‐
vis [52]. The rate of perforation after colonoscopy ranges from 0.1-0.3% [19] and may be in‐
creased (along with the risk of hemorrhage) in those physicians who have a low procedure
volume [53]. It has been suggested that physicians who have a high perforation rate should
be evaluated for inappropriate colonoscopy practice technique [54].
Perforation risk for polypectomy may be minimized by proper technique. One should avoid
ensnaring colonic folds, particularly when the anatomy is obscured by large penduculated
or sessile lesions. By not properly lifting an ensnare polyp into the lumen of the colon before
applying current, there may be spread of thermal injury to the deeper layers of the bowel
wall increasing the risk of delayed perforation. Likewise, a pedunculated polyp should not
be resected close to the bowel wall. Care should be taken to leave some residual stalk. The
polypectomy snare should be tightly closed before applying coagulation in order to avoid
the tip of the snare behind the polyp from touching the bowel wall.
Endoscopic mucosal resection for the piecemeal removal of benign appearing sessile colonic
adenomas has become routine. Endoscopic submucosal dissection is a resection technique
applied to early gastrointestinal cancers. Complications rates are higher with endoscopic
submucosal dissection than with endoscopic mucosal resection with perforations occurring
in up to 10 percent of patients. Often these perforations can be managed by endoscopic clip‐
ping and conservative therapy, however surgery is still required in some cases and pro‐
longed hospital stays are common. [55-57].
All patients found to have evidence of colonic perforation following colonoscopy should be
seen in surgical consultation because perforation often requires surgical repair which in
some cases may be accomplished using a laparoscopic technique with avoidance of divert‐
ing colostomy formation [58,59]. It has been reported that nonsurgical management may be
appropriate for some individuals [60,61] but these patients should still undergo surgical
consultation and close monitoring for signs of deterioration. Successful endoscopic repair of
an iatrogenic colonic perforation occurring during diagnostic colonoscopy has been reported
[62] and the efficacy of a new Over-the Scope-Clip (OTSC-Ovesco Endoscopy AG, Tübingen,
Germany) device (a bear trap-like, large clip with a wingspan of 12 mms. that grasps much
more tissue than the small endoscopic clips used previously and can create a full-thickness
closure of perforations up to 3 cms. in diameter) in treating acute perforation of the gastroin‐
testinal tract has been reported [63].
5. Miscellaneous complications of colonoscopy with and without
polypectomy
5.1. Abdominal discomfort
Commonly reported but minor complications of colonoscopy include bloating and abdomi‐
nal discomfort and or pain [64-66]. The incidence of these complications may be reduced by
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avoiding “looping” of the colonoscope, avoiding excess traction applied to the bowel mes‐
entery, adequately removing insufflated gas, using carbon dioxide instead of insufflated air
[67] and by using a water insufflation technique instead of the insufflation of gas [68].
5.2. Postpolypectomy electrocoagulation syndrome
Postpolypectomy electrocagulation syndrome refers to a transmural burn and localized per‐
itonitis occurring up to a few days after the removal of a polyp without clinical or radio‐
graphic evidence of perforation of the viscus. Patients may present with localized abdominal
pain, fever, and leukocytosis. Inpatient [69] and outpatient [70] therapy have both proven to
be successful in treatment of this complication.
5.3. Infection
Transient bacteremia after colonoscopy with polypectomy is rare and signs and symptoms
of infection are even rarer [71,72]. Current guidelines exist generally advocating against an‐
tibiotic prophylaxis for those undergoing colonoscopy with or without polypectomy [73].
As these represent only guidelines it is best for the endoscopist to consult with the patient
and the referring physician before deciding to forego the use of antibiotic prophylaxis in
certain clinical situations (prosthetic heart valve, history of endocarditis, newly placed pros‐
thetic joint, etc.). Both diverticulitis [74] and appendicitis [75] the latter possibly due to bar‐
otrauma  have  been  reported  complicating  colonoscopy  done  with  and  without
polypectomy. These clinical possibilities must be kept in mind in patients with post-proce‐
dure abdominal pain.
5.4. Rare complications
Rare complications of colonoscopy with and without polypectomy have been reported and
include infections related to instrument cleanliness [76] incarceration of the colonoscope in
an inguinal hernia [77], splenic injury during colonoscopy [78], and intracolonic gas explo‐
sion during colonoscopic polypectomy [79,80]. CT colonography, the alternative to colono‐
scopy in many patients, however, is not without its own complications and adverse events
[81].
6. Conclusion
It is incumbent upon physicians performing colonoscopy to stay current in their field, keep
abreast of the medical literature and the ongoing technological advances associated with
endoscopic equipment and technique, and to be meticulous in their approach to detail in
caring for their patients, particularly when gastrointestinal endoscopic diagnostic and ther‐
apeutic procedures are involved.
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abreast of the medical literature and the ongoing technological advances associated with
endoscopic equipment and technique, and to be meticulous in their approach to detail in
caring for their patients, particularly when gastrointestinal endoscopic diagnostic and ther‐
apeutic procedures are involved.




♥Obtain informed consent from the patient prior to the colonoscopy procedure with emphasis on the risks of,
benefits of and alternatives to the proposed procedure
♥Be cognizant of your limitations as an endoscopist
♥Be certain that all necessary equipment to perform the colonoscopy procedure (diagnostic and therapeutic) is
available and in working order
SEDATION RELATED COMPLICATIONS
♥Perform and document a medical history and physical examination prior to the initiation of the procedure. Include
a review of the patient’s current medications, known allergies, past experiences with anesthesia, Mallampati score
and ASA Physical Status Classification
♥Ensure that the patient is properly monitored during the procedure including blood pressure, pulse, oximetry,
capnography monitoring if available, cardiac rhythm monitoring, and airway management. If working with an
anesthesiologist thoroughly discuss with your colleague the patient’s medical history and the goals of the
procedure. Maintain a dialogue with the anesthesiologist throughout the procedure
♥Ensure that tracheal intubation and cardiac defibrillation equipment as well as resuscitation medications are
available and have up to date certification in Advanced Cardiac Life Support
COLONIC HEMORRHAGE ASSOCIATED WITH POLYPECTOMY
♥Take a history of the patient’s anticoagulant use, antiplatelet agent use, and past history of bleeding diathesis if
any
♥Be thoroughly familiar with proper snare electrocautery polypectomy technique including the use of saline or
epinephrine injection into the base of the polyp before initiating electrocautery
♥Avoid the use of the “hot biopsy” technique for small (several millimeter) polyps
♥Have available for use if necessary clips, ligatures, epinephrine, a bipolar electrocautery device and/or an argon
plasma coagulation device or heater probe
♥Give specific written post-procedure instructions to the patient regarding the use of anticoagulants and
antiplatelet agents
COLONIC PERFORATION ASSOCIATED WITH POLYPECTOMY
♥Cite the risk of colonic perforation when obtaining informed consent
♥Avoid ensnaring colonic folds
♥Do not perform polypectomy when the anatomy is obscured by the size or shape of the lesion or the adequacy of
the preparation
♥Have training and familiarity with endoscopic clipping techniques
♥Have a predetermined “game plan” to expeditiously evaluate a patient suspected of having a perforation
MISCELLANEOUS COMPLICATIONS OF COLONOSCOPY WITH AND WITHOUT POLYPECTOMY
♥If available, use carbon dioxide for colonic insufflation
♥Monitor the degree of abdominal distension by palpation throughout the procedure
♥Examine the patient in the recovery area post procedure to ensure that there has been adequate evacuation of
colonic gas
♥Be cognizant of and practice infection control measures routinely
♥Keep abreast of the medical literature and ongoing technological advances associated with endoscopic
equipment and technique
Table 1. Recommendations to prevent specific colonoscopy complications
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1. Introduction
Colonoscopy is a common procedure in medical practice for a variety of gastrointestinal in‐
dications. It is widely used in the United Stated, especially since 2001, when Medicare ex‐
panded its coverage for screening for colorectal cancer to include colonoscopy. An estimated
14.2 million colonoscopies were performed in 2002 in the United States, with screening indi‐
cations representing half of cases [1]. Although generally considered a safe procedure, com‐
plications of colonoscopy as an invasive procedure should be noted. Complications vary
from minor symptoms such as minor abdominal discomfort to more serious complications
such as colonic perforation, cardiopulmonary arrest, or even death (Table). Although most
studies have focused on serious complications, the less serious complications are important
because they are more frequent than reported and may have an impact on willingness of pa‐
tients and their peers to undergo future colonoscopy. Colonoscopy complications are cate‐
gorized as immediate; occurring during the procedure or before discharge from endoscopy
unit, or delayed; occurring within 30 days of the procedure. We will present in this chapter
these potential complications in detail.
2. Complications of colonoscopy
2.1. Death
Death has been reported as a complication of colonoscopy in 30 days from the procedure. Its rate
varies between studies from 0 to 83.3 per 10,000 colonoscopies [2-15]. In 3 studies with a total of
16,747 patients of mean age 59 years, there was no single death within 30 days of colonoscopy
[6-8]. In a study in outpatient colonoscopy in the Medicare population by using Surveillance,
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Epidemiology and End Result (SEER) database, there were 53 deaths within 30 days of 53,220
patients (9.9 deaths per 10,000 colonoscopies) [2]. The main focus in that study was not the death
rate but the serious gastrointestinal and cardiopulmonary events which increased with ad‐
vance age, history of stroke, congestive heart failure (CHF), chronic obstructive pulmonary dis‐
ease (COPD), atrial fibrillation, diabetes mellitus (DM), and use of polypectomy.
Most deaths are not related directly to the procedure itself, rather to severe underlying comor‐
bidities such as CHF, severe underlying coronary artery disease, COPD, cirrhosis, stroke, and
pneumonia [3,4,11]. In a study of 9,223 patients from the UK, there were 10 deaths within 30
days of procedure (10.8 deaths per 10,000 colonoscopies); however, four cases were considered
to be due to severe comorbidities rather than the procedure itself [4]. The mean age of study pop‐
ulation was 58 years (range: 16-95 years) with 14.1% were 75 years or older. The reported causes
of death were pneumonia, CHF, myocardial infarction, stroke and cirrhosis [4]. In a study of
13,580 patients, one single death occurred during colonoscopy in patient with massive GI bleed‐
ing (0.7 deaths per 10,000 colonoscopies) [5]. One single death occurred in 26,162 colonoscopies
in another study done by Tran (0.38 deaths per 10,000 colonoscopies) which occurred in a pa‐
tient with underlying coronary artery disease and COPD who developed perforation and died
postoperatively from myocardiac ischemia [11].
Polypectomy has been shown to be an independent risk factor for death. In a study from
Germany with 82,416 colonoscopies, death rate was 0.1 per 10,000 colonoscopies, which was
7-fold higher if polypectomy was performed [9].
However, the mortality rate was as high as 83.3 deaths per 10,000 colonoscopies in an Aus‐
tralian study of 23,508 outpatients with 196 deaths within 30 days of the procedure, al‐
though only 3 deaths were attributed to the colonoscopy itself (1.2 deaths per 10,000
colonoscopies) [13]. In a 2010 review of complications of colonoscopy from large studies,
there were 128 deaths attributed to colonoscopy among 371,099 colonoscopies (3.4 deaths
per 10,000 colonoscopies) [14,15].
2.2. Cardiopulmonary complications
Cardiopulmonary complications may be related to the preparation, conscious sedation, or
the procedure itself. It might occur during or immediately after the procedure, including
respiratory depression, hypoxia, dyspnea, hypotension, hypertension, bradycardia, tachy‐
cardia, vasovagal reactions, cardiac arrhythmias, and chest pain. Most of these events occur
at endoscopy unit; however, they may occur days after the procedure. Fortunately, most of
these complications are self-limited and resolve with minor interventions. In a study of
21,375 patients by Ko,et al. there were 160 cases of respiratory depression (74.8 per 10,000
colonoscopies) [3]. Also in this study, there were 105 cases of immediate cardiovascular
complications (49.1 per 10,000 colonoscopies), with the vast majority being hypotension (65
cases; 30.4 per 10,000 colonoscopies) and bradycardia (32 cases; 14.9 per 10,000 colonoscop‐
ies). Vasovagal reaction occurred in 14 cases (6.5 per 10,000 colonoscopies), tachycardia in 2
cases (0.9 per 10,000 colonoscopies), and hypertension in one case (0.4 per 10,000 colonos‐
copies). One hundred and thirty four cases required supplemental oxygen (62.6 per 10,000
colonoscopies), 48 cases intravenous fluids (22.4 per 10,000 colonoscopies), 29 cases nalox‐
Colonoscopy and Colorectal Cancer Screening - Future Directions216
one (13.5 per 10,000 colonoscopies), 20 cases atropine (9.3 per 10,000 colonoscopies), and 16
cases required flumazenil (7.4 per 10,000 colonoscopies).
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Minor GI symptoms 133.1-4100
Cerebrovascular events 0.8-6.5
Table 1. Rate of complications of colonoscopy
In a retrospective study of 174,255 colonoscopies in the Clinical Outcomes Research Initia‐
tive (CORI) database, there were 1995 unplanned cardiopulmonary events (114.4 per 10,000
colonoscopies) which were significantly higher than in EGD [16]. Hypotension occurred in
867 cases (48 per 10,000 colonoscopies), bradycardia in 507 cases (28 per 10,000 colonoscop‐
ies), vasovagal reaction in 341 cases (19 per 10,000 colonoscopies), transient hypoxia in 410
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prolonged hypoxia in 14 cases ( 0.7 per 10,000 colonoscopies), hypertension in 38 cases(2.1
per 10,000 colonoscopies), arrhythmia in 34 cases (1.9 per 10,000 colonoscopies ), chest pain
in 14 cases (0.7 per 10,000 colonoscopies), respiratory distress in 13 cases(0.7 per 10,000 colo‐
noscopies), tachycardia in 13 cases (0.7 per 10,000 colonoscopies), pulmonary edema in 4
case (0.2 per 10,000 colonoscopies), wheezing in 3 cases (0.1 per 10,000 colonoscopies), and
tracheal compression in one case (0.05 per 10,000 colonoscopies) [16]. The risk factors were
advanced age, high American Society of Anesthesiologists (ASA) class, inpatient status, trainee
participation, and non-university and veterans hospitals [16].
Higher doses of meperidine required for colonoscopy were associated with higher cardio‐
pulmonary events, whereas there was an inverse association with doses of fentanyl and
midazolam in the study by Sharma [16]. The association between lower dose of benzodiaze‐
pines use in endoscopy and cardiopulmonary events was suggested first in a small earlier
study [17]. Droperidol has been used effectively for conscious sedation in difficult endos‐
copy, but has notable potential complications including QT prolongation and torsade de
pointes. In one study, the use of droperidol for conscious sedation was not associated with
increased cardiopulmonary events [16].
In a study of 53,220 outpatient colonoscopies in the Medicare population using the SEER data‐
base and diagnosis coding system, there were total of 1030 cardiovascular events (193.5 per
10,000 colonoscopies) with arrhythmias compromised more than half events which were statis‐
tically significant than matched group [2]. There were 241 cases of acute coronary syndrome
and 115 cases of cardiopulmonary arrest in 30 days which was not statistically significant from
matched group. Advanced age, polypectomy during procedure, CHF, atrial fibrillation, DM,
COPD, and stroke were the independent risk factors for adverse cardiovascular events [2]. It has
been shown that life expectancy decreases significantly for patients with 3 or more chronic con‐
ditions at the time of colon cancer diagnosis, illustrating importance of considering chronic co‐
morbidities in elderly patients when evaluating for screening colonoscopy [18].
In a study of 82,416 colonoscopies from Germany, there were 12 cases of cardiopulmonary com‐
plications during the procedure (1.4 per 10,000 colonoscopies); oxygen desaturation in 7 cases
(0.8 per 10,000 colonoscopies) which were treated by oxygen supplement or flumazenil, brady‐
cardia in 3 cases (0.3 per 10,000 colonoscopies) which were treated by atropine, and hypotension
in 2 cases (0.2 per 10,000 colonoscopies) which were treated by intravenous fluids [9]. Most of
these complications occurred in patients received the combination of benzodiazepines with
opioids, whereas no cardiopulmonary event was recorded when use propofol [9].
Appropriate evaluation for anesthesia risk, identifying high-risk patients, consulting other
specialties based on their comorbidities, and appropriate monitoring before, during and af‐
ter the procedure may reduce the rate of cardiopulmonary complications.
2.3. Perforation
Colonic perforation may occur due to therapeutic endoscopic interventions, barotrauma due
to air insufflation during colonoscopy, mechanical forces against colon wall, or during ma‐
neuvering of the scope. Persistent abdominal pain after colonoscopy and abdominal disten‐
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sion may present initially, however a late presentation with abdominal abscess is possible.
Although plain X-Rays may reveal sub-diaphragmatic free air, CT scan is more sensitive to
detect any free air in the abdomen and pelvis which should be considered in cases with high
suspicion of perforation. The rate of perforation varies between studies from 0.4-19 cases per
10,000 colonoscopies.
There were 4 cases of perforation in a study of 82,416 colonoscopies without poypectomy
(0.4 per 10,000 colonoscopies), but it was 14 times higher if polypectomy was performed
during the procedure (6.3 per 10,000 colonoscopies) [9]. Although the majority of polypecto‐
my was done in the left colon, half of the perforations after polypectomy occurred in the
right colon [9].
In another study of 21,375 patients, there were 4 cases of perforation (1.8 per 10,000 colonos‐
copies); all of them female, two occurred without biopsy or polypectomy [3]. The risk of se‐
rious complications including perforation, GI bleeding, post-polypectomy syndrome and
diverticulitis (all combined) increased with pre-procedure warfarin use and performance of
polypectomy with cautery [3].
In a population-based cohort study of 67,632 colonoscopies performed in persons between
50-75 years of age, there were 37 cases of perforation (5.4 per 10,000 colonoscopies); 57%
were detected on the day of procedure, 92% within 2 days, and all within 5 days [19]. In 62%
of these cases snare polypectomy was performed. The median length of stay was 6 days
(0-18), comparing to 2 days (0-15) when GI bleeding occurred as a complication of colono‐
scopy. Although 68% of them underwent surgery; one of them died after hemicolectomy,
32% were treated conservatively without mortality [19].
In a study of 53,220 Medicare beneficiaries (age 66-95 years) who had outpatient colonosco‐
py, there were 33 cases of perforation (6.2 per 10,000 colonoscopies) with 21 cases of them
(63.6%) underwent polypectomy [2]. The independent risk factors for serious gastrointesti‐
nal complications including perforation and GI bleeding were advanced age, DM, CHF,
COPD, atrial fibrillation, stroke, and performing polypectomy [2].
A study from the UK with 9,223 pediatric and adult patients, there were 12 cases of per‐
foration (13 per 10,000 colonoscopies);  half  of  them diagnosed at  the time of  colonosco‐
py,  another two before discharge from the unit,  and the rest  presented 1,  7,  16,  and 24
days  after  the  procedure  [4].  Four  of  the  perforations  followed biopsy  or  polypectomy
from 1841  patients  underwent  any  kind of  therapeutic  or  diagnostic  interventions  (21.7
per 10,000 colonoscopies).
There were 15 cases of perforation in a study of 16,318 patients (9.1 per 10,000 colonoscop‐
ies); 12 cases either had biopsy or polypectomy (80%) [12]. The rate of serious complications
(including perforation, bleeding, diverticulitis, postpolypectomy syndrome; all combined)
after removal of polyps larger than 10 mm was significantly higher than in those with re‐
moval of smaller polyps. All perforations were detected in 7 days of the procedure. The risk
factors were increasing age, female gender, and polypectomy.
In a large retrospective cohort study of 277,434 patients, 228 cases of perforation occurred
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struction as an indication for the colonoscopy, significant comorbidities, and performance of
invasive interventions during the procedure.
In an Australian study of 23,508 patients over 10 years, there were 23 perforations (9.7 per
10,000 colonoscopies), 78% occurred with a mucosal intervention (hot snare polypectomy)
[13]. The rectosigmoid was the most common site of perforation, followed by the cecum.
Surgical intervention was performed in 83%, and one death occurred. Median time to diag‐
nosis was 1 day (0-5 days) with length of hospitalization stay 8 days (3-26 days).
The sigmoid colon is probably susceptible to perforation due to the mechanical forces on the
sigmoid during colonoscopy, the common occurrence of diverticular disease in sigmoid, and
frequency of colonic polyps in this area. The relatively thin-walled right colon is more pre‐
disposed to barotrauma and thermal injury during polypectomy.
Twenty cases of perforation occurred in a study of 10,486 patients (19 per 10,000 colonos‐
copies);  65% in sigmoid colon and 25% in cecum [10].  Comparing to  flexible  sigmoido‐
scopy, there were only two cases of perforation in 49,501 sigmoidoscopies (0.4 per 10,000
sigmoidoscopies).  Although most  of  perforations (91%) detected in 2 days of  colonosco‐
py,  9% presented after  2  weeks with abdominal  abscess.  All  patients  except  an 87 year
old who died underwent surgery with 37% required only simple closure without any re‐
section. The average length of stay was 7.7 ± 2.8 days. Female gender was an independ‐
ent risk factor for perforation.  Transmural electrocautery burns (36%),  mechanical  injury
(32%) from the tip and shaft of scope, and barotrauma (5%) were the main mechanisms
of perforation [10]. Defects caused by diagnostic intervention tend to be larger than those
caused by electrocautery injury.
Perforations occurring more often in female which may be due to frequency of pelvic sur‐
gery in females, diverticular disease, or the higher likelihood of looping because of longer
colonic lengths [3,10,21].
In a large study of 116,000 patients underwent colonoscopy at ambulatory centers, 37 cases
of perforation occurred (3.1 per 10,000 colonoscopies); most of them female (73%), 49% had
diverticular disease, 54% had history of pelvic or colon surgery [21]. Sigmoid colon was the
most common site of perforation (62%) then ascending colon (16%). The time to diagnosis
ranged from immediate (29 patients) to 3 days (8 patients). Surgery was performed in 95%,
and conservative treatment in the rest. No mortality occurred.
Although surgery consultation should be obtained in any case of perforation, conservative
treatment with bowel rest, hydration, and intravenous antibiotics has been increasingly
used in selected cases [5,19,21]. There are also case reports revealing successful closure with
endoscopic clips to repair perforations [22].
In a study of 97,091 outpatient colonoscopies, the rate of perforation was 8.5 per 10,000 colo‐
noscopies. The risk factors for colonoscopy-related perforation were older age, increased co‐
morbidity score, polypectomy, and low-volume endoscopists (when perforation combined
with bleeding) [23]. However, this finding was different from a study by Wexner which
showed neither an absolute number of prior colonoscopies, nor any ongoing annual experi‐
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ence affected the serious complication rates [5]. Also Ko and colleagues did not find any re‐
lation between complication rate and annual colonoscopy volume, trainee participation, or
practice setting [3].
Preventative measures to avoid perforation have been suggested, including decreasing the
risk of barotrauma by minimal air insufflation, minimizing loop formation, encouraging the
use of cold techniques in the removal of small polyps, and injection of saline into the submu‐
cosa for removal of flat or sessile polyps [14,15].
2.4. Bleeding
Colonic bleeding is the most common serious complication following colonoscopy. Al‐
though it may occur after diagnostic procedure, it mostly follows therapeutic colonoscopy
from either biopsy or polypectomy, and can be immediate or delayed up to several weeks
after colonoscopy.
In a population-based study of 97,091 patients aged 50-75 years, bleeding rate within 30
days was 16.4 per 10,000 outpatient colonoscopies. The independent risk factors for colo‐
noscopy-related  bleeding  were  older  age,  male  gender,  polypectomy,  and  low-volume
endoscopists [23].
In another population-based, matched cohort study of 53,220 Medicare patients of age 66-95
years, there were 340 cases of GI bleeding (63.8 per 10,000 outpatient colonoscopies) which
was significantly higher than matched group [2]. The risk of bleeding was 4 times higher
when polypectomy was performed (21 bleeding episodes per 10,000 colonoscopies without
polypectomy compared to 87 per 10,000 colonoscopies with polypectomy). Older age, histo‐
ry of COPD, CHF, atrial fibrillation, and stroke were other independent risk factors for seri‐
ous GI events (bleeding and perforation) [2].
In a study of 23,508 patients, 49 cases of GI bleeding occurred (20.8 cases per 10,000 colonos‐
copies); all cases associated with biopsy or polypectomy, median time to presentation with
bleeding was 6 days (0-14 days), and length of stay was 2 days (1-18 days) [13]. No death
was contributed to bleeding, none required surgery, colonoscopic interventions was per‐
formed in 4 cases (8%), and blood transfusion in 7 cases (14%) [13].
Use of aspirin or any other non-steroidal anti-inflammatory drugs (NSAIDs) alone does not
increase risk of postpolypectomy bleeding. Thus, the American Society for Gastrointestinal
Endoscopy (ASGE) recommends continuing aspirin and NSAIDs if one of them is used
alone and if its use is necessary [24-27]. However, there is some evidence that combination
of aspirin with one or more NSAIDs may increase the risk of bleeding after polypectomy;
therefore discontinuation of NSIADs 2-3 days before polypectomy is recommended in pa‐
tients receiving aspirin [24-27]. Also, use of clopidogrel alone does not increase risk of post‐
polypectomy bleeding; however, concomitant use of aspirin or any other NSAIDs increases
the risk of bleeding [3,24,25,28].
Pre-procedure warfarin use increases risk of bleeding after colonoscopy, thus discontinua‐
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rin or its equivalents is important in high risk patients for thrombosis such as a mechanical
cardiac valve [3,14,24,25,29].
A prospective cohort study of 21,375 patients of age over 40 years using CORI database,
there were 34 cases of GI bleeding requiring hospitalization within 30 days following colo‐
noscopy (15.9 per 10,000 colonoscopies), and half of them required blood transfusion [3].
Pre-procedure warfarin use and snare polypectomy with cautery had an increased risk of
serious complications. Risk increased even further if more than one polypectomy with cau‐
tery was done.
Size of resected polyps, number of polyps removed, and histology type of polyps have been
reported as increased risk factors for postpolypectomy bleeding [3,28-30].
Management of bleeding detected during colonoscopy can be performed with endoscopic
approach; however, delayed bleeding is managed conservatively with bowel rest, intrave‐
nous hydration and blood transfusion if required. Repeat colonoscopy is often required for
hemostasis. Angiographic embolization and surgery are preserved for selected cases with
massive, severe, persistent bleeding [3,15,31]. However, many cases of bleeding are minimal
and self-limited.
Twenty one cases of bleeding occurred within 30 days in a study of 24,509 patients aged 16
years or older who underwent lower GI endoscopy including colonoscopy and sigmoido‐
scopy (8.5 per 10,000 colonoscopies) [31]. Seven of them required blood transfusion, 15 re‐
quired repeat endoscopy and 2 required laparotomy. The average time to present was 6
days (0-16 days).
Some measures suggested to decrease the bleeding rate after polypectomy including use of
cold snare instead of hot biopsy forceps, prophylactic use of mechanical methods such as
clips and detachable snare loops, and injection of epinephrine into submucosa of large ses‐
sile polyps [14,15,32].
2.5. Postpolypectomy electrocoagulation syndrome
Postpolypectomy  syndrome  results  from  electrocoagulation  injury  to  the  bowel  wall
when electrocautery  is  used which causes  transmural  burn and focal  peritoneal  inflam‐
mation without radiologic evidence of frank colonic perforation. It is characterized by se‐
vere localized abdominal pain, fever, localized peritonitis signs, and leukocytosis without
any radiologic evidence of perforation. Patients usually present within 1-5 days after co‐
lonoscopy performed with electrocautery polypectomy. The rate of this syndrome varies
from 0.3 to 9.3 cases per 10,000 colonoscopies, depending on differences in defining this
syndrome [12,14,15,31].
In  a  study  of  16,318  patients  aged  40  years  or  older,  6  cases  of  postpolypectomy  syn‐
drome  occurred  in  11,083  colonoscopies  with  biopsy  performed  (5.4  cases  per  10,000
colonoscopies)  [12].
The recognition of postpolypectomy syndrome is of importance because it does not require
surgical treatment as frank perforation. The diagnosis can be made by CT scan in the appro‐
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priate clinical scenario which shows focal thickening of the colonic wall at a polypectomy
site with peri-colonic fat stranding [33]. The treatment is conservative, including bowel rest,
intravenous hydration and antibiotics [15,33]. Outpatient management with oral antibiotics
also has been reported [12].
Postpolypectomy syndrome occurs more often with resection of large sessile polyps when
prolonged, high thermal energy is applied. Therefore saline injection into the sub mucosa of
large sessile polyps before polypectomy may decrease the rate of this complication [33].
2.6. Gas explosion
Gas explosion during colonoscopy is rare but has potential life-threatening consequences
including death.  It  triggers  when three  elements  are  available  in  the  colon lumen:  high
level  of  combustible gases such as hydrogen and methane produced by fermentation of
non-absorbable carbohydrates by colonic flora,  high level of  oxygen, and electrical  ener‐
gy  that  produces  heat  such  as  electrocautery  and  argon  plasma  coagulation  [15,34,35].
High levels  of  hydrogen and methane are  produced in  the  colonic  lumen by fermenta‐
tion of non-absorbable carbohydrates (lactulose,  mannitol)  or incompletely absorbed car‐
bohydrates (lactose, fructose, sorbitol) by the colonic bacteria, or the presence of stool in
the colonic lumen due to poor cleansing preparation or using enema for sigmoidoscopy
[15,34-38].  In  a  review in  2007  searching  from 1952-2006,  there  were  only  ten  cases  re‐
ported  in  the  literature  including  one  case  from  the  reviewer  [15,34].  Most  of  cases
caused  colonic  perforation  with  one  death.  Bowel  preparation  using  manitol  which  is
rarely used in current practice for colonic cleansing, using cleansing solutions containing
sorbitol, or using enemas containing no fermentable agents were participating factors for
gas  explosions  [34].  Newer  bowel  preparation  solutions  such  as  polyethylene  glycol
(PEG) and sodium phosphate are safer for electrocautery and argon plasma coagulation
by not producing inflammable levels of hydrogen and methane. Using argon plasma co‐
agulation  during  sigmoidoscopy  following  enemas  carries  risk  for  gas  explosion  which
should only be performed after complete colonic preparation with new solutions not con‐
taining manitol or sorbitol. It has been suggested using frequent air insufflation and suc‐
tion before performing these procedures,  using carbon dioxide during colonoscopy,  and
using oral antibiotics to decrease combustible levels of hydrogen and methane in colonic
lumen when using manitol or sorbitol [15,35-37].
2.7. Acute diverticulitis
Acute diverticulitis is another potential complication of colonoscopy. It  is caused by mi‐
croscopic perforation of the colon which may develops following colonoscopy in persons
with pre-existing  diverticulosis  due to  barotrauma or  mechanical  forces  from the  endo‐
scope. Acute diverticulitis following colonoscopy has been poorly investigated and infre‐
quently  mentioned in  studies  reporting other  complications  of  colonoscopy.  The rate  of
diverticulitis  as  a  complication  of  colonoscopy  has  been  reported  from 0.8  to  8.4  cases
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priate clinical scenario which shows focal thickening of the colonic wall at a polypectomy
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In a study of 16,318 patients aged 40 years or older,  there were 6 cases of  diverticulitis
within 30 days of colonoscopy (3.6 cases per 10,000 colonoscopies); 2 cases required sur‐
gery and the rest were treated conservatively, 5 of them developed in colonoscopy with
biopsy performed [12].
In another study of 21,375 patients aged 40 or older, there were 18 cases of diverticulitis within
30 days of colonoscopy (8.4 per 10,000 colonoscopies) with majority did not require hospitaliza‐
tion [3]. The risk factors for serious GI complications (perforation, bleeding, postpolypectomy
syndrome, and diverticulitis) were prior warfarin use, and polypectomy with cautery; howev‐
er, these risks were not individualized to each complication but all combined [3].
In third study of 24,509 outpatients who underwent colonoscopy or sigmoidoscopy, there 2 cas‐
es of acute diverticulitis within 30 days of colonoscopy (0.8 per 10,000 colonoscopies) [31].
2.8. Infection
Transient bacteremia can occur during and after colonoscopy due to bacterial translocation
of normal colonic flora to blood stream. Then these bacteria may potentially adhere to dis‐
tant tissue such as endocardium and artificial devices, however clinical infections are rare.
Transient bacteremia associated with colonoscopy occurs in average of 4.4% ranging from
0-25% [24,39,40]. However, harmless transient bacteremia occurs in some daily activities
such as tooth brushing in 23-68% [24,39,41]. These isolated bacteria during colonoscopy are
generally believed to have little potential to cause endocarditis. The most common isolated
organisms are normal skin flora which could contamination during blood draw [24,42,43].
Despite more than 14 million colonoscopies are performed each year in the United States,
there have been only 15 reported cases of infectious endocarditis with temporal relation
with colonoscopy; thus, potential side effects of prophylactic antibiotic outweigh their possi‐
ble benefit of preventing endocarditis [24,39,44]. Due to the lack of convincing evidence of
risk of endocarditis, both the American Heart Association (AHA) and ASGE have revised
their recommendations against prophylactic antibiotics before colonoscopy [39,44].
In cirrhotic patients with or without ascites in the absence of acute GI bleeding who undergo
colonoscopy, the risk of bacteremia is low. In a study of 58 cirrhotic patients who underwent
colonoscopy, there were 4 cases of positive blood culture (6.9%) without in development of
infections [42].
Patients on peritoneal dialysis may be at risk for infectious complications after colonoscopy.
There are several reported cases of peritonitis in patients on peritoneal dialysis after colono‐
scopy especially postpolypectomy [45,46]. The International Society for Peritoneal Dialysis
(ISPD) in 2005 recommended prophylactic antibiotics and emptying the peritoneal fluid be‐
fore colonoscopy; however 2010 ISPD recommendations did not address these prevention
strategies [47,48].
Infections in prosthetic joints has been reported after colonoscopy, however the risk is too
low which led ASGE to recommend against using prophylactic antibiotics for patients who
have prosthetic orthopedic devices undergoing colonoscopy [39,49,50].
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Acute appendicitis following colonoscopy has been described in the literature. In a review in
2008, there were only 12 cases reported in literature from 1985 to 2007 [51]. Pre-existing sub‐
clinical disease of the appendix, barotrauma, impaction of stool into the appendix, direct in‐
tubation of appendiceal lumen, and focal edema in appendiceal orifice from trauma leading
to obstruction are proposed mechanisms of acute appendicitis after colonoscopy [51].
Pneumonia within 30 days of colonoscopy has been reported. In a study of 21,375 patients,
there were 2 cases of pneumonia within 30 days of colonoscopy (0.9 cases per 10.000 colo‐
noscopies) [3]. Another study of 24,509 patients, 1 case of pneumonia developed in 30 days
of colonoscopy (0.4 per 10,000 colonoscopies) [31]. The mechanism is mostly aspiration sec‐
ondary to sedation and anesthesia more than related to the procedure itself.
Local infections in perineum including perianal abscess and Fournier’s gangrene have been
described following colonoscopy. In a study of 3,196 patients, there was one case of Fourni‐
er’s gangrene occurring 2 days after colonoscopy (3.1 cases per 10,000 colonoscopies) [6]. In
another study of 21,375 patients, 2 cases of perirectal abscess occurred during 30 days of co‐
lonoscopy (0.9 per 10,000 colonoscopies) [3]. The mechanism is local mechanical trauma to
the perineum area during the procedure.
2.9. Abdominal pain and other minor GI symptoms
Although abdominal pain can be the symptom of above mentioned serious complications,
less severe abdominal discomfort is more common following colonoscopy. The mechanism
is multifactorial including mechanical trauma, barotrauma, gaseous distension secondary to
air insufflation. It is usually self-limited and rarely required hospitalization; however it is of
importance because it may affect the adherence for any future surveillance colonoscopy. In a
study by Ko et al. there were 5 cases of abdominal pain requiring hospitalization (2.3 cases
per 10,000 colonoscopies) [3]. In a study of 53,220 patients, abdominal pain occurred in 176
patients (33 cases per 10,000 colonoscopies), paralytic ileus in 172 patients (32.3 cases per
10,000 colonoscopies), and nausea and vomiting in 361 patients (67.8 cases per 10,000 colo‐
noscopies) which all were significantly higher compared to the matched group [2]. The risk
of these symptoms was higher if polypectomy was performed.
Minor adverse events that defined as any health problem that patient experienced in 30 days
of colonoscopy not requiring a hospital visit were reported in telephone interview in 466 pa‐
tients of a study of 1,528 patients (41%) with majority were GI symptoms including 195 cas‐
es of abdominal discomfort, 64 cases of self-limited rectal bleeding which lasted 1-3 days, 6
cases of nausea, and 62 cases of change in bowel habits including diarrhea (n=20), constipa‐
tion (n=11), flatulence (n=8), fecal incontinence(n=3), fecal urgency (n=3), and mucus dis‐
charge (n=2) [8]. There were also 2 cases of severe abdominal pain that required
hospitalization. Among the patients who were not retired and reported minor adverse
events, 26.1% missed one extra day of work after the day of procedure, 5.9% missed 2 days
beside the day of colonoscopy, and 8.8% missed 3 days or more [8].
Minor complications occurred in 162 subjects (34%) in a prospective cohort study by Ko et
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were more common in women, and when the procedure lasted 20 minutes or longer. Colon‐
ic preparation was reported by patients as the most difficult part of the procedure in 77%.
Most patients (94%) missed 2 or fewer days from normal activities for the preparation, pro‐
cedure itself, or recovery [52].
These minor adverse events have 3 aspects of effect; they are inconvenience to patients, have
indirect cost by missing work, and can affect the willingness of patients to undergo any fur‐
ther colonoscopy in future if need it.
Reducing looping of  the  endoscope and minimizing air  insufflation may decrease some
of  these symptoms [53].  It  has been also suggested using carbon dioxide,  which is  rap‐
idly absorbed and excreted through lungs,  as  an insufflating gas for  colonoscopy to re‐
duce  these  symptoms  [54,55].  Also  water  immersion  technique  instead  of  air
insufflation has been proposed to reduce these minor events especially in cases of  min‐
imal  sedation [56]  (Leung 2010).
2.10. Miscellaneous
The most serious miscellaneous complications have reported within 30 days of colonoscopy
are cerebrovascular accident (CVA), transient ischemic attack (TIA), and pulmonary embo‐
lisms which most likely related to temporary cessation of anticoagulation agents and anti‐
platelet medications peri-procedure period [3,6-8,13].
Stroke or TIA occurred within 30 days of colonoscopy in 3.3 cases per 10,000 colonoscopies
in study of 21,375 patients [3]. In a study of 1,528 patients, there was one case of TIA, and
one case of pulmonary embolism within 30 days of colonoscopy (6.5 cases of each per 10,000
colonoscopies) [8]. A third study of 23,508 patients, there were two cases of TIA and reversi‐
ble ischemic neurologic deficit lasting 24 hours and 72 hours, occurring in recovery period
following the procedure (0.8 per 10,000 colonoscopies) [13]. However, these rates are compa‐
rable with the expected annual adjusted rate of stroke in general population [3].
Splenic hematoma and rupture, intramural hematoma, subcutaneous emphysema in the ab‐
sence of frank colonic perforation, tearing of mesenteric vessels with intra-abdominal bleeding,
thrombosis in carotid-subclavian artery bypass graft, thrombophlebitis in the intravenous site,
intestinal obstruction, and ischemic and chemical colitis secondary to glutaraldehyde or air in‐
sufflation have been reported following colonoscopy in literature [3,14,15,23,31,57,58].
2.11. Polyp and cancer miss rates
Although it is not a true complication of colonoscopy, missing colorectal polyps and cancer
is of importance because it affects patient’s safety, malpractice, and determining the surveil‐
lance interval for repeat colonoscopy. In a study of 235 patients, the miss rate for advanced
adenomas which defined as polyps ≥10 mm with or without a villous component or high-
grade dysplasia was 2.5% and 3.3% for patients who had complete colonoscopy and satisfac‐
tory colon preparation on second and third repeat colonoscopy, respectively [59]. There was
no cancer missed [59].
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In another prospective study with repeated colonoscopy performed within 2 months of first
colonoscopy, the miss rate of colorectal polyps was 21.2%; however, as number of polyps
found on first colonoscopy increased, the miss rate increased to reach 77.8% when 4 polyps
found [60]. The miss rate decreased inversely with polyps’ size from 23.9% with polyps of
1-4 mm to 10% for polyps of size ≥10 mm [60].
However,  the  overall  miss  rate  for  adenomas  was  as  high  as  24%  in  a  study  of  183
patients  who  underwent  2  consecutive  colonoscopies  on  the  same  day.  The  miss  rate
increased  with  number  of  polyps  detected  on  first  colonoscopy,  inversely  with  polyps’
size,  and right  colon [61].
In a systematic review of 6 studies of a total of 465 patients, the pooled polyps miss rate was
22% which increased inversely with polyps’ size to reach 26% for polyps of 1-5 mm [62].
Also withdrawal time of endoscope is an important factor for detecting adenomas with min‐
imal recommended time of 6 minutes. The detection rates for adenomas ≥ 10 mm were only
2.6% for endoscopists with mean withdrawal time less than 6 minutes, compared to 6.4% for
those with withdrawal time greater than 6 minutes [63]. Therefore, polyp miss rate increases
with short withdrawal time.
3. Complications associated with specific colonoscopic interventions
3.1. Colonoscopic tattooing
Colonic tattooing is an injection of permanent dye into the submucosal layer of colon wall
that adjacent to the lesion for easier future localization either for surgical resection or colo‐
noscopic follow-up. Although three studies with a total of 264 patients who underwent colo‐
noscopic tattooing reported no fever, abdominal pain, or any major complications [64-66], a
systematic review of 447 patients with colonoscopic tattooing described 5 cases of complica‐
tions with only one was an overt clinical complication (22.3 per 10,000 tattooing) [67].
It  has  been  reported  cases  of  intramural  hematoma,  colonic  abscess,  rectus  muscle  ab‐
scess  following  colonoscopic  tattooing,  bowel  obstruction,  retroperitoneal  colonic  perfo‐
ration  due  to  localized  necrosis,  adhesion  ileus,  and  spread  of  the  dye  following
colonoscopic  tattooing [68-75].
3.2. Colonic balloon dilation
Colonic dilation has been used as a non-surgical treatment for benign strictures that associ‐
ated with Crohn’s disease and those at surgical anastomoses [76].
In  a  systematic  review  in  2007  of  13  studies  with  347  patients  with  Crohn’s  disease
with  colonic  strictures  who  underwent  695  sessions  of  colonic  dilation,  there  were  14
cases  of  major  complications  (201.4  cases  per  10,000  colonic  dilations);  13  cases  being
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Two prospective studies with a total of 42 patients with benign colorectal anastomotic steno‐
sis, not associated with Crohn’s disease, who underwent 81 sessions of colonic dilation re‐
ported no procedure-related complications [78,79].
3.3. Colonic stent placement
Self-expandable metal stents (SEMS) have been used in the management of colorectal obstruc‐
tion as a bridge to surgery or as a palliative treatment especially malignant obstruction. In a
pooled analysis of 54 studies with 1,198 patients who underwent colonic stent placement, the
major complications related to stent placement included stent migration (11.81%), reobstruc‐
tion (7.34%), perforation (3.76%), and mortality (0.58%) [80]. The risk factors for stent migration
which may occur proximally or distally were using covered stent, laser treatment, dilation prior
stent insertion, and the use of chemotherapy and radiotherapy. The causes for reobstruction
were tumor ingrowth (73.2%), fecal impaction, mucosal prolapse, stent migration, tumor over‐
growth, and peritoneal seeding. The reobstruction was significantly higher in uncovered stents.
The perforation was related to stent wires, balloon dilation, guide wires, or related to laser re‐
canalization prior stent placement. The death was related to colonic perforation and its conse‐
quences in majority of cases [80].
In another systematic review of 1,785 patients with 1,845 stent placements, colonic reob‐
struction in 12%, migration of the stent occurred in 11%, perforation in 4.5%. Other reported
complications of stent placement included GI bleeding, anal pain, abdominal pain, and ten‐
esmus which were relatively rare and generally well tolerated by patients [81]. It is not rec‐
ommended to perform dilation around the time of stent placement due to increased
perforation risk [76,80].
Despite  of  the  early  termination  of  3  randomized  controlled  trials  comparing  SEMS  to
surgery  because  of  high  rate  of  complications  in  SEMS groups,  a  recent  systematic  re‐
view  in  2012  with  234  patients  including  these  3  trials  showed  that  the  clinical  perfo‐
ration  rate  was  6  9%  and  the  silent  perforation  rate  14%.  There  was  no  difference
between  SEMS  arm  and  emergent  surgery  in  primary  anastomosis,  permanent  stoma,
in-hospital  mortality,  anastomotic  leak,  30-day  reoperation  and  surgical-site  infection
rates  [82-85].
3.4. Colonic decompression tube placements
Transanal endoscopic decompression tube placement has been used in acute colorectal ob‐
struction or pseudo-obstruction before surgery or stenting.
In 5 series consisting of 153 patients with acute colonic obstruction treated with transanal
decompression tube placement, two cases of bowel perforation occurred (1.3%) [86-90].
In a series of 50 patients with acute colonic pseudo-obstruction who underwent 54 decom‐
pression tube placements, one case of bowel perforation occurred (2%), and overall in-hospi‐
tal mortality was 30% reflecting severe underlying comorbidities [91].
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3.5. Percutaneous endoscopic colostomy
Percutaneous endoscopic colostomy (PEC) is considered a minimally invasive endoscopic
procedure that has been used as an alternative modality to surgery in poor surgical candi‐
dates who have recurrent sigmoid volvulus, recurrent colonic pseudo-obstruction, neuro‐
genic bowel or severe slow-transit constipation [76,92-94].
The complications of PEC that has been reported are fecal peritonitis (8.5%), fecal leakage,
recurrent infections (77%), buried internal bolster, abdominal wall bleeding and pain
[92-94]. All-cause mortality has been reported as high as 26% reflecting the often frail pa‐
tients who undergo PEC [92-94].
3.6. Colonic hemostasis
Colonic hemostasis devices are used to treat GI bleeding including diverticular bleeding,
postpolypectomy bleeding,  angiodysplasia,  and  radiation-induced  angioectasias.  Colonic
hemostasis  devices  include  contact  thermal  devices  (eg,  heater  probe  [HP],  multipolar
electrocautery [MPEC] probes, and hemostatic graspers),  noncontact thermal devices (eg,
argon plasma coagulator [APC]), mechanical devices (eg, band ligators, clips, and loops)
and injection needles [95].
Initial  worsening of bleeding may occur when applying any of these devices which can
be successfully treated by an additional application of the same or different device [15].
Colonic  perforation especially  right  colon has  been reported as  high as  2.5% with ther‐
mal  devices  [15,95,96].  Distention of  the  GI  tract  with  argon gas,  submucosal  emphyse‐
ma,  pneumomediastinum,  pneumoperitoneum,  and  gas  explosion  has  been  reported  as
complications of ACP [95,97,98].
There are multiple reports of premature deployment of the clip, and the failure to separate
the clip from the catheter after deployment [95]. Colonic perforation, initial worsening
bleeding, clip retention, immediate or delayed bleeding secondary to slippage of loop when
using detachable loop ligating devices have been described [95,99].
The complications of injection needles are usually related to injected substances such as car‐
diac arrhythmias and hypertension due to epinephrine, however, there are reports of nee‐
dles separating from the catheter in the patient and requiring retrieval, and of needles
failing to extend from their sheaths [95].
3.7. Foreign body removal
Colorectal foreign bodies may result from the insertion in the rectum for sexual pleasure,
non-sexual purposes such as body packing of illicit drugs for transportation purposes, acci‐
dentally, by swallowing solid objects such as bones and toothpicks, or migration into the co‐
lon from the adjacent organs such as intrauterine contraceptive devices and inguinal hernia
mesh [15,100-103]. Numerous kinds of objects have been described in the literature includ‐
ing fruits, vegetables, cans, bottles, bull horn, batteries, light bulbs, cosmetic containers, and
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vic pain, abdominal pain, the peritoneal signs if perforation occurs, rectal bleeding, rectal
mucous drainage, fecal incontinence, bowel obstruction, or drug overdose if bag ruptures
during removal attempts in body pocking of illicit drugs [15,100,101,104].
These symptoms and the management varies considerably based on the type of inserted ob‐
jects (sharp versus blunt), traumatic or not, and illicit drug involved or not [15,101]. Manage‐
ment of colorectal foreign bodies can be challenging and a systematic approach should be
employed including abdominal plain film and CT scan to evaluate for free intra-abdominal
air, shape and size of object, and its location and relations to the pelvis [15,100,101]. The ma‐
jority of cases can be successfully managed conservatively, but occasionally such as large ob‐
jects or tightly wedged in the pelvis surgical intervention is warranted [15,100]. It not
recommended removing drug-containing bags endoscopically because of potential rupture
of bags that can lead to systemic absorption of the drug which may cause death from rapid
drug overdose [15,105].
3.8. Advanced techniques for colonoscopic tissue removal
These advanced techniques include endoscopic mucosal resection (EMR) and endoscopic sub‐
mucosal dissection (ESD) that have been used to remove benign and early malignant lesions
that confined to superficial layers (mucosa and submucosa) [15,106]. Perforation and bleeding
are the most common complications for EMR and ESD which are more frequent than with
standard polypectomy [15]. The size of lesion, location, histology, the type of device used, and
operator experience are the factors that affects complication rates [15,107-109].
Intraprocedural bleeding rate has been reported over 10% in several large studies with de‐
layed bleeding to up to 14% [15,101,102]. Bleeding usually is managed endoscopically, al‐
though it may require blood transfusion [15,110].
Perforation may occur in 0-5% and 5-10% in EMR and ESD respectively which is usually rec‐
ognized during the procedure and managed endoscopically, although delayed perforation
has been reported in 0.4% [15,107-111].
4. Conclusion
Despite these varieties of potential complications of colonoscopy and colonoscopic interven‐
tions, they occur in low rate. It is important for both patients and physicians to know these po‐
tential complications. Informing patients regarding the symptoms of these complications is of
importance to seek medical attention in timely manner without delay. Also knowledge of these
potential complications their frequency, risk factors, and appropriate interventions is essential
for endoscopists to minimize their incidence, detect and treat them without delay.
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Additional information is available at the end of the chapter
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1. Introduction
Capsule endoscopy was independently invented in the last decade of the 20th century by Ga‐
briel Iddan and Paul Swain. They both were committed to develop a wireless camera that
would transmit images for the insides of the digestive tract to an extracorporeal receiver.
They faced many significant challenges. The last hurdle to be taken was made possible by
the miniaturization of the photosensitive chip (CMOS). This device transmits images in digi‐
tal format and is very economical with modest energy consumption. In this capsule the fol‐
lowing elements were implanted: a light source (LED), a lens, the photosensitive chip, a
power source (batteries) and a transmitter with and antenna (see Figure 1).
In the year1996 the stomach of a pig was visualized by this method. The importance of this
discovery remained as yet elusive to the medical community at large. Yet Paul Swain and
Gabriel Iddan pursued their invention. Internal Review Board approval was obtained and
the first human ingestion of a wireless capsule endoscope was performed by Paul Swain in
Israel on October 17th 1999. In the year 2000 the scientific journal Nature realized that some‐
thing of importance was taking place and devoted an article to wireless capsule endos‐
copy[1]. The question had to be addressed whether capsule endoscopy was a cute high tech
toy or whether this device had clinical importance for the medical community. The results of
a double blind controlled study comparing capsule endoscopy to push enteroscopy (the best
available method at that time) in patients with occult gastrointestinal bleeding were present‐
ed at the Digestive Disease Week meeting in Atlanta in the year 2001. Capsule endoscopy
was superior to push enteroscopy at a rate of two to one[2]. A few months later the US Food
and Drug Administration approved the use of capsule endoscopy. From there on capsule
endoscopy has captured the field of small bowel endoscopy. Capsule endoscopy of the
small bowel was superior to conventional methods in diagnosing NSAID induced enterop‐
athy, Crohn’s disease of the small bowel, tumors of the small bowel and other diseases. Di‐
rect visualization of the gastrointestinal mucosa was superior to barium studies. For this
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reason the gastroscope had replaced upper gastrointestinal series, the colonoscope had re‐
placed barium enemas and it was now the capsule endoscopy’s turn to replace the small
bowel follow through examinations.
Figure 1. Optical dome, 2 Lens holder, 3. Lens, 4.Illuminating LEDs (light emitting diodes), 5. CMOS (Complementary
Metal Oxide Semiconductor) image, 6. Battery, 7.ASIC (Application Specific Integrated Circuit) transmitter, 8. Antenna
Once capsule endoscopy had proven itself as a very useful and important diagnostic tool in
the work up of small bowel disease, the concept of non invasive endoscopy sought expan‐
sion to other areas of the gastrointestinal tract as well. This chapter deals with capsule en‐
doscopy of the colon.
2. History of capsule endoscopy of the colon
In contrast to capsule endoscopy of the small bowel, capsule endoscopy of the colon faces
serious challenges for the following reasons.
1. Problem:
The small bowel is narrow (hence its name). As the capsule camera enters the small bowel it
remains by and large fixed in its orientation and facing the same direction, either camera
first or transmitter first. The capsule as a rule does not flip around its own axis. The capsule
travels along its journey through the small bowel in the same orientation as it enters the
small bowel. For this reason the single camera of the capsule will screen the entire small
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bowel mucosa either in forward view if the capsule enters the small bowel with the camera
end first or in backward view if the capsule enters with the transmitter end first. This is not
true for the colon. In the large bowel with its wide diameter the capsule can tumble around
its axis. A capsule with a single camera would screen certain areas twice and other areas not
at all.
Solution:
The engineers solved this challenge by offering a colon capsule that has two cameras, one
camera at each end. The colonic mucosa is visualized from both directions simultaneously.
This guarantees complete visual coverage of the entire colonic surface.
2. Problem:
The capsule transit time to reach the end of the colon is significantly longer than the time
required for the capsule to reach the cecum and the colon capsule consumes more energy
than the small bowel capsule since it transmits images from two cameras. Yet the energy
supply is limited to two watch batteries.
Solution:
To reduce energy requirements the colon capsule was put to sleep for an hour and a half,
five minutes after ingestion. This hour and a half of transmit time became now available for
transmission from the colon.
3. Problem:
The third hurdle is bowel cleansing. In standard colonoscopy some minimal amount of liq‐
uid debris can be aspirated, yet minimal amount of debris may compromise the capsule’s
ability to identify pathological findings.
Solution:
A more vigorous bowel preparation had to be offered to patients to assure proper cleansing
for colon capsule examinations.
The first colon capsule was tested in the year 2005 and 2006[3]. The results of three studies
were encouraging. Firstly the bowels could be adequately cleansed in 72 to 84% of patients.
Secondly the capsule passed through the entire gastrointestinal tract while transmitting im‐
ages from the entire colon in 81% of patients within 8 hours. Finally the capsule did indenti‐
fy pathologies such as polyps, tumors, colitis, diverticulosis and internal hemorrhoids. Proof
of principle had been obtained. However the sensitivity of 58 to 64% to identify patients
with polyps equal to or larger than 6 mm as compared to standard colonoscopy was subop‐
timal and fell short of expectations [4].
3. New features of colon capsule 2
The shortcomings of this first colon capsule were analyzed and the capsule underwent a
thorough overhaul. The second generation colon capsule has the following improvements.
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small bowel. For this reason the single camera of the capsule will screen the entire small
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bowel mucosa either in forward view if the capsule enters the small bowel with the camera
end first or in backward view if the capsule enters with the transmitter end first. This is not
true for the colon. In the large bowel with its wide diameter the capsule can tumble around
its axis. A capsule with a single camera would screen certain areas twice and other areas not
at all.
Solution:
The engineers solved this challenge by offering a colon capsule that has two cameras, one
camera at each end. The colonic mucosa is visualized from both directions simultaneously.
This guarantees complete visual coverage of the entire colonic surface.
2. Problem:
The capsule transit time to reach the end of the colon is significantly longer than the time
required for the capsule to reach the cecum and the colon capsule consumes more energy
than the small bowel capsule since it transmits images from two cameras. Yet the energy
supply is limited to two watch batteries.
Solution:
To reduce energy requirements the colon capsule was put to sleep for an hour and a half,
five minutes after ingestion. This hour and a half of transmit time became now available for
transmission from the colon.
3. Problem:
The third hurdle is bowel cleansing. In standard colonoscopy some minimal amount of liq‐
uid debris can be aspirated, yet minimal amount of debris may compromise the capsule’s
ability to identify pathological findings.
Solution:
A more vigorous bowel preparation had to be offered to patients to assure proper cleansing
for colon capsule examinations.
The first colon capsule was tested in the year 2005 and 2006[3]. The results of three studies
were encouraging. Firstly the bowels could be adequately cleansed in 72 to 84% of patients.
Secondly the capsule passed through the entire gastrointestinal tract while transmitting im‐
ages from the entire colon in 81% of patients within 8 hours. Finally the capsule did indenti‐
fy pathologies such as polyps, tumors, colitis, diverticulosis and internal hemorrhoids. Proof
of principle had been obtained. However the sensitivity of 58 to 64% to identify patients
with polyps equal to or larger than 6 mm as compared to standard colonoscopy was subop‐
timal and fell short of expectations [4].
3. New features of colon capsule 2
The shortcomings of this first colon capsule were analyzed and the capsule underwent a
thorough overhaul. The second generation colon capsule has the following improvements.
Colon Capsule Endoscopy: Quo Vadis?
http://dx.doi.org/10.5772/53055
245
The angle of view of this new colon capsule camera was extended from 154 to 172 degrees
for each camera. This change provides a near full panorama view (see Figure 2).
C2 172C1 154 0
0
Figure 2. The left side image demonstrates the angle of view of the out dated C1 colon capsule. The right hand image
demonstrates the angle of view of the C2 colon capsule with a near panoramic view.
The Data Recorder 3 (DR3), the device that collects the transmitted digital information from
the capsule, is a true revolution in capsule endoscopy. Smart features have been imbedded
in this device. Bidirectional communication between capsule and DR3 takes place. The DR3
receives information from the capsule and accordingly directs the capsule with correspond‐
ing instructions. The capsule receives online orders by the DR3. The capsule transmits its
images at four images per second when in stationary condition. When DR3 recognizes that
the incoming images indicate that the capsule is in motion it orders the capsule to raise the
transmission rate to 35 images per second. This entire circle of receiving optical information
from the capsule, online analysis by the DR3 and execution of the DR3 orders by the capsule
takes place within a split second. Furthermore, DR3 also communicates with the patient un‐
dergoing the colon capsule examination and instructs the patient if and when to take a pro‐
kinetic agent, which shortens gastric transit time and moves the capsule more expediently
form stomach into small bowel. The DR3 notifies the patient
a. when to ingest the first booster laxative which accelerates small bowel transit time of
the capsule and keeps the colon clean,
b. if and when to ingest a second booster laxative
c. if and when to insert a bisacodyl suppository
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d. and finally notifies that the patient may eat and that the procedure is over.
This is how the second generation colon capsule system works. Three minutes after swal‐
lowing the capsule the rate of transmission is reduced to 16 images per minute to conserve
energy. The received images are constantly analyzed by DR3. If after one hour DR3 notices
that the colon capsule has not left the stomach it will instruct the subject by ringing an alarm
tone and activating a vibrating device attached to the antenna to look at the LCD screen
where the digit 0 is displayed. The patient’s instruction sheet indicates that the appearance
of digit 0 requires the subject to take a prokinetic agent such domperidone or metoclopra‐
mide. However if the capsule has left the stomach and entered the small bowel, the smart
features of DR3 recognize that the capsule is now in the small bowel. DR3 orders the capsule
to raise its transmission rate from 16 images per minute to 4 images per second and the pa‐
tient to ingest the booster laxative. The purpose of this booster laxative is to shorten small
bowel transit time of the colon capsule and to maintain adequate cleanliness of the bowel.
Furthermore, all incoming images from the colon capsule are analyzed online by this “intel‐
ligent” DR3 that recognizes if the capsule is stationary or in motion. Once DR3 recognizes
that the capsule is in motion it orders the capsule to raise its transmission rate of images to a
staggering 35 frames per second. As mentioned, the process of recognition to execution
takes place in a fraction of a second. This rapid transmission rate (35 frames per second) pro‐
vides adequate number of colonic images while the capsule is in motion especially while fly‐
ing through the transverse colon.
Polyp size is of course clinically very relevant. The larger the size of a polyp the greater the
chances that the polyp has advanced neoplastic changes. The software program for colon
capsule 2 is equipped with a polyp size assessor. The cursor is drawn from one side of the
polyp to the other and the algorithm spits out the size of the polyp in mm. The same polyp
seen from distance or from close up will have the same size measurement.
These technological achievements are very impressive (a data recorder communicating with
capsule and patient, a data recorder that analyzes images, determines location, position –sta‐
tionary versus motion, and accordingly alters transmission rate of frames per second by the
capsule). Yet the gnawing question remains. Is this device medically relevant?
4. Results of clinical trials with colon capsule 2
We engaged in a five center prospective double blind feasibility study in Israel in which this
second generation colon capsule was compared to standard colonoscopy for the identifica‐
tion of patients with colonic polyps. 104 patients were enrolled. Whereas in the European
multicenter trial published in 2009 the sensitivity to identify patients with polyps was only
58% the sensitivity in the multicenter Israel trial with the second generation colon capsule
rose to 89% [5]. This marked improved diagnostic sensitivity was reproduced by a recent
European study with the second generation colon capsule [6]. This improvement (raise in
diagnostic sensitivity from 58% to 89%) has to be attributed to the revolutionary new capsu‐
le platform of this second generation colon capsule for the following reasons. Firstly, the
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images at four images per second when in stationary condition. When DR3 recognizes that
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transmission rate to 35 images per second. This entire circle of receiving optical information
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takes place within a split second. Furthermore, DR3 also communicates with the patient un‐
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kinetic agent, which shortens gastric transit time and moves the capsule more expediently
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d. and finally notifies that the patient may eat and that the procedure is over.
This is how the second generation colon capsule system works. Three minutes after swal‐
lowing the capsule the rate of transmission is reduced to 16 images per minute to conserve
energy. The received images are constantly analyzed by DR3. If after one hour DR3 notices
that the colon capsule has not left the stomach it will instruct the subject by ringing an alarm
tone and activating a vibrating device attached to the antenna to look at the LCD screen
where the digit 0 is displayed. The patient’s instruction sheet indicates that the appearance
of digit 0 requires the subject to take a prokinetic agent such domperidone or metoclopra‐
mide. However if the capsule has left the stomach and entered the small bowel, the smart
features of DR3 recognize that the capsule is now in the small bowel. DR3 orders the capsule
to raise its transmission rate from 16 images per minute to 4 images per second and the pa‐
tient to ingest the booster laxative. The purpose of this booster laxative is to shorten small
bowel transit time of the colon capsule and to maintain adequate cleanliness of the bowel.
Furthermore, all incoming images from the colon capsule are analyzed online by this “intel‐
ligent” DR3 that recognizes if the capsule is stationary or in motion. Once DR3 recognizes
that the capsule is in motion it orders the capsule to raise its transmission rate of images to a
staggering 35 frames per second. As mentioned, the process of recognition to execution
takes place in a fraction of a second. This rapid transmission rate (35 frames per second) pro‐
vides adequate number of colonic images while the capsule is in motion especially while fly‐
ing through the transverse colon.
Polyp size is of course clinically very relevant. The larger the size of a polyp the greater the
chances that the polyp has advanced neoplastic changes. The software program for colon
capsule 2 is equipped with a polyp size assessor. The cursor is drawn from one side of the
polyp to the other and the algorithm spits out the size of the polyp in mm. The same polyp
seen from distance or from close up will have the same size measurement.
These technological achievements are very impressive (a data recorder communicating with
capsule and patient, a data recorder that analyzes images, determines location, position –sta‐
tionary versus motion, and accordingly alters transmission rate of frames per second by the
capsule). Yet the gnawing question remains. Is this device medically relevant?
4. Results of clinical trials with colon capsule 2
We engaged in a five center prospective double blind feasibility study in Israel in which this
second generation colon capsule was compared to standard colonoscopy for the identifica‐
tion of patients with colonic polyps. 104 patients were enrolled. Whereas in the European
multicenter trial published in 2009 the sensitivity to identify patients with polyps was only
58% the sensitivity in the multicenter Israel trial with the second generation colon capsule
rose to 89% [5]. This marked improved diagnostic sensitivity was reproduced by a recent
European study with the second generation colon capsule [6]. This improvement (raise in
diagnostic sensitivity from 58% to 89%) has to be attributed to the revolutionary new capsu‐
le platform of this second generation colon capsule for the following reasons. Firstly, the
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three previous studies with the first generation colon capsule had a very similar design as
the present studies with colon capsule 2 and are thus comparable. Secondly, good bowel
cleansing is a determining factor for a successful study. Good bowel cleansing was obtained
at similar rates in the studies with colon capsule 1 as in the new studies with colon capsule
2. Thirdly, capsule exrection of a capsule still transmitting images is a prerequisite for a suc‐
cessful colon capsule study. Capsule excretion rates of the studies with colon capsule 1 and
the studies with colon capsule 2 were the same. The only factor which set this second gener‐
ation colon capsule study apart from the previous studies is the new technological platform.
It is for this reason that we credit the improvement in technology for the improved diagnos‐
tic sensitivity of 30%.
Colon capsule 2’s negative predictive value of 97% is very high and is clinically very mean‐
ingful. The physician discussing the results of a negative colon capsule 2 study with his pa‐
tient can reassure her/him that that a negative colon capsule 2 study has a 97% accuracy that
there are no polyps.
The fact that the smart features of DR3 enable communication with the patient has opened
the door to offer colon capsule examination as an out of clinic procedure [7].
5. Colon capsule endoscopy, Quo Vadis?
In the year 2011 the European Society of Gastrointestinal Endoscopy(ESGE) recognized the
potential that colon capsule endoscopy offers and ordered the establishment of evidence
based guidelines for colon capsule endoscopy[8]. This initiative was endorsed by the gov‐
erning board of ESGE.
Technical concerns in relation to colon capsule endoscopy were addressed. Will the colon be
adequately cleansed for high quality inspection? Will the power of the batteries within the
capsule supply adequate energy to transmit images from the colon until excretion of the
capsule? The experts therefore formulated precise guidelines and devoted an entire section
on how to perform capsule endoscopy. To achieve high quality colon capsule endoscopy
(good bowel preparation, high rate of capsule passage rate through entire colon and proper
reading) strict implementation of all guidelines must be followed (diet, laxatives, booster in‐
gestion, controlled frame rate during reading).
Here are some of the attractive features of colon capsule endoscopy that are mentioned in
the published guidelines.
• “CCE (Colon capsule endoscopy) has consistently been shown to be a very safe proce‐
dure: no major complication has been reported in over 1500 procedures, of which around
40% were in asymptomatic individuals. CCE also appears to be a feasible procedure, with
a very low rate of technical failures (i. e. 3%) and a high capsule excretion rate of about
90%”.
• “A previous cost–effectiveness analysis has compared first-generation CCE with colono‐
scopy in a screening setting. Although CCE was not a cost-effective alternative when
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equal uptake (adherence to participate in colon cancer screening) was assumed, it became
an efficient option when it was assumed that uptake of CCE would be higher than that of
colonoscopy for CRC screening, a premise that has not been demonstrated yet.”
• “CCE is a feasible and safe tool for visualization of the colonic mucosa in patients with
incomplete colonoscopy and without stenosis.”
• “Small-bowel capsule endoscopy provides a very high diagnostic yield for small-bowel
mucosal lesions and its use is recommended in specific scenarios of IBD (Inflammatory
Bowel Disease). Similarly, CCE could be used to identify mucosal changes in the colorec‐
tal mucosa. …”
We will dwell on two mentioned issues raised in the European Guidelines, namely the use
of capsule colonoscopy in screening for colonic polyps and the use of capsule endoscopy in
incomplete colonoscopy.
6. Can colon capsule endoscopy play a role in clinical medicine today?
a. Screening patients for presence of colonic polyps as primary colon cancer prevention.
Colonoscopy is the accepted gold standard and the most sensitive method to investigate pa‐
tients for the presence of colonic polyps. While colon cancer screening programs are availa‐
ble the participation rate of the general population has been disappointingly low. The
reasons for the low adherence rate are multifactorial. Colonoscopy is associated with dis‐
comfort/pain, so there is a need for sedation, there are complications, albeit small, the proce‐
dure leads to loss of work and there is the issue of the invasion of one's privacy. Recently it
has been reported that post procedural pain necessitating visits to the emergency room fol‐
lowing colonoscopy has been underestimated. While these reservations may appear trivial
to gastroenterologists, this is perceived differently in the general public. Inadomi et al pub‐
lished the results of a prospective randomized trial [9]. In the office setting eligible patients
were offered either colonoscopy or fecal occult blood testing (FOBT). 12 months thereafter
38% of patients offered colonoscopy had completed the procedure, while 31% more, a total
of 69% of patients offered FOBT had done the test.
They concluded that our common practice of universally recommending only colonoscopy
may actually reduce adherence to colorectal cancer screening.
In a prospective study performed in Germany to examine whether colon capsule endoscopy
could increase adherence to screening colonoscopy in a healthy population Groth et al
found that offering capsule endoscopy led to a fourfold increase of screening uptake com‐
pared to standard colonoscopy [10].
Rex and Lieberman published a survey study that colon capsule endoscopy could raise col‐
orectal cancer screening adherence rates among patients who decline screening colonosco‐
py. This was especially apparent when the participants in this survey were offered colon
capsule endoscopy as an out of clinic test with no loss of work. We published a cohort study
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the present studies with colon capsule 2 and are thus comparable. Secondly, good bowel
cleansing is a determining factor for a successful study. Good bowel cleansing was obtained
at similar rates in the studies with colon capsule 1 as in the new studies with colon capsule
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Technical concerns in relation to colon capsule endoscopy were addressed. Will the colon be
adequately cleansed for high quality inspection? Will the power of the batteries within the
capsule supply adequate energy to transmit images from the colon until excretion of the
capsule? The experts therefore formulated precise guidelines and devoted an entire section
on how to perform capsule endoscopy. To achieve high quality colon capsule endoscopy
(good bowel preparation, high rate of capsule passage rate through entire colon and proper
reading) strict implementation of all guidelines must be followed (diet, laxatives, booster in‐
gestion, controlled frame rate during reading).
Here are some of the attractive features of colon capsule endoscopy that are mentioned in
the published guidelines.
• “CCE (Colon capsule endoscopy) has consistently been shown to be a very safe proce‐
dure: no major complication has been reported in over 1500 procedures, of which around
40% were in asymptomatic individuals. CCE also appears to be a feasible procedure, with
a very low rate of technical failures (i. e. 3%) and a high capsule excretion rate of about
90%”.
• “A previous cost–effectiveness analysis has compared first-generation CCE with colono‐
scopy in a screening setting. Although CCE was not a cost-effective alternative when
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incomplete colonoscopy and without stenosis.”
• “Small-bowel capsule endoscopy provides a very high diagnostic yield for small-bowel
mucosal lesions and its use is recommended in specific scenarios of IBD (Inflammatory
Bowel Disease). Similarly, CCE could be used to identify mucosal changes in the colorec‐
tal mucosa. …”
We will dwell on two mentioned issues raised in the European Guidelines, namely the use
of capsule colonoscopy in screening for colonic polyps and the use of capsule endoscopy in
incomplete colonoscopy.
6. Can colon capsule endoscopy play a role in clinical medicine today?
a. Screening patients for presence of colonic polyps as primary colon cancer prevention.
Colonoscopy is the accepted gold standard and the most sensitive method to investigate pa‐
tients for the presence of colonic polyps. While colon cancer screening programs are availa‐
ble the participation rate of the general population has been disappointingly low. The
reasons for the low adherence rate are multifactorial. Colonoscopy is associated with dis‐
comfort/pain, so there is a need for sedation, there are complications, albeit small, the proce‐
dure leads to loss of work and there is the issue of the invasion of one's privacy. Recently it
has been reported that post procedural pain necessitating visits to the emergency room fol‐
lowing colonoscopy has been underestimated. While these reservations may appear trivial
to gastroenterologists, this is perceived differently in the general public. Inadomi et al pub‐
lished the results of a prospective randomized trial [9]. In the office setting eligible patients
were offered either colonoscopy or fecal occult blood testing (FOBT). 12 months thereafter
38% of patients offered colonoscopy had completed the procedure, while 31% more, a total
of 69% of patients offered FOBT had done the test.
They concluded that our common practice of universally recommending only colonoscopy
may actually reduce adherence to colorectal cancer screening.
In a prospective study performed in Germany to examine whether colon capsule endoscopy
could increase adherence to screening colonoscopy in a healthy population Groth et al
found that offering capsule endoscopy led to a fourfold increase of screening uptake com‐
pared to standard colonoscopy [10].
Rex and Lieberman published a survey study that colon capsule endoscopy could raise col‐
orectal cancer screening adherence rates among patients who decline screening colonosco‐
py. This was especially apparent when the participants in this survey were offered colon
capsule endoscopy as an out of clinic test with no loss of work. We published a cohort study
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of 41 patients who underwent colon capsule endoscopy as an out of clinic study. Successful‐
ly completed colon capsule endoscopy examinations in this out-of-clinic trial, including cap‐
sule excretion rates and colon cleansing levels were similar to those of the two published in-
clinic trials. This study concluded that second generation colon capsule endoscopy may be
offered as an out-of-clinic medically supervised procedure [11].
To summarize the above: offering colonoscopy only in colon cancer screening programs re‐
duces adherence. Loss of work and the need to have a person accompany the subject to be
screened by colonoscopy are significant reasons for decreased adherence to undergo colono‐
scopy screening. Reduced adherence compromises the effectiveness of colonoscopy even if
colonoscopy admittedly is the gold standard. Colon capsule endoscopy can offer itself as a
non invasive test to identify patients with colonic polyps. In the future colon capsule endos‐
copy could be offered as an out of clinic test which potentially could further increase adher‐
ence rates for colon cancer screening programs. Modern technology has set the tone.
Invasive diagnostic tests will be replaced with less or non invasive tests. Colon capsule en‐
doscopy may fit this paradigm.
b. Incomplete Colonoscopy.
For colonoscopy to reduce colon cancer rates certain criteria have to be met. Colonoscopy
has to be carried out by competent endoscopists (operator dependent). Bowel cleansing has
to be optimal. Cecal intubation has to be achieved (complete colonoscopy). Incomplete colo‐
noscopy, ie the failure to intubate the cecum with the colonoscope, in general practice is
higher than expected [12]. Complete colonoscopy rates have been reported from 60% to over
90% [13],[14],[15]. If for whatever reason complete colonoscopy cannot be achieved then in‐
gestion of the colon capsule endoscope for visualization of the uninspected part of the colon
is feasible. Colon capsule endoscopy in this setting may be especially attractive since it is the
right colon which is usually not visualized in incomplete conventional colonoscopy whereas
the right colon is routinely visualized by capsule endoscopy. A prospective multicenter Eu‐
ropean study demonstrated that colon capsule endoscopy in case of incomplete colonoscopy
(74 cases) or contraindicated colonoscopy (26 cases) yields a high number of relevant diag‐
nostic findings (36 %) including one right sided colonic cancer. Furthermore, the authors re‐
port that during a one year follow up of this study no adenocarcinoma of the colon was
missed by the colon capsule[16]. It should be emphasized that this study was performed
with the inferior (today outdated) first generation colon capsule.
7. Conclusion
Colon capsule endoscopy has come a long way in a very short time. Technological develop‐
ments are so rapid that studies performed in the years 2006 and 2007 with the first genera‐
tion of colon capsules are already outdated. Second generation colon capsule endoscopy has
a diagnostic sensitivity of 89% or higher to identify patients with polyps equal to or larger
than 5 mm. In addition to this high sensitivity colon capsule endoscopy is non invasive,
painless, protects one’s privacy, may be offered in the future as an out of clinic (or possibly
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home procedure) and for all these reasons may increase adherence rates to participate in co‐
lon cancer screening. Therefore colon capsule endoscopy may become clinically important
to practicing gastroenterologists.
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1. Introduction
Colorectal carcinoma ranks as the third most commonly diagnosed cancer and the second
leading cause of death from cancer in the United States [1]. It is estimated that more than
150,000 new cases are diagnosed with more than 50,000 dying from the disease yearly in
the U.S. alone [1]. Similar to other cancers, it is often diagnosed at advanced stage, after
the patient has developed symptoms. Many colon cancer deaths can be avoided because
mostly they arise from adenomatous polyps, which may be detectable years before malig‐
nant transformation.
Since the first report of a complete examination of the entire colon using a flexible endo‐
scope, optical colonoscopy (OC) has evolved to be the current gold standard for evaluation
of the colon [2]. OC has several limitations and drawbacks as a population-based screening
tool. It is an invasive procedure requiring sedation. An escort is usually required to take the
patient home, which increases the cost of the procedure from a societal perspective. OC also
carries a small but significant risk of perforation and death. The risk of colonic perforation is
about 1 per 1,000 cases and death is approximately 1 in 5,000 cases [3-5]. Failure to reach the
cecum (5-10%) and missed polyps (10-20%) also are known limitations of the current gold
standard test [6-9].
Computed tomographic colonography (CTC), also known as "virtual colonoscopy" was first
described more than a decade ago [10]. In the early 1990’s, several pilot studies evaluated
the feasibility of (CTC) [11]. The advantages of developing a computerized-based screening
tool includes: increased accessibility, non-invasiveness, and no sedation required [12]. These
advantages of CTC may help to increase compliance with current screening recommenda‐
tion guidelines [13].
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1. Introduction
Colorectal carcinoma ranks as the third most commonly diagnosed cancer and the second
leading cause of death from cancer in the United States [1]. It is estimated that more than
150,000 new cases are diagnosed with more than 50,000 dying from the disease yearly in
the U.S. alone [1]. Similar to other cancers, it is often diagnosed at advanced stage, after
the patient has developed symptoms. Many colon cancer deaths can be avoided because
mostly they arise from adenomatous polyps, which may be detectable years before malig‐
nant transformation.
Since the first report of a complete examination of the entire colon using a flexible endo‐
scope, optical colonoscopy (OC) has evolved to be the current gold standard for evaluation
of the colon [2]. OC has several limitations and drawbacks as a population-based screening
tool. It is an invasive procedure requiring sedation. An escort is usually required to take the
patient home, which increases the cost of the procedure from a societal perspective. OC also
carries a small but significant risk of perforation and death. The risk of colonic perforation is
about 1 per 1,000 cases and death is approximately 1 in 5,000 cases [3-5]. Failure to reach the
cecum (5-10%) and missed polyps (10-20%) also are known limitations of the current gold
standard test [6-9].
Computed tomographic colonography (CTC), also known as "virtual colonoscopy" was first
described more than a decade ago [10]. In the early 1990’s, several pilot studies evaluated
the feasibility of (CTC) [11]. The advantages of developing a computerized-based screening
tool includes: increased accessibility, non-invasiveness, and no sedation required [12]. These
advantages of CTC may help to increase compliance with current screening recommenda‐
tion guidelines [13].
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2. Technique
As advancements in scanner technology and three-dimensional (3D) post-processing helped
develop this method to mature into a potential option in screening for colorectal cancer, the
fundamentals of the examination remained the same. It is a minimally invasive, CT-based
procedure that simulates conventional colonoscopy using 2D and 3D computerized recon‐
structions [10]. CTC utilizes computer virtual-reality techniques to navigate inside a three-
dimensionalz (3D) patient-specific colon model reconstructed from abdominal CT images,
looking for polyps.
CTC examination starts by inflating a cleansed colon with room air or carbon dioxide (CO2)
introduced through rectal catheter [14]. With the patient in a prone position, air or CO2 is
insufflated under gentle pressure to ensure adequate distention of the bowel. The insuffla‐
tion of gas is usually associated with a mild degree of patient discomfort or pain [15]. Al‐
though not common, vaso-vagal reactions can occur, especially if with small bowel
distention occurs [16].
Then abdominal CT slice images are taken in seconds (during a single breath hold) with sub
millimeter resolution in both axial and transverse directions resulting in excellent contrast
between the colon wall and the lumen. The sliced images are stacked together as a volume
image, from which the colon model is constructed. Image segmentation is necessary for the
construction of an accurate colon model. Computer graphics are heavily involved to navi‐
gate or fly through inside the 3D colon model. The patient is scanned in both a prone and
supine view [17]. Using a second view significantly improves the ability to identify patients
with polyps 0.5 cm in diameter or larger [18].
CTC can be performed in patients with prior abdominoperineal resection and sigmoid co‐
lostomy,  although increased difficulties  with CO2 retention and adequate  bowel  disten‐
tion exist [19]. The prevalence of transient bacterium after CTC is low therefore it follows
that patients with at risk cardiac lesions should not require antibiotic prophylaxis before‐
hand [20].
Most commonly used bowel preparations include sodium phosphates, magnesium citrate
and polyethylene glycol (PEG) [21]. Typical oral preparations used for bowel cleansing are:
4 L of PEG solution; 90 ml of phosphosoda; or 300 ml of magnesium citrate. Polyp detection
is comparable for all three preparations, although phosphosoda has a significantly higher
patient compliance and the least residual stool [22]. Residual fluid coverage negatively af‐
fects the quality of CTC [23].
The use of fecal tagging agents and intravenous contrast is not standardized. CTC experts
were surveyed regarding their practice patterns [24]. Thirty-eight percent performed fecal
tagging regularly and 81% [21/26] believed intravenous contrast was not necessary [24].
Non-operator  dependent  false  positives  and false  negatives  occur  with  CTC.  For  exam‐
ple,  inadequately  tagged stool  can have the  same density  as  a  polyp,  however  the  two
can  sometimes  be  distinguished  by  comparing  prone  and  supine  views,  since  stool  is
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usually mobile and polyps are not.  The rectal balloon is a potential  blind spot for CTC,
sometimes masking significant lesions [25, 26]. Also, poor colonic distention can result in
a false negative reading [27].
3. Screening for colorectal cancer: CTC vs. OC
The primary aim of CTC is the detection of colorectal polyps and carcinomas, however; the
precise role of CTC in screening asymptomatic patients is controversial [28]. Studies using
patients with known adenomas generally report higher accuracy, while studies employing
asymptomatic screening subjects report lower accuracy [28]. Two key areas have held back
the widespread application of CTC as a screening test. These key areas are: [1] the variable
sensitivity of CTC reported in mass screening programs (see Table) and [2], the expertise re‐
quired to interpret the examination. These two areas are related [29]. Despite these draw‐
backs, the American College of Radiology, has endorsed the use of CTC as a screening tool
for colo-rectal cancer stating that the sensitivity and specificity of CTC are high enough and
comparable to those of OC [30]. In addition, CTC has received the endorsement of a multi-
society task force that included the American Cancer Society and U. S. Multi-society Task
Force on Colorectal Cancer [31].
Studies reveal a wide variation in performance measures (sensitivity and specificity) regard‐
ing polyp detection rates, especially for smaller polyps [10]. In an early feasibility study of
44 patients, CTC demonstrated reasonable sensitivity (83%) and specificity (100%) for pol‐
yps larger than 8 mm in size [32]. A second early study performed in 87 patients at high risk
for colorectal neoplasia identified 49 patients with a total of 115 polyps and 3 carcinomas
[33]. CTC identified all 3 cancers. The sensitivity was 91% for polyps that were 10 mm or
more in diameter, 82% [33/40] that were 6 to 9 mm, and 55% [29/53] that were 5 mm or
smaller [33]. There were 19 false positive findings of polyps and no false positive findings of
cancer. In a larger study of 300 patients CTC demonstrated a sensitivity equal to 90% for
polyps 10 mm or larger and 80.1% for polyps at least 5 mm in size [34]. The overall specifici‐
ty for this study was 72.0% [34]. All 8 carcinomas in the study were detected by CTC.
Two later studies assessing the accuracy of CTC had varying results. Pickhardt et al. evalu‐
ated 1,233 asymptomatic patients with CTC and same-day OC [35]. The sensitivity of CTC
for adenomatous polyps at least 10 mm in size was 93.8% and 88.7% for polyps at least 6
mm in size, which was comparable to OC. The specificity of CTC for adenomatous polyps at
least 10 mm in size was 96.0% and 79.6% for polyps at least 6 mm in size. These encouraging
results were followed a year later by less optimistic findings from a study by Cotton et al.,
that analyzed 600 participants undergoing both CTC and OC [36]. In the Cotton study, 104
of the participants (17.3%) had lesions sized at least 6 mm. The sensitivity of CTC for detect‐
ing 1 or more lesions sized at least 6 mm was only 39.0% and for lesions sized at least 10
mm, it was 55.0% (95% Cl, 39.9% - 70.0%) [36]. The specificity of CTC for detecting partici‐
pants without any lesion sized at least 6 mm was 90.5% and without lesions sized at least 10
mm, 96.0% (95% Cl, 94.3% - 97.6%). CTC missed 2 of 8 cancers [36]. Lack of adequate radiol‐
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In a subsequent study of 2,531 asymptomatic patients, radiologists trained in CTC reported
the accuracy of finding histologically confirmed adenomas [37]. The sensitivity for large ad‐
enomas [10 mm or larger) and medium-sized adenomas (6 – 9 mm) was 90% and 78% re‐
spectively [37]. CTC failed to detect a lesion measuring 10 mm or more in diameter in 10%
of patients [37]. Pickhart et al. found that the positive predictive values (PPV) for polyps
with threshold sizes 6 mm, 8 mm, and 10 mm are: 92.3%, 93.0%, and 93.1% respectively [38].
Others have also found that for significant adenomas, the PPV of CTC is high and ranges
from 96 – 99% [37, 39].
Meta-analysis is a tool that attempts to summarize varying results across multiple studies.
Meta-analysis of data suggests CTC has excellent per-patient average sensitivity and aver‐
age specificity for detection of adenomatous polyps and cancer [40]. In one meta-analysis,
2,610 patients were included for study [41]. Large polyps (10 mm or greater) had a per-pa‐
tient average sensitivity of 93% (95% CI,73% - 98%) and specificity of 97% 9(95% CI, 95% -
99%) [41]. The sensitivity and specificity decreased to 86% (95% CI: 75% - 93%) and 86%
(95% CI, 76% - 93%), respectively, when the threshold was lowered to include medium sized
polyps (6 mm to 9 mm). These findings are similar to another more recent meta-analysis us‐
ing average risk patients that found a sensitivity of 87% and specificity of 97.6% for polyps
at least 10 mm in size [42].
One of the problems of evaluating the test performance of CTC is the use of OC as the gold
standard because OC has a miss-rate for polyps and cancer as well. In one study, Pickhardt
et al. compared 1,233 asymptomatic adults who underwent same-day CTC and blinded seg‐
mental OC [43]. Polyps that were detected by CTC but initially missed by OC were consid‐
ered missed polyps for OC. It was found that OC had a miss rate of 12% for adenomas 10
mm or greater. Of the missed polyps on OC, 14/15 (93.3%) non-rectal neoplasms were locat‐
ed on a fold. Five of 6 (83.3%) missed rectal lesions were located within 10 cm of the anal
verge [43].
Another study analyzed 286 tandem colonoscopies [44]. The OC miss rates for adenomas 5
mm and larger and advanced adenomas (≥ 10 mm or high grade dysplasia) were: 11% and
9% respectively [44]. Therefore, OC does have a significant miss rate for adenomas 5 mm
and larger and/or advanced adenomas. In fact, the OC miss-rate is similar to the CTC miss-
rate for polyps 6-9 mm in size [27]. It should also be pointed out that in screening studies,
CTC and OC have similar detection rates for advanced neoplastic polyps and cancer, 3.2%
vs. 3.4% respectively [45]. OC detects significantly more adenomas less than 5 mm of size
although the benefit of this remains to be seen [46]. In summary, CTC appears to have simi‐
lar sensitivity to OC in detecting polyps 5 mm or greater when performed by readers with
high experience [47].
The detection of flat adenomas are a major concern for colo-rectal cancer screening since
these polyps are at a higher risk of harboring advanced pathology and are more difficult to
detect by CTC as well as OC [48, 49]. In the general population, there is wide variation in the
reported incidence of flat lesions, which may in part be due to the lack of a uniform defini‐
tion of flat polyps. Various definitions of flat polyps have been used in CTC studies. For ex‐
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ample, in one study flat polyps were defined as those having a height less than one-half of
their width [50]. In other studies, a definition of 3 mm or less in height is used [51].
The sensitivity for flat polyps appears to be lower than non-flat polyps, however, Pickhardt
et al. found that the sensitivity of CTC for detecting flat adenomas measuring 6 mm or
greater was similar to that of non-flat polypoid lesions [50]. Others have found lower sensi‐
tivities for flat polyps ranging from 15% to 65% [52]. Regardless of reader skills, truly flat or
depressed adenomas will most likely pose a challenge for CTC. Also, flat carpet lesions of
the colon can be difficult to detect by CTC [53].
CTC readers may not report polyps less than 5 mm in size [54]. The justification for this is
that small polyps are usually benign and rarely harbor cancer or have much prognostic sig‐
nificance. In a large OC screening study, advanced histology was found in only 1.7% of pol‐
yps sized 5 mm or less indicating the lack of reporting of these small polyps by CTC may be
justified [55]. On the other hand, 6.6% of polyps sized 6 to 9 mm, had an advanced histology
implying polyps of this size if found on CTC should be followed up with OC in the near
future [55]. This last point is somewhat contentious and some radiologic guidelines suggest
surveillance with CTC after a shortened interval as an acceptable option for polyps 6 – 9 mm
in size [56].
We feel a reasonable algorithm for CTC screening might be: 1. follow-up screening in 5
years if no polyps are found: 2. Follow-up CTC or OC in 5 years for polyps smaller than 5
mm: 3. OC if polyps measuring 6 mm or greater are found [57]. This algorithm is consistent
with clinical sentiment since 71% of primary care physicians and 86% of gastroenterologists
would send patients with polyps 5 mm in size or greater for a follow-up OC [58]. If this ap‐
proach were adopted, a referral rate for OC of about 8% - 14% would be expected in the gen‐
eral population [45, 59]. Using a 6 mm threshold however may be very costly. A decision-
analysis estimated that to prevent one colon cancer death would require over 9,000 OCs,
resulting in 10 additional perforations at an incremental cost of $327,853 dollars [60].
4. Other uses of CTC
4.1. After incomplete colonoscopy
Sometimes OC can not be completed to the cecum due to technical factors such as prior ab‐
dominal surgery, colon length and number of flexures [61]. An important use of CTC is ex‐
amination of the colon after incomplete OC [62]. In a retrospective study, 88/546 patients
had lesions 6 mm or greater on CTC after incomplete OC. OC was repeated if findings on
CTC were significant. The PPV of CTC for masses, large polyps, and medium polyps were
90.9% and 91.7%, and 64.7% respectively [63].
It may be valuable to perform a low-dose diagnostic CT before rectal tube insertion in pa‐
tients referred for incomplete colonoscopy. In one study of 262 patients referred for incom‐
plete OC, colon perforation was found on the low-dose CT scans of two of the 262 patients




In a subsequent study of 2,531 asymptomatic patients, radiologists trained in CTC reported
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abdominal discomfort at the time of CTC. Therefore, the rate of occult colonic perforation
after incomplete colonoscopy may warrant a spot CT prior to full examination.
4.2. For symptoms
CTC is being increasingly used for the radiological evaluation of colorectal symptoms. In
symptomatic patients, CTC is equivalent to OC for diagnosing colon cancer and clinically
significant polyps [65]. In a retrospective study of 1,177 older symptomatic patients, 59 inva‐
sive CRC were detected [66]. Three small colorectal cancers were missed by CTC. CTC has a
high sensitivity (95%) and negative predictive value (99.7%) in excluding a CRC in patients
with colorectal symptoms [66].
4.3. Inflammatory bowel disease and diverticulitis
CTC may be useful for diagnosing and managing patients with inflammatory bowel disease
(IBD) [67]. CTC correctly identified acute and chronic IBD in 63.6%, and 100% of cases, re‐
spectively [68]. CTC was also helpful in assessing post-op strictures in Crohn’s disease pa‐
tients [69]. Perianastomotic narrowing or stenosis was detected by CTC in 11 of 15 patients.
The sensitivity and specificity for perianastomatic narrowing were 73% and 100% respec‐
tively [69]. The risk of perforation, especially in patients with severe active colitis is a poten‐
tial worry. Currently there is not enough data to measure the true risk in patients with
severe active disease [70].
Examination of the colon is usually necessary after an adequate rest period for evaluation of
patients with diverticulitis. CTC appears comparable to OC in the evaluation of these pa‐
tients and is a reasonable alternative in follow-up of patients with symptomatic diverticular
disease [71]. Diverticulosis may however, increase the chance of having a false positive test
for polyps on CTC due to the appearance of inverted diverticula and fecoliths[72]. On the
other hand, CTC may be helpful in diagnosing complications of diverticular disease and in‐
flammatory bowel disease, such as colo-vesicular fistulae [73].
4.4. Detection of tumor for surgery
CTC is very useful in detecting colon cancer after incomplete colonoscopy and also for eval‐
uating potential metastases [74-76]. CTC can help localize polyps or cancer prior to laparo‐
scopic surgery and detect synchronous lesions beyond the reach of OC due to obstructing
lesions [77, 78]. In fact, CTC is superior to OC in the localization of colonic tumors prior to
surgery [79]. CTC is also a safe and useful method for preoperative examination of the prox‐
imal colon after metallic stent placement in patients with acute colon obstruction caused by
cancer [80].
CTC is useful in surveillance after surgery for colo-rectal cancer, detecting local recurrence
and metastasis [81-84]. In patients with ovarian cancer CTC may be helpful in detecting rec‐
tosigmoid wall involvement wall and predict the need for rectosigmoid resection [85]. The
sensitivity, specificity, PPV and negative predictive value of CTC for the prediction of recto‐
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sigmoid resection in patients with ovarian cancer in one study were: 100%, 64.7%, 72.7% and
100%, respectively [85].
5. Reader experience and accuracy
Individual accuracy of reading polyps with CTC is highly variable among radiologists and
depends largely on training and experience [86-88]. There is a significant learning curve in‐
volved in the interpretation of CTC studies, with performance improving with operator ex‐
perience [89, 90]. Radiologists working in nonacademic centers may have less accurate
results than would be expected from published data originating from experienced academic
centers [91]. The steep learning curve involved with reading CTC has led some thought
leaders to advise against widespread colorectal cancer screening programs with CTC out‐
side of academic centers [29].
False negatives are a major concern, i.e. missing significant lesions. It appears that many
false negatives are due to observer error and not due to the technical capabilities of CTC. For
instance in one study, 53% of missed polyps (60 of 114) were attributed to observer-related
errors, and 26% were attributed to errors classified as technical [92]. This implies that with
improvements in reader skill the sensitivity of finding significant lesions would be accepta‐
ble and comparable to OC [90]. Technical factors that appear to be associated with higher
accuracy include meticulous bowel preparation and inflation, multidetector CT, combined
two and three-dimensional visualization [28, 93].
6. Radiation exposure
Radiation exposure at the time of CTC screening leads to a slight but increased risk of devel‐
oping cancer at a future time [94]. Therefore, reducing radiation exposure is a major chal‐
lenge for CTC screening.Currently, CTC scanning delivers a significant amount of X-ray
radiation exposure to the patient [95]. In 2004, a survey of 28 institutions revealed the me‐
dian effective dose of radiation was 5.1 mSv (range 1.2 mSv - 11.7 mSv) per position and the
median mAs value was 67 mAs[96].
Given current CT technology, a simple and effective strategy to reduce radiation would be
to lower the mAs level (i.e. deliver less X-ray photons to the body) during the data acquisi‐
tion. This strategy would however, lead to a higher noise signal in the acquired data. Recent
efforts on modeling a solution to avoid this noise artifact are aimed at minimizing the noise
prior or during image reconstruction. Despite the great effort on this solution in the past
decade, CTC still faces challenges at a mAs level lower than 50 [97].
A feasibility study examined low radiation doses from 10mAs to 40 mAs using adaptive
statistical iterative reconstruction (ASIR) models [98]. Eighteen patients were scanned with a
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ASIR in the prone position. No significant image quality differences were seen between
standard-and low-dose images using 40% ASIR. The results of this pilot study show that the
radiation dose during CTC can be reduced 50% below currently accepted low-dose techni‐
ques without significantly affecting image quality when ASIR is used [98]. Larger studies
are needed to confirm this observation. Despite the increasing use of multi-slice scanners,
which are slightly less dose-efficient, the median effective dose remained approximately
constant between 1996 and 2004 [96]. Of 83 institutions, 62% used 64-detector row CT and 17
(50%) used dose modulation [99].
If the current CTC standards for radiation exposure are used for colorectal cancer screening,
CTC is still be a viable screening tool, even after taking into account the increased risks of
developing future cancers. Using a Monte Carlo simulation, it was found that for every 1
radiation-related cancer caused by CTC screening, 24 – 35 colorectal cancers would be pre‐
vented, implying a favorable risk to benefit ratio in favor of using CTC as a screening tool
[100]. This model assumed using CTC every 5 years in patients aged 50 – 80 years old and
using an estimated mean effective dose per CTC screening study of 8 mSv for women and 7
mSv for men.
An alternative solution to minimize the radiation is to use magnetic resonance imaging
(MRI) instead of CT for virtual colonoscopy, i.e., MR colonography (MRC) [101]. However,
this MRC alternative solution has several limitation compared to CTC. Currently it is more
costly, more sensitive to motion and other artifacts, and has lower spatial resolution but
with improvements with technology these disadvantages may be minimized.
7. Patient preferences
When asked if they would prefer CTC or OC, patients more often prefer CTC [102]. In one
study, 696 asymptomatic patients at high risk for colorectal cancer screening underwent
both CTC and OC [103]. Patients were asked using standardized forms about preparation
inconvenience and discomfort, examination discomfort and examination preference. Over‐
all, patients preferred CTC to OC (72.3% vs. 5.1%; P <0.001). Reported discomfort however,
was similar for CTC and OC (P = 0.63). In another study that evaluated patients with a histo‐
ry of diverticulitis, 74% preferred CTC preferred over OC [71]. Patients found colonoscopy
more uncomfortable (p < 0.03), more painful (p < 0.001), and more difficult (p < 0.01) than
CTC [71].
Other studies conflict with those mentioned above. Even though CTC is a less invasive alter‐
native than OC, procedural pain is not uncommon. In several studies, the pain associated
with CTC was higher than that associated with OC, albeit there is no sedation given for the
former test [104]. Using a time-trade off technique, 295 patients reported statistically more
pain and discomfort after CTC and showed preference for optical colonoscopy [105]. The
pain during CTC however, is usually not so severe as to abort the test [33].
In a well-designed study, 111 patients underwent CTC followed immediately by OC [15].
The preference  for  either  examination was evaluated after  completion of  both examina‐
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tions.  Of  the  68  patients  who  favored  one  examination,  56  [82%)  preferred  CTC  (P  <
0.00001). CTC was regarded as "not painful" by 62 (57%) of 108 patients compared with 28
(26%) for colonoscopy [15].
Intuitively we may believe that CTC, being a noninvasive test, would be preferred to OC
by most patients. However, when the risks of finding lesions that require follow-up and
other  factors  are  taken into  account,  patient  preferences  may change.  In  one study,  OC
was preferred over CTC as the need for a follow-up test  increased,  as the likelihood of
missing cancers or polyps increased, and as the cost for CTC increased (the odds rato of
preferring CTC to OC ranged from 0.65 to 0.80)[106]. Therefore, an informed decision re‐
garding CTC vs. OC should include a discussion of the benefits, risks, costs and associat‐
ed  uncertainties  of  the  tests.  In  summary,  patients  usually  prefer  CTC  to  OC  but  the
preference is most likely dependent on a number of other factors such as insurance cover‐
age, type of sedation used locally for OC, and the risk of finding a significant polyp on
CTC thereby requiring a follow-up OC.
8. Extracolonic findings
Extracolonic findings are an important issue for CTC as they increase costs and patient risk
by incurring addition tests. The frequency of extracolonic findings in the literature varies
considerably as there are no standards for their reporting nor what constitutes a clinically
significant extra-colonic finding. Some of the extracolonic lesions found are clinically impor‐
tant although most of them are incidental. In addition to increasing costs of CTC screening
programs, they may cause undue worry and anxiety for the patient.
The prevalence of extracolonic findings can be as high as 40% - 75% and are increased with
patient age [107-109]. Most extracolonic findings are incidental and not clinically important.
The most common extracolonic findings causing further evaluation in one study were lung
nodules and indeterminate kidney lesions adding a cost of $248 dollars per patient enrolled
for CTC screening [110].
In general, significant extracolonic findings are found in about 10 - 23% of patients undergo‐
ing CTC [111-113]. Potentially important extracolonic findings were seen in 15.4% (89 of 577)
of patients in one study, with a work-up rate of 7.8% (45 of 577)[114]. In another study only
4.4% - 6.0% of patients required follow-up radiologic testing for the extracolonic findings
[109]. Another study showed that 10% of 681 patients screened for colon cancer had extraco‐
lonic findings of high clinical importance [115].
Although extracolonic finding add cost to CTC screening programs, they may benefit pa‐
tients by diagnosing other potentially malignant lesions [112]. Unsuspected cancers (colonic
and extra-colonic) are found in about 0.5% of screening cases [116]. In a large study,
36/10,286 patients (0.35%) undergoing a screening examination had an unsuspected extraco‐
lonic cancer which included renal cell carcinoma (n = 11), lung cancer (n = 8), non-Hodgkin
lymphoma (n = 60, and a variety of other tumors (n = 11)[116). Other studies report a higher
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9. Computer-Assisted Diagnosis (CAD)
An intensive area of research is the development of computer-assisted diagnosis (CAD) al‐
gorithms. CAD can assist radiologists as a second reader to improve accuracy [117, 118]. It
has been shown that CAD can aid trained radiologists in the detection of significant pol‐
yps [119].CAD significantly improved polyp detection by 12% in one study, (from 48 to
60%) with only a moderate increase in interpretation time [120].  Another study demon‐
strated that using CAD in second-read mode increased accuracy in 13 of 19 readers 968%);
CAD  increased  sensitivity  of  finding  polyps  but  decreased  specificity  slightly  [121].  In
general,  using  CAD increases  polyp  detection  but  also  increases  false  positives  as  well
[122, 123].
Using CAD as a primary reader is feasible but early studies showed less sensitivity than hu‐
man readers [124]. The sensitivity of CAD detected polyps 10 mm or greater was 64%
(18/28) in one study [125]. In a later study of 1,186 patients undergoing both CTC and OC on
the same day, CAD had a sensitivity of 89.3% (25/28; 95% CI: 71.8%-97.7%) for detecting ad‐
enomatous polyps at least 1 cm in size [126]. The false-positive rate was 2.1% (95% CI: 2.0% -
2.2%). CAD detected both of the carcinomas in the study group. In this study, CAD had a
per-patient sensitivity comparable to that of OC for adenomas at least 8 mm in size [126].
Another study found a per-patient sensitivity of 96% was for CAD (in patients with a me‐
dian polyp diameter of 6 mm) using external validation [127]. Several CAD polyp detection
systems exist such as Polyp Enhanced Viewing (PEV) and the Summers computer-aided de‐
tection (CAD) system (National Institutes of Health (NIH)). These systems vary and have
trade-offs in terms of sensitivity and specificity [128].
10. Safety
It is difficult to make a head-to-head comparison of the safety of CTC vs. OC since they are
different technologies with varying risks. In one study, CTC screening was performed in
3,120 adults and compared to primary OC screening in 3,163 adults. There were seven co‐
lonic perforations in the OC group and none in the CTC group [45]. Colonic perforation has
been reported with CTC but its occurrence is rare [129, 130]. Nine perforations out of 17,067
CTC examinations (0.052%) were reported in one study [131]. In another study of 11, 870
CTC studies, the perforation rate was 0.059% [132].
Possible factors that contribute to perforation are presence of an inguinal hernia contain‐
ing colon (n = 4), severe diverticulosis (n = 3), and obstructive carcinoma (n = 1)[132, 133].
In cases of obstructing lesions, gas should be insufflated slowly [133]. Colonic pneumato‐
sis  is  rarely  seen  (0.11%)  in  CTC studies  and  should  not  be  confused  with  perforation
[134,  135].  Overall,  potentially  serious adverse  events  related to  CTC occur  in  less  than
0.10% of patients [131].
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11. Cost-effectiveness
With a 6-mm size threshold for polyps, the overall referral rate to optical colonoscopy is
about 15% [114]. CTC is usually a less expensive test than OC, however the total costs may
not be less if one considers all of the variables such as compliance rates and referral rates for
OC after detecting lesions. Using a Markov model, screening by CTC costs $24,586 per life-
year saved compared to $20,930 for OC screening [136]. CTC becomes a more cost-effective
test as the compliance rate for screening increases or if the cost for CTC is 54% lower than
OC. On the other hand in a recent analysis both CTC and OC were more costly and less ef‐
fective than FOBT plus flexible sigmoidoscopy[137].
A Markov model was used to estimate the cost-effectiveness of CTC screening in an Italian
population. In this study, colorectal cancer was reduced by 40.9% and 38.2%, with OC and
CTC respectively. As compared to no screening, both CTC and OC were shown to be cost-
saving with CTC being the less expensive option [138]. Since CTC can accurately detect and
simultaneously screen for aortic aneurysms, cardiac atherosclerotic risk factors and osteopo‐
rosis, the benefits of CTC screening in an elderly population may be even more cost-effec‐
tive than previously thought [139-141].
12. New directions – Noncathartic bowel preparations
One new hope for the future is for patients to undergo CTC without laxatives or the need
for a purgative bowel preparation. Patients would only need to ingest fecal tagging agents
such as Gastroview or barium, one to two days before the test [142]. A pilot study using a
noncathartic bowel preparation (low fiber diet and fecal tagging) had disappointing results
demonstrating that the lack of bowel cleansing made the examination subjectively harder to
interpret and likely missed significant polyps [143]. A subsequent study however using a
noncathartic bowel preparation was performed in a high risk population [144]. Subjects in‐
gested 21.6 g of barium in nine divided doses. This study demonstrated that the sensitivity
of CTC using a non-cathartic bowel preparation for polyps greater than 9 mm was over 90%
[144].
Limited or non-cathartic bowel preparations may be especially useful in the frail or elderly
patient. In a prospective study, 67 elderly patients with reduced functional status under‐
went CTC using a limited bowel preparation consisting of a low-residue diet for 3 days, 1 L
of 2% oral diatrizoatemeglumine (Gastrografin) 24 hours before CTC, and 1 L of 2% oral
Gastrografin over the 2 hours immediately before CTC [145]. No cathartic preparation was
administered. All colonic segments were graded from 1 to 5 for image quality (1, unreada‐
ble; 2, poor; 3, equivocal; 4, good; 5, excellent). Overall image quality was rated good or ex‐
cellent in 84% of the colonic segments. Colonic abnormalities were identified in 12 patients
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Ref. (%)Sensitivity (%)Sensitivity (%)Specificity (N) Patients
6 – 9 mm 1 cm or more
33 82 91 79 87
34 80 90 72 300
35 89 94 79 – 96 1,233
36 39 55 91 – 96 600
37 78 90 90 2,531
41* 86 93 97 2,610
42* 76 – 83 83 – 88 91 – 98 4,086
* Meta-analysis
Table 1. Sensitivity and specificity of polyps detected by CTC.
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Colorectal cancer (CRC) represents a major public health problem worldwide. 
Fortunately most CRCs originate from a precursor lesion, the adenoma, which is 
accessible and removable. This is the rationale for CRC screening programs, which 
are aimed to diagnose CRC at an early stage or even better to detect and resect the 
advanced adenoma before CRC has developed. In this background colonoscopy 
emerges as the main tool to achieve these goals with recent evidence supporting its role 
in CRC prevention. This book deals with several topics to be faced when implementing 
a CRC screening program. The interested reader will learn about the rationale and 
challenges of implementing such a program, the management of the detected lesions, 
the prevention of complications of colonoscopy, and finally the use of other screening 
modalities that are emerging as valuable alternatives. The relevance of the topics 
covered in it and the updated evidence included by the authors turn this book into a 
very useful tool to introduce the reader in this amazing and evolving field.
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